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Abstract  
 
Untreated HIV infection is well known to have profound effects on CD4 T cell phenotype and function, 
ultimately leading to CD4 T cell depletion, AIDS and death. HIV is also known to affect B cell function and 
phenotype, resulting in impaired and dysregulated humoral immunity. Studies in HIV infected adults have 
demonstrated that Highly Active Antiretroviral Therapy (HAART) only partially restores B cell phenotype and 
function.  HIV infected adults and children on HAART remain at persistently high risk of pneumococcal 
disease and mount suboptimal responses to pneumococcal vaccines. The nature of persistent indirect 
effects of HIV infection on B cell immunity remain under investigated in the paediatric population.   
 
Using flow cytometry we have shown that children and adolescents with perinatally acquired (paHIV) have 
persistent abnormalities in B and T cell phenotype despite fully suppressive HAART. Pneumococcal 
serotype specific IgG, acquired through natural exposure, was present at baseline, although at a lower 
concentration than in healthy controls for some serotypes. Vaccination with 13-valent pneumococcal 
conjugate vaccine (PCV13) was immunogenic, however serological responses to certain serotypes were 
impaired in comparison to healthy controls. In vitro whole blood cytokine responses to vaccine carrier protein 
were present at baseline and increased following immunisation, although the diversity and magnitude of 
antigen specific cytokine release was restricted in comparison to healthy controls. A greater proportion of life 
spent with undetectable viral load was associated with a more intact B cell phenotype and more robust 
serotype specific IgG vaccine responses for some vaccine serotypes. Nasopharyngeal pneumococcal 
carriage isolates were detected in a small proportion of children with paHIV, all of which were non-PCV13 
serotypes. 
 
These results, while providing an insight into the immunogenicity and mechanism of action of conjugate 
vaccines outside of the infant period, have wider implications for pneumococcal vaccination and HAART 
treatment practices for children and adolescents with paHIV. 
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“In our endeavors to recall to memory something long forgotten, we often find ourselves upon the very verge 
of remembrance, without being able, in the end, to remember.” 
- Edgar Allen Poe, from “Ligeia”. 1938 
 
 
“Academicians are more likely to share each other's toothbrush than each other's nomenclature.” 
 - M. Michael Cohen, Jr., from “The Child With Multiple Birth Defects.” 1982. 
 
 
“Pneumococcus is altogether an amazing cell. Tiny in size, simple in structure, frail in make-up, it possesses 
physiological functions of great variety, performs biochemical feats of extraordinary intricacy and, attacking 
man, sets up a stormy disease so often fatal that it must be reckoned as one of the foremost causes of 
human death. Furthermore, living or dead, whole or in part, on entering the animal body Pneumococcus 
starts a train of impulses, stimulating all the reactions grouped under those inclusive phenomena known as 
immunity.” 
- Benjamin White, from “The Biology of Pneumococcus” 1938. 
 
 
"It has all been most interesting." 
- the last words of Lady Mary Wortley Montagu, 
  (writer, poet, socialite, feminist and early supporter of vaccination) 1762. 
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Chapter 1: Background 
 
1.1 Perinatally acquired Human Immunodeficiency Virus (paHIV) infection and Acquired Immune 
Deficiency Syndrome (AIDS) 
 
1.1.1 Global epidemiology 
Since the first cases of paediatric AIDS were described in the early 1980’s [1, 2] childhood HIV infection and 
AIDS have escalated to become a global challenge. The latest Joint United Nations Programme on 
HIV/AIDS (UNAIDS) report estimates that in 2011, approximately 330 000 (280 000- 380 000) children were 
born with HIV bringing the total number of children under 15 estimated to be living with HIV to 3.4 million (3.1 
million- 3.9 million). The estimated number of AIDS related deaths in this age group in 2011 was 230 000 
(200 000- 270 000). The vast majority of the new infections in children occurred in sub-Saharan Africa. This 
is a reflection of the overall burden of HIV infection in women of childbearing age in this region and limited 
provision of interventions targeted at prevention of mother to child transmission (PMTCT) [3]. 
 
HIV transmission from mother to infant (vertical transmission) can occur antenatally, perinatally or postnatally 
[4]. The risk of vertical transmission can be reduced from as high as 40% with no intervention to around 1% 
by implementing various measures including appropriate antenatal antiretroviral therapy (ART), intrapartum 
ART, elective caesarean section in cases with detectable maternal viral load, early neonatal post exposure 
prophylaxis and exclusive formula feeding [5, 6]. Unfortunately multiple factors contribute to suboptimal 
implementation of these interventions in resource poor countries. In West and Central Africa region, for 
example, estimated ART coverage rates for PMTCT are still as low as 27% (23-30%) [3]. 
 
Highly active antiretroviral therapy (HAART) has been shown to lead to decreased morbidity and mortality in 
paediatric HIV in both resource rich [7-10] and resource poor settings [11-14] however access to HAART for 
children is limited in many of the countries with the highest requirement. Access for those children in need of 
ART (see Section 1.1.6 for discussion on treatment guidelines) was estimated to be only 28% (25-32%) 
globally in 2011, with some countries estimated to be achieving access rates as low as 8% [3]. Difficulties in 
diagnosis of HIV infection, rapid disease progression and problems in developing appropriate drug 
formulations for children all contribute to coverage figures that are frequently worse than those observed for 
adults in the same geographical region [3, 15].  
 
Despite these issues, globally, the overall rate of new HIV infections in children is fortunately dropping. The 
death rate due to AIDS is decreasing and the overall number of children living with HIV is starting to plateau 
[3]. As access to ART increases in resource poor settings the numbers of children surviving to older 
childhood and adolescence will increase and problems currently affecting HIV infected children and 
adolescents in the resource rich setting will become increasingly relevant. 
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1.1.2 UK epidemiology 
The British Paediatric Surveillance Unit (BPSU) has collected data on paediatric HIV and AIDS since 1986 
[16]. In 1989 the National Study of HIV in Pregnancy and Childhood (NSHPC) was established for the UK 
and Ireland. This is a confidential national reporting scheme for pregnancies in HIV infected women (through 
obstetric services), babies born to HIV infected women (through BPSU) and other children with HIV infection 
and AIDS (also through BPSU). The NSHPC collect demographic data and limited follow up information on 
HIV exposed and infected children [17, 18]. In 2000 the Collaborative HIV Paediatric Study (CHIPS) was 
established to collect data on children treated in Paediatric European Network for Treatment of AIDS 
(PENTA) associated centres in the UK and Ireland [18, 19]. CHIPS currently collects long term clinical and 
immunological follow up data on all HIV-infected children reported to the NSHPC [17, 18]. 
 
The number of children under NSHPC/CHIPS follow-up steadily increased from the 1980’s until around 5 
years ago when numbers plateaued and have subsequently decreased (Fig. 1).  
 
                 
 
 
 
 
This pattern can be mainly attributed to the introduction of HAART as standard therapy for children in 1997, 
introduction of voluntary antenatal HIV testing for pregnant UK women in 2000, effective implementation of 
PMTCT protocols leading to a reduction in the rate of vertical transmission for babies born in the UK to 
around 1% [5, 19] and a gradual increase in the number of adolescents transitioning to adult services [20]. 
Since the introduction of HAART for children, there has been a substantial decrease in the mortality 
associated with paediatric HIV infection [19, 21]. The median age of the cohort has steadily increased, the 
age distribution is shifting upwards (Fig. 2) and the number of children who have transitioned or are due to 
transition to adult services is also steadily increasing [20]. 
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Figure 1. Number of HIV-1 infected children registered in NSHPC/CHIPS follow-up in the UK 
and Ireland by year (adapted from data provided by CHIPS: CHIPS report 2012) 
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The large majority of children have vertically acquired HIV-1 infection. Of the 1188 children currently under 
NSHPC/CHIPS follow up 51% are female, 51% were born abroad, 80% are of Black African ethnicity and 
51% are followed up in a London clinic (Data provided by CHIPS: CHIPS report 2011-2012) 
 
1.1.3 Cluster of differentiation (CD)4 T cell immunology and paediatric HIV infection 
HIV-1 is a species of retrovirus in the genus lentivirus [22], first identified in 1983 [23] and proven to be the 
causative agent in AIDS in 1984 [24, 25]. Prior to 1986 HIV virus was known by other names including 
human T-lymphotropic virus- III (HTLV-III) or lymphadenopathy-associated virus (LAV) [26]. There are 
currently two known species of HIV: HIV-1 and HIV-2. The virological and immunological profile and pattern 
of disease associated with HIV-2 infection is somewhat different to that associated with HIV-1, HIV-2 having 
a lower rate of disease progression and a frequently milder disease course [27]. HIV-1 is the predominant 
species in the world today, whereas HIV-2 is found mainly in certain West African Countries (e.g. Guinea 
Bissau) or countries with close ties to these regions (e.g. Portugal) [28]. There are 140 cases of HIV-2 
currently reported in the UK [29]. 39 pregnancies in 28 HIV-2 infected women have been reported to the 
NSHPC, with no known mother to child transmission [30] and there are no reported cases of paediatric HIV-2 
in the UK (personal communication with CHIPS/NSHPC). The work in this project is therefore solely related 
to paediatric HIV-1 infection. HIV-1 will be referred to as HIV unless otherwise stated.  
 
HIV mainly gains entry to target cells through glycoprotein 120 (gp120), a viral envelope glycoprotein, 
binding to CD4 molecules on the target cell surface [31]. CXC chemokine receptor (CXCR) 4 and CC 
chemokine receptor (CCR) 5 are important co-receptors for cell entry [32, 33]. In vivo HIV infection is 
therefore predominately restricted to cells expressing these molecules i.e. CD4+ T cells, 
monocyte/macrophages and dendritic cells [34, 35], although other mechanisms of cell entry exist e.g. Fc 
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Figure 2. Age distribution of HIV-1 infected children in NSHPC/CHIPS follow-up in the UK 
and Ireland by year (adapted from data provided by CHIPS: CHIPS report 2011-2012) 
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receptor, dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) and complement receptors (CR) 
[36, 37]. The immunopathology of HIV infection is brought about primarily through the virus’s effect on 
infected CD4+ T cells, although there are many indirect effects of infection on other aspects of host 
immunity. 
 
CD4+ T cells are a subset of CD3+ lymphocytes, classically referred to as T helper cells (Th). They are 
termed “helper” cells as their main role is to provide antigen specific “help” to other arms of the immune 
response e.g. B Cells, macrophages. They express a T cell receptor (TCR) and CD4, which acts as a co-
receptor. They recognise antigen, in the context of major histocompatibility complex (MHC) class II 
molecules expressed on the surface of professional antigen presenting cells (APCs) [38]. CD4+ T cells can 
be divided into subsets based on expression of certain cell surface molecules, cytokine production and 
characteristic transcription factors. These include classical T helper 1 (Th1) and T helper 2 (Th2) subsets in 
addition to more recently defined T helper 17 (Th17), regulatory T cells (Tregs) and follicular T helper cells 
(TFH). It has been proposed that CD4+ cells are induced to follow a specific developmental pathway 
depending on cytokine exposure and patterns of co-stimulation at the time of antigen presentation and 
during subsequent development. In this way the CD4+ T cell response is thought to adapt according to the 
nature of the invading pathogen/ immune response required (Fig. 3) [39]. 
 
 
 
 
 
 
 
 
 
 
 
 
The mechanisms by which HIV infection alters CD4+ T cell number and function are still incompletely 
understood, however processes such as direct cytopathic effect of viral proteins, apoptosis thorough immune 
activation, destruction of lymphoid tissue, decreased thymic output, cell mediated anti-CD4 cytotoxicity, 
autophagy and anti-CD4 autoantibodies have all been implicated [36, 40, 41] It is generally agreed that 
immune activation is a key mechanism by which HIV has its effect both in the T cell compartment and more 
generally in the immune system as a whole [42]. 
 
The differential effect of HIV on CD4+ T cell subsets has been discussed for some time [36, 43-45] however 
changes in more recently defined CD4+ T cell subsets resulting from HIV infection are only starting to be 
investigated [36, 46-50]. CD4+ T cells originate in the bone marrow, develop in the thymus then circulate 
through peripheral blood and take up residence and circulate through secondary lymphoid structures such as 
the spleen, lymph nodes and mucosa associated lymphoid tissue (MALT) [51]. HIV infection impacts on 
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Figure 3. A simplified overview of CD4+ T cell subsets. CD4+ T cells can be divided into subsets according to characteristic 
polarising cytokines, transcription factors, homing receptors and effector cytokines. It is proposed that each subset influences 
predominately one cell type and has a characteristic role to play in host defence (adapted from Sallusto et al  [39]). 
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CD4+ T cell development and function in each of these sites, with different patterns of involvement observed 
at different stages of infection [52-61]. Horizontal transmission of HIV usually results in an insult to a fully 
developed immune system, whereas at the time when vertical transmission occurs (in utero, perinatally or 
postnatally) all aspects of immunity, including CD4+ T cells, are still developing [62]. The impact of HIV 
infection on the developing, immature immune system is different to that seen following horizontal 
transmission. This is reflected in the pattern of disease, virology and immunology observed in paediatric 
infection [63-65]. 
 
With respect to the immunological characteristics of paediatric infection, exposure to maternal infection, even 
without transmission, has an effect on immune phenotype at birth and during infancy. In comparison to 
unexposed healthy infants, various studies on cord blood mononuclear cells (CBMC) and/or peripheral blood 
mononuclear cells (PBMC) from HIV exposed uninfected infants (HEU) have been shown to have lower 
CD4+ T cell number and/or percentages [66-71]. PBMC from HEU have been shown to produce less 
interleukin (IL)2 (a Th1 cytokine) on stimulation with the mitogen phytoheamagglutinin (PHA) [72], however 
intracellular IL2 producing CD4+ T cells were more frequent in HEU PBMC on stimulation with the mitogen 
phorbol myristate acetate (PMA) and ionomycin. Higher production of IL10 (Th2 cytokine) has been 
demonstrated in HEU CBMC stimulated with PHA [73], whereas CBMC stimulated with anti-CD3 and anti-
CD28 have been shown to produce less IL10 and more interferon gamma (IFNγ) and tumour necrosis factor 
alpha (TNFα) (Th1 cytokines) but only in HEU of mothers with detectable viraemia [74]. CBMC from HEU 
produced less IL12 (monocyte derived Th1 cytokine) when stimulated with Staphylococcus aureus Cowan 
(SAC) when compared to unexposed controls. The pattern of maturation of the IFNγ response to whole blood 
stimulated with PHA seen over the first 6 weeks of life in unexposed infants was shown to be absent in a 
proportion of HEU, many of whom had relatively high IFNγ responses at birth [75]. These at times conflicting 
observations could be partially explained by the different mitogen/ T cell stimulating condition used, or 
different patient group demographics. Although somewhat contradictory, these studies clearly demonstrate 
differences in immune phenotype between HEU and unexposed controls.  
 
Furthermore, expression of CD38 (a T cell activation marker) on CD4+ T cells of HEU is increased in the first 
year of life [72, 76]. CD4+ T cells isolated from HEU cord blood have also been shown to be more prone to 
apoptosis [77]. HEU have a lower proportion of naive and a higher proportion of memory CD4+ T cells at 
birth [67, 76], a pattern that may persist into later childhood [66].  Lower CD4 + T cell T cell receptor excision 
circle (TREC) levels, demonstrated at birth, suggesting a decrease in thymic output compared to healthy 
unexposed controls, may contribute to these findings.  Although many of these abnormalities might be 
attributed to the effects of HIV infection in the mother, as more and more infants are exposed to ART as part 
of PMTCT programmes the potential impact of maternal ART and infant postexposure prophylaxis on these 
immune parameters must also be borne in mind [70, 71]. 
 
Investigating the implications of these subtle variations in immune phenotype will be of increasing 
importance as the numbers of infants being born uninfected through successful PMTCT programmes 
increases globally. Indeed, the increased morbidity observed in some studies of HEU [78-81] may be 
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partially attributable to altered immune function, and there may well be implications for routine vaccine 
responses [82].  
 
As observed in adults, if left untreated, vertically transmitted HIV infection leads to a progressive decline in 
CD4+ T cell number and percentage [83], over and above that which is normally observed in early childhood 
[84, 85] or HEU [70, 85, 86]. Plasma viral load is usually relatively low at birth (unless transmission has 
occurred in utero) then subsequently rises rapidly in the first 2 months of life after which there is a steady 
decline in plasma viral RNA levels [87-89]. This is in contrast to the pattern observed in primary horizontal 
HIV infection in adults in whom there is usually an initial rapid rise in viral load followed by a similarly rapid 
fall in viral load to a much lower steady state [52, 90]. The cause of this drop in viraemia after primary 
infection in the absence of ART is not completely understood, however it is thought to be due mainly to 
acquired HIV specific CD8+ T cells responses [91-93], bringing viraemia to a lower set point and possibly 
related to an overall decrease in the number of cells capable of supporting active infection having an effect 
on viral replication potential [52, 90]. In addition, innate immunity, B cells, antibody and even CD4+ T cells 
themselves are all thought to have a role in controlling virus and determining this viral load set point [63, 65, 
94-97]. 
 
As well as differences in viral load kinetics, differential effects of HIV on a child’s developing immune system 
are reflected in characteristic patterns of CD4+ T cell depletion and disease progression. Following vertical 
infection, around 25% of children if untreated will rapidly progress to AIDS in the first year of life and 40% will 
have an AIDS diagnosis by the age of 4 years [98]. This is in contrast to observations in adults in whom a 
much lower proportion rapidly progress and a longer AIDS free period is the norm [99].  
 
Many aspects of early life immunity [100, 101] may contribute to the different viral kinetics and immunology 
observed following vertical transmission. Certain aspects of infant immunology may be protective, whereas 
others may be detrimental [15, 102]. The thymus is relatively bulky and active in early life [103], which may 
well contribute to new variant-specific cytotoxic T cell responses more commonly observed in children than 
adults following viral escape mutation [104]. This relatively preserved thymic activity in infancy is also 
thought to have implications for immune reconstitution following initiation of HAART (see below). Despite the 
potential advantages of having an active thymus, the observed increased severity of untreated disease in 
infants suggests that, in the absence of HAART, the disadvantages of being an infant by far outweigh the 
benefits. Indeed, an active thymus may even be detrimental to the HIV infected infant, serving as a large 
source of cells vulnerable to infection [105] and the immaturity of the immune system as a whole during 
infancy [62] may well have far reaching implications for disease outcome.  
 
Other viral and host factors may hinder effective control of infant infection. Transmission occurs more 
frequently in the context of high maternal viral load [5, 97]. Certain human leukocyte antigen (HLA) class I 
types are associated with better or worse viral control [106-108]. It follows that infants at greater risk of 
infection are also more likely to have inherited an HLA class I allele associated with poorer viral control [107, 
108]. Moreover, infants are infected with virus that has existed in the context of the maternal and often 
paternal immune system. The transmitting virus may have evolved mutations specifically adapted to 
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existence in a host with a specific HLA class I genotype. Infants therefore inherit a virus that may have 
already adapted to escape control by the HLA class that they have also inherited from their parents [107, 
109].  
 
Differences between adult and paediatric HIV infection also become apparent when commencing ART. 
When starting treatment, dynamics of T cell recovery and immune reconstitution observed in peripheral 
blood are different from those observed in adults. In addition to the subsets mentioned above, CD4+ T cells 
can be further divided by expression of surface markers into naive, effector memory and central memory 
populations [110]. In children commencing ART there is initial replenishment of naive CD4 cell numbers and 
subsequent restoration of cells with memory phenotype [111]. This is in contrast to the pattern in adults in 
whom there is initial replenishment of the memory CD4+ T cell pool followed by gradual increases in naive 
cell numbers [112]. In healthy individuals, thymic function naturally decreases with age as demonstrated by 
studies quantifying TRECs, a marker used to assess thymic activity [103]. HIV leads to decreased thymic 
function in both children and adults [102, 103]. The different pattern of CD4+ T cell subset recovery observed 
in children is thought to be a reflection of relatively preserved thymic function and output potential in children 
[67, 95, 102, 113-116]. 
 
Changes in HIV specific CD4+ and CD8+ T cell populations occur after commencing effective HAART. In 
children HIV specific CD4+ T cell responses increase, whereas the magnitude of HIV specific CD8+ T cell 
responses decrease over time. The breadth of these CD8+ T cell responses is however maintained [95]. 
Once more, differences in the potential for immune restoration are observed between adults and children, 
children having a much higher proportion of HIV specific CD4+ T cells in peripheral blood than adults 
following initiation of therapy [117].  
 
Despite these differences in the immunological response to HAART, the pattern of virological response is 
somewhat similar in adults and children. A characteristic biphasic virological response is observed with an 
initial rapid decrease in plasma viral load followed by a slower exponential decrease. The clearance rates 
observed for adults and children are roughly equivalent. It has been proposed that this biphasic response 
could reflect death rates of different susceptible cell populations i.e. initially productively infected cells, 
subsequently long lived/latently infected cells [118, 119]. 
 
1.1.4 B cell immunology and paediatric HIV-1 infection 
Although the impact of untreated HIV infection on CD4+ T cells is the main driving force for HIV associated 
disease, the disruptive effect that infection has on other aspects of immunity should not be underestimated. 
There is little evidence to suggest that HIV can infect B cells in vivo however infection has wide ranging 
consequences for B cell phenotype and function. Following the dramatic success of HAART in restoring T 
cell populations, it is increasingly important to investigate the possible reversible and irreversible B cell 
deficits that are brought about by HIV [120]. 
 
B cells are lymphocytes with an essential role in the production of antibody and humoral immunity. They 
characteristically express a B cell receptor (BCR) and mostly develop in the bone marrow, from where they 
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emigrate in the form of transitional B cells [121, 122]. Transitional B cells mature in the periphery into naive 
mature B cells expressing surface bound immunoglobulin D and M (IgD/IgM) [122] and following antigenic 
challenge have the potential to differentiate into antibody secreting plasma cells (via a plasmablast stage) or 
memory B cells [121, 123-125]. 
 
Plasma cells secrete antibody and can either be short-lived or long-lived depending on the nature of 
antigenic challenge, T cell help, BCR affinity and the developmental state of the B cell from which they arise 
[126, 127]. They can develop following the germinal centre (GC) reaction (see below) or independently of 
this process [127-130].  
 
Memory B cells can be defined as “long-lived quiescent B cells expressing somatically mutated IgV genes 
that are capable of eliciting rapid and robust responses compared with corresponding  antigen-inexperienced 
naive B cells” [124]. They can be subdivided into various subsets according to surface marker expression. 
The origin and classification of these subsets is a matter of debate, with some confusion attributable to 
differences between mice and humans [131-133], however two main subsets are relatively well defined in 
humans; class switched and IgM memory B cells [124, 134].  
 
B cells can respond to antigen by producing antibody through either T cell dependent (TD) or T cell 
independent (TI) mechanisms. TD antigens are classically proteins that can be processed and presented in 
the context of MHC class II molecules on the surface of APCs. TI antigens can be divided into TI type 1 and 
TI type 2 antigens. TI type 1 antigens, such as lipopolysaccharide (LPS), polyclonally stimulate B cells to 
produce antibody predominately via toll-like receptor interaction. TI type 2 antigens are usually larger 
repetitious molecules such as bacterial cell wall polysaccharides that stimulate antigen specific B cells 
through direct BCR cross-linking [128, 135]. 
 
Class switched memory B cells mainly develop following the GC reaction, whereby antigen specific B cells 
come into contact with helper T cells specific for the same antigen in GCs in secondary lymphoid tissue. The 
helper T cells responsible for this B cell help are termed follicular T helper cells (TFH) [136-144]. The 
interaction between TFH and B cell in the GC microenvironment results in class switch recombination (CSR), 
whereby the immunoglobulin isotype changes from IgM/IgD to an alternative one e.g. IgG, and affinity 
maturation, whereby, through the process of somatic hypermutation, the affinity of the antibody for the 
antigen is optimised. The GC reaction ultimately results in either long-lived plasma cells that migrate to settle 
in niches in the bone marrow [128], secreting antibody long term or class switched memory B cells that 
persist and circulate awaiting secondary antigenic challenge following which they can rapidly differentiate 
into antibody secreting plasma cells [123].  
 
The origin of IgM memory B cells in humans is debated. It now seems clear that memory B cells which 
express cell surface IgM may not result from a single developmental pathway. It is currently thought that a 
proportion of them develop independently of the GC reaction, responding to TI antigens such as bacterial 
cell wall polysaccharides by rapidly differentiating into plasma cells secreting IgM [145]. On the other hand, it 
has been proposed that IgM memory B cells can also develop as a result of the germinal centre reaction 
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minus CSR, these being true IgM memory B cells. A final possibility it is that they may result from a separate 
antigen independent B cell lineage. These are thought to represent a more innate like B cell subset, 
equivalent to marginal zone and B1a cells in mice (see below). The debate is ongoing [146-148]. 
 
A further subset of B cells termed B1 cells, which can be further subdivided into B1a and B1b cells have 
been well characterised in the mouse, and are also thought to represent more innate-like B cells, responding 
to TI antigens [133]. Recent reports of an identifying marker for this subset in humans [149] met with some 
controversy [150-152]. As they are still not clearly defined as a population in humans, they will not be 
discussed further in the context of this work. See Fig. 4 for an overview of human B cell development. 
 
 
Just as with T cell immunity, B cell immunity is functionally immature at birth and develops into the adult 
phenotype over the course of childhood [62, 153]. Overall circulating B cell counts are highest in infancy then 
gradually decrease throughout childhood and adolescence. As overall B cell numbers decrease so do the 
absolute numbers of memory B cells. The proportion of B cells that are IgM and class-switched memory B 
cells gradually increases with age as the proportion of naive B cells correspondingly decreases [84, 154]. 
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Figure 4. Simplified overview of peripheral B cell development. Immature B cells leave the bone marrow as transitional cells. 
These develop into naive mature B cells. Once activated these cells can either develop into short lived antibody secreting 
plasma cells or enter the germinal centre and develop into either class switched memory B cells or long lived antibody 
secreting plasma cells which migrate to persist in bone marrow niches. IgM memory B cells may develop through a number of 
proposed pathways including an antigen independent pathway direct from transitional cells, an extrafollicular antigen 
dependent pathway, or through the germinal centre reaction. 
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The proportion of B cells with transitional phenotype is highest in infancy then decreases with age [84]. 
Antibody responses to both protein/TD and especially polysaccharide/TI antigens are weaker and shorter 
lasting in infancy. The latter observation is thought to contribute to the increased vulnerability of children of 
this age to bacterial pathogens such as Streptococcus pneumonia, Neisseria meningitidis and Haemophilus 
influenzae all of which have a coating polysaccharide cell wall [153, 155].  
 
Since the very earliest days of HIV research, abnormalities of the B cell compartment and humoral immunity 
were noted to be a prominent feature of HIV/AIDS in both adults [156] and children [157]. Untreated adult 
HIV infection is associated with a number of B cell and humoral abnormalities [120]. The observed 
abnormalities are listed in Box 1. Many of these abnormalities may be reversed by HAART, however certain 
aspects of memory B cell phenotype and function persist.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In 2001 De Milito et al demonstrated that adult HIV infection is associated with decreased memory B cell 
number and percentage, irrespective of whether the patient is on HAART [158], a finding that was 
subsequently confirmed by Chong et al in 2004 [159]. De Milito’s group went on to demonstrate that 
abnormalities in B cell number and phenotype occur early in primary HIV infection and are potentially 
reversible at this stage through the early use of HAART [160]. D’Orsogna et al demonstrated chronic HIV 
infection to be associated with decreased total B cell numbers but to have no effect on total memory B cell 
percentages. Class switched memory B cells were decreased in both treatment naive patients and those on 
HAART. They also demonstrated decreased IgM memory B cells in a subset of patients with low CD4 count 
<300 cells/µl, whereas patients on HAART had equivalent numbers to healthy controls, suggesting HAART 
restored this population [161]. In contrast to these findings Hart et al demonstrated that HIV infected adults 
have decreased memory B cell percentages, irrespective of treatment status. IgM memory B cell 
Hypergammaglobulinaemia  
↑ polyclonal B cell activation  
↑ cell turnover  
↑ autoantibodies 
↑ B cell malignancy 
 
↑ activation markers  
↑ plasmablasts 
↑ immature/transitional B cell  
↑ activated mature B cell  
↑ exhausted/ tissue like B cell 
 
↓ memory B cell numbers 
↓ memory B cell function 
 
Box 1. B cell abnormalities observed in HIV infection 
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percentages were lower than in healthy controls in both treatment naive patients and those on HAART, and 
this correlated with poor responses to the TI pneumococcal polysaccharide vaccine (PPV). Approximately 
25% of patients had a significant reduction in class switched memory B cell percentage in both patient 
groups and this was associated with poor responses to TD tetanus vaccination [162]. More recently 
Grevenynghe et al have again confirmed decreased circulating memory B cells percentages in HAART 
treated aviraemic adults compared to healthy controls, but when examining memory subsets, only class-
switched memory B cells were found to be significantly lower [163]. Johannesson et al did not include a 
healthy control group but did find adults on suppressive HAART to have a significantly higher class switched 
memory B cell count than HAART naive patients, but no difference in class switched proportion or IgM 
memory cell count or proportion [164]. Although these studies are in some aspects contradictory and do not 
investigate the effect of treatment longitudinally, observations together indicate that initiation of HAART in 
chronic adult HIV infection may not fully restore B cell abnormalities established early in infection and have 
implications for optimising treatment strategies and optimal vaccination strategies.  
 
The Moir group have published extensively on B cell abnormalities in HIV infected adults [120, 165]. Rather 
than using IgD/IgM to classify memory subsets they have employed CD21 (Complement Receptor 2 (CR2)) 
to identify populations of circulating CD21lo B cells that are observed with increased frequency in adult 
infection. They also demonstrated this CD21lo population to be made up of transitional B cells (CD10+CD27-
CD21lo), activated mature B cells (CD10-CD27+CD21lo), plasmablasts (CD10-CD27++CD21lo) and a newly 
characterised subset with an exhausted phenotype termed “tissue like/exhausted” memory B cells (CD10-
CD27-CD21lo) [120]. Recent longitudinal data from the Moir group in adults commencing HAART in early and 
chronic HIV infection, have again suggested that early HAART may prevent irreversible changes in B cell 
phenotype [165]. A summary of the abnormalities of these B cell subsets in adult HIV infection is shown in 
Fig. 5.  
 
The B cell compartment in HIV infected children has been less extensively investigated. Jacobsen et al 
found that HIV infected children on HAART with undetectable viral load had reduced IgD+ memory B cell 
percentage compared to those on treatment with detectable viral load, treatment naive patients and healthy 
controls [166]. Ghosh et al demonstrated decreased class switched and IgM memory B cell percentage and 
number in HIV infected children when compared to healthy controls. In contrast to the findings of Jacobsen 
et al, children with an HIV viral load (VL) >500 Eq/ml had lower class switched memory B cell counts than 
children with VL<500 Eq/ml (the patients presumably on treatment although this is not reported) [167].  
 
Pensieroso et al found total memory B cell percentages in HIV infected children who started treatment early 
to be equivalent to those in age matched healthy controls, whereas patients who started HAART later had 
lower memory B cell percentages than healthy controls. The early treatment group was also found to have 
relatively preserved responses to common vaccine antigens as measured by serum antibody and antigen 
specific B cell enzyme linked immunosorbant SPOT (ELISPOT). IgM and class switched memory B cell 
populations were not significantly different between HIV infected children and healthy controls, irrespective of 
treatment status [168]. Iwajomo et al studied B cell immune phenotype in a cohort of East African HIV 
infected children who were not on HAART. They found decreased proportions of naive mature and resting 
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memory B cells and correspondingly increased activated mature B cells. In addition they found a decrease in 
IgM memory B cell numbers compared to healthy controls [169]. These results together, as with those in 
adults are somewhat contradictory and are not longitudinal, however they strongly suggest that abnormalities 
in B cell memory phenotype and function occur in paediatric infection, and that early HAART may prevent or 
reverse changes that at a later stage may be irreversible.  
 
 
 
 
B cells play an essential part in the response to many routine vaccinations administered during childhood 
[170]. In addition, it is becoming increasingly apparent that B cells are not only important as a source of 
antibody but that they also have an immunomodulatory role through antigen presentation to T cells, 
costimulation and cytokine production [171, 172]. As HAART allows survival into adult life following vertical 
infection, it is important to ensure adequate protection against vaccine preventable diseases. The impact of 
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Figure 5. Summary of B cell phenotypic abnormalities observed during HIV infection. Cells in boxes are seen to change in 
proportion during chronic infection. Transitional cell numbers increase with CD4+ T cell lymphopenia. Exhausted and activated 
mature memory B cells and plasmablasts are increased in association with viraemia. Resting memory B cells are decreased during 
HIV infection. (hi = high, lo = low). (Adapted from review by Moir et al 2009 [120]) 
 
	   	   	   	  24 
HIV on a child’s developing B cell immunity must be borne in mind when planning treatment and vaccination 
schedules.  
 
1.1.5 Innate immune dysfunction in paediatric HIV-1 infection  
HIV is also known to disrupt innate immune cells and pathways [65, 173]. Decreased natural killer (NK) cell, 
natural killer T (NKT) cell and dendritic cell (DC) number and function have all been demonstrated in 
paediatric infection, especially in children with detectable viral load and low CD4+ T cell counts [173-175]. 
These deficits are only partially restored by HAART [173, 174]. Cytokine production by PBMC in response to 
Toll-like receptor (TLR) agonists is decreased in children on HAART [173]. Decreased neutrophil count and 
abnormalities of neutrophil function have been demonstrated in untreated HIV infected children [176-178], 
however it should be noted that antiretroviral treatment can itself contribute to decreased neutrophil counts 
both in HIV infected and HEU children [178]. Increased complement activation and consumption have been 
demonstrated in children with HIV [179], although the ability of HIV patient serum to opsonise pneumococci 
with complement in vitro, at least in adults, does not seem to be compromised [180]. Disruptions of many 
other aspects of innate immune function have been demonstrated in adults but are yet to be explored in 
children. Similarly the effect of HAART in restoring innate immune function in children is only beginning to be 
investigated [65]. 
 
1.1.6 Staging and treatment of paediatric HIV-1 infection 
The first specific antiretroviral drug, zidovudine (AZT), was approved for use in humans in 1987. The efficacy 
of AZT as monotherapy was limited, often rapidly resulting in HIV viral drug resistance mutations and loss of 
virological suppression. Since then, a range of antiretroviral medications have been developed which are 
divided into classes of drug with differing mechanism of action. Since 1997 the use of combination therapy 
also known as HAART, employing drugs from 2 or more different classes has resulted in the potential for 
long term virological suppression (<50 viral RNA copies/ml peripheral blood), maintained CD4 T cell count, 
substantially decreased morbidity and increased survival in both adult and paediatric cohorts. Briefly, the 
classes of currently available antiretroviral medications include: inhibitors of viral reverse transcriptase 
(nucleotide/nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase 
inhibitors (NNRTI)), inhibitors of viral protease (protease inhibitors (PI)), inhibitors of integration into the host 
genome (integrase inhibitors), inhibitors of gp41 mediated viral/host cell fusion (fusion inhibitors), and drugs 
which prevent viral co-receptor binding via CCR5 blockade (CCR5 receptor antagonists). Efficacy of HAART 
is assessed clinically and by monitoring peripheral blood HIV viral load (using PCR) and CD4 count (using 
flow cytometry) [500, 501].  
 
Different groups recommend different staging and treatment strategies for paediatric HIV. World Health 
Organisation (WHO) guidelines are more tailored for use in developing countries. Centers for Disease 
Control and Prevention (CDC) guidelines are used mainly in North America and PENTA guidelines are 
followed in the UK and Europe. For the purposes of this report the PENTA guidelines will be referred to 
unless otherwise stated [181]. CDC and WHO staging are listed in Appendix 1 and 2. The PENTA treatment 
recommendations are summarised in Table 1. Guidance on appropriate drug treatment regimens to use is 
listed in Appendix 3. 
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HAART has resulted in a dramatic decrease in morbidity and mortality in vertically acquired HIV in the UK 
[10, 19, 21]. Recently it has become clear that all infants diagnosed with HIV should be commenced on 
HAART [7, 11, 181]. Potential drug toxicities of HAART are many and varied [181].  An important question 
that is yet to be answered is whether HAART can be safely interrupted following initiation in infancy in order 
to minimise long-term potential drug toxicity. Evidence for the possible detrimental effects of treatment 
interruption in HIV infected adults has been provided by the Strategies for Management of Antiretroviral 
Therapy (SMART) study group’s large randomised controlled trial of CD4 count guided treatment 
interruption. An excess of opportunistic disease and death from any cause was observed in those 
randomised to treatment interruption [182]. Subsequent analysis of stored samples showed IL6 and D-dimer 
levels to be strongly related to all-cause mortality, treatment interruption being associated with an increase in 
these markers [502]. IL6 and high sensitivity CRP (hsCRP) were independently predictive of opportunistic 
disease [503]. Compared to healthy controls, adults with HIV had higher levels of hsCRP, IL6 and D-Dimer, 
even when on fully suppressive HAART [504], these markers being associated with an increased risk of 
cardiovascular disease [505]. A similar (although smaller) trial of treatment interruption in children with paHIV 
(PENTA 11) has found no excess morbidity or mortality in those randomised to treatment interruption, 
despite evidence of immune activation being demonstrated at the cellular level [183,184, 506]. A preliminary 
report on immunological and virological effects of PTI in HIV infected children showed increased viral load 
and CD4 cell activation and a decrease in CD4 cell number. The relative proportions of CD4 cell subsets 
changed initially but quickly returned to baseline. [183, 185]. This is an area of ongoing research in paediatric 
HIV (PENTA 11 and CHER trial) [7, 183, 184]. The effect of treatment interruption on B cell immunology in 
children has not as yet been reported.  
 
A further important question is whether to raise the CD4 cut off for initiation of treatment in children 
diagnosed outside of the infant period, in line with current CDC paediatric guidelines [186] or possibly even 
to consider starting treatment in all children irrespective of immune/virological status, in line with current CDC 
adult guidelines [187]. Increasing evidence of detrimental effects of ongoing viral replication and the 
immunological benefits of earlier HAART initiation must be considered in the context of potential drug 
toxicity, logistic, financial and epidemiological factors in both resource rich and resource poor settings. Both 
these key questions are subject to ongoing debate. 
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Age Means of assessment Treatment guidance  
Clinical Treat all 
Immunological Treat all 
0-11 months 
Virological Treat all 
Clinical Treat CDC stage B or C/ WHO stage 3 or 4 
Immunological (CD4%/count) Treat <25% or <1000 cells/µl 
12-35 months 
Virological Consider >100 000 copies/ml 
Clinical Treat CDC stage B or C/ WHO stage 3 or 4 
Immunological (CD4%/count) Treat <20% or <500 cells/µl 
36-59 months 
Virological Consider >100 000 copies/ml 
Clinical Treat CDC stage B or C/ WHO stage 3 or 4 
Immunological (CD4%/count) Treat <350 cells/µl 
5 years + 
Virological Consider >100 000 copies/ml 
 
Table 1. Table summarising PENTA treatment guidelines for HIV infected children. 
 
1.1.7 Vaccine responses in paediatric HIV-1 infection 
Vaccine responses in healthy infants are generally less robust than in older children and young adults [153]. 
Many studies have demonstrated impaired responses to a variety of vaccines in the context of paediatric HIV 
infection [188-191]. In HIV infected children on HAART, the basic quantification of T and B cell numbers and 
phenotype as well as vaccine responses show residual deficits in humoral and cellular immunity, despite 
recovery of CD4+ T cell numbers and suppression of viral load [168, 188-190, 192-205]. Many routine 
vaccines require T cell help for B cells for an effective serological response and the establishment of immune 
memory. There are many points along the pathway from innate immunity and antigen presentation to 
acquired cell mediated and humoral response that are potentially disrupted by HIV, and not completely 
restored by HAART. It is possible that HAART may fail to restore number and/or function of the T cell subset 
necessary for B cell help, namely follicular T helper (TFH) cells. This in conjunction with persistent B cell 
defects could explain observed poor vaccine responses. Irreversible disruption of the TFH compartment may 
well contribute to the persistent observed B cell abnormalities described above.  
 
Forster et al were the first to describe a circulating subset of CD4+ T cells expressing cell surface Burkitt’s 
lymphoma receptor 1 (BLR1) [206]. BLR1 is a chemokine receptor, later renamed CXCR5, and is now 
known to be one of the characteristic surface markers used to identify TFH [136, 137, 139]. Strictly speaking 
TFH by definition should be localised to the lymph node, however a proportion of circulating CD4+ T cells 
have TFH phenotypic characteristics and in vitro functional properties [207-209]. It has been proposed that 
these cells are a circulating equivalent of true TFH and are a reflection of GC function [141]. These circulating 
cells will be referred to as TFH-like cells in this report. 
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Forster et al also showed in 1997 that HIV infected adults with lower peripheral blood CD4+ T cell counts 
had a higher proportion of CD45RO+ memory cells but a lower proportion of CD45RO+ expressing CXCR5 
[210]. There have been few further studies of this circulating subset in the context of adult or paediatric HIV 
until a recent study by Rabian et al, which showed that in HIV infected adults vaccinated with a 
pneumococcal conjugate vaccine (PCV - see Section 1.3), higher baseline circulating TFH-like cell numbers 
correlated with more sustained in vitro cellular responses to diphtheria toxin [48]. The carrier protein for the 
PCV is cross-reacting material 197 (CRM197), which is a modified diphtheria toxin [211, 212]. This result 
suggests that a subset of HIV infected children may respond sub-optimally to vaccination with a conjugate 
vaccine and that responses may correlate with circulating TFH-like cell number. The group did not report any 
correlation between treatment history and TFH-like cell numbers nor did they compare with healthy controls. 
Pallikuth et al subsequently found no difference in the frequency of TFH-like cells in HIV infected adults 
compared to healthy controls. However, successful antibody response to influenza vaccine was associated 
with an increase in circulating TFH-like cells 1 month post-immunisation in a subset of HIV infected adults and 
healthy controls [47]. To our knowledge there is no published data on circulating TFH-like cells in HIV infected 
children. 
 
1.2 Streptococcus pneumoniae 
 
Streptococcus pneumoniae (also known as pneumococcus) is a gram-positive diplococcus with a 
polysaccharide capsule, which can be found naturally colonising the upper respiratory tract, especially in 
young children [213, 214]. Capsular polysaccharide helps to differentiate pneumococci into 46 serogroups 
and 93 currently recognised serotypes [215]. Not all serotypes are potentially invasive and only a relatively 
small proportion of serotypes commonly cause disease in humans [216]. 
 
1.2.1 Global epidemiology 
Streptococcus pneumoniae is a leading cause of paediatric morbidity and mortality throughout the world, 
causing disease ranging from otitis media, to pneumonia, meningitis and septicaemia [216, 217]. O’Brien et 
al applied comprehensive, clear and rigorous methods to estimate the burden of pneumococcal infection in 
children under 5 at global, regional, sub-regional and country level using systematic, transparent methods 
including a comprehensive literature review. The report highlights the importance of this infection throughout 
the world as a leading cause of paediatric morbidity and mortality. It estimates that in 2000, approximately 
14.5 million episodes of serious pneumococcal disease occurred globally in children aged 1-59 months 
(uncertainty range 11.1-18.0 million). Pneumococcal disease caused 826 000 deaths (582 000- 926 000) in 
this age group, of which 91 000 (63 000- 102 000) were HIV-positive and 735 000 (519 000- 825 000) were 
HIV-negative. Of the deaths in HIV-negative children over 61% occurred in 10 African and Asian countries. 
The 735 000 (519 000- 825 000) deaths in HIV-negative children accounts for 11% (8-12%) of the 6.6 million 
total deaths in this age group in that year. (Fig. 6) It should be noted that this analysis includes data on 
meningitis, pneumonia and non-meningitis, non-pneumonia invasive disease (defined as isolation of S 
pneumoniae from a normally sterile body fluid). Of these 3 outcomes pneumonia was by far the most 
common. The study did not include data on upper respiratory tract infection such as otitis media attributable 
to S. pneumoniae. The authors concluded that these are likely to be underestimates of overall diseases 
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burden due to limited reporting and culturing practices, alongside a substantial burden of non-severe/non-
invasive pneumococcal infection [218]. Incidence of invasive pneumococcal disease (IPD) varies 
substantially by age, genetic background, socioeconomic status, immune status and geographical location 
[219]. 
 
 
 
Figure 6. HIV negative pneumococcal deaths in children aged 1–59 months per 100 000 children younger than 5 years (Figure from 
O’Brien et al 2009 [218]) 
 
1.2.2 UK epidemiology 
Streptococcus pneumoniae is one of the most frequent causes of invasive bacterial diseases in children in 
the UK. It has been reported to be the second most common bacterial cause of death in previously healthy 
children [220]. 7-valent PCV (PCV7 – see Section 1.3.1) was introduced into the national infant schedule in 
2006. The epidemiology of pneumococcal disease in England and Wales from 1996-2006 has recently been 
summarised in a report by the Health Protection Agency (HPA) [221]. The burden of disease was 
considerable with peaks in the incidence of IPD in children under 2 years and adults over 75 years.  Over the 
10-year period overall incidence in all age groups ranged from 8.8 to 11.9 per 100 000/year. Incidence in 
under 2 year olds in 2005/2006 was 41.4/100 000. There was seasonal variation in reporting with peaks in 
the winter months. A diagnosis of meningitis was most common in children under 1 year (30% of IPD). For 
children under 2 years, 74% of isolates were PCV7 vaccine serotypes. The study noted that there were 
natural variations in serotype frequency over the 10-year period prior to introduction of PCV7, which should 
be taken in to consideration when monitoring the impact of vaccination introduction [221]. 
 
Following the introduction of universal immunisation with PCV7 in the UK there was a dramatic reduction in 
the rates of IPD in both children under two and older unvaccinated age groups (through herd immunity). In 
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contrast to this there was a significant increase in the incidence of IPD due to non-vaccine serotypes in all 
age groups, a phenomenon referred to as serotype replacement. The decrease in overall rates of IPD, 
although still significant, was therefore less substantial than if assessing vaccine serotypes alone [222]. 13-
valent PCV (PCV13) replaced PCV7 in early 2010. There is less published data available regarding changes 
in IPD since then. Miller et al have reported early data for the UK, indicating that PCV13 has resulted in 
similar reductions in IPD due to the extra 6 serotypes in the vaccinated age group [223].  
 
Since the introduction of PCV7, the HPA has reported weekly cumulative incidence of IPD in the UK 
according to age and PCV7 serotype vs. non-PCV7 serotype and subsequently PCV13 serotype vs. non-
PCV13 serotype. From current graphs it appears that there has been a sustained decrease (almost 
elimination) of IPD due to PCV7, ongoing decreases in IPD due to extra PCV13 serotypes in vaccinated age 
groups (as reported by Miller et al) and a downwards trend in PCV13 serotypes in older age groups 
indicating successful herd protection. It is too early to say whether the phenomenon of replacement is 
occurring to the same extent as occurred with PCV7 [224]. Further effectiveness data is eagerly awaited.  
 
1.2.3 Pneumococcal immunity 
Pneumococcal virulence mechanisms are many and varied. The two most important virulence factors for 
invasive disease are thought to be the polysaccharide capsule and pneumolysin. Capsular polysaccharide 
prevents mucosal clearance, is antiphagocytic, sterically inhibits complement and immunoglobulin binding to 
host receptors, restricts autolysis and reduces antibiotic exposure. Pneumolysin is an exotoxin that is 
cytolytic, inhibits epithelial cell ciliary action, impairs respiratory burst, activates complement and stimulates 
cytokine and chemokine production. Other virulence factors include surface adhesins, anticomplement 
factors, metal binding transporters, bacterocidin and biofilm formation [219, 225, 226].  
 
Most elements of the immune system, to a lesser or greater extent, may contribute to protection against 
Streptococcus pneumoniae. Antibacterial peptides such as β-defensins, lactoferrin and cathelicidin have all 
been shown to have anti-pneumococcal properties [227, 228]. The innate immune system relies on an array 
of receptors that recognise certain relatively conserved bacterial molecules. These receptors are called 
pattern recognition receptors (PRRs) and the structures they recognise are called pathogen-associated 
molecular patterns (PAMPs) [229]. PRRs can be extracellular, membrane-bound or cytoplasmic. Currently 
recognised PRRs include TLRs, C-type lectin receptors, scavenger receptors, complement receptors, NOD-
like receptors (NLR), complement, pentraxins (e.g. C-reactive protein (CRP)) and collectins (e.g. mannose 
binding lectin (MBL)) [230-232]. A number of human PRRs recognise pneumococcal PAMPs. TLR 2,4 and 9 
recognise pneumococcal lipoteichoic acid (LTA), pneumolysin and DNA respectively [219]. The increased 
susceptibility to IPD observed in individuals with deficiency in TLR signalling pathway might reflect the 
importance of TLRs in protection against pneumococcus in humans [233, 234]. Other PRRs specifically 
implicated in protection against pneumococcus include complement, soluble CD14, CRP, surfactant protein-
D (SP-D (a collectin)), NOD2 (an NLR) and macrophage receptor with collagenous structure (MARCO - a 
macrophage scavenger receptor) [219, 235].  
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It is generally accepted that host defence against pneumococcus is primarily mediated by opsonisation and 
phagocytosis [236, 237]. Animal models of pneumococcal infection have demonstrated that alveolar 
macrophages are the initial cell responsible for phagocytosis of pneumococci infecting the lung. Neutrophils 
are then recruited and quickly take over as the main phagocytic cell, the role of macrophages then changing 
to clearance of apoptotic neutrophils [238, 239]. Human neutrophils readily kill pneumococci in vitro [240]. 
Indeed the ability of human neutrophils to kill pneumococci is the basis of the pneumococcal 
opsonophagocytic assay (OPA). This assay uses an immortalised human neutrophil cell line to assess the 
functional ability of human antibody to cause opsonophagocytosis and killing of pneumococci (see Section 
1.3.3) [241]. Defects in the complement pathway predispose to IPD in humans, further evidence of the 
importance of opsonisation [236]. With respect to macrophages, it has been shown in adults that alveolar 
macrophages produce inflammatory cytokines including IL8, a neutrophil attractant chemokine in response 
to pneumococci [242]. It is clear that there is an essential close collaboration between phagocytic cells, 
complement pathways and antibody in the human response to pneumococcal infection that contributes to 
protection as well as pathogenesis of disease [219, 235-237]. Furthermore, studies in mice suggest that NKT 
cells and γδ T cells may promote neutrophil-mediated protection against pneumococcal infection through 
interferon gamma and TNFα production respectively [243, 244]. 
 
Capsular polysaccharide is predominately a TI antigen, in that production of antibody by B cells against 
capsular polysaccharide does not require T cell help [245]. Recently, however, it has become apparent that 
CD4+ T cells do, nevertheless, play a role in pneumococcal immunity, particularly in relation to carriage 
[226]. It is generally agreed that nasopharyngeal colonisation is a necessary precursor to IPD [213, 246, 
247]. Studies in mice have shown that CD4+ T cells infiltrate lung tissue infected with pneumococci and that 
pneumolysin stimulates CD4+ T cell chemotaxis [235, 248]. It appears that CD4+ T cells provide protection 
against colonisation in both an antibody dependent and independent mechanism. Antibody deficient mice 
were protected from subsequent pneumococcal colonisation following intranasal challenge with live 
pneumococci, whereas CD4+ T cell deficient mice were not [249]. In studies in humans, antibody responses 
to pneumococcal protein antigens have been shown to be T-cell dependent, primarily through IL10 and IFNγ 
production [250]. Malley et al have subsequently hypothesised that pneumococcal protein specific Th17 cells 
may be the CD4+ T cells responsible for protection against pneumococcal colonisation through IL17 
mediated neutrophil recruitment [251].  
 
CD8+ T cells recognise antigen in the context of MHC class I and therefore are primarily involved in 
response to pathogens accessing the cytosolic compartment such as viruses and intracellular bacteria [38]. 
There is limited data on their importance in protection against pneumococus [252] and they are not currently 
considered to play a major role in response to pneumococcal vaccines. For these reasons, while 
acknowledging that they play a key role in the immune response to HIV infection, they are not a main focus 
of this work. 
 
Antibody in serum (IgM and IgG) and secreted at mucosal sites (IgA) are considered to be a major factor in 
defence against pneumococcal colonisation and infection. In support of this, patients with defective antibody 
production/ or hypogammaglobulinaemia (e.g. common variable immunodeficiency (CVID)) are vulnerable to 
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pneumococcal infection [253] and serum therapy, popular in the early 20th century, is effective against 
pneumococcal infection [254]. Anticapsular polysaccharide antibodies are thought to be of particular 
significance. Indeed, levels of serum anticapsular IgG are used as a read out of polysaccharide containing 
pneumococcal vaccine efficacy [255] (see Section 1.3.3). 
 
A proportion of serum IgM that can bind capsule polysaccharides is present without prior antigen exposure, 
even at birth. These polyreactive antibodies have broad antibacterial activity and are termed natural antibody 
[256, 257]. The source of natural antibody has been shown to be B1a and marginal zone cells in mice. The 
cell subset responsible for natural antibody production in humans is not clear, however IgM memory B cells 
are thought to contribute [125]. It has been proposed that natural antibodies are an important first line 
defence against bacterial infection, bridging the gap between innate and acquired immunity [257, 258].  
 
Anticapsular antibody is also produced following exposure to capsular polysaccharide antigen, either through 
natural exposure (colonisation [259] or infection [260]), or through vaccination (polysaccharide or conjugate 
[261]). Antibody is initially produced by short-lived plasma cells that develop from naive mature B cells 
following primary antigen exposure. Depending on the nature of the antigen, primary exposure can lead to 
GC formation and differentiation into memory B cells or long-lived plasma cells that subsequently home to 
the bone marrow and secrete antibody [123, 126, 129, 130]. (See Section 1.1.4) Memory B cells provide a 
more rapid and robust response following secondary antigen exposure [123]. The relative contribution of 
each of the B cell subsets in protection against pneumococcus is not completely clear and most likely 
changes with age and antigen exposure. 
 
Children under 2 years of age have higher rates of pneumococcal colonisation [262] and are especially 
vulnerable to IPD [221]. Children have a relative insufficiency of IgG2 antibody, which is the main subclass of 
IgG induced by natural exposure and polysaccharide vaccination in adults [263, 264]. This supports the 
possibility that inadequate antibody responses to pneumococcal capsular polysaccharide may well be 
contributory to increased vulnerability in this age group. Relatively deficient antipneumococcal immune 
responses can be related to the general immaturity of the immune system during infancy [153]. More 
specifically, children under 2 develop poor responses to TI polysaccharide antigens when compared with TD 
protein antigens [265]. One proposed reason for this is functional immaturity of the spleen, in particular a 
region called the marginal zone, in which there is an accumulation of IgM memory B cells (see Section 1.1.4 
for discussion on origin of this B cell subset) It has been proposed that early life immaturity of the splenic 
marginal zone (including decreased expression of the complement receptor CD21 on IgM memory B cells) 
corresponds to an equivalent immaturity of the IgM memory B cell compartment and therefore impairment of 
antipolysaccharide antibody responses [148, 266]. The observation that asplenic patients are more 
susceptible to IPD adds weight to this theory [267]. Circulating IgM memory B cells are however present at 
birth, be it in smaller numbers, and in some asplenic patients [148] so it seems unlikely that the relationship 
is as straightforward as this and that the increased risk of pneumococcal colonisation and IPD in early 
childhood is more likely to be multifactorial [153].  
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It has been demonstrated that the age specific incidence of IPD decreases prior to the natural acquisition of 
putative protective levels of anticapsular polysaccharide antibody. This suggests that other factors such as 
antipneumococcal protein antibodies or T-cell immunity are important in protection against IPD and take time 
to develop in early life, most likely as a result of antigen exposure during carriage in infancy [249]. Antibodies 
against pneumococcal proteins common to all serotypes have been shown to be protective against 
pneumococcal carriage. Novel vaccination strategies employing pneumococcal proteins are currently under 
investigation [251, 268].  
 
1.2.4 Streptococcus pneumoniae infection in the context of paediatric HIV infection 
Children and adults with untreated HIV infection are at increased risk of pneumococcal infection. The 
incidence of pneumococcal bacteraemia or invasive disease is up to 40-fold higher in HIV infected children 
compared to uninfected children. Reports of mortality rates from IPD are variable but it seems that they are 
generally the same as uninfected children. The introduction of HAART has been associated with a 
decreased incidence of IPD in HIV infected children and adults, however rates are still higher than in the 
uninfected population [269-272]. There is only limited published data on the effect of HAART on 
pneumococcal colonisation in HIV infected children. Very high rates of carriage were found in HIV infected 
East African children and were not significantly different between HAART treated and untreated children 
[273]. Lower rates of carriage were reported in the South American setting, but again no significant effect of 
HAART on carriage status was shown [274]. 
 
The potential reasons for the increased risk of pneumococcal disease despite restoration of peripheral blood 
CD4 cell numbers in HIV infected children are many. As discussed above, almost all aspects of a child’s 
immunity are affected by HIV infection, and many of these are involved in defence against pneumococcal 
infection. For example, HAART may not completely restore phagocytic cell function [275] and may actually 
contribute to phagocyte dysfunction and depletion [71]. Adult and child NK cell numbers and phenotype and 
observed changes in adult γδ mucosal and circulating cell populations are not completely restored by HAART 
[173, 276, 277]. NKT and dendritic cell numbers are lower in children on HAART than healthy controls [173] 
and abnormalities in complement and MBL pathways in adults have been shown to persist on treatment 
[278]. The persistent B cell abnormalities on HAART have been discussed in Section 1.1.4.  
 
HAART’s ability to restore individual CD4+ T cell subsets in children has not been explored in detail. In 
particular, with respect to pneumococcal immunity, the potential for HAART to restore Th17 and TFH cell 
number and function has not been fully addressed.  When considering the reasons for impaired 
pneumococcal immunity (both naturally acquired and through immunisation) and the persistent B cell 
abnormalities observed in children on HAART, it is important to explore the contribution that a possible 
disruption in TFH cell number and TFH-B cell helper function might be making. 
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1.3 Pneumococcal conjugate vaccines 
 
1.3.1 History 
The first attempts at vaccination against pneumococcal disease with a whole cell vaccine took place in South 
Africa 100 years ago by a team based in the Inoculation Department of St Mary’s Hospital London [279, 
280]. This team was lead by Sir Almroth Wright, and included Leonard Colebrook, William Parry Morgan and 
Robert Dodgson, all of whom were alumni of St Mary’s Hospital Medical School [281-283]. Following this a 
number of studies were undertaken using pneumococcal polysaccharide vaccine, however it was not until 
1945 that well designed randomised trials definitively demonstrated efficacy of polysaccharide vaccine 
against invasive disease [279]. Initially a hexavalent vaccine was marketed. This was replaced in 1977 by a 
14-valent vaccine, with demonstrated efficacy of 76%-92% in South African adult miners. In 1983 the 23-
valent polysaccharide vaccine (PPV) was introduced in the USA and was introduced into the UK schedule 
for adults over 65 years old in 2003 [155, 284]. The true efficacy of the 23-valent polysaccharide vaccine in 
adults is not completely clear, and somewhat controversial however it probably has an efficacy of 
approximately 50-70% in preventing pneumococcal bacteraemia, but limited/no efficacy against non-
bacteraemic pneumococcal pneumonia [285] [284, 286, 287]. PPV is a TI antigen and therefore does not 
generally lead to the establishment of immune memory and is ineffective in children under 2 years of age 
[288], an age group most at risk of invasive disease [221].  
 
The inadequacies of polysaccharide vaccines has lead to the introduction and development of vaccines 
consisting of bacterial polysaccharide conjugated to a carrier protein, so called conjugate vaccines. The first 
conjugate vaccines were developed in the 1929, when Avery et al showed that conjugation of pneumococcal 
polysaccharide to a protein carrier enhanced immunogenicity [289]. Haemophilus influenzae type b (Hib) 
conjugate vaccines have been available since the 1980’s and have been recommended in the UK routine 
vaccination schedule since 1992. They have proven to be highly effective in reducing the disease burden of 
this previously common pathogen. The next conjugate vaccine to be introduced into the UK schedule was 
the Neisseria meningitidis serogroup C (MenC) conjugate vaccine in 1999. This vaccine has led to a similarly 
profound reduction in the incidence of invasive serogroup C meningococcal disease. The most recent 
addition to the conjugate vaccine armoury is the pneumococcal conjugate vaccine, first recommended in the 
UK for use in certain at risk populations in 2002 and subsequently for universal use in 2006 [284]. Until April 
2010, the pneumococcal conjugate vaccine in use in the UK was PCV7 (Wyeth). The 7 serotypes covered by 
PCV7 caused approx 70% of invasive pneumococcal disease in children under 5 in the UK prior to its 
universal recommendation in 2006 [290]. Due to limitations in the demonstrated effectiveness of the vaccine 
as a result of serotype replacement [222, 291], a 13- valent conjugate vaccine (PCV13 – Wyeth) has now 
been licensed and is recommended in the UK national schedule [284].   
 
1.3.2 Mechanism of action 
The pneumococcal conjugate vaccine consists of pneumococcal polysaccharide conjugated to a protein 
carrier called CRM197, a modified diphtheria toxin [155, 288]. The mechanism of action and reasons for the 
immunological advantages of the pneumococcal conjugate vaccine over polysaccharide vaccines are 
incompletely understood, but it is thought that the presence of a protein attached to the polysaccharide 
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converts the TI antigen into a TD one. Most polysaccharide antigens cannot be processed and presented by 
MHC class II on the APC surface [292]. It has been proposed that B cells with a BCR specific for the 
polysaccharide internalise the vaccine and process the CRM197 for presentation in the context of MHC class 
II. T cells possessing a TCR specific for CRM197 epitopes then provide T cell help for the polysaccharide 
specific B cell through cytokine production and costimulation, allowing GC formation and establishment of B 
cell memory [155, 288]. This hypothesis is supported by studies in humans that demonstrate CRM197 
specific CD4+ T cell responses in conjunction with polysaccharide specific B cell responses and antibody 
production following immunisation with conjugate vaccines [293, 294]. Recent evidence, however from 
murine studies suggests that this model might not be the whole story, and that parts of the polysaccharide 
bound to CRM197 may be presented as glycopeptides in the context of MHC class II [295, 296]. The 
importance of this in the mechanism of action of conjugate vaccines in humans is yet to be established. It is 
interesting to note that the long held belief that TI antigens cannot lead to the establishment of immune 
memory or long lived plasma cells has also recently been called into question in murine models of 
pneumococcal immunity with some evidence also in humans [297, 298].   
 
1.3.3 Immunological correlates for efficacy of PCV 
Efficacy is a measure of how well a vaccine works. Strictly speaking true vaccine efficacy (VE) is calculated 
from the results of randomized, placebo-controlled clinical trials and is defined as the percentage reduction in 
the incidence of a disease in the vaccinated (Ivac) compared to the incidence of the disease in the 
unvaccinated (Iunv): 
 
 
 
or alternatively represented as: 
 
 
 
 
 
where RR = Relative risk of disease. 
 
Vaccine effectiveness, often confused with vaccine efficacy is also a measure of how well a vaccine works. 
However, it is a measure of how well a vaccine works when used in the target population. It takes into 
account both direct and indirect effects of vaccination and is calculated using results of observational 
epidemiological studies e.g. case-control studies [299].  
 
Four phases of clinical study are required for vaccine development and licensing. Phase I studies involve 
small numbers of adult subjects and give preliminary data on safety and immunogenicity. Phase II studies 
involve larger numbers and are used to investigate optimal dosing and formulation and to give further 
information on immunogenicity and safety. Phase III studies include larger numbers and usually include key 
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efficacy trials. The results of these efficacy trials will determine licensing decisions by regulatory bodies such 
as the European Medicines Agency (EMA) or the Food and Drug Administration (FDA). Post licensing, 
phase IV studies are large-scale epidemiological studies designed to assess effectiveness and safety [300-
302]. 
 
In order for a vaccine to be licensed for clinical use clinical efficacy should ideally have been demonstrated 
[255]. This is not, however, essential and vaccines may be licensed on the basis of immunogenicity data 
alone [300].  Immunogenicity in this instance is used as a surrogate for vaccine efficacy. This is usually only 
possible if a proven correlation between an immunological endpoint and clinical efficacy has previously been 
demonstrated or following seroepidemiological studies. Immunological endpoints that have been used for 
this purpose for licensure of vaccines against Hib, MenC and Streptococcus pneumoniae and include both 
quantitative and functional serological responses [255, 303-305]. 
 
One way to assess immunity following conjugate vaccination is to measure serotype specific IgG using 
enzyme linked immunosorbant assay (ELISA) [255]. It is not necessarily the case that all measured serotype 
specific antibody is functional. The antibody may not bind antigen or the strength of binding may not be 
optimal. Avidity assays measure the strength of antigen/antibody binding. Patient serum is added to antigen-
coated plates. The measured amount of antibody bound after incubating with serial dilutions of ammonium 
thiocyanate is then used to calculate an avidity index [255, 306]. 
 
In addition to the strength of antibody binding, the ability of antibody to elicit killing of bacteria is of 
fundamental importance. The way in which this can be assessed is by an OPA in the case of pneumococcal 
immunity or the serum bactericidal activity (SBA) in the case of Haemophilus and Meningococcus. OPA 
involves incubating serial dilutions of patient plasma, together with complement and the pneumococcal 
serotype of interest. The maximum dilution of serum that leads to 50% phagocytosis or killing is then used to 
calculate the opsonophagocytic index [241, 255]. Immunological memory can be demonstrated by enhanced 
quantitative antibody responses or antibody avidity following booster dose of the vaccine when compared to 
age matched non-primed subjects [307]. 
 
Following a WHO consultation in 2003 a series of recommendations were made which are used to set the 
immunological criteria for demonstrating non-inferiority of new conjugate vaccines against existing vaccines 
for protection against invasive pneumococcal disease. The protective antibody concentration was calculated 
from pooled efficacy and immunogenicity trials based on the assumption that if a vaccine has for example 
80% efficacy, then 80% of vaccinated individuals should have serum antibody concentrations above the level 
of protection. A cumulative distribution curve of serum antibody concentrations one month after a three-dose 
course of vaccination, pooled from three PCV7 efficacy studies therefore allowed estimation of the protective 
threshold of 0.35 µg/ml [308].  
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This cut off is accepted bearing in mind some assumptions: 
 
- antibody concentration at the 1 month time point after vaccination predicts protection 
- that protection against disease is a step-wise function  (when in reality it is continuous) 
- that protective levels are similar across serotype 
 
It should also be noted that this cut off does not in reality relate to individual protection or risk of disease, it is 
purely used as a cut off for showing non-inferiority when comparing pneumococcal conjugate vaccines 
efficacy against invasive pneumococcal disease [255]. This serological cut off is the primary end point for 
current efficacy trials. Secondary end points that are also required include demonstration of 
opsonophagocytic activity and also immunological memory following boosting [255, 307].  
 
The WHO recommendations have been very useful in expediting the licensure of novel higher valency 
pneumococcal conjugate vaccines, however there is ongoing debate about whether the 0.35mcg/ml cut off is 
an adequate indicator of efficacy, especially in HIV infected children. It is generally accepted that an OPA 
titre would be a more useful and accurate measure of immunity, however due to problems with 
standardisation of this assay, primary endpoints using OPA are yet to be established [309].  
 
1.3.4 Immunogenicity, efficacy and effectiveness of PCV  
The immunogenicity, efficacy and effectiveness of PCV7 and other PCVs with differing carrier proteins and 
valencies against IPD, acute otitis media and pneumonia has been demonstrated in a number of different 
settings in varying schedules [310-315]. Efficacy for vaccine serotype IPD ranges from 77%-97%, 35-89% 
for all serotype IPD, 21-37% for all cause pneumonia and 6-7% for all cause AOM [316]. A Cochrane review 
has summarised the findings from PCV efficacy trials in HIV negative children less than 2 years of age to 
date. The pooled vaccine efficacy estimate for vaccine serotype IPD was 80% (95% confidence interval (CI) 
58%-90%, p<0.0001); all serotypes-IPD, 58% (95% CI 29%-75%, p=0.001); WHO X-ray defined pneumonia 
was 27% (95% CI 15%-36%, p<0.0001); clinical pneumonia was 6% (95% CI 2%-9%, p=0.0006); and all-
cause mortality, 11% (95% CI -1% - 21%, p=0.08) [317]. 
 
The EMA extensively reviewed the information available on PCV13, as part of the licensing procedures in 
Europe.  Fourteen clinical trials in Europe, India and the USA, including one study from the UK, supplied 
data on safety and immunogenicity. The report summary concluded that the vaccine is immunogenic, as 
assessed by IgG ELISA and OPA for all 13 serotypes, and leads to the establishment of immune memory, 
as demonstrated by an anamnestic response following a booster dose. PCV13 is slightly less immunogenic 
than PCV7 overall, and OPA values were relatively low for 3 of the 6 new additional serotypes, however the 
clinical relevance of these findings and potential impact on efficacy are unknown. The safety profile is 
comparable to that of PCV7, with no new risks identified. Marketing authorisation was granted and the 
PCV13 has now superseded PCV7 in the UK schedule for all indications [284, 318].  
 
Several groups have assessed in vitro responses of PBMC when stimulated with the vaccine antigen 
CRM197 by measuring cytokine responses either by ELISPOT assay or by measuring cytokine 
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concentrations in culture supernatants.  Kamboj et al measured CRM197 specific IL2, 4, 5, 10 and IFNγ 
production by PBMC using ELISPOT pre and post immunisation with Hib/CRM197 conjugate vaccine, and 
found CRM197 induced a mixed Th1/Th2 response, numbers of IL2 and IL5 secreting cells correlating with 
levels of anti-Hib polysaccharide IgA (Kamboj 2001). The same group also measured CRM197 specific 
production of the same cytokines (plus IL6) by PBMC, using ELISPOT and ELISA following vaccination with 
PCV. A mixed Th1/Th2 responses was again observed but no correlation with polysaccharide specific 
antibody responses (Kamboj 2003). Vernacchio et al measured IL4, 5, 10, 13 and IFNγ in PBMC culture 
supernatants following immunisation with PCV and various doses of adjuvant, and found mixed Th1/Th2 
responses with differing dose dependent effects of adjuvant concentration on cytokine responses 
(Vernacchio 2002). A neonatal/infant study by Van den Biggelaar et al measured the concentrations of IL5, 
6, 10, 13, IFNγ and TNFα in PBMC culture supernatants when stimulated with CRM197, after 2 different 
schedules of PCV administration (neonatal vs. infant). Again, a mixed Th1/Th2 response was demonstrated, 
however the responses were skewed towards Th2 in the neonatal cohort [319]. 
 
In addition to classically Th1/Th2 related cytokines, IL21 is particularly of interest in the context of our study. 
IL21 is one of the characteristic cytokines produced by TFH cells in the germinal centre and is a key cytokine 
responsible for allowing class-switch recombination and somatic hypermutation [320]. IL21 has been found 
to be at lower concentrations in serum samples from adult HIV infected patients compared to HIV uninfected 
controls. These low levels correlate with low CD4 count and are partially restored with HAART. HIV infection 
of CD4 cells in vitro leads to a decrease in IL21 production capabilities [321, 322]. Pallikuth et al 
demonstrated successful antibody responses to an influenza vaccine to be associated with an increase in 
serum IL21 1 month post immunisation in both healthy controls and a subset of HIV infected patients [323].  
 
1.3.5 Immunogenicity, efficacy and effectiveness of PCV in the context of HIV  
The immunogenicity and efficacy of PCV, in the context of both adult and paediatric HIV, has been 
extensively reviewed by Bliss et al in 2007 and subsequently updated by Nunes et al in 2012. Safety data 
from all available studies in HIV infected children suggest that PCV is well tolerated with an acceptable rate 
of adverse reactions. One five-year follow up study in Africa found lower CD4 percentage in children 
receiving PCV compared to placebo although the significance of this has not been established. No studies in 
children have reported effects on viral load although 2 studies in adults reported no changes in viral load with 
administration of PCV. In terms of immunogenicity, it should be noted that an equivalent immunological 
correlate of vaccine efficacy to that used by the WHO (described in Section 1.3.3) has not been established 
for HIV infected children [270, 271].  
 
Eleven immunogenicity studies in children were reviewed from the USA, Europe and South Africa [270, 271]. 
For reasons that are not clear, one study from South America was not included in the most recent review 
despite fulfilling the search criteria [324] and a further study from Thailand has been published subsequent to 
review publication [325]. There is a great deal of variation in study setting, age group, vaccine valency, 
schedule used, immunological end-points, proportion of children on HAART, inclusion of uninfected control 
group and use of avidity/OPA. In summary, however, evidence to date indicates that PCV is immunogenic in 
children with HIV, but less so than in uninfected children. For children not on HAART, quantitative (IgG 
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ELISA) and qualitative (OPA) primary antibody responses are less robust and shorter lasting than in healthy 
children, and anamnestic responses are also reduced. For children on HAART it appears that quantitative 
responses are improved and may be equivalent to those in uninfected children, but the quality of antibody 
response as assessed by OPA is still not as strong and poorly correlates with IgG ELISA [270, 324, 326]. 
The reasons behind the deficient antibody responses to PCV in children both on and off HAART have not 
been investigated in detail in paediatric HIV infected children. 
 
Only the South African studies including children mainly not on HAART have formally assessed clinical 
efficacy [312, 327]. Vaccination with a nine-valent PCV provided protection against vaccine-serotype 
invasive disease (65% [95% CI 24–86%; p=0·006]), however this was lower than in uninfected children (83% 
[39–97%; p=0·003]). A significant reduction in pneumonia was only demonstrated in uninfected children (2–
35%; p=0·03). 5-year follow-up demonstrated a substantial reduction in efficacy against vaccine-type IPD in 
HIV infected children when compared with uninfected controls (38·8% [–7·8% to 65·2%]) vs. (77·8% [34·4–
92·5%]) [270, 312, 327]. 
 
Steenhoff et al showed no further reduction in incidence of IPD in a cohort of HIV infected children following 
the introduction of PCV7 into the national schedule in the USA, although conclusions are limited due to 
relatively small sample size and rates of IPD [328].  In contrast, the potential indirect effect of universal PCV7 
vaccination in protecting families infected/affected by HIV was demonstrated in a study by Flannery et al, 
which demonstrated a reduction in overall IPD, but especially vaccine serotype, in HIV infected adults since 
the introduction of PCV7 into the US national schedule [329]. A recent randomised double-blind placebo 
controlled trial in mainly HIV infected adolescents (>15 years) and adults, the majority of whom were not on 
HAART, investigated the efficacy of PCV7 in preventing IPD in patients that had previously had documented 
IPD. The study gave an estimated vaccine efficacy in this context of 74% (95% CI, 30-90%) [330]. 
 
To our knowledge, there are at present no published reports of PCV13 immunogenicity, efficacy or 
effectiveness in HIV infected individuals. 
 
1.3.6 Using PCV as a tool to probe T/B cell interaction and function in paediatric HIV infection 
As described above, pneumococcal conjugate vaccine is thought to act as a TD antigen, enlisting T cell help 
in the establishment of B cell antibody responses. This project aimed to investigate the reasons for immune 
dysfunction of HIV infected children both on and off HAART by using administration of PCV to probe T and B 
cell responses to vaccine antigens. Antibody responses to vaccine capsular polysaccharides as well as 
carrier protein specific T cell responses were measured, alongside detailed peripheral blood B and T cell 
immunophenotyping in order to better understand the reasons for B cell immune dysfunction in this 
vulnerable group and to further delineate possible mechanisms of action of pneumococcal conjugate vaccine 
outside of the infant period. 
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Chapter 2: Hypothesis and aims 
 
2.1 Hypothesis 
 
 
Irreversible loss of circulating TFH-like cells is associated with impaired B cell memory responses in HIV 
infected children. 
 
2.2 Aims 
 
 
1. To characterise peripheral blood B and T cell phenotype in HIV infected children compared to 
healthy child and young adult controls. 
2. To assess associations between clinical parameters such as treatment history and detectable viral 
load and B and T cell phenotype. 
3. To assess stability of B and T cell subsets over time. 
4. To assess serum serotype specific pneumococcal IgG concentrations by ELISA pre, 1 month post 
and 6 months post immunisation with PCV13 in children with paHIV compared to healthy controls. 
5. To assess in vitro cytokine responses following whole blood culture with the vaccine carrier protein 
CRM197 and to test for correlations between balance of cytokine production and vaccine 
immunogenicity. 
6. To assess serum IL21 levels pre and post immunisation, and to assess correlation with serotype 
specific vaccine immunogenicity. 
7. To assess NP carriage pre and post immunisation, effects of immunisation on carriage and effects of 
carriage on immunogenicity. 
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Figure 7. Diagram summarising the main study hypothesis. a) Ongoing HIV viraemia results in reduced circulating CD4+ T cell numbers, 
including circulating TFH-like (identified as CD4+, CD45RO+, CXCR5+). This is associated with decreased memory B cell numbers 
(identified as CD19+CD27+). b) suppression of HIV viraemia results in increased circulating CD4+ T cells, however we hypothesise that 
the circulating TFH-like and memory B cell populations are incompletely restored and that this is associated with impaired antibody 
response to vaccine antigens. (HAART= Highly Active Antiretroviral Therapy, MB = memory B cell) 
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Chapter 3: Materials and methods 
 
3.1 Recruitment and consent 
 
3.1.1 Study setting 
The study took place in the setting of the HIV Family Clinic at St. Mary’s Hospital. This clinic has been 
established for over 15 years and is one of the largest in the UK. It has followed over 300 children with HIV 
infection and currently actively cares for over 120 children and their families. All children are seen at 3-
monthly intervals or more often, as clinically indicated. Regular blood samples are taken for the monitoring of 
HIV disease, such as CD4 count and viral load measurements. 
 
3.1.2 Ethical considerations 
Ethical approval to perform the study was obtained from the Riverside Research Ethics Committee, Charing 
Cross Hospital, London (REC reference number: 09/H0706/23). Local Site Specific Approval was obtained 
from the Research and Development Office, St Mary’s Hospital, London (R&D reference number: 
08/GC/004). Documents  (including substantial amendment for PCV13) are included in Appendix 4 and 5. 
 
3.1.3 Funding 
Research was fully funded by a National Institute of Health Research (NIHR) Research Training Fellowship 
competitively awarded to Dr Alasdair Bamford. Additional funding for consumables was also competitively 
awarded to Dr Bamford by the European Society for Paediatric Infectious Diseases (ESPID). Vaccine and 
vaccine carrier protein were generously provided by Wyeth and Pfizer.  
 
3.1.4 Study design 
Intervention cohort: 
HIV infected child patients (CP) consenting to be vaccinated had blood samples taken at baseline for T and 
B cell immunophenotyping, serological studies, and cytokine release assay. They then received one dose of 
PCV13 (Pfizer, Batch number: E27415). The next blood sample was taken 1 month post immunisation for 
serology and cytokine release assay and at 6-9 months for T and B cell immunophenotyping, serological 
studies, and cytokine release assay. Blood sampling was timed to coincide with routine lymphocyte 
quantification and VL assessment via the National Health Service (NHS) laboratory. Those consenting to 
have nasopharyngeal (NP) carriage swabs taken had swabs taken at baseline and 6-9 months later. 
 
HIV infected controls: 
CP consenting to have just blood monitoring had blood taken at two time-points, baseline and 6-9 months 
later but did not receive PCV13.  As for the intervention cohort, blood sampling was timed to coincide with 
routine lymphocyte quantification and VL assessment via the NHS laboratory. Those consenting to have NP 
carriage swabs taken had swabs taken at baseline and 6-9 months post immunisation. 
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Child healthy controls (CHC): 
Healthy children matched for age and sex and consenting to be in the study had blood sampling at one time 
point only for T and B cell immunophenotyping, serological studies and cytokine release assay. They did not 
receive PCV13. Lymphocyte quantification was performed via NHS laboratory services (see Section 2.2.3). 
 
Adult healthy controls (AHC): 
Adults consenting to be in the study had blood and NP swabs taken and received PCV13 as for the 
intervention cohort. Lymphocyte quantification was performed via NHS laboratory services. See Fig. 8 for 
flow chart of study design. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.5 Study populations 
The HIV Family Clinic cohort includes 130 children. CHC were recruited from otherwise healthy children 
attending for pre-operative assessment or GP phlebotomy services at St Mary’s Hospital. AHC were 
recruited from staff and students of Imperial College Healthcare NHS Trust and Imperial College London. 
None of the study subjects had received PCV13 prior to study entry.  
 
3.1.6 Recruitment 
Recruitment took place between 07/08/09 and 10/05/11. Parents and children attending St Mary’s family 
clinic were approached for inclusion in the study. Otherwise healthy children and their parents attending for 
pre-operative assessment or GP phlebotomy sessions requiring routine blood tests were approached for 
recruitment as child healthy controls. Adult healthy controls were recruited through poster advertisement 
within Imperial College Healthcare NHS Trust and Imperial College London. 
 
 
 
 
 
CP AHC CHC 
Consent Consent Consent 
Carriage Unvaccinated Vaccinated 
Blood set 1 + 
swab 
Blood set 1 + 
swab Blood set 1  Swab 
Blood set 2 Blood set 2 
Blood set 1 + 
swab Swab Blood set 1  
Booster 
Blood set 2 
Vaccinate 
Vaccinate 
1 month 
0 months 
6 months 
7 months 
Figure 8. Flow chart for all study participants. Bl d set 1 = Serology, flow cytometry, cytokine release assay. Blood set 2 = 
Serology, cytokine release assay. (CP= child patient, AHC = dult h althy control, CHC=child healthy control) 
	   	   	   	  42 
3.1.7 Consent 
In line with ethical requirements, parents of all children included in the study provided informed consent for 
study entry. Those children deemed competent provided informed consent. The opportunity to provide 
informed assent was given to children deemed not competent to give consent. If there was disagreement 
between child and parent about inclusion in the study they were no longer eligible for study entry. If a child 
was competent to provide informed consent but unaware of their HIV diagnosis, they were ineligible for 
inclusion in the study. Informed consent was provided by adult healthy controls. All consent forms and 
information sheets were designed accordingly and in an age-appropriate from. 
 
3.1.8 Inclusion/exclusion criteria 
 
HIV INFECTED PCV13 RECIPIENTS: 
Inclusion criteria 
- Any patient attending St Mary's Hospital paediatric HIV clinic 
Exclusion criteria  
- Patients younger than 2 months or older than 18 years 
- Patients with other additional forms of immune suppression e.g. malignancy or medication 
- Patients with previous reaction to PCV13 or any of its components 
- Patients who are pregnant or planning to become pregnant 
- Patients competent to give consent but unaware of HIV diagnosis 
- Disagreement between child and parent about inclusion in the study 
 
HIV INFECTED (UNVACCINATED) CONTROLS: 
Inclusion criteria  
- All patients attending St Mary's Hospital paediatric HIV clinic 
Exclusion criteria  
- Patients younger than 2 months or older than 18 years 
- Patients with other additional forms of immune suppression e.g. malignancy or drugs 
- Patients who are pregnant or planning to become pregnant 
- Patients competent to give consent but unaware of HIV diagnosis 
- Disagreement between child and parent about inclusion in the study 
 
CHILD HEALTHY CONTROLS: 
Inclusion criteria 
- Healthy children in the care of St Mary's having blood taken for another clinical reason 
Exclusion criteria 
- Age younger than 2 months or older than 18 years 
- Known immunosuppression or immunodeficiency 
- Febrile illness 
- Pregnancy  
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ADULT HEALTHY CONTROLS: 
Inclusion criteria 
- Age between 18 and 30 years 
Exclusion criteria 
- Previous reaction to PCV13 or any of its components 
- Known immunodeficiency or immunosuppression 
- Febrile illness 
- Pregnancy or planned pregnancy 
 
3.1.9 Demographic and clinical information 
For CP, background demographic and clinical information, including vaccination and treatment history were 
obtained from parent interview, clinical notes, GP records, hospital pathology records and Parent-Held Child 
Health Record or “Red Book”. For CHC, background demographic and clinical information, including 
vaccination history were obtained from parent interview, hospital notes, GP records and Red Book. For AHC, 
background demographic and clinical information, including vaccination history were obtained from interview 
and/or GP records. All information was recorded in Case Report Forms (CRFs). Any changes in clinical 
status or adverse events were recorded in the CRF at all subsequent study participant contacts. 
 
3.1.10 Vaccine and vaccination 
At the time of study planning and during initial stages of the research PCV7 was recommended as part of the 
national schedule. PCV7 for the study was kindly supplied by Wyeth Pharmaceuticals. As of April 2010, 
PCV13 was recommended for all indications in the UK schedule. As a result, recruitment of subjects to be 
vaccinated was on hold while a major amendment to the ethical approval was applied for and approved, and 
a supply of PCV13 was kindly supplied by Pfizer. Prior to the change in national guidelines a total of 8 
healthy adult controls had been recruited and vaccinated with PCV7. 
 
1 dose (0.5ml) of Prevenar (PCV7) contains: 
Pneumococcal polysaccharide serotype 4   2 µg 
Pneumococcal polysaccharide serotype 6B   4 µg 
Pneumococcal polysaccharide serotype 9V   2 µg 
Pneumococcal polysaccharide serotype 14   2 µg 
Pneumococcal oligosaccharide serotype 18C   2 µg 
Pneumococcal polysaccharide serotype 19F   2 µg 
Pneumococcal polysaccharide serotype 23F   2 µg 
 
All polysaccharides are conjugated to the CRM197 carrier protein and adsorbed on aluminium phosphate 
(0.5 mg) [331]. 
 
1 dose (0.5ml) of Prevenar 13 (PCV13) contains: 
Pneumococcal polysaccharide serotype 1  2.2 µg 
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Pneumococcal polysaccharide serotype 3   2.2 µg 
Pneumococcal polysaccharide serotype 4   2.2 µg 
Pneumococcal polysaccharide serotype 5   2.2 µg 
Pneumococcal polysaccharide serotype 6A  2.2 µg 
Pneumococcal polysaccharide serotype 6B  4.4 µg 
Pneumococcal polysaccharide serotype 7F  2.2 µg 
Pneumococcal polysaccharide serotype 9V  2.2 µg 
Pneumococcal polysaccharide serotype 14  2.2 µg 
Pneumococcal polysaccharide serotype 18C   2.2 µg  
Pneumococcal polysaccharide serotype 19A  2.2 µg 
Pneumococcal polysaccharide serotype 19F  2.2 µg 
Pneumococcal polysaccharide serotype 23F  2.2 µg 
 
All polysaccharides are conjugated to CRM197 carrier protein and adsorbed on aluminium phosphate (0.125 
mg aluminium) [332] (Additional serotypes to PCV7 in italics). Both vaccines were administered as an 
intramuscular injection into the anterolateral aspect of the thigh for infants and into the deltoid muscle for 
older children and adults.  
 
3.1.11 Safety monitoring 
All study subjects receiving vaccine were provided with detailed contact information and were asked to 
contact the research team or clinical team should they suffer AE following vaccination. All AEs were 
recorded in the CRF. A history of adverse events was sought at each subsequent contact. Any serious 
adverse events were reported according to Good Clinical Practice (GCP) guidance to Imperial College 
London, vaccine manufacturer, funding body and research ethics committee, as well as via standard national 
Medicines and Healthcare Products Regulatory Agency (MHRA) “Yellow card” reporting system.  
 
2.2 Plasma viral load and lymphocyte quantification 
 
3.2.1 Blood sampling 
All blood samples for CP and CHC were taken at the same time as other routine blood tests by the attending 
clinician or trained phlebotomist. Blood samples from AHC were taken by trained medical or laboratory staff. 
A minimum of 5mls and a maximum of 10mls extra blood were taken for all investigations. At least 1ml of 
blood was collected in a preservative free lithium heparin containing Vacutainer (BD) for the cytokine release 
assay. At least 2ml of blood was collected in EDTA containing Vacutainer (BD) for flow cytometry. At least 
2ml of blood was collected in a SST II Advance Vacutainer (BD) for serological analysis.  
 
3.2.2 HIV viral load  
Plasma HIV RNA viral load (VL) were measured as part of routine care using a branched chain DNA assay 
(Siemens Systems) via St Mary’s Hospital NHS Virology Laboratory. The assay was carried out according to 
manufacturers instructions giving a detection range of 50-500000 copies/ml. 
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3.2.3 Lymphocyte quantification 
Quantification of lymphocyte subsets were undertaken in the Department of Immunology, St Mary’s Hospital 
and the Department of Immunology, Chelsea and Westminster Hospital using 4 colour flow cytometry. 
Briefly, whole blood (EDTA) was stained with monoclonal antibodies (CD45-FITC, CD4-RD1, CD8-ECD, 
CD3-PC5, CD56-RD1, CD19-ECD, CD16-PE (Beckman Coulter)) and evaluated using an FC500 flow 
cytometer (Beckman Coulter). 
 
3.3 Immunophenotyping of B and T cell subsets by flow cytometry 
 
3.3.1 Lymphocyte populations of interest 
We identified T and B cell subsets from whole blood using 6 colour flow cytometry and the following surface 
markers [120, 140, 145]: 
 
Memory T cells:    CD3+ CD4+ CD45RO+  
Follicular T helper-like cells (TFH-like): CD3+ CD4+ CD45RO+ CXCR5+  
ICOS+ TFH-like:    CD3+ CD4+ CD45RO+ CXCR5+ ICOS+ 
 
Transitional B cells:   CD19+ CD10+ CD27- 
Plasmablasts:    CD19+ CD10- IgD- CD27++ 
 
Naive B cells:    CD19+ CD10- IgD+ CD27- 
IgD+ memory B cells:   CD19+ CD10- IgD+ CD27+ 
IgD- memory B cells:   CD19+ CD10- IgD- CD27+ 
Double negative B cells:  CD19+ CD10- IgD-CD27- 
 
Naive mature B cells   CD19+ CD10- CD21+CD27- 
Resting memory B cells   CD19+ CD10- CD21+ CD27+ 
Activated mature B cells  CD19+ CD10- CD21- CD27+ 
Exhausted/Tissue like memory B cells: CD19+ CD10- CD27- CD21-  
  
3.3.2 Lymphocyte immunophenotyping method 
For each subject, 150µl of whole blood was added to 8 flow cytometry tubes (BD) (4 x B cell tubes and 4 x T 
cell tubes). Samples were washed twice in 2ml of phosphate buffered saline (PBS) (Oxoid) (5 mins x 400g). 
Cells in B cell tubes were then resuspended in 100µl of near-IR-fluorescent reactive dye (Invitrogen) diluted 
1:1600 in PBS. Cells in T cell tubes were resuspended in 100µl of red-fluorescent reactive dye (Invitrogen) 
diluted 1:1600 in PBS. All tubes were then incubated in the dark at room temperature for 30 minutes. All 
tubes were subsequently washed once in 1ml PBS (5 mins x 400g). Monoclonal antibodies were added to 
each tube as per Table 2. Tubes were incubated in the dark at room temperature for 30 minutes.  
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Lysis of erythrocytes and fixation of staining was performed using an automated TQ Prep System (Beckman 
Coulter). Cells were washed twice in 2ml PBS (5 mins x 400g) and resuspended in 300µl PBS. Acquisition 
was performed on an LSR II (BD Biosciences). A minimum of 10000 CD19 events and 30000 CD4 events 
were acquired for the B and T cell tubes respectively. Data was analysed using FlowJo software v.9.4 (Tree 
Star). 
 
Tube Antibody Volume 
T CD3 APC-Cy7^ 
CD4 PE-Cy7* 
CXCR5 Axf647^ 
ICOS PE^ 
CD45RO FITC^ 
CD14 ECD* 
CD19 ECD* 
5µl 
10µl 
5µl 
20µl 
10µl 
5µl 
5µl 
TmCXCR5 CD3 APC-Cy7^ 
CD4 PE-Cy7* 
ICOS PE^ 
CD45RO FITC^ 
CD14 ECD* 
CD19 ECD* 
5µl 
10µl 
20µl 
10µl 
5µl 
5µl 
TmCD45RO  CD3 APC-Cy7^ 
CD4 PE-Cy7* 
CXCR5 Axf647^ 
ICOS PE^ 
CD14 ECD* 
CD19 ECD* 
5µl 
10µl 
5µl 
20µl 
5µl 
5µl 
TmICOS CD3 APC-Cy7^ 
CD4 PE-Cy7^ 
CXCR5 Axf647^ 
CD45RO FITC^ 
CD14 ECD* 
CD19 ECD* 
5µl 
10µl 
5µl 
10µl 
5µl 
5µl 
B IgD FITC* 
CD21 PE^ 
CD27 APC^ 
CD19 PE-Cy7* 
CD10 PerCP° 
CD3 APC-Cy7^ 
2µl 
5µl 
5µl 
5µl 
10µl 
5µl 
BmCD27 IgD FITC* 
CD21 PE^ 
CD19 PE-Cy7* 
CD10 PerCP° 
CD3 APC-Cy7 
2µl 
5µl 
5µl 
10µl 
5µl 
BmCD21 IgD FITC* 
CD27 APC^ 
CD19 PE-Cy7* 
CD10 PerCP° 
CD3 APC-Cy7^ 
2µl 
5µl 
5µl 
10µl 
5µl 
BmCD10 IgD FITC* 
CD21 PE^ 
CD27 APC^ 
CD19 PE-Cy7* 
CD3 APC-Cy7^ 
2µl 
5µl 
5µl 
5µl 
5µl 
 
 
Table 2. List of monoclonal antibodies used for lymphocyte immunophenotyping *Beckman coulter, ^BD 
biosciences, °ExBio (APC=Allophycocyanin, APC-Cy7=Allophycocyanin-cyanine 7, Axf647=Alexafluor-647, 
PE=Phycoerythrin, FITC=Fluorescein isothiocyanate, ECD=Electron Coupled Dye, PE-Cy5=Phycoerythrin-
Cyanine 7, PerCP=Peridinin chlorophyll protein) 
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3.3.3 Optimisation of flow cytometry method 
Some of the populations of interest (especially ICOC+ TFH-like cells) are relatively rare in whole blood. For 
this reason it is important to ensure that there are adequate controls in the flow cytometry panels to ensure 
that the cells detected are a true population [333, 334]. There follows a discussion on the controls that have 
been incorporated into the flow cytometry methods in order to ensure data collected is of a high quality. 
 
Titration of monoclonal antibodies: 
Monoclonal antibody titration experiments were performed for each monoclonal antibody used. For each 
titration experiment, the monoclonal antibody of interest was added to 150µl of whole blood at a range of 
volumes, the top volume being that recommended by the manufacturer, subsequent volumes determined by 
serial halving of this volume. Optimum volume of monoclonal antibody to be used was determined as the 
volume leading to the largest value for the ratio of mean fluorescence intensity (MFI) of the positive 
population to MFI of the negative population [334]. 
 
Compensation controls: compensation beads vs. stained cells: 
In order to accurately compensate for fluorescence spillover it is relatively common practice to use single 
stained cells as compensation controls. This is only really accurate, however, if using the same monoclonal 
antibody/fluorochrome combination in the single stain compensation tube as in the complete panel. If the 
expression of the marker on the cell type of interest is not clearly positive or negative, this becomes 
inaccurate. In this instance, it is possible to use the same fluorochrome conjugated to an antibody specific for 
a surface antigen with a clear positive/negative population (e.g. CD8). However this adds an element of 
inaccuracy as the fluorochrome may behave differently when bound to another antibody or if the 
manufacturing process is not the same. This is especially true for tandem dyes. Compensation beads 
provide a solution to this problem as they are designed to bind any fluorochrome/antibody combination with a 
distinct positive and negative population. This allows use of the same monoclonal antibodies as in the panel, 
irrespective of the pattern of expression on cells [333, 334]. Compensation beads (BD) were therefore used 
as compensation controls for flow cytometry in this project. 
 
Gating controls: Fluorescence minus one (FMO) vs. isotype: 
Gating controls are necessary when there is no clear division of positive from negative expression of a cell 
surface marker. For isotype control gating, an antibody that is not specific for any human marker, labelled 
with the same fluorochrome as that used in the flow panel, is employed to detect any nonspecific binding and 
therefore a true boundary between positive and negative expression. Historically this has been the main 
method used for gating. However more recently the accuracy of this technique has been called into question. 
The monoclonal antibody/fluorochrome combination used in the isotype control may be similar to the 
antibody used in the panel, but it is not exactly the same and therefore patterns of non-specific binding will 
not be identical. In addition, unless the experiment consists of a separate tube for each antibody of interest, 
in which only the relevant antibody is replaced by the corresponding isotype control, the effect of 
fluorescence spillover from other antibodies in the panel will not be accounted for [333, 335]. 
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FMO controls are considered to be a solution to this problem and there use is generally encouraged. An 
FMO control consists of a tube which lacks the antibody of interest. This is used to gate a true negative 
population and accounts for fluorescence spillover from other fluorochromes in the panel. It could be argued 
that this does not detect non-specific binding, however it is thought that if an antibody has been titrated 
accurately there should be negligible background staining. Moreover, spillover induced background is a more 
prominent feature of multicolour flow cytometry [333, 335]. FMO controls are therefore used as gating 
controls in this project. 
 
Internal negative control: 
If there is a population within the cell type of interest that is negative for the marker of interest, this can serve 
as an internal negative control. By using this approach the internal negative cells have been exposed to all 
the same conditions as the cell of interest including the monoclonal antibody of interest. Any non-specific 
binding of the antibody will be present on internal negative and the fluorescence spillover effects will also be 
equivalent. An internal negative control is therefore included in the T cell flow cytometry panel. 
 
Internal positive control: 
When a marker is rarely expressed (e.g. CD10 on B cells), it is important to assess that the 
antibody/fluorochrome specific for that marker is still functioning. CD10 is also expressed on granulocytes 
[336]. For this reason CD10 staining of granulocytes (identified through forward scatter (FSC) vs. side scatter 
(SSC)) was confirmed for B cell tubes. 
 
Live/dead discrimination and dump channel: 
Non-specific binding of monoclonal antibodies to dead cells can lead to significant measurement errors. A 
viability dye, such as an amine reactive dye, can be utilised to identify and gate out dead cells. These dyes 
penetrate the dead cell’s damaged membrane and bind to amine groups in the cytoplasm. They also bind to 
amine groups on the cell surface but at a much lower intensity. Their use has been validated for cell surface 
immunophenotyping [337, 338] and they are therefore included in our staining methods. Irrelevant cell 
populations can be excluded from analysis using a dump channel, which contains antibodies specific for 
unwanted cells labelled with fluorochromes which all read in the same fluorescence channel [337-339]. For 
this reason the T cell panel in this project includes anti-CD19 and anti-CD14 labelled with a fluorochrome 
that reads in the same fluorescence channel as the amine reactive dye. The B cell panel includes anti-CD3 
labelled with a fluorochrome that reads in the same fluorescence channel as the amine reactive dye.  
 
Doublet discrimination: 
Cells can adhere to each other to form clumps or doublets, therefore producing inaccurate results. Doublets 
can be reliably gated out by plotting FSC area vs. FSC height, as the readout for these values from a single 
cell should be proportional [340]. A doublet discrimination stage is therefore included in the gating strategy in 
this project.  
 
3.3.4 Gating strategy 
Figures 9 and 10 provide an overview of the gating strategies used throughout this project. 
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Figure 9. Gating strategy for identification of B cell subsets. Following identification of live CD3- cells. CD19+ B 
lymphocytes were identified by sequentially gating FSC-A vs SSC-A, FSC-A vs FSC-H and CD19 vs SSC-A.CD10+CD27- 
(transitional B cells) and IgD-CD27++ (plasmablasts) were then quantified. 
 
The remaining cells were subdivided in 2 different ways: CD27 vs IgD and CD27 vs CD21 resulting in the identification of 8 
further subsets as described in Section 2.3.1. Controls were utilised as described in Section 2.3.3. 
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Figure 10. T cell gating strategy. Following identification of live CD19- CD14- cells. CD4+ T lymphoctyes were 
identified by sequentially gating FSC-A vs SSC-A, FSC-A vs FSC-H and CD3 vs CD4. 
 
Following identification of CD45RO+ CD4+ T cells, TFH like cells were identified and characterised by expression 
of CXCR5 and ICOS. Controls were utilised as described in Section 2.3.3. 
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3.4 Whole blood cytokine release assay 
 
In order to investigate T cell responses to the PCV13 carrier protein, CRM197, a novel whole blood cytokine 
release assay was developed. Whole blood was chosen over PBMC as the use of whole blood is more likely 
to represent the natural in vivo environment in which antigen is encountered [341] and is better suited to the 
often small amounts of blood obtainable from young children and infants.  
 
3.4.1 Time course experiments 
An initial time course experiment was performed in order to identify the optimum concentration of CRM197 
and time points for harvesting culture supernatants. Whole blood (Lithium heparin) from a healthy adult 
control was diluted 1:10 in RPMI (Sigma Aldrich). 180µl of dilute whole blood solution was added to 
individual wells in a 96 well tissue culture plate (Nunc) containing either 20µl RPMI (Sigma Aldrich) (negative 
control), 20µl of a 10µg/ml solution anti-CD3 monoclonal antibody (Mabtech) in RPMI (positive control - final 
concentration 1µg/ml), or 20µl of CRM197 in RPMI at a concentration of 20, 100, 200, and 300µg/ml (final 
concentrations 2,10,20 and 30µg/ml respectively). Samples were then incubated in a humidified incubator, at 
37°C in a 5% CO2 atmosphere. Culture supernatants were harvested daily from day 1 to 6 then stored at -
80°C for subsequent cytokine analysis, as described below. 
 
3.4.2 Cytokine measurement in whole blood culture supernatants using Mesoscale Discovery (MSD) 
platform 
The cytokine content of culture supernatants were measured with MSD ultrasensitive cytokine detection 
plates (MSD). A Th1/Th2 10-plex kit was used for the initial time course experiment / assay development. 
The cytokines measured by this kit include IL1β, IL2, IL4, IL5, IL8, IL10, IL12p70, IL13, IFNγ and TNFα. A 
custom made 5 plex kits measuring IL1β, IL5, IL10, IL13 and IFNγ was used for assessing supernatants from 
the main study. The assay works on the basic principle of an ELISA with plates precoated with spots of a 
range of cytokine specific capture antibodies. A detection antibody bound to a marker with 
electrochemiluminescent properties is then used to detect bound cytokine. An electric current is passed 
through the plate and light emitted is detected with a camera specific for the type of assay.  
 
The kits were processed as per manufacturers instructions. Briefly, culture supernatants were defrosted to 
room temperature. Samples were prepared for the calibration curve by taking the provided 10000pg/ml 
cytokine standard solution and performing serial 1:4 dilution. The 96 well MSD plate was then blocked by 
adding 25µl of blocking solution to each well and incubating for 30 minutes with vigorous shaking at room 
temperature. 25µl of each calibrator solution or culture supernatant was added to separate wells with one 
duplicate for each sample. Samples were then incubated for 2 hours with vigorous shaking at room 
temperature. The plate was then washed 3 times with PBS + 0.05% Tween-20 (Oxoid) 25µl of detection 
antibody solution was then added to each well, followed by 2 hour incubation with vigorous shaking. After 3 
further washes, 150µl of read buffer was then added to each well and the plate was read immediately on the 
SECTOR® imager (MSD). The lower limit of quantification (LLQ) for the assay was set at the lowest point on 
the standard curve with a coefficient of variation (CV) reliably less than 25% and a back calculated cytokine 
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concentration within 20% of the actual calibrator concentration. Readings below this were reported as half 
this value. 
 
3.4.3 Serum IL21 measurement using MSD platform 
Prototype MSD plates for IL21 detection were used to measure IL21 in serum samples. The plates were 
manufactured by MSD using commercially available IL21 ELISA reagents (eBioscience). Serum samples 
were defrosted to room temperature. Samples were prepared for the calibration curve by taking the 
10000pg/ml cytokine solution (eBioscience) and performing 1:4 serial dilutions in ELISA assay diluent (EAD) 
(eBioscience). The 96 well MSD plate was blocked by adding 200µl EAD to each well and incubating for 1 
hour at room temperature. The plate was then washed 3 times with PBS + 0.05% Tween-20. 100µl of 
calibrators or serum sample were added to separate wells with one duplicate per sample. Samples were 
incubated over night at 4°C then washed 3 times with PBS + 0.05% Tween-20. 25µl of biotin labelled IL21 
detection Ab (eBioscience) (2µl/ml) was added to each well then incubated for 1 hour with vigorous shaking 
at room temperature. Plates were then washed 3 times and 25µl streptavidin/SULFO-TAGTM (MSD) added to 
each well. Following a further 3 washes, 150µl of read buffer was then added to each well and the plate was 
read immediately on the SECTOR® imager (MSD). The LLQ for the assay was set as described in Section 
3.4.2. Readings below this were reported as half this value. 
 
3.5 Assessment of pneumococcal serology 
 
3.5.1 Sample preparation 
Blood collected in SST II Advance Vacutainer (BD) was centrifuged for 10 minutes at 1400g. Serum was 
aspirated and separated into 500µl aliquots for subsequent storage at -80°C.  
 
3.5.2 Anticapsular IgG ELISA 
Pneumococcal capsular polysaccharides specific IgG for all strains contained in the PCV13 was measured 
by ELISA after absorption with cell wall and 22F polysaccharide as previously described, and described in 
detail by the Goldblatt laboratory (see Appendix 6). Briefly, sera are mixed before analysis with an absorbent 
containing cell wall polysaccharide (CPS) (Statens Serum Institute) and 22F capsular polysaccharide 
(American Type Culture Collection (ATCC)) to neutralize antibody binding to CPS and other common 
contaminants present in the pneumococcal polysaccharide coating antigens. ELISA microtitre plates 
(Greiner) are coated with pneumococcal polysaccharide by adsorbing individual pneumococcal 
polysaccharide serotype antigens (ATCC) to ELISA plates. Dilutions of absorbed sera are then added to the 
ELISA plates. The serotype specific antibody bound to the ELISA plate is detected with goat anti-human IgG 
antibody (all 4 IgG subclasses) conjugated with alkaline phosphatase (Biosource), followed by addition of the 
substrate, p-nitrophenyl phosphate (Sigma). The optical density of each well is measured at 405 nm and 620 
nm using a Multiskan EX microtitre plate reader (Thermo Life Sciences). By comparing the optical density of 
the sample wells to that of the standard, human anti-pneumococcal reference serum 007sp (FDA), the level 
of antibody in the human serum can be calculated. 
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3.6 Pneumococcal nasopharyngeal carriage detection 
 
Nasopharyngeal swabs were collected and processed according to the WHO working group standard 
method for detecting upper respiratory carriage of Streptococcus pneumoniae [342]. 
 
3.6.1 NP swab technique 
Samples were obtained with a deep nasopharyngeal swab using a paediatric size rayon tipped swab 
(Medical Wire and Equipment). The study subject’s head was tipped back slightly and the swab passed 
directly backwards, parallel to the floor of the nasopharynx. The swab was left for five seconds and rotated 
through 180 degrees before removing. Once collected the swab tip was cut off using sterile scissors into a 
2ml microtube (Sarstedt) containing skim-milk tryptone-glucose-glycerin (STGG) transport medium, prepared 
according to instruction provided by the CDC (see Appendix 7). The sample was then transported to the lab, 
vortexed then separated into 2 x 1ml aliquots (1 containing the original swab tip) and stored at -80°C. 
 
3.6.2 Isolation of Streptococcus pneumoniae from NP swabs 
Once 10 or more samples were collected and stored, samples were further processed in batches. The 
aliquots not containing the original swab tip were transported to Imperial College Healthcare NHS Trust 
Department of Microbiology, Charing Cross Hospital. Samples were defrosted and vortexed and 50 µl of 
vortexed specimen inoculated onto Columbia blood agar plus aztreonam selective plates (Oxoid) (primary 
plate) and incubated overnight at 37°C in 3-10% CO2. From the primary plate, 2 presumptive pneumococcal 
colonies were streaked on to a Columbia blood agar plate (Oxoid). An optichin disc (Oxoid) was placed on 
the plate and again incubated overnight as above. From the optichin plate, confirmed pneumococcal 
colonies were streaked on to a Columbia blood agar plate to make a lawn, then incubated overnight as 
above. Pure growth was harvested with a plastic inoculation loop (Medical Wire & Equipment) and dispensed 
into STGG storage medium, prepared according to protocol provided by the CDC (see Appendix 7) and 
stored at -80°C for subsequent serotype identification (see below). 
 
3.6.3 Serotype identification  
Pneumococcal isolates were transported to the HPA Respiratory and Systemic Infection Laboratory (RSIL) 
where samples were serotyped using their standard latex agglutination method. Samples were defrosted to 
room temperature, subcultured on Columbia blood agar plates  (HPA media services) with an optochin disc 
(MAST) and cultured over night at 35°C in 4-5% CO2. If there was pure growth Todd-Hewitt broth (HPA 
media services) was inoculated with a heavy inoculum of fresh pneumococcal culture and incubated 
overnight at 35°C in 4-5% CO2. The cultures were then centrifuged at 1500rpm for 30 minutes.  
Supernatants were removed leaving a few drops in each tube and the cell pellets resuspended in the 
remaining small amount of fluid. The suspension was used to perform slide agglutination using pooled and 
individual pneumococcal polysaccharide antisera (Statens Serum Institute) in a stepwise identification 
process. 10µl of bacterial suspension was placed on a glass slide using a plastic pipette. Antisera were 
added using a 1µl plastic loop and mixed briefly. Agglutination was classified as a positive result. If there was 
no agglutination with any antiserum, bile solubility was assessed. If bile soluble the sample was reported as 
non-typeable (NT). 
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3.7 Statistical analysis 
 
The analysis of the data has been guided by statistical advice received from the Department of Statistics at 
Imperial College (Dr Elena Kulinskaya) and Department of Statistics at Institute of Child Health (Dr Deborah 
Ridout). Analysis of and extrapolation from existing data in the literature [198, 343] confirmed that our study 
would be adequately powered to detect differences in serum antibody pre and post vaccination and between 
groups according to the proposed stratifications. All analysis was performed by Alasdair Bamford using Stata 
IC version 12.1 for Mac (StataCorp) and Prism 5 for Mac OS X (GraphPad), with the guidance of Dr Deborah 
Ridout of the Institute of Child Health statistical advisory service. Specific analytical methods are described 
for each chapter. Prior to data analysis an analysis plan was formulated. In summary, data was initially 
inspected and assessed for completeness. Summary statistics were produced and the distribution of 
continuous data was assessed using both visual and statistical methods for assessing normality. Data was 
analysed using parametric tests when possible, using log transformation of data when appropriate and 
necessary. Linear regression and one way and repeated measures analysis of variance and covariance 
were used as appropriate following assessment for violation of test assumptions. When necessary, non-
parametric tests were employed. A significance level of p<0.05 was considered significant while 
acknowledging that a lower cut off might be considered more appropriate in the context of multiple 
comparisons (as discussed in Section 6.5). 
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Chapter 4: B and T cell phenotype 
 
4.1. Introduction 
 
4.1.1 B cell phenotype in perinatally acquired HIV (paHIV) 
There are few published papers describing the phenotype of B cells in the context of paediatric HIV, with 
partially contradictory results [166-169, 344]. Nevertheless it is now clear that paHIV is associated with B cell 
phenotypic abnormalities both on and off HAART. How these phenotypic abnormalities impact upon antibody 
responses to vaccine antigens, and how treatment history impacts upon potential for B cell immune 
preservation/reconstitution remains to be explored [168, 169]. 
 
More is known about B cell phenotypic abnormalities and their association with impaired vaccine responses 
in adults. The published literature confirms that some but not all of these abnormalities may be reversed by 
HAART and that earlier HAART may increase potential for maintenance of normal B cell phenotype and 
function [120, 160, 165, 188]. It is well known that there are differences in the immunological and virological 
features of paHIV and adult infection and caution must therefore be taken when making extrapolations from 
adult data to the paediatric population [111, 344]. PaHIV results in an insult to a relatively naive and still 
developing immune system, which can in turn be directly related to differences in the dynamics of viral 
replication, immunosuppression, clinical progression and response to HAART.  
 
4.1.2 Circulating TFH-like cells in paHIV 
Despite contributing up to around 10% of circulating CD4+, to our knowledge there is very little data 
concerning circulating TFH-like cells in children in health or disease [209, 345] and no published data on TFH 
in paHIV. This is perhaps unsurprising considering the ongoing debate over the last 15 years concerning 
their relationship to true lymphoid tissue TFH [136, 137]. It is now increasingly clear that they are directly 
related to their GC counterparts [207, 208, 346] and data is emerging regarding the effect of HIV on this 
subset in adults and the resulting implications for T dependent vaccine responses [46-48, 347, 348]. 
 
4.1.3 Relevance to pneumococcal immunity 
Children with paHIV are particularly susceptible to pneumococcal infection and remain at increased risk of 
invasive disease even when on suppressive HAART. Pneumococcal conjugate vaccines have been shown 
in both adults and children with HIV, to provide further protection against invasive disease, albeit less so than 
in healthy children in the context of paediatric infection [270, 271]. Antibody response to pneumococcal 
conjugate vaccines is key to their efficacy and it is generally accepted that conjugate vaccines result in the 
provision of T cell help to pneumococcal polysaccharide specific B cells [155]. It is thought that through this 
mechanism they are more effective at promoting class-switch recombination, affinity maturation and the 
establishment of immune memory in comparison to polysaccharide vaccines, at least in young children. 
However serum IgG responses to PCV in children with paHIV are less robust than in healthy children, most 
likely as a result of a combination of effects on T and B cell phenotype and function [270, 271]. 
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By using multicolour flow cytometry we have characterised B and T cell subsets in peripheral blood of 
children with paHIV, healthy children and healthy young adults. We hypothesise that these subsets in 
particular, are likely to be of importance in the response to PCV and in the following chapter we will 
investigate how any observed alteration in cell phenotype impacts upon serological response to vaccination. 
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4.2 Chapter aims 
 
i) To compare lymphocyte, B and T cell subset phenotype of children with paHIV with that of healthy children 
and healthy young adults 
 
iii) To compare lymphocyte, B and T cell subsets phenotypically between healthy young adults and children 
with paHIV pre and post immunisation with PCV13 
 
iv) To investigate how clinical history impacts upon T and B cell phenotype in paHIV 
 
v) To investigate correlation between T cell and B cell phenotype in children with paHIV 
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4.3 Methods 
 
A general overview of methods used to immunophenotype T and B cell subsets is provided in Section 2.3. 
The following is a further in-depth discussion of the choice of markers and the gating strategies used for 
investigation of B and T cell phenotypes applied throughout the work of this thesis. The following 
considerations were of importance when designing the flow cytometry panel used in this study: 
 
1. Published and generally accepted methods for B cell immunophenotyping 
2. Published observations of B cell abnormalities in HIV infected adults and children 
3. Current practices regarding quality control in flow cytometry  
4. Limitations of the available flow cytometer  
5. Availability of fluorochrome/antibody combinations and fluorescence spillover 
6. The use of small volumes of whole blood  
7. Cost 
 
4.3.1 B cell gating strategy 
Immunophenotyping of human B cells has lagged behind that observed in the T cell field. However, in recent 
years circulating human B cell subsets have been characterised in increasing detail and with increasing 
complexity [349-351]. As with other lymphocyte subsets, there still remains a certain lack of consensus 
regarding the ontogenic relationship between observed cell types, nomenclature and the relationship 
between observed phenotype and function.  
 
IgD and CD27 have classically been used to identify the following subsets of circulating CD19+ B cells [145]: 
 
- IgD+CD27- (naive)  
- IgD+CD27+ (IgD+ memory) 
- IgD- CD27+ (class switched memory) 
- IgD- CD27- (double negative) 
 
IgD+ memory B cells have been shown to predominantly consist of cells co-expressing IgD and IgM, leading 
some to use them as a surrogate for IgM+ memory B cells. This classification system is complicated by the 
fact that circulating populations of IgD+IgM-CD27+ and IgD-IgM+CD27+ have been characterised, although 
they are relatively minor populations [349, 350, 352]. For some time CD27 was considered to be a definitive 
memory marker, however CD27-IgD- memory cells have now also been identified and characterised in 
healthy human subjects [146, 353]. 
 
This classification system was included for reasons of consistency and comparability with published data in 
healthy and diseased adults and children and the nomenclature described above will also be used, accepting 
its limitations. 
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Circulating transitional B cells, and their subsets, may be identified using various combinations of markers 
and are characteristically CD38+CD24+CD10+ [354]. For logistic reasons it was desirable to use only one 
marker to identify this subset and therefore CD10 was chosen. This marker has previously been used to 
investigate transitional B cell numbers in HIV infected children and adults [355] [169, 344, 356] [357]. CD10 
also identifies a minor subset of “germinal centre founder” B cells, a proportion of which are CD27+ [165, 
355, 358], for this reason transitional cells were identified as CD19+CD10+CD27-. 
 
Circulating plasmablasts may be identified in a number of ways including CD27++CD38++IgD [349]. For the 
purposes of this study they were identified as CD19+CD10- IgD- CD27++ [350, 352]. 
 
Moir et al have extensively investigated B cell phenotype in adults with HIV [120]. Part of their work has 
involved the characterisation of a CD21lo population demonstrated to be abnormally increased in this patient 
group. Through a series of carefully designed experiments they have shown that this CD21lo can be further 
subdivided into various subsets. CD27+/++CD21lo cells have been characterised as activated mature B cells 
and plasmablasts [120]. CD27-CD21lo cells include a subset of transitional cells [122, 355] but also a newly 
defined subset of cells with an exhausted phenotype, termed “exhausted” or “tissue-like” memory B cells. 
Phenotype and function of the latter subset has been extensively characterised using other specific surface 
markers such as Fc-receptor-like-4 (FCRL4) [359]. We have found it difficult to define a consistent gating 
strategy, using FMO controls, for a “lo” subset.  For this reason this subset, which from now on will be 
referred to as tissue like/ exhausted memory B cells, were identified as CD27-CD21-. Activated mature B 
cells were accordingly defined as C27+CD21-. 
 
4.3.2 T cell gating strategy 
As discussed in Chapters 1 and 2 the main hypothesis of this study relates to the subset of circulating TFH-
like cells. This subset is a relatively recently characterised helper T cell subset [137]. As with the circulating 
B cell subsets described above definitive phenotypic and functional characterisation of lymphoid tissue TFH 
and their circulating counterparts are still subject to much debate in the literature. However it is generally 
now agreed that circulating TFH-like cells are a subset directly related to TFH in lymphoid tissue and that they 
are identified by expression of CXCR5 [207, 208, 346]. Various other markers have been employed including 
CD57, ICOS, PD-1, CD40L and OX40, but CXCR5 is the surface marker most consistently used to identify 
this circulating subset in humans [207, 208, 346]. For the purposes of this study circulating TFH-like cells are 
defined as CD4+CD45RO+CXCR5+. Inducible T-cell costimulator (ICOS) was initially included as a subset 
specific marker (as it is expressed at high levels by lymphoid TFH), however since devising the panel its utility 
as a specific marker in circulating TFH has been disproved [136, 137, 207, 208]. In order to focus on the 
project main hypothesis and to limit complexity of data analysis the T helper cell subsets of interest have 
been defined as CD4+CD45RO+ (CD45RO+ T helper cells), CD4+CD45RO+CXCR5+ (circulating TFH-like cells) 
and CD4+CD45RO+CXCR5+ICOS+ (ICOS+ circulating TFH-like cells). 
 
The overall gating strategy is shown in Figs. 9 and 10 in Chapter 2. 
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4.3.3 Statistical analysis 
For baseline comparisons, Chi2 and Fisher’s exact test were used to compare proportions. Mann-Whitney U 
test was used to compare baseline age and for contrasting baseline cell subset data between child and adult 
groups. Hodges-Lehman median differences with 95% confidence intervals were also calculated. For direct 
comparison of cell subsets from the two groups of children, data was log transformed and compared using 
linear regression analysis to allow for adjustment for age and to assess age*group interactions. Wilcoxon-
Sign rank was used to assess for changes in cell subsets at baseline compared to 6 months post 
immunisation. Hodges-Lehman median difference and 95% confidence interval were also calculated. Linear 
regression was used to assess for effects of clinical history on subsets, after log transformation, within the 
CP group, and also to assess for correlation between T and B cell subsets. 
 
 
 
 
 
 
	   	   	   	  61 
4.4 Results 
 
3.4.1 Recruitment 
An overview of study numbers and recruitment is shown in Fig. 11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AHC 
n=35 
 CHC 
n=30 
  CP 
n=58 
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n=1 
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1 month: 
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IL21:  
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n=27 
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      IgG:  
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n=48 
n=48 
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6 month: 
 
NP:  
T/B:  
IgG:  
n=27 
n=27 
n=27 
   NP:  
T/B:  
IgG:  
n=4*** 
n=8 
n=8 
 NP:  
T/B:  
IgG:  
n=47**** 
n=48 
n=48 
        
        
*1 insuff 
** 3 insuff 
*** 4 refused 
**** 1 refused 
      
 
Figure 11. Overview of recruitment to study (AHC = Adult Healthy Control, CHC = Child Healthy Control, CP = Child Patient, NP = 
nasopharyngeal swab, T/B = immunophenotyping, IgG = pneumococcal serology, WBA = whole blood assay, IL21 = serum IL21 
determination) 
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4.4.2 Baseline characteristics  
The baseline characteristic of those included in the assessment of B and T cell phenotype are summarised 
in Table 3.  
 
  CHC 
(n=30) 
 AHC 
(n=27) 
 CP 
(n=56) 
 
Sex Female 14 (46.7) 16  (59.3) 25 (44.6) 
 Male 16 (53.3) 11 (40.7) 31 (55.4) 
Ethnicity White 4 (13.3) 19 (70.4) 2 (3.6) 
 Mixed 0 (0) 2 (7.4) 3 (5.4) 
 Asian 0 (0) 4 (14.8) 3 (5.4) 
 Black 
Caribbean 
4 (13.3) 0 (0) 2 (3.6) 
 Black African 13 (43.3)** 0 (0) 45 (80.4)* 
 Other 9 (30) 2 (7.4) 1 (1.8) 
Born in UK  29 (96.7)** 20 (74.1)*** 28 (50) 
Age/months  107.5 (19-195) 322† (245-359) 151.5φ (12-209) 
Nadir CD4%   - - - - 13 (0-48) 
Proportion of life 
undetectable 
 - - - - 0.47 (0-0.98) 
VL <50 copies/ml  - - - - 44 (78.6) 
Treated 1st year  - - - - 10 (17.9) 
Treated 1st 2 years  - - - - 15 (26.8) 
Lymphocyte  lymphcells/µl 2139 (1666-3414) 1833φζ (1377-2125) 2390.5 ‡ (1764-3300.5) 
subsets CD3 cells/µl 1575.5 (1166-2486) 1464ζ (1094-1706) 1889.5 ‡ (1345.5-2516.5) 
 CD3 % 71.6 (66.6-78.3) 74.7 (70.1-79.1) 74.35 (68.9-79) 
 CD4 cells/µl 833.5 (647-1391) 803 (694-1061) 855 ‡ (525.5-1133.5) 
 CD4 % 43.1 (36.7-46.5) 43.8ζ (39.8-50.6) 34.55 ‡ (27.2-40.8) 
 CD8 cells/µl 529.5 (356-907) 500ζ (383-557) 895.5 §° (626-1070.5) 
 CD8 % 23.8 (21.6-27.2) 26.3ζ (22.2-28.9) 32.7 ‡ (28.6-42.8) 
 CD19 cells/µl 446.5 (272-679) 255φζ (153-326) 403 § (267.5-573.5) 
 CD19 % 18.2 (14.5-24.2) 11.4φζ (8.9-16.8) 17.05 § (13-20.9) 
 CD56 cells/µl 134.5 (82-205) 173ζ (96-263) 119 ‡ (72-186) 
 CD56 % 5.4 (2.9-8.2) 9.4φζ (6.5-12.7) 4.4 (2.8-6.9) 
 
 
Table 3. Baseline characteristics for all study participants assessed by flow cytometry. Sex, ethnicity, UK origin, HIV viral load status, 
treated in the 1st year of life and treated in the 1st 2 years of life are presented as number and percentage. Age, nadir CD4% and 
proportion of life undetectable are presented as median and range. Lymphocyte subsets are presented as median and interquartile 
range. Parameters for which significant differences between groups were found are highlighted in blue. (CHC= child healthy control, 
AHC= adult healthy control, CP = child patient, VL = HIV viral load, PCV7 = 1-valent pneumococcal conjugate vaccine, PPV= 
pneumococcal polysaccharide vaccine) 
*  Proportion significantly different: CP vs. CHC (p<0.005) 
**  Proportion significantly different: CHC vs. AHC (p<0.005) 
*** Proportion significantly different: AHC vs. CP (p<0.05) 
† Median significantly different from CP and CHC (p<0.001) 
φ Median significantly different from CHC (p<0.05) 
ζ Median significantly different from CP (p<0.05) 
‡ Significant age*group interaction when comparing CHC vs. CP (p<0.05) 
§ Significant independent age effect when comparing CHC vs. CP (p<0.05) 
° Significant independent group effect when comparing CHC vs. CP (p<0.05) 
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4.4.3 Demographic information 
Chi2 or Fisher’s exact test were used as appropriate to compare proportions in each group. 
The proportions that were male did not differ by group: 53.3%, 40.7% and 55.4% for CHC, AHC and CP 
respectively (p=0.444). The proportions that were of black ethnicity differed between groups being higher in 
CP (84%) compared to CHC (56.6%) (p=0.006) which in turn was higher when compared to AHC (0%) (p< 
0.001). The proportions born in the UK also differed between groups being higher in CHC (96.7%) compared 
to AHC (74.1%) (p=0.021) which in turn was higher when compared to CP (50%)  (p=0.037). As the age 
distributions were non-parametric and not amenable to uniform transformation Mann-Whitney U test was 
employed to compare ages between groups. As expected from the study design the age of AHC (median= 
322 months) was higher when compared to CHC (median = 107.5 months) (p<0.001) and CP (median = 
151.5 months) (p<0.001). CHC median age was lower than CP (p=0.009). 
 
4.4.4 Lymphocyte subsets 
 
Children with paHIV have significantly different lymphocyte subsets when compared to young adult healthy 
controls 
 
The data for each of lymphocyte subsets were skewed. Log transformation normalised the data, however 
non-homogeneity of variance precluded use of parametric t-test for comparisons of CP and CHC with AHC. 
Mann-Whitney U test was used to detect differences in median lymphocyte subset absolute numbers and 
percentages. Hodges-Lehman median differences with 95% CI were calculated. The results of this analysis 
are shown in Table 4. 
 
 
 
As can be seen from Table 4, a greater number of differences were observed when comparing CP to AHC 
than when comparing CHC to AHC. Regarding absolute cell counts: CHC had a significantly higher 
lymphocyte and B cell counts than AHC, whereas CP had higher absolute lymphocyte, T cell, CD8 cell and B 
Table 4. Results of comparison of lymphocyte subsets of each of the child cohorts with the adult cohort. Percentages are of 
absolute lymphocyte count. Regarding absolute cell counts: CHC had a significantly higher lymphocyte and B cell counts 
than AHC, whereas CP had higher absolute lymphocyte, T cell, CD8 cell and B cell count. Regarding percentages: CHC 
had higher B cell percentage and lower NK cell percentages, whereas CP had higher B cell and CD8 percentages and 
lower CD4 and NK cell percentages (Lymph= lymphocytes, abs = absolute count in cells/µl, Med diff = median difference, 
CI = confidence interval, 
 CHC vs. AHC CP vs. AHC 
 Med diff 95%CI p Med diff 95%CI p 
Lymph abs 470.50 -1.00 -   1111.00 0.0449 557.00 237.00 -   929.00 0.0029 
CD3 abs 231.00 -64.00 -   690.00 0.1048 438.00 203.00 -   739.00 0.0021 
CD3% -2.85 -6.60 -   1.20 0.1873 -0.50 -3.80 -   2.80 0.7706 
CD4 abs 64.00 -115.00 -   291.00 0.4196 7.00 -164.00 -   183.00 0.8918 
CD4% -3.50 -6.92 -   0.50 0.0747 -11.20 -15.10 -   -7.00 <0.0001 
CD8 abs 63.00 -58.00 -   243.00 0.2915 394.00 283.00 -   511.00 <0.0001 
CD8% -1.20 -3.80 -  1.20 0.2987 7.90 4.90 -   11.90 0.0001 
CD19 abs 198.50 86.00 -   330.00 0.0003 158.00 88.00 -   236.00 0.0001 
CD19% 6.10 2.70 -   9.38 0.0002 4.48 2.20 -   7.00 0.0009 
CD56 abs -43.00 -93.00 -   5.00 0.0709 -53.00 -95.00 -   -3.00 0.0232 
CD56% -3.90 -5.90 -   -1.70 0.0011 -4.50 -6.50 -   -2.80 <0.0001 
 
	   	   	   	  64 
cell count. Regarding percentages: CHC had higher B cell percentage and lower NK cell percentages, 
whereas CP had higher B cell and CD8 percentages and lower CD4 and NK cell percentages. Results are 
also shown in Figure 12. Further direct comparison of CHC with CP group is described below. 
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Figure 12 a-k) Scatter plots illustrating absolute counts and 
percentages for lymphocyte subsets in each group. a) overall 
lymphocyte counts, b) CD3+ cell counts, c) CD3+ cell % d) CD4+ 
cell count e) CD4+ cell % f) CD8+ cell count g) CD8+ cell % h) 
CD19+ cell count i) CD19 cell % j) CD56+ cell counts k) CD56 cell 
%. Median and interquartile ranges are shown. Significance level is 
shown where significant differences occurred at the p<0.05 level. 
Regarding absolute cell counts: CHC had a significantly higher 
lymphocyte and B cell counts than AHC, whereas CP had higher 
absolute lymphocyte, T cell, CD8 cell and B cell count. Regarding 
percentages: CHC had higher B cell percentage and lower NK cell 
percentages, whereas CP had higher B cell and CD8 percentages 
and lower CD4 and NK cell percentages (CHC= child healthy 
control, AHC = Adult healthy control, CP= Child patient) 
a) 
b) c) 
d) e) 
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Figure 12 continued. 
f) g) 
h) i) 
j) k) 
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Children with paHIV have significantly different lymphocyte subsets when compared with healthy children 
despite effective HAART 
 
To compare baseline lymphocyte subsets between CP and CHC groups we performed linear regression 
analysis to allow adjustment for age and to investigate any age*group interactions. All subset data was log 
transformed prior to analysis and ages were converted to years for ease of interpretation. The results of 
these comparisons are shown in Table 5. 
 
Log transformation of a dependent variable affects the interpretation of regression coefficients. For this 
reason the antilog of the regression coefficient is reported. The independent variable, “group”, is a 
categorical variable and therefore the antilog of the regression coefficient is the ratio of the geometric mean 
of the dependent variable in the two compared groups. For example, from Table 5 it can be seen that there 
is a significant effect of group on CD8+ absolute count. The antilog of the regression coefficient is 1.69. This 
indicates that if age is kept constant the geometric mean of the absolute CD8+ absolute count is predicted to 
be 1.69 times higher in the CP group than the geometric mean of the CHC group. This effect is shown in Fig. 
13A. 
 
The independent variable, age, is a continuous variable. The antilog of the regression coefficient is the ratio 
of the predicted dependent variable following a unit increase in the independent variable. Using the absolute 
CD8+ cell count as an example again, it can be seen that there is a significant effect of age. The antilog of 
the regression coefficient is 0.961. Therefore for a one year increase in age there will be an approximately 
4% decrease in the absolute CD8+ cell count. This again can be seen from Fig. 13A. 
 
Table 5. Results of linear regression analysis comparing lymphocyte subsets for CHC with CP. Antilog regression coefficients are 
reported with 95% CI. When a significant age*group interaction was demonstrated, only the interaction coefficient is reported. When 
interaction was non-significant age and group effects are reported individually. Percentages are of absolute lymphocyte count. 
Significant age*group interactions were present for lymphocyte, T cell, CD4 cell and NK cells. The only subset for which there was a 
significant independent group effect after adjusting for age was CD8+ absolute count. There was no difference between groups after 
adjusting for age in CD19+ cell absolute count. Age*group interactions were present for CD8% and CD4%.There was no difference in 
CD19 % or NK % after adjusting for age. (Lymph = lymphocyte, abs = absolute count in cells/µl, coef = regression coefficient, CHC = 
child healthy control, AHC = adult healthy control, CP = child patient) 
 Age*Group Age 
 
Group 
 antilog 
coef 
antilog 95% CI p value antilog 
coef 
antilog 95% CI p value antilog 
coef 
antilog 95% CI p value 
Lymp abs 0.962 0.927 -  0.999 0.043         
CD3 abs 0.954 0.919 -  0.991 0.017         
CD3%     1.004 0.999 -  1.009 0.151 1.026 0.975 -  1.080 0.321 
CD4 abs 0.916 0.874 -  0.959 <0.001         
CD4% 0.950 0.921 -  0.981 0.002         
CD8 abs     0.961 0.939 -  0.985 0.002 1.690 1.349 -  2.117 <0.001 
CD8% 1.035 1.006 -  1.064 0.017         
CD19 abs     0.926 0.899 -  0.953  <0.001 1.142 0.869 -  1.501 0.337 
CD19%     0.973 0.956 -  0.989 0.002 0.963 0.818 -  1.133 0.642 
CD56 abs 0.910 0.838 -  0.987 0.024         
CD56%     1.028 0.994 -  1.064 0.102 0.813 0.591 -  1.118 0.199 
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The interpretation of the antilog of the regression coefficient for the interaction term is slightly more complex. 
It is effectively a ratio of change per unit increase in age for one group vs. change per unit increase in age for 
the other group. For example, from Table 5 it can be seen that there is a significant age*group interaction for 
the CD3+ cell count. The antilog of the regression coefficient, 0.954, is a measure of how different the 
change in CD3+ cell count with age is for CP when compared to the change in CD3+ cell count with age is for 
CHC. This difference in regression slopes can be seen from Fig. 13B. 
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Figure 13A. Illustrative example of regression plots comparing log 
transformed CD8 cell counts between healthy controls and children with 
paHIV. Demonstrates separate age and group effects (CHC = child 
healthy controls, CP = child patients, blageyears = baseline age in years. 
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Figure 13B. Illustrative example of regression plots comparing log 
transformed CD3 cell counts between healthy controls and children with 
paHIV. Demonstrates age*group interaction (CHC = child healthy controls, 
CP = child patients, blageyears = baseline age in years) 
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Absolute cell counts:  
Significant age*group interactions were present for lymphocyte, T cell, CD4 cell and NK cells. Lymphocyte 
counts were higher in younger children in the CP group than the CHC group, but more equivalent in the older 
children. A similar pattern was observed for CD3+ absolute cell counts. For absolute CD4+ cell count, 
younger CP had higher counts than CHC and older CP had lower counts than CHC. For absolute CD56+ cell 
count, older children in the CP group tended to have lower cell counts than CHC of a similar age. The only 
subset for which there was a significant independent group effect after adjusting for age was CD8+ absolute 
count, with higher CD8+ counts in CP group than in CHC group. There was no difference between groups 
after adjusting for age in CD19+ cell absolute count.  
 
Subset percentages:  
Age*group interactions were present for CD8% and CD4%. For CD8%, older CP had higher cell percentages 
than CHC of a similar age. And conversely, older CP had lower CD4% than CHC of a similar age. There was 
no difference in CD19% or NK cell % after adjusting for age. 
 
All these effects remained significant at p<0.05 level after adjusting for detectable viraemia.  
 
Overall these results indicate significant differences in lymphocyte subsets between children with paHIV and 
healthy children, the pattern of difference often varying with age. These observed differences are present 
despite the majority of the HIV infected children included in the study being on effective HAART with 
undetectable HIV viral load. Results are also shown in Figure 14. 
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Figure 14. a-k) Regression plots comparing healthy 
children with children with paHIV. Significant age*group 
interactions were present for lymphocyte, T cell (CD3), 
CD4 cell, and NK  cell (CD56) counts (p<0.05) and for CD4 
cell percentage (p<0.005). Significant independent age 
effects were present for CD8 cell and B cell (CD19) counts 
and B cell percentage (p<0.005). Significant independent 
group effect was present for CD8 cell count (p<0.005). 
(CHC= child healthy control, CP = child patient, blageyears 
= baseline age in years). 
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Figure 14. continued. 
f) CD8+ cell count 
 
g) CD8+ cell percentage 
 
h) CD19+ cell count 
 
i) CD19+ cell percentage 
 
j) CD56+ cell count 
 
k) CD56+ cell percentage 
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4.4.5 B and T cell subsets  
 
Children with paHIV have significantly different B and T cell subsets when compared to healthy young adults 
 
A summary of B and T cell subsets from each group is presented in Table 6. In order to limit the number of 
comparisons being made, only percentages of B and T cell subsets were analysed. As for lymphocyte 
subsets, B and T cell subset percentages for AHC were first compared with CP and CHC. Mann-Whitney U 
test was used to detect differences in median B and T cell subset percentages. Hodges-Lehman median 
differences with 95% CI were calculated. The results of this analysis are shown in Table 7.  
 
For B cell subsets the differences between CP and AHC mirrored those observed between CHC and AHC. 
Median transitional cell percentages were higher in both child groups than AHC. When using CD21 vs. CD27 
to subdivide B cells, median naive mature and tissue like/ exhausted cell percentages were higher in both 
child groups (CHC vs. AHC: p=0.0034 and p<0.0001 respectively. CP vs AHC: p<0.0001 and p<0.0001 
respectively) and median resting memory percentages were lower (p≤0.0001). When using IgD and CD27 to 
subdivide B cells median IgD+ memory and median class switched memory percentages were lower in both 
child groups compared to adults (CHC vs AHC: p=0.002. CP vs AHC: p<0.0001) and median naive and 
double negative B cell percentages were higher (CHC vs AHC: p=0.0034 and p=0.0484 respectively. CP vs. 
AHC: p<0.0001 and p=0.001 respectively). Median CD45RO+ percentages were lower in both child groups 
compared to adults (p<0.0001) and median CXCR5+ICOS+ percentages were higher than in adults (CHC vs 
AHC: p=0.0002. CP vs. AHC: p=0.0017). Median CXCR5+ percentages were higher in the CHC group 
compared to AHC (p=0.0002), however there was no difference when comparing CP with AHC (p=0.2474). 
 
 
 73 
 
Table 6. Summary of results for B and T cell subsets. Transitional (CD19+CD27-CD10+) and plasmablast (CD19+CD10-CD27+IgD-) cells reported as a proportion of CD19+ cells. Remaining B cell 
subsets reported as a proportion of CD19+ after exclusion of CD10+ and plasmablasts (naive mature (CD19+CD10-CD27-CD21+), resting memory (CD19+CD10-CD27+CD21+), activated mature 
(CD19+CD10-CD27+CD21-), exhausted/tissue like (CD19+CD10-CD27-CD21-), naive (CD19+CD10-CD27-IgD+), IgD+ memory (CD19+CD10-CD27+IgD+), switched memory (CD19+CD10-CD27+IgD-), 
double negative (CD19+CD10-CD27-IgD-)). CD45RO+ reported as a proportion of CD4+. CXCR5+ and CXCR5+ICOS+ reported as a proportion of CD4+CD45RO+. When comparing CP and CHC group 
with AHC group, significant differences were present for most subsets, consistent with published reference range data and expected changes with age. The magnitude of these differences was greater 
for the CP group than the CHC group (see Table 7). Of note CXCR5+ cell percentages were significantly higher in the CHC group than AHC group, which was not the case for CP compared to AHC. 
When comparing CHC with CP group using geometric mean, significant differences in resting memory, naive, IgD+ memory, switched memory and CXCR5+ (TFH-like) cells were observed after 
adjusting for age (p<0.05). (CHC= child healthy control, CP = child patient, AHC = adult healthy control, Med = median, GM= geometric mean) 
°  Significant difference in median when compared to AHC (p<0.05) 
* Significant difference in geometric mean after adjusting for age (p<0.05) 
 
 
 CHC AHC CP 
 Med 95%CI GM 95%CI Med 95%CI GM 95%CI Med 95%CI GM 95%CI 
transitional % 1.26° 0.61 - 2.38 1.20 0.86 - 1.66 0.49 0.30 - 0.89 0.51 0.36 - 0.74 1.47° 0.85 - 1.95 1.34 1.09 - 1.65 
plasmablast % 0.98 0.49 - 1.48 0.88 0.66 - 1.16 0.60 0.40 - 1.00 0.67 0.50 - 0.89 0.79 0.40 - 1.41 0.84 0.63 - 1.10 
                   
naive mature % 72.65° 66.20 - 79.40 71.83 68.40 - 75.42 63.50 50.90 - 75.40 60.61 55.43 - 66.28 76.55° 71.00 - 81.00 73.96 69.91 - 78.25 
resting memory % 20.50° 14.00 - 27.60 18.77 15.95 - 22.09 33.50 22.50 - 46.00 31.15 25.76 - 37.65 15.50° 10.00 - 18.05 12.62* 10.78 - 14.78 
activated mature % 2.01 1.47 - 2.50 2.06 1.62 - 2.64 1.78 1.19 - 2.33 1.78 1.49 - 2.14 1.66 1.12 - 3.44 1.89 1.46 - 2.46 
exhausted/tissue like % 4.04° 2.32 - 5.84 3.76 2.99 - 4.72 1.41 1.20 - 1.77 1.56 1.31 - 1.86 4.40° 3.07 - 7.96 5.06 4.13 - 6.20 
                   
naive % 72.40° 63.70 - 79.80 70.38 66.55 - 74.44 60.80 47.60 - 71.00 57.94 52.41 - 64.05 76.70° 69.00 - 82.70 75.44* 72.78 - 78.20 
IgD+ memory % 11.30° 6.52 - 13.50 9.82 8.24 - 11.71 15.70 9.61 - 22.20 15.22 12.29 - 18.85 7.43° 4.79 - 10.20 6.60* 5.66 - 7.68 
Switched memory % 11.50° 7.69 - 16.30 11.31 9.46 - 13.52 18.00 12.20 - 22.70 17.19 14.17 - 20.86 10.50° 6.59 - 12.75 8.71* 7.34 - 10.34 
Double negative % 4.47° 3.14 - 6.32 4.69 3.86 - 5.70 3.57 2.36 - 4.67 3.49 2.88 - 4.24 5.52° 3.59 - 7.96 5.26 4.51 - 6.12 
                   
                   
CD45RO+% 31.30° 25.30 - 40.40 32.05 28.38 - 36.20 50.20 40.10 - 56.50 48.15 44.06 - 52.62 36.25° 27.55 - 43.00 34.10 31.01 - 37.51 
CXCR5+% 27.19° 20.71 - 32.90 26.26 23.69 - 29.10 19.49 15.11 - 22.78 17.22 13.23 - 22.41 23.77 12.65 - 29.41 17.36* 13.93 - 21.64 
CXCR5+ICOS+% 0.80° 0.36 - 1.17 0.75 0.53 - 1.07 0.22 0.14 - 0.53 0.26 0.18 - 0.38 0.55° 0.27 - 1.53 0.59 0.43 - 0.82 
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Overall both healthy children and children with paHIV had a similar pattern of differences in median T and B 
cell subsets when compared to healthy young adults. However these differences tended to be more extreme 
for the CP group and in the case of CXCR5+ T cells there is divergence in that healthy children had a higher 
percentage when compared to adults whereas the HIV cohort showed no difference. Further direct 
comparison of CHC with CP group is discussed below. 
 
Children with paHIV have significantly different B and T cell subsets when compared with healthy children 
despite effective HAART 
 
As when comparing baseline lymphocyte subsets between CP and CHC groups linear regression analysis 
was used to compare B and T cell subsets adjusting for age and to investigate any age*group interactions. 
All subset data was log transformed prior to analysis and ages were converted to years for ease of 
interpretation. The results of these comparisons are shown in Table 8. 
 
No significant age*group interaction effects were observed. The antilog regression coefficients reported in 
Table 8 can be interpreted as described in Section 4.4.4. After adjusting for age there were significant 
 CHC v AHC CP v AHC 
         
B cell subsets Med diff 95%CI p Med diff 95%CI p 
         
transitional % 0.74 0.29 -  1.10 0.0005 0.86 0.52 -  1.12 <0.0001 
plasmablast % 0.19 -0.03 -  -0.03 0.2698 0.10 -0.10 -  0.39 0.4659 
         
naive mature % 10.45 3.40 -  17.60 0.0034 14.75 7.20 -  21.40 <0.0001 
resting memory % -14.40 -21.10 -  -7.30 0.0001 -20.30 -27.10 -  -13.70 <0.0001 
activated mature % 0.13 -0.34 -  0.67 0.5650 -0.04 -0.51 -  0.53 0.9033 
tissue like/ exhausted % 2.26 1.17 -  3.53 <0.0001 2.80 1.97 -  4.25 <0.0001 
         
naive % 11.80 4.40 -  19.40 0.0035 16.75 9.30 -  23.90 <0.0001 
IgD+ memory % -6.49 -10.40 -  -1.73 0.0021 -9.56 -5.20 -  -13.60 <0.0001 
switched memory % -6.10 -9.90 -  -2.30 0.0023 -8.46 -11.70 -  -4.70 <0.0001 
double negative % 0.96 0.01 -  2.08 0.0484 1.85 0.84 -  2.99 0.0010 
         
T cell subsets         
         
CD45RO+ % -15.80 -21.70 -  -10.10 <0.0001 -13.35 -18.5 -  8.00 <0.0001 
CXCR5+ % 8.02 4.34 -  11.69 0.0002 3.17 -1.64 -  7.15 0.2474 
CXCR5+ICOS+ % 0.45 0.18 -  0.70 0.0002 0.29 0.12 -  0.51 0.0017 
 
Table 7. Results of comparison of B and T cell subsets of each of the child cohorts with the adult cohort. Transitional 
(CD19+CD27-CD10+) and plasmablast (CD19+CD10-CD27+IgD-) cells reported as a proportion of CD19+ cells. Remaining B 
cell subsets reported as a proportion of CD19+ after exclusion of CD10+ and plasmablasts (naive mature (CD19+CD10-
CD27-CD21+), resting memory (CD19+CD10-CD27+CD21+), activated mature (CD19+CD10-CD27+CD21-), exhausted/tissue 
like (CD19+CD10-CD27-CD21-), naive (CD19+CD10-CD27-IgD+), IgD+ memory (CD19+CD10-CD27+IgD+), switched memory 
(CD19+CD10-CD27+IgD-), double negative (CD19+CD10-CD27-IgD-)). CD45RO+ reported as a proportion of CD4+. CXCR5+ 
and CXCR5+ICOS+ reported as a proportion of CD4+CD45RO+. When comparing CP and CHC group with AHC group, 
significant differences were present for most subsets, consistent with published reference range data and expected 
changes with age. The magnitude of these differences was greater for the CP group than the CHC group. Of note CXCR5+ 
cell percentages were significantly higher in the CHC group than AHC group, which was not the case for CP compared to 
AHC. Median values for each subset are reported in Table 6. (Lymph= lymphocytes, abs = absolute count in cells/µl, Med 
diff = median difference, CHC = Child healthy control, AHC = Adult healthy control, CP = Child patient) 
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differences in B cell subsets. Using CD27 vs. CD21 to subdivide B cells, resting memory percentages were 
lower in patients than healthy controls. When using CD27 vs. IgD to subdivide B cells, both IgD+ and class 
switched memory percentages were lower and naive percentages were higher in patients than healthy 
controls. Only the difference between class switched memory percentages lost significance at the p<0.05 
level after adjusting for detectable viraemia (VL>50 RNA copies/ml).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After adjusting for age, geometric mean CXCR5+ percentages were lower in CP than in CHC. This remained 
significant at the p<0.05 level after correcting for detectable viraemia.  
 
In summary, these results show that there are abnormalities of B cell subset distribution in children with 
paHIV when compared to healthy children. Memory B cell percentages are lower and naive B cell 
percentages are correspondingly higher. In addition to the relative deficiency in memory B cell subsets, there 
is a significantly lower proportion of TFH-like cells in children with paHIV compared to healthy children. These 
differences are present despite the majority of the infected children being on effective HAART and remain 
significant after adjusting for detectable viraemia. Representative contour plots for gating CD27 vs. CD21 
and CD27 vs IgD for CD19+CD10-B cells are shown in Figure 15. 
 Age    Group    
 antilog 
coef 
antilog 95% CI p antilog 
coef 
antilog 95% CI p 
         
transitional % 0.942 0.907 -  0.979 0.003 1.312 0.914 -  1.885 0.139 
plasmablast % 1.066 1.019 -  1.115 0.006 0.805 0.526 -  1.233 0.315 
         
naive mature % 0.994 0.985 -  1.003 0.178 1.047 0.960 -  1.143 0.296 
resting memory % 1.002 0.975 -  1.029 0.886 0.669 0.518 -  0.864 0.002 
activated mature % 1.014 0.971 -  1.059 0.517 0.884 0.585 -  1.333 0.551 
tissue like/ exhausted % 0.998 0.964 -  1.034 0.929 1.352 0.967 -  1.892 0.078 
         
naive % 0.997 0.990 -  1.004 0.431 1.080 1.011 -  1.153 0.023 
IgD+ memory % 0.994 0.968 -  1.021 0.670 0.682 0.529 -  0.879 0.004 
switched memory % 1.024 0.994 -  1.054 0.112 0.724 0.551 -  0.952 0.021 
double negative % 1.012 0.984 -  1.040 0.404 1.086 0.838 -  1.409 0.527 
         
CD45RO+ % 1.041 1.025 -  1.056 <0.001 0.957 0.831 -  1.101 0.535 
CXCR5+ % 0.970 0.938 -  1.003 0.072 0.717 0.523 -  0.985 0.040 
CXCR5+ICOS+ % 0.927 0.878 -  0.977 0.006 0.961 0.579 -  1.593 0.875 
 
Table 8. Results of linear regression analysis comparing B and T cell subsets for CHC with CP. Antilog regression 
coefficients are reported with 95% CI. Transitional (CD19+CD27-CD10+) and plasmablast (CD19+CD10-CD27+IgD-) 
cells reported as a proportion of CD19+ cells. Remaining B cell subsets reported as a proportion of CD19+ after 
exclusion of CD10+ and plasmablasts (naive mature (CD19+CD10-CD27-CD21+), resting memory (CD19+CD10-
CD27+CD21+), activated mature (CD19+CD10-CD27+CD21-), exhausted/tissue like (CD19+CD10-CD27-CD21-), naive 
(CD19+CD10-CD27-IgD+), IgD+ memory (CD19+CD10-CD27+IgD+), switched memory (CD19+CD10-CD27+IgD-), double 
negative (CD19+CD10-CD27-IgD-)). CD45RO+ reported as a proportion of CD4+. CXCR5+ and CXCR5+ICOS+ reported 
as a proportion of CD4+CD45RO+.When comparing CHC with CP group using geometric mean, significant differences 
in resting memory, naive, IgD+ memory, switched memory and CXCR5+ (TFH-like) cells were observed after adjusting 
for age (p<0.05). Geometric means for each subset are reported in Table 6. (Lymph = lymphocyte, abs = absolute 
count in cells/µl, coef = regression coefficient, CHC = child healthy control, AHC = adult healthy control, CP = child 
patient) 
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Figure 15 a-c. Typical contour plots from a) a healthy adult (AHC), b) a healthy child (CHC) and c) a child with paHIV (CP). Key 
differences between the groups when gating CD27 vs. CD21 and CD27 vs. IgD on CD19+CD10+ lymphocytes are illustrated. 
Healthy children have higher proportions of naive B cell subsets (CD27-) and a correspondingly lower proportion of memory 
subsets (CD27+) compared to healthy adults. Children with paHIV have even lower proportion of memory subsets compared to 
healthy controls. 
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4.4.6 Stability of subsets over time 
There was no loss to follow and data was complete for all study subjects. 
 
Baseline lymphocyte, B cell and T cell subsets were compared with the same parameters 6 months following 
vaccination for the child patient and adult healthy control groups. Data did not fit assumptions for parametric 
paired comparisons therefore non-parametric Wilcoxon Signed Rank test was used. Hodges-Lehman 
median paired  differences with 95% CI were also calculated. Results are reported in Tables 9 and 10. 
 
Secondary to study design and logistic considerations the number of days from baseline to follow up flow 
cytometric assessment was longer for CP (median= 259 days) than AHC (median= 210 days) (median 
difference = 52.5 days (95%CI: 34-72 days) p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AHC 
Baseline  
(median) 
6 months 
(median) med diff 95% CI p 
      
Lymph abs 1833.0 1787.0 -85.5 (-328.0-158.5) 0.456 
CD3 abs 1464.0 1347.0 -39.0 (-206.5-146.0) 0.701 
CD3 % 74.7 74.5 0.9 (-0.7-2.4) 0.244 
CD4 abs 803.0 795.0 -9.8 (-105.0-108.0) 0.885 
CD4 % 43.8 47.4 0.0 (-2.2-2.2) 0.970 
CD8 abs 500.0 489.0 -1.8 (-56.5-68.0) 0.943 
CD8 % 26.3 25.1 0.8 (-0.3-1.5) 0.150 
CD19 abs 255.0 208.0 -9.5 (-38.0-18.0) 0.435 
CD19 % 11.4 11.9 -0.6 (-1.4-0.2) 0.170 
CD56 abs 173.0 168.0 -8.2 (-58.0-43.0) 0.614 
CD56 % 9.4 9.0 -0.4 (-2.5-1.4) 0.631 
 
CP      
      
Lymph abs 2349.5 2189.0 242.8  (84.0- 414.5) 0.005 
CD3 abs 1854.5 1654.5 202.8 ( 72.5-319.5) 0.004 
CD3 % 75.5 76.2 -0.9 (-2.4-0.5) 0.230 
CD4 abs 855.0 797.0 66.8 (9.5- 133.0) 0.024 
CD4 % 34.6 36.1 -1.6 (-2.7--0.5) 0.007 
CD8 abs 913.5 791.0 106.5 (37.0- 180.0) 0.009 
CD8 % 33.0 34.8 0.4 (-1.3-1.5) 0.542 
CD19 abs 403.0 357.5 47.0 (10.0- 85.0) 0.020 
CD19 % 17.3 16.6 0.6 (-0.4-1.6) 0.200 
CD56 abs 119.0 123.5 1.5 (-12 - 13.5) 0.802 
CD56 % 4.4 5.1 -0.5 (-2.5-1.4) 0.123 
 
 Table 9. Lymphocyte subsets at baseline compared with those at 6 months post immunisation for CP and AHC. 
Wilcoxon Signed Rank test was used to compare paired data and Hodges-Lehman median paired differences with 
95% CI were calculated. Significant decreases are highlighted in red, significant increases, in green. There was no 
significant change in lymphocyte subsets over 6 months in the AHC group. Observed changes in lymphocyte subsets 
over 6 months in the CP group were as might be expected with increasing age and ongoing antiretroviral therapy. 
(abs= absolute cell count in cell/µl, med dif = median difference, CP= Child patient, AHC= Adult healthy control) 
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Young adult lymphocyte subset absolute numbers remained stable whereas those in children with paHIV 
changed over 6 months following vaccination 
 
AHC lymphocyte subset absolute numbers and percentages did not significantly change over 6 months.  
 
Only vaccinated children in the CP group were included for longitudinal subset analysis. 
 
CP absolute lymphocyte count decreased over 6 months (med diff = 242.8 cells/µl (95%CI: 84-441.5 cells/µl, 
p=0.005)). The absolute CD4 count decreased (med diff = 66.8 cells/µl (95%CI: 9.5-133cells/µl), p=0.024)) 
as did the CD8 count (med diff = 106.5 cells/µl (95%CI: 37-180 cells/µl), p=0.009)) and CD19 count (med diff 
= 47.0 cells/µl (95%CI: 10-85 cells/µl), p=0.02). 
 
CP lymphocyte percentages did not significantly change over 6 months apart from CD4%, which increased 
(med diff =  -1.6% (95%CI: -2.87- -0.5) p=0.007). 
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AHC 
Baseline  
(median) 
6 months 
(median) med diff 95% CI p 
B cell subsets      
transitional % 0.5 0.4 0.1 (0.0-0.3) 0.108 
plasmablast % 0.6 0.8 0.0 (-0.3-0.3) 0.971 
      
naive mature % 62.0 59.6 2.3 (0.4-4.1) 0.023 
resting memory % 35.3 37.6 -1.8 (-3.4-0.1) 0.061 
activated mature % 2.0 2.2 0.0 (-0.6-0.2) 0.471 
tissue like/ exhausted % 1.4 1.5 0.1 (-0.4-0.2) 0.728 
      
naive % 60.4 57.8 1.7 (0.3-3.3) 0.017 
IgD+ memory % 15.9 16.5 -1.1 (-2.4-0.2) 0.093 
switched memory % 19.5 19.1 -1.0 (-2.1-0.1) 0.072 
double negative % 3.6 3.4 -0.1 (-0.2-0.4) 0.631 
T cell subsets      
CD45RO+ % 50.2 48.9 -1.3 (-3-0.3) 0.075 
CXCR5+ % 19.5 19.7 1.4 (-2-4.2) 0.269 
CXCR5+ICOS+ % 0.2 0.2 0.1 (0.0-0.27) 0.164 
 
CP      
B cell subsets      
transitional % 1.5 0.9 0.4 (0.2-0.7) 0.001 
plasmablast % 0.9 0.8 -0.2 (0.0-0.49) 0.073 
      
naive mature % 76.4 75.8 1.4 (-0.15-2.94) 0.086 
resting memory % 15.2 16.7 -1.3 (-2.22--0.35) 0.008 
activated mature % 2.0 2.1 0.0 (-0.4-0.3) 0.927 
tissue like/ exhausted % 4.4 5.1 0.1 (-1.3-1.5) 0.963 
      
naive % 76.4 74.0 1.8 (0.4-3.3) 0.021 
IgD+ memory % 8.0 7.6 -0.5 (-1.1-0.3) 0.211 
switched memory % 10.5 11.9 -0.9 (-1.6-0.0) 0.049 
double negative % 5.3 5.6 -0.4 (-0.1-0.0) 0.062 
T cell subsets      
CD45RO+ % 36.0 35.7 -0.3 (-1.5-1.1) 0.659 
CXCR5+ % 23.6 24.1 -2.4 (-5.4-0.1) 0.050 
CXCR5+ICOS+ % 0.6 0.5 0.3 (0.1-0.5) 0.012 
 
Table 10.  B and T cell subsets at baseline compared with those at 6 months post immunisation for CP and AHC. Wilcoxon 
Signed Rank test was used to compare paired data and Hodges-Lehman median paired differences with 95% CI were 
calculated. Transitional (CD19+CD27-CD10+) and plasmablast (CD19+CD10-CD27+IgD-) cells reported as a proportion of CD19+ 
cells. Remaining B cell subsets reported as a proportion of CD19+ after exclusion of CD10+ and plasmablasts (naive mature 
(CD19+CD10-CD27-CD21+), resting memory (CD19+CD10-CD27+CD21+), activated mature (CD19+CD10-CD27+CD21-), 
exhausted/tissue like (CD19+CD10-CD27-CD21-), naive (CD19+CD10-CD27-IgD+), IgD+ memory (CD19+CD10-CD27+IgD+), 
switched memory (CD19+CD10-CD27+IgD-), double negative (CD19+CD10-CD27-IgD-)). CD45RO+ reported as a proportion of 
CD4+. CXCR5+ and CXCR5+ICOS+ reported as a proportion of CD4+CD45RO+.Significant decreases are highlighted in red, 
significant increases, in green. Only minor changes in proportion of B and T cell subsets occurred over 6 months and these 
were as might be expected with aging: lower proportions of naive subsets and higher proportions of memory subsets. (med diff 
= median difference, CP = Child patient, AHC = Adult healthy control) 
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Minor changes in B and T cell subset percentages occurred over 6 months following vaccination in both 
young healthy adults and children with paHIV. 
 
B cell subset percentages remained stable on the whole over 6 months any significant changes being 
relatively slight.  
 
For AHC, if classifying using CD27 vs. CD21, naive mature percentage decreased slightly (med diff= 2.3% 
(95%CI:0.4-4.1%) p=0.023). If using CD27 vs. IgD, naive percentage decreased slightly (med diff =1.7% 
(95%CI: 0.3-3.3%) p=0.017). 
 
For CP, transitional cell percentage decreased (med diff=0.4% (95%CI: 0.2-0.7%) p= 0.001). If classifying 
using CD27 vs. CD21, resting memory percentage increased (med diff= -1.3% (95%CI: -2.2- -0.35%) 
p=0.008). If using C27 vs. IgD, naive percentage decreased (med diff = 1.8%  (95%CI: 1.5-3.3%) p=0.021) 
and switched memory percentage increased (med diff = -.9% (95%CI: -1.64- -0.01%) p=0.049) although the 
latter was borderline significant. 
 
T cell subsets percentages also remained stable apart from CP CXCR5+ICOS+ percentages, which 
decreased (med diff= 0.3% (95%CI: 0.06-0.53%) p=0.011). 
 
There were no significant changes in any subset for the unvaccinated CP group over 6 months, although 
sample size was small and therefore conclusions are limited (data not included). 
 
As can be seen from the confidence intervals for median differences the variation in subsets over time was 
relatively minor with more rare populations showing a greater degree of variation relative to their absolute 
percentages. 
 
4.4.7 Impact of treatment history on lymphocyte, T and B cell subsets in children with paHIV 
Multiple linear regression was employed to investigate the relationship between lymphocyte, B cell and T cell 
subsets and clinical history for the CP group, while adjusting for age. Clinical variables assessed included 
viral load >50 RNA copies/ml (yes/no), treatment started in the 1st year of life (yes/no), treatment started in 
the 1st two years of life (yes/no), nadir CD4 %, and proportion of life with viral load <50 RNA copies/ml 
expressed as a percentage. Subset absolute numbers and percentages were log transformed and therefore 
the antilog of regression coefficients and confidence intervals are reported and should be interpreted as 
described in Section 4.4.4. The results of this regression analysis for effects of detectable viral load and 
proportion of life undetectable are shown in Tables 11 and 12. 
 
Alterations in lymphocyte subsets are associated with detectable viraemia, while higher CD4 percentages 
are associated with a higher proportion of life spent with an undetectable viral load. 
 
From Table 11 it can be seen that after adjusting for age, having a detectable viral load was associated with 
significantly lower CD4+ and CD56+ cell counts (p<0.0001 and p=0.021 respectively) and percentages 
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(p<0.0001 and p=0.005 respectively) and higher CD8+ counts (p=0.002) and percentages (p<0.0001). A 
larger proportion of life with undetectable viral load was associated with higher CD4+ counts (p=0.001) and 
percentages (p<0.0001) and lower CD8+ counts (p=0.004) and percentages (p<0.0001) having adjusted for 
age. However after adjusting for detectable viraemia only a higher CD4 percentage was significantly 
associated with a longer proportion of life spent with undetectable viral load.  
 
Treatment in the first year of life was also found to be associated with higher CD4 percentage after adjusting 
for age and detectable viraemia (antilog regression coefficient = 1.3233 (95%CI: 1.0848-1.6144) p= 0.0070). 
There was no association of nadir CD4% or treatment in the first 2 years of life with any lymphocyte subset 
after adjusting for age and detectable viraemia.  
 
 
 
 
Detectable viraemia is associated with higher proportions of activated and tissue like/ exhausted memory B 
cells whereas a higher proportion of life spent with undetectable viraemia is associated with higher IgD+ and 
class switched memory B cells 
 
From Table 12 it can be seen that after adjusting for age, and when subdividing B cells using CD21 vs. 
CD27, undetectable viral load was associated with lower proportions of activated mature and tissue like/ 
exhausted memory B cells (p= 0.003 and p<0.0001 respectively) and correspondingly higher proportions of 
resting memory and naive mature B cells (p=0.001 and p=0.025 respectively). When using IgD vs. CD27, 
 VL detectable (yes/no) Percentage of life VL undetectable  
 antilog 
coef 
antilog 95%CI p  antilog 
coef 
antilog 95%CI p 
lymphocyte abs         
cd3 abs         
cd3%         
cd4 abs 1.696 1.312 - 2.191 <0.0001 1.007 1.003 - 1.012 0.0010 
cd4% 1.765 1.489 - 2.092 <0.0001 1.008 1.005 - 1.011 <0.0001 
cd8 abs 0.644 0.491 - 0.845 0.0020 0.994 0.989 - 0.998 0.0040 
cd8% 0.668 0.565 - 0.789 <0.0001 0.995 0.992 - 0.997 <0.0001 
cd19 abs         
cd19%         
cd56 abs 1.757 1.090 - 2.830 0.0210     
cd56% 1.854 1.210 - 2.840 0.0050     
 
Table 11. Results of separate linear regression analyses for viral load detectable and proportion of life undetectable after adjusting for 
age. Antilog of regression coefficients and 95% CI and corresponding p values are reported. Only results with a p value of <0.05 are 
shown for simplicity. After adjusting for age, having a detectable viral load was associated with significantly lower CD4+ and CD56+ cell 
counts and percentages and higher CD8+ counts and percentages.A larger proportion of life with undetectable viral load was associated 
with higher CD4+ count and percentage and lower CD8+ count and percentages, having adjusted for age. However after adjusting for 
detectable viraemia only a higher CD4percentage was significantly associated with a longer proportion of life spent with undetectable viral 
load. (abs = absolute cell count in cells/µl, VL = viral load, coef= regression coefficient) 
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undetectable viral load was associated with higher class switched memory B cell proportions (p=0.048). 
Typical contour plots for CD27+ vs. CD21 for a viraemic child compared to a child with VL < 50 copies/ml are 
shown in Figure 16 a) and b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A larger proportion of life spent with undetectable viral load was associated with a higher proportion of 
resting memory, IgD+ memory and class switched memory B cells (p<0.0001, p=0.014 and p=0.001 
respectively). These associations remained significant at the p<0.05 level after adjusting for detectable 
viraemia. Lower tissue like/ exhausted memory B cells were also associated with a larger proportion of life 
spent undetectable (p=0.002), however this was non-significant at the p<0.05 level after adjusting for 
detectable viraemia. 
 
No association was found between any B cell subset and treatment commenced in the 1st year of life, 
treatment commenced in the 1st two years of life or nadir CD4%. 
 
Treatment in infancy and a larger proportion of life with undetectable viral load are associated with lower 
CD45RO+ T helper cell proportions 
 
As can be seen in Table 12, after adjusting for age, a larger proportion of life spent undetectable was 
associated with lower proportions of CD45RO+ T helper cells (p=0.026). In addition treatment commenced in 
the first year of life was also associated with lower CD45RO+ cell proportions (antilog regression coefficient = 
0.7494 (95%CI: 0.5936-0.9460) p= 0.0160). These associations remained significant at the p<0.05 level after 
correcting for detectable viraemia. No other association was found between T cell subsets of interest and 
clinical parameters assessed.  
 
 
Figure 16 a) and b). Typical contour plots demonstrating the marked differences observed when plotting CD19+CD10- cells 
as CD27 vs. CD21. Note how detectable viral load is associated with an over representation of CD21- populations ie. 
activated mature (CD27+CD21-) and tissue like/exhausted (CD27-CD21-) cells. 
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In summary, the differences in T and B cell subsets observed in children with paHIV are more pronounced in 
children not on fully suppressive HAART. However as described above, abnormalities in B cell memory 
populations are observed even when children are successfully treated. More severe abnormalities are also 
associated with a longer proportion of life spent with a detectable viral load.  
 
 
 
 
4.4.8 Correlation between T cell subset and B cell subset phenotype 
 
Linear regression of log transformed subset data was used to assess correlation between T cell subsets and 
B cell subsets in the CP group after adjusting for age. Log transformation of both the dependent and 
independent variable affects interpretation of the regression coefficient. If the regression coefficient = β, then 
a 10% increase in the independent variable would predict the dependent variable to increase by a factor of 
1.10^β. For example, if the coefficient is 0.9 then a 10% increase in the independent variable predicts the 
dependent variable to increase by a factor of 1.100.9 = 1.09 i.e. an approximately 9% increase. If the 
coefficient = 0.5 then a 10% increase in the independent variable predicts the dependent variable to increase 
 VL detectable (yes/no) Percentage of life VL undetectable 
 antilog 
coef 
antilog 95%CI p  antilog 
coef 
antilog 95%CI p 
B cell subsets         
transitional % 0.584 0.360 - 0.948 0.0300     
plasmablast %         
         
naive mature % 1.167 1.020 - 1.335 0.0250     
resting memory % 1.863 1.302 - 2.666 0.0010 1.013 1.008 1.018 <0.0001 
activated mature % 0.399 0.220 - 0.722 0.0030     
tissue like/ exhausted % 0.406 0.260 - 0.634 <0.0001 0.988 0.981 0.996 0.0020 
         
naive %         
IgD+ memory %     1.007 1.002 1.013 0.0140 
switched memory % 1.517 1.003 - 2.294 0.0480 1.011 1.005 1.017 0.0010 
double negative %          
T cell subsets         
CD45RO+ %     0.997 0.994 0.999 0.0260 
CXCR5+ %         
CXCR5+ ICOS+ %         
 
Table 12. Results of separate linear regression analyses for viral load detectable and proportion of life undetectable after 
adjusting for age. Antilog of regression coefficients and 95% CI are reported. Transitional (CD19+CD27-CD10+) and plasmablast 
(CD19+CD10-CD27+IgD-) cells reported as a proportion of CD19+ cells. Remaining B cell subsets reported as a proportion of 
CD19+ after exclusion of CD10+ and plasmablasts (naive mature (CD19+CD10-CD27-CD21+), resting memory (CD19+CD10-
CD27+CD21+), activated mature (CD19+CD10-CD27+CD21-), exhausted/tissue like (CD19+CD10-CD27-CD21-), naive 
(CD19+CD10-CD27-IgD+), IgD+ memory (CD19+CD10-CD27+IgD+), switched memory (CD19+CD10-CD27+IgD-), double negative 
(CD19+CD10-CD27-IgD-)). CD45RO+ reported as a proportion of CD4+. CXCR5+ and CXCR5+ICOS+ reported as a proportion of 
CD4+CD45RO+.Only results with a p value of <0.05 are shown for simplicity. Having a detectable viral load was associated with 
higher transitional, activated mature and tissue like/exhausted percentages and lower naïve mature, resting memory and 
switched memory percentages. A higher percentage of life spent with undetectable viral load was associated with higher resting 
memory, IgD+ memory and switched memory percentages and lower CD45RO+ T cell percentage.(abs = absolute cell count in 
cells/µl, VL = viral load, coef= regression coefficient) 
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by a factor of 1.100.5 = 1.05 i.e. an approximately 5% increase. Negative coefficients indicate a negative 
correlation between dependent and independent variable.  
 
In children with paHIV, memory B cell proportions correlate with CD4 percentage 
 
Out of the T cell subsets of interest (CD4+, CD4+CD45RO+, CD4+CD45RO+CXCR5+, 
CD4+CD45RO+CXCR5+ICOS+) only CD4 percentage was found to significantly correlate with B cell subsets 
after adjusting for age. CD4 percentage significantly correlated with resting memory B cell percentage 
(regression coefficient = 0.957, (95%CI: 0.564-1.350) p<0.001) tissue like/ exhausted memory B cell 
percentage (regression coefficient =-0.903, (95%CI: -1.459- -0.348) p=0.002) IgD+ memory B cell 
percentage (regression coefficient =0.478, (95%CI: 0.042-0.915) p=0.032) and class switched memory B cell 
percentage (regression coefficient =0.791, (95%CI: 0.329-1.254) p=0.001). After correcting for detectable 
viraemia, the correlation with tissue like/ exhausted memory B cells was non-significant at the p<0.05 level. 
Overall this indicates that any given age a higher CD4 percentage is associated with a higher proportion of 
resting memory B cells (if using CD27 vs. CD21 to classify) and higher proportions of class switched and 
IgD+ memory B cells (if using CD27 vs. IgD to classify).  
 
 
4.5 Discussion 
 
This work has expanded upon the few existing published reports on perturbations in B cell phenotype in 
children with paHIV. We have confirmed that abnormalities of B cell phenotype persist despite effective 
HAART and that this is impacted upon by the proportion of life spent with an undetectable viral load. We 
have also shown for the first time that circulating CD45RO+CXCR5+ follicular like T helper cells are 
decreased in children with HIV when compared to healthy controls. 
 
Age related changes in lymphocyte subsets are well documented [84, 85, 154, 345, 356, 360, 361]. Changes 
in lymphocyte subset absolute number and proportion are most dramatic in the first 2 years of life, thereafter 
changes are more gradual through childhood, adolescence and in to early adulthood. Differences between 
the young adult and child groups were therefore to be expected.  
 
The median ages of the CHC, CP and AHC group were 9, 13 and 27 years respectively. If the children in the 
CP group were not HIV infected, it would be reasonable to predict (in view of their slightly older age) that 
their lymphocyte subsets would be more similar group to those of the AHC group. However we have 
demonstrated that in the context of paHIV, lymphocyte subsets significantly differ from those of healthy 
young adults, much more so than expected due to differences in age. This is despite the majority of children 
(78.6%) being on fully suppressive HAART.  
 
The healthy children in the study had a higher median absolute lymphocyte count, B cell count and B cell 
percentage and a lower median NK cell percentage than the young healthy adults. This is consistent with 
published data [84, 85, 154, 345, 356, 360, 361]. All of these differences were present in the HIV infected 
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children, however in addition they had a lower median CD4 percentage and absolute NK cell count and 
higher median CD8 absolute cell count and percentage. As well as being of relevance for the analysis of 
vaccine specific cytokine responses in Chapter 6, this is also indicative of persistent lymphocyte 
abnormalities in the HIV infected children on HAART. 
 
Further evidence to this effect was provided by direct comparison of healthy children with HIV infected 
children. CD4 absolute cell counts are expected to decrease with age however the difference between 
younger and older children were much more extreme for HIV infected children, older HIV infected children 
having lower CD4 counts than uninfected children of a similar age. CD4 percentages are expected to be 
higher in older healthy children however the opposite was true of the HIV infected children. CD8 absolute cell 
counts are expected to be lower in older children. This was true for both healthy and HIV infected children, 
however the latter had consistently higher CD8 absolute cell counts than uninfected children throughout 
childhood. CD8 percentages are expected to remain relatively constant throughout childhood, if anything 
increasing slightly. This was found for healthy control children, however the CD8 percentages were much 
higher in older HIV infected children. NK cell numbers are expected to be slightly lower in older children. This 
pattern was observed in HIV infected children but to a greater extent than in healthy children. There were no 
significant differences between healthy and HIV infected children with respect to absolute B cell counts and 
percentages and NK percentages, which followed the expected age related patterns of change. [84, 85, 154, 
345, 356, 360, 361]. 
 
Overall these observed differences in lymphocyte subsets are consistent with published data on immune 
reconstitution in HAART treated children. It has been demonstrated that despite suppressive HAART, some 
children continue to have lower CD4 percentages. It is also well recognised that CD8 cell counts and 
percentages remain elevated when the HIV viral load is undetectable [95, 362-366]. NK cells are less well 
studied in HIV infected children, with conflicting reports. It has been shown that there is no difference in NK 
cells between HIV infected and uninfected children, however, it has also been reported that NK cells 
numbers and proportions are lower than in healthy controls [173, 175]. Our data indicates lower absolute 
counts in older children but no differences in NK cell percentages, which may to some extent explain 
conflicting findings to date.  
 
These differences in lymphocyte subset might be explained by viraemic children being included in the 
analysis. However these were relatively few in number and the age, group and interaction effects remained 
significant after adjusting for detectable viraemia.  
 
There are many possible reasons for incomplete immune reconstitution on HAART. It is interesting to 
speculate that these persistent abnormalities may, to some extent, be related to the historical deferral of 
treatment until lower CD4 thresholds than is currently practice. Recent evidence suggests that this may be 
the case for ultimate CD4 count recovery potential in children with paHIV [367]. 
 
There is less published data on normal B cell subset variation with age, but proposed reference ranges are 
available for a proportion of the subsets assessed in this study.  As with lymphocyte subsets there are 
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changes in absolute count and percentage throughout childhood and therefore it is expected that the 2 child 
groups will differ from the young adult group.   
 
At time of writing there are published reference ranges for transitional cells and plasmablasts, and for 
subsets as defined by CD27 vs. IgD, albeit with slightly varying gating strategies and methods for reporting 
proportions (usually percentage of total B cells) [84, 154, 360, 368, 369].  However as yet there is to our 
knowledge, no published data on natural changes in subsets defined by CD27 vs. CD21 with age.  
 
When comparing healthy young adults with healthy children, we observed differences in B cell subsets that 
are consistent with published reference ranges. Adults had higher proportions of IgD+ and class switched 
memory and correspondingly lower proportions of naive and double negative B cells.  Adults also had a 
lower proportion of transitional B cells. If subdividing B cells by CD27 and CD21 expression, children had 
higher proportions of naive and tissue like/ exhausted memory B cells than young adults and a lower 
proportion of resting memory B cells. There was no significant difference in the proportion of activated 
mature B cells. This pattern of differences in B cell subsets was also true for the HIV infected children when 
compared as a whole with the healthy young adults. These findings are consistent with both of the child 
groups having less CD27+ memory B cells than young healthy adults.   
 
Despite these apparent similarities when comparing the child groups with the young adult group individually, 
further direct comparison between the HIV infected and uninfected children revealed additional differences in 
B cell subset distribution. After adjusting for age, children with HIV had lower IgD+, class switched and 
resting memory B cell proportions and higher naive B cell proportions, although the difference in class 
switched memory B cells was non-significant after correcting for viraemia.  
 
Four other groups have investigated some or all of these populations in HIV infected children. Jacobsen et al 
[166] used IgD and CD27 to characterise B cell subsets. They reported lower IgD+ memory B cell proportions 
in children with suppressed viral load on HAART, which is in agreement with our data. In contrast to our data 
they report no difference in these subsets when comparing viraemic children with healthy children, leading 
them to suggest that detectable virus may in some way sustain numbers of this subset. Our data are more in 
keeping with observations by our group in HIV infected adults, which show reduction in IgD+ memory B cells 
proportions irrespective of treatment status [162]. Ghosh et al also reported decreased IgD+ memory B cells 
in HIV infected children compared to healthy controls, however they do not report differences between 
viraemic and aviraemic children [167].  Iwajomo et al studied a large cohort of untreated HIV infected 
children in Africa and found there to be decreased IgD+ memory B cells compared to healthy children, 
however they report analysis of only absolute cell counts rather than number which limits direct comparison 
[169].  
 
Jacobsen et al found no significant difference in class switched memory B cell percentages between HIV 
infected and healthy children [166]. We have shown a lower proportion of switched memory percentages in 
children with HIV however this was non significant after adjusting for viraemia, detectable virus being 
associated with lower class switched memory B cells. This is more in keeping with Ghosh et al, who report 
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lower proportions of class switched memory B cells in children with HIV compared to healthy controls and 
lower class switched memory B cells to be associated with higher HIV viral load [167]. It is also consistent 
with Cagigi et al who have shown decreased proportions of class switched memory B cells in older HIV 
viraemic children but not those with undetectable virus [344].  Iwajomo et al found no difference in class 
switched memory B cells, however again it should be noted that they report absolute cell counts and not 
proportions [169].  
 
In an adult study, our own group found low class switched memory B cells in a proportion of HIV infected 
patients, but there was no significant difference between viraemic and non-viraemic patients [162].  
 
Only one paediatric study has reported on B cell subpopulations characterised using CD21 and CD27. 
Iwajomo et al report on a cohort of HIV infected children that were not as yet on HAART. They found 
decreased percentages of naive mature and resting memory and higher percentage of activated mature. 
These changes were evident even in children with relatively high CD4 percentages. They did not report on 
tissue like/ exhausted memory B cells [169].  
 
We found resting memory percentages to be lower in the HIV infected children when comparing them with 
the healthy control children. However when evaluating the effects of detectable viral load on these subsets 
within the patient group we found viraemia to be associated with significantly higher activated mature B cells 
and tissue like/ exhausted B cell proportions and lower resting memory and naive mature B cell proportions 
which is consistent with the findings of Iwajomo et al [169].  
 
When comparing the HIV infected group of children as a whole with healthy control children we found no 
difference in the proportion of transitional B cells. Within the HIV infected group there was a significant effect 
of viraemia, children with a detectable viral load having a higher proportion of transitional B cells. Cagigi et al 
demonstrated that viraemia was associated with a lack of physiological age related decline in transitional 
cells [344], consistent with our findings, whereas Iwajomo et al found no significant difference between 
viraemic HIV infected and control children [169]. Malaspina et al have shown transitional cell percentages to 
be increases in adults and to correlate with CD4 lymphopenia and raise serum IL7, leading them to 
hypothesise a causal relationship between low CD4 count and increased transitional cells. This is supported 
by the observations by the same group that these correlations are also observed in patients with idiopathic 
CD4 lymphocytopenia [355, 370]. Cagigi et al found that in children with paHIV, the age related physiological 
decrease in transitional cell proportions is lost and that this is related to detectable viraemia and did not 
correlate with CD4 count. Serum IL7 concentrations were decreased compared to healthy controls [344]. 
This suggests a possibly distinct mechanism for increased transitional cell proportions in children with paHIV.  
 
Published reference ranges for CD45RO+ cell percentages for the paediatric age range are available [84, 
85]. These clearly show a natural increase in the proportion of CD4+ that are CD45RO+ throughout 
childhood. In accordance with this, our data show that both child groups had lower CD45RO+ cell 
percentages than the young adult group. When comparing the HIV infected children with the healthy control 
children as a whole there were also found to be no significant differences. Studies in the pre HAART era 
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have shown that the proportions of CD4+ cells positive for CD45RO+ are higher for young children with HIV 
but lower for older children when compared with healthy controls [371, 372]. Later studies have shown that 
HAART treated children with a low CD4 count have a higher proportion of CD45RO+ cells whereas children 
on HAART with a normal CD4 count have similar proportions to healthy controls [114, 373]. The fact that the 
majority of children have relatively preserved CD4 percentages (11 children less than 25%, 10 of whom have 
detectable viral load) could explain why there are no statistically significant differences in this marker. CD4 
percent did, however show a strong negative correlation with CD45RO percent in the CP group (data not 
reported).  
 
Only one paper to our knowledge has published reference ranges for CD45RO+CXCR5+ cells for children. 
Schatorjé et al demonstrated that the proportion of CD4+CD45RO+ cells that are positive for CXCR5 is stable 
at around 20% from around 2 years of age through to adult life if anything decreasing slightly with age [345]. 
Our data comparing the child groups with the young healthy adults shows them to have higher median 
proportions of this subset. Direct comparison of HIV infected children with healthy children demonstrated HIV 
infected children to have lower proportions of this subset after adjusting for age.  
 
Of the clinical parameters examined for effects on lymphocyte and B and T cell subsets, detectable viraemia 
and the proportion of life with undetectable viral load appear to have the greatest impact. Detectable 
viraemia is associated with lower CD4 and NK cell percentages and higher CD8 percentages. It is also 
associated with higher proportions of transitional, activated mature and tissue like/ exhausted memory B 
cells and lower proportions of naive mature, resting memory and class switched memory B cells.  
 
It is of particular interest that within the HIV infected group, having detectable viraemia does not have a 
significant effect on naive and IgD+ memory percentages nor on CD45RO+CXCR5+ percentages. As 
mentioned above, these populations were lower in HIV infected children than healthy control children. This 
then reinforces the point that changes in these subsets are not fully corrected by suppressive HAART 
 
A larger proportion of life spent with undetectable viral load is associated with a higher CD4 percentage, 
higher proportions of resting memory, IgD+ memory and switched memory B cells and lower proportion of 
CD45RO+ T cells. Treatment commenced in the first year of life was associated with higher CD4 percent and 
lower CD45RO+ percent. As discussed above, publications to date have reported conflicting results with 
respect to the effects of viraemia on B cell subsets [166, 167, 169, 344]. Seen together with our results it 
now seems very clear that detectable viraemia has a substantial impact on B cell phenotype, specifically in 
relation to CD21 expression, activation and exhaustion, in much the same way has been shown in adults 
with HIV infection [120]. 
 
It has been suggested that for children with paHIV, the timing of HAART commencement and consequently 
the proportion of life spent with undetectable viral load impacts on potential for immune reconstitution of both 
the T cells compartment [367] and the B cell compartment [168, 203]. Similar findings in adults  [165, 374], 
along side an increasing body of clinical evidence of benefit, have contributed to reconsideration of current 
American adult treatment guidelines and a decision to offer HAART to all patients irrespective of CD4 count/ 
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stage of disease [375]. Our findings are consistent with a view that allowing a child to remain viraemic is 
associated with significant B cell phenotypic changes and that the longer a child is on suppressive HAART 
the better in terms of preventing possibly irreversible changes to B cell phenotype. This in turn is likely to 
have significant implications for the HIV infected child’s potential to respond to vaccines dependent on 
antibody responses for protective efficacy. 
 
As discussed in Section 1.1.4 the development of class switched memory B cells is dependent on T-B 
interaction in the germinal centres of secondary lymphoid organs. Follicular T helper cells, through direct cell 
contact and cytokine production contribute to the development of class switched, affinity matured B cells 
which exit the germinal centre reaction to become either memory B cells or long lived plasma cells. It 
therefore seems likely that HIV induced perturbations of T cell phenotype and function will have direct effects 
on B cell development and phenotype. Consistent with this view we have shown a higher CD4 percentage to 
be associated with higher resting memory B cells and class switched memory B cells (depending on how 
subsets are characterised). We have also shown that higher CD4+ T cells are associated with a higher 
percentage of IgD+ memory B cells, a subset not known to be dependent on T cells for their development. 
This is suggestive of the likely possibility that other factors contribute to B cell abnormalities in the context of 
HIV infection.  
 
Lymphocyte, B and T cell subsets changed in frequency over time to a certain extent, more so for the HIV 
infected children than the healthy adults. It is not possible to determine the significance and cause of these 
changes, partially as a result of the fact numbers in the paediatric unvaccinated cohort were small and it was 
not a randomised, placebo controlled study. All of the observed changes are consistent with those expected 
with ongoing aging of the immune system and as described above, these changes are less rapid in early 
adulthood than in childhood. Other contributory factors in the child patient group are ongoing immune 
reconstitution as a result of HAART and effects of vaccination. This study was not designed to assess this, 
however these results are important to note when considering the results of antigen specific cytokine release 
assay in Chapter 6. 
 
We have shown that these two flow cytometric panels allow assessment of some of the key T and B cell 
subsets thought to be involved in effective humoral immune responses and that these subsets remain 
relatively stable over a 6 months period in children infected with HIV. This suggests their use should 
therefore be encouraged in studies of antibody responses in children with not just HIV but other forms of 
congenital and acquired immune deficiency. In conjunction with flow cytometric techniques for detection of 
antigen specific T and B cell (e.g. tetramer staining and fluorescent labelled antigen respectively) it should be 
possible to elucidate the respective roles of the cell types involved in the response to T dependent antigens 
in humans.  
 
HIV infection in humans, although not directly infecting B cells, is known to be associated with multiple B cell 
abnormalities including increased cell turnover [376], activation [159, 377], apoptosis [377, 378], exhaustion 
[359], cell death [376], terminal differentiation [158], immature phenotype [355], hypergammaglobulinaemia 
[1, 379], B cell malignancy [380] and autoimmunity [381, 382]. 
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The reasons for B cell dysfunction and phenotypic abnormalities in HIV infection are still not completely 
delineated [40, 120, 383-385], however it is clear that it a multifactorial process.  
 
Animal models can be employed to some extent to clarify the pathogenic mechanisms of immune 
dysfunction relating to humoral immunity observed in HIV infection. Recent studies of SIV infection in non-
human primates have served to delineate in some detail the changes that occur in lymphoid architecture, TFH 
and their associated B cells in lymph nodes and peripheral blood in the acute and chronic stages of infection 
[59] [386] [387-390]. A common finding of these studies and investigation of acute/early HIV infection in adult 
humans [160, 165], is that dramatic changes occur in B cell phenotype, function, activation status and 
distribution at the very earliest stages of retroviral infection, and that early ART, to some extent can reverse 
this process. On the other hand, starting HAART in chronic HIV infection leads to a less complete 
nomalisation of the B cell compartment [158, 159, 162, 165]. 
 
Since the earliest days of the HIV epidemic, HIV has been known to have direct effects on B cells [391]. HIV 
may have direct effects on B cells via complement bound to  virus particles binding surface CD21, although 
the levels of cell associated virus are relatively low and therefore this is not likely to be a main contributing 
factor [392]. HIV associated proteins e.g. Negative Regulatory Factor (Nef) [393-395] and gp120 [396] have 
been shown to affect B cell function [383]. Disruption of secondary lymphoid tissue architecture and lymph 
node fibrosis has been shown in both SIV models [390] and human HIV infection [397, 398]. Altered 
germinal centre homing chemokine receptor expression on B cells has also been demonstrated [399]. In 
both children and adults, it is now generally accepted that a key contributory factor in progressive disruption 
of B and T cell immunity associated with HIV infection is generalised immune activation [40, 384, 400]. The 
precise mechanism of this immune activation is still not completely clear however there is a growing body of 
evidence supporting a role of translocation of microbial products such as LPS from the gut, homeostatic 
response to lymphopenia, direct viral effects and indirect viral effects through alteration of the cytokine milieu 
and cell-cell signalling [40, 383, 384, 401-403].  
 
In the absence of HIV infection, there is increasing evidence of reciprocal relationship between B cell 
development and T cell development especially relating to TFH in the context of the germinal centre [137, 
404, 405]. It is therefore interesting to speculate that T cell independent abnormalities of B cell phenotype 
brought about by HIV infection, may in turn affect TFH development. B cells already compromised by HIV 
infection prior to T cell contact would not only respond less effectively to help from (also impaired) CD4+ T 
cells but also prevent effective further development of TFH. Add to this the fact that the follicular dendritic cell 
network is also directly affected by HIV [406], then the 3 major players in the GC reaction are compromised 
before they have even encountered each other and one might predict that further development of both T and 
B cells within this microenvironment might be impaired. This concept can be expanded to hypothesise an 
important contribution of disrupted B cell effector/regulatory activity to T cell abnormalities in HIV 
pathogenesis [407]. 
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Little is known about the role of TFH in HIV infection in general and how they might be implicated specifically 
in relation to disruption/dysregulation of humoral immunity.  In 1997, in one of the first papers to describe 
circulating CD4+CD45RO+CXCR5+ cells, Forster et al found the proportion of this subset to be lower in adults 
with HIV than in healthy controls [210]. In the intervening 15 years there has been an ever-expanding 
literature characterising these cells in detail in the germinal centres of mice, accompanied by frequent debate 
on the relationship between these “true” follicular T helper cells and the circulating equivalent in humans. It 
has recently been more accepted that although phenotypically quite different to their lymph node resident 
counterparts, circulating TFH-like cells are indeed directly related and therefore of relevance to both normal 
and dysregulated humoral immunity [207, 208, 346]. Despite the well-documented defects observed in 
humoral immunity in HIV infection, there has been very little further work until now investigating the effect of 
HIV on this subset in humans. Mounting evidence for their involvement in dysregulated humoral immunity in 
autoimmune diseases such as SLE and dermatomyositis [208, 408], further supports their likely importance 
in the context of paHIV. 
 
Rabian et al, in a study of pneumococcal vaccines in HIV infected adults, found an association between 
higher TFH cell counts and more robust in vitro cellular response to vaccine carrier protein, however they 
reported only circulating TFH-like cell numbers and did not compare with healthy controls [48]. Pallikuth et al 
report no difference from healthy controls in the frequency of circulating TFH (defined as CD4+CXCR5+) in 
chronically HIV infected adults with good CD4 counts and suppressed virus. They demonstrated that 
expansion of antigen specific IL21 producing TFH with the capacity to provide B cell help one month post 
immunisation was a characteristic of those patients who responded successfully to 2009 H1N1/09 flu 
vaccine. In addition post vaccination TFH frequency correlated positively with memory B cell frequency and 
H1N1 antibody titres [47]. 
 
Yue et al found there to be a higher proportion of IL21 producing CD4 cells in peripheral blood of HIV 
infected adults. These cells were of effector memory phenotype, enriched for CXCR5 and HIV specificity. 
They did not however report overall frequency of CXCR5+ T helper cells [348]. Lindqvist et al report data on 
lymph node histology from chronically HIV infected adults compared to healthy controls. Interestingly, they 
found HIV infected lymph nodes to have high frequency of IL21 producing TFH in lymph nodes irrespective of 
HAART status. These cells were found to be responsive to HIV antigens and their frequency correlated with 
higher plasma cell and germinal centre cell B cell and lower late memory B cell frequency (as classified by 
IgD and CD38) [46]. At the 2012 Conference on Retroviruses and Opportunistic Infections (CROI), Connick 
et al presented data on ex vivo infection of human lymphoid tissue with HIV and found CXCR5+ T helper cells 
to be more permissive to HIV infection than CXCR5- T helper cells [409]. The Lindqvist study highlights the 
importance of considering the limitations of studies of peripheral blood immune phenotype and reminds us 
that changes in cell subsets in the periphery may represent redistribution rather than a change in overall cell 
numbers. 
 
One clear limitation of our study is the choice of surface markers used to identify B cell and T cell subsets 
and the possibility that they may not reliably identify distinct subsets. The reasoning behind the choices of 
markers used and their limitations is discussed in Section 4.3, however it should be again noted that 
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additional transitional (CD24, CD38) and plasmablast (CD24, CD38, CD138) markers as well as markers of 
class switch, immune activation and exhaustion would have enhanced our B cell findings, allowing further 
detailed characterisation of the observed phenotypic abnormalities. The debate as to the origin and function 
of circulating CD4+CXCR5+ T cells is ongoing. Shane Crotty, a key player in the TFH world, recently 
presented data at the Keystone Conference on Immunological Mechanisms of Vaccination (Ottawa, Canada, 
2012), further characterising this subset with the addition of the markers PD-1 and CXCR3 to more 
specifically identify a true circulating counterpart to TFH cells. We hope that our data might provide a piece of 
the jigsaw in the quest to understand this CXCR5+ population and how it may or may not be involved in the 
response to T cell dependent vaccine antigens in both healthy and HIV infected individuals. 
 
4.6 Conclusion 
 
Taken together, findings from this work, other studies of humans HIV infection and non-human primate SIV 
models, are indicative of a complex interplay between HIV, TFH and B cells in lymphoid tissue and peripheral 
circulation, to the detriment of humoral immunity, which is only partially corrected by HAART. Current 
evidence suggests there may be an accumulation of HIV specific and/or infected TFH in lymph nodes, which 
correlates with altered lymph node B cell phenotype. This is reflected in altered T and B cell phenotype in the 
peripheral blood, which in turn can be correlated with impaired response to vaccination. To our knowledge, 
this is the first study of circulating TFH in children with paHIV either in relation to B cell phenotype or vaccine 
responses. Our results not only emphasise that T and B cell abnormalities persist in children with HIV 
despite suppressive HAART, but also suggest that earlier and sustained HAART may well serve to maximise 
potential for normal immune development. 
 
It is likely that the impact of HIV and HAART on the child’s relatively naive and developing immune system 
will have implications for humoral immunity that may differ from the limited observations in adults to date. 
The majority of vaccinations are administered in childhood, and are expected to give life long protection 
against vaccine preventable disease [189]. This should be borne in mind when considering treatment options 
and timing of vaccinations in this especially vulnerable group. 
 
The next chapter will examine how observed phenotypic differences in this cohort of children with paHIV 
relate to serological response to the 13-valent pneumococcal conjugate vaccine 
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Chapter 5: Pneumococcal serology 
 
5.1 Introduction 
 
5.1.1 Pneumococcal vaccination and the HIV infected child 
HIV infected children are at increased risk of invasive pneumococcal disease. HAART reduces this risk to 
some extent yet it is still greater than that of the HIV uninfected population [270-272]. Pneumococcal 
polysaccharide vaccine has been available for many years and its use is currently recommended in the UK 
for children over the age of 2 years that are particularly at risk of pneumococcal disease, including those with 
HIV [284], despite a lack of evidence of efficacy in children with paHIV and very limited, and somewhat 
controversial evidence of efficacy in adults with HIV [270, 271]. Pneumococcal conjugate vaccines have 
proven efficacy when administered to HIV infected infants [312, 327] and adults [330]. They are therefore 
likely to be efficacious in older children and adolescents with paHIV.  
 
5.1.2 Immunogenicity in older children with paHIV: a special case? 
Studies of pneumococcal conjugate vaccines in HIV infected individuals of all ages have mainly shown that 
immunogenicity is impaired in comparison to healthy controls [271]. When considering the effects of HIV 
infection on responses to pneumococcal vaccines it is important to acknowledge that a different pattern of 
impairment may be present in older children with paHIV compared to HIV infected infants or adults.  
 
The infant’s immune system is relatively naive to pneumococcus and also functionally immature. The 
response to pneumococcal conjugate vaccine will be in the main part, a primary one, on the background of 
an immature immune system trying to cope with the frequently high viral loads and rapid progression 
associated with infant HIV infection. On the other hand, adults with horizontally acquired HIV become 
infected when they have already encountered and established a certain degree of immunity to many of the 
pathogenic pneumococcal serotypes. The response to pneumococcal vaccination in this context will be 
determined in part by the specific impact that HIV has on the fully developed and pneumococcal antigen 
experienced immune system. The older child with paHIV has survived infancy but their immune system has 
developed (and is still developing) under the influence of HIV, with or without the benefit of HAART. They will 
have developed a certain degree of pneumococcal immunity through natural exposure but this will have 
been modified by alterations of both the innate and acquired immune system caused by HIV. Any 
abnormality of immune phenotype found to be characteristic of this patient group, is likely to contribute to 
similarly characteristic responses to pneumococcal conjugate vaccine.  
 
There are few studies of licensed pneumococcal conjugate vaccine in older HIV infected children and no 
published data to date on PCV13 in any HIV infected age group [271]. Through studying serological 
responses to PCV13 and relating them to abnormalities of immune phenotype in older children with paHIV, 
we hope to not only provide immunogenicity data, but also to use the vaccine as a probe in order to clarify 
the nature of the persistent defects of humoral immunity observed in children on HAART [168, 190].  
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5.2 Chapter Aims 
 
i) To assess baseline serotype specific pneumococcal serology in children with paHIV compared to healthy 
children and healthy young adults using ELISA and to compare pre-existing functional immunity for selected 
serotypes using OPA. 
 
ii) To assess immunogenicity of PCV13, 1 month post immunisation in children with paHIV compared to 
healthy young adults using ELISA. 
 
iii) To assess persistence of serotype specific pneumococcal antibody, 6 months post immunisation in 
children with paHIV compared to healthy young adults using ELISA. 
 
iv) To assess pneumococcal nasopharyngeal carriage in children with paHIV compared to healthy children 
and healthy young adults. 
 
v) To investigate association between both clinical and immunological parameters and the serological 
response to PCV13 in children with paHIV. 
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5.3 Statistical analysis 
 
For baseline comparisons, Chi2 and Fisher’s exact test were used to compare proportions. Mann-Whitney U 
test was used to compare baseline age and for contrasting baseline cell subset data between child and adult 
groups. Hodges-Lehman median differences with 95% confidence intervals were also calculated. For direct 
comparison of cell subsets from the two child groups, data was log transformed and compared using linear 
regression analysis to allow for adjustment for age and to assess age*group interactions. Mann-Whitney U 
test was used to compare time between vaccination and blood sampling between groups. Chi2 and Fisher’s 
exact tests were used to compare baseline proportions above a cut off antibody concentration between 
groups. One way analysis of variance (ANOVA) with Bonferroni correction was used to compare log 
transformed antibody concentrations at baseline between the 3 groups.  
 
Chi2 was used to compare proportions above a cut off antibody level between groups at each time point post 
immunisation and McNemar’s test was used to detect changes in proportion from baseline within groups. 
Repeated measures ANOVA and analysis of covariance (ANCOVA), the latter including baseline 
concentration as a covariate, were used to compare log transformed antibody concentrations between and 
within group. Post hoc analyses for simple effects were then performed as appropriate. Linear regression 
was used to determine associations between clinical/immunological parameters and baseline/1 month 
antibody concentrations.  
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5.4 Results 
 
There was no loss to follow up and only 1 sample out of 271 was insufficient in volume for analysis. This 
sample was from an adult healthy control one month post immunisation. This subject was therefore excluded 
from all serological comparisons.  
 
5.4.1 Baseline characteristics 
Baseline characteristics are shown in Table 13. 
 
In view of exclusion of one adult healthy control and the intention to compare only the vaccinated groups 
directly, comparison of baseline characteristics was repeated as in Chapter 4. When comparing only the 
vaccinated children with child and adult healthy controls the pattern of differences were as in Chapter 4 apart 
from for absolute lymphocyte count comparison of CHC with CP. This showed separate age and group 
effects in place of an age*group interaction, total lymphocyte being higher in the patient group and 
decreasing with age in both groups.  
 
Prior to this study, 10/56 (18%) and 2/56 (3.6%) of the children with paHIV had received 1 or 2 doses of PPV 
respectively. Median time since last dose of PPV was 46 months (range: 10-99 months). 1/56 (1.8%), 2/56 
(3.6%) and 5/56 (8.9%) of children with paHIV had received 1,2 or 3 doses of PCV7 respectively. Median 
time since last dose of PCV7 was 16 months (range: 9-28 months). 2/30 (6.7%), 1/30 (3.3%), 6/30 (20%) of 
healthy control children had received 1, 2 or 3 doses of PCV7 respectively. Median time since last dose of 
PCV7 was 26 months (range: 12-99 months). No healthy young adult had received PCV or PPV and no 
study participant had ever received PCV13. 
 
Using Mann-Whitney U test to compare timing of blood sampling in relation to vaccination, there was no 
significant difference in the timing of vaccination to 1 month follow up for CP (med= 32 days) compared to 
AHC (med = 32 days) (med diff = 1 day (95%CI: -2- 5 days) p=0.440) or of vaccination to 6 month follow up 
for CP (med = 199.5 days) compared to AHC (med=209) (med diff = 9 days (95%CI: -8-25 days) p=0.316). 
 
5.4.2 Baseline serology 
Reverse cumulative distribution (RCD) curves are a useful way of visually summarising complex serological 
data sets for different groups at different time points. They plot antibody concentration on the x axis and the 
proportion of subjects above this cut off on the y axis. RCD curves including baseline serum pneumococcal 
polysaccharide specific IgG concentrations for AHC, CHC and CP are shown in Figure 17. 
 
Proportion in each group above a cut of 0.35µg/ml and 1µg/ml are reported in Tables 14 and 15. The 
rationale for using these cut-offs is discussed in Sections 1.3.3 and 5.5. 
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  CHC 
(n=30) 
 AHC 
(n=26) 
 CPv 
(n=48) 
 CPu 
(n=8) 
 
Sex  Female 14 (46.7) 15 (57.7) 21 
 
(43.8) 
 
4 
 
(50) 
 
 Male 16 (53.3) 11 (42.3) 27 
 
(56.3) 
 
4 
 
(50) 
 
Ethnicity White 4 (13.3) 19 (73.1) 2 (4.2) 0 (0) 
 Mixed 0 (0) 2 (7.7) 3 (6.3) 0 (0) 
 Asian 0 (0) 3 (11.5) 2 (4.17) 1 (12.5) 
 Black Caribbean 4 (13.3) 0 (0) 2 (4.17) 0 (0) 
 Black African 13 (43.3) 0 (0) 38 (79.2) 7 (87.5) 
 Other 9 (30) 2 (7.7) 1 (2.1) 0 (0) 
Age/months  107.5 (19-195) 330 (245-359) 154 (12-209) 131 (81-189) 
Lymphocyte lymph cells/µl 2139 (1666-3414) 1807.5 (1377-2115) 2349.5 (1764-3308.5) 2548 (1709.5-3000.5) 
subsets CD3 cells/µl 1575.5 (1166-2486) 1389 (1094-1706) 1854.5 (1390.5-2518) 1897.5 (1215-2362.5) 
 CD3 % 71.6 (66.6-78.3) 75.3 (70.1-79.1) 75.45 (68.9-79.6) 71.8 (65.8-74.9) 
 CD4 cells/µl 833.5 (647-1391) 794 (694-1061) 855 (525.5-1118) 878.5 (565-1207) 
 CD4 % 43.1 (36.7-46.5) 44.55 (39.8-50.6) 34.55 (27.2-40.8) 35.8 (27.9-42.2) 
 CD8 cells/µl 529.5 (356-907) 497 (383-557) 913.5 (659-1074.5) 695.5 (579-952) 
 CD8 % 23.8 (21.6-27.2) 26.25 (22.2-28.9) 32.95 (28.9-44.5) 31.7 (24.6-39.1) 
 CD19 cells/µl 446.5 (272-679) 257 (153-326) 403 (266-570.5) 378.5 (267.5-622) 
 CD19 % 18.2 (14.5-24.2) 12 (8.9-16.8) 17.3 (12.96-21.4) 16.8 (13.5-18.7) 
 CD56 cells/µl 134.5 (82-205) 172.5 (96-188) 119 (72-184.5) 125.5 (68.5-318.5) 
 CD56 % 5.4 (2.9-8.2) 9.35 (6.5-12.1) 4.35 (2.8-5.6) 7.35 (3.05-11.8) 
Prev PCV7  9 (30.0) 0 (0) 7 (14.6) 1 (12.5) 
Prev PPV  0 (0) 0 (0) 12 (25.0) 0 (0) 
Nadir CD4%  - - - - 13 (0-48) 15 (0-33) 
Proportion of life 
undetectable 
 - - - - 0.49 (0-0.98) 0.44 (0.03-0.94) 
VL <50 copies/ml  - - - - 34 (72.3) 7 (77.8) 
Treated 1st year  - - - - 7 (14.9) 3 (33.3) 
Treated 1st 2 years  - - - - 12 (25.3) 3 (33.3) 
 
Table 13.  Baseline characteristics for all study participants assessed for pneumococcal serology. Sex, ethnicity, HIV viral load status, treated in the 
first year of life, treated in the 1st 2 years of life, previous PCV7 and previous PPV are presented as number and percentage. Age, nadir CD4% and 
proportion of life undetectable are presented as median and range. Lymphocyte subsets are presented as median and interquartile range. (CHC= 
Child healthy control, AHC= Adult healthy control, CPv = Child patient (vaccinated) , CPu = Child patient (unvaccinated), VL = HIV viral load, PCV7 
= 7-valent pneumococcal conjugate vaccine, PPV= pneumococcal polysaccharide vaccine) 
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Figure 17 a-m). Reverse cumulative distribution curves showing the proportion of individuals above increasing concentrations of 
serotype specific antibody for healthy children, young healthy adults and children with paHIV. Baseline antibody concentration data is 
displayed in black. Post immunisation data for young healthy adults are shown in red and for HIV infected children, in green. Vertical 
grey lines indicate cut off of 0.35 µg/ml and 1 µg/ml. GMCs were higher at baseline for AHC than CP for 6/13 serotypes: 7F, 9V, 14, 
18C, 19F and 23F (p< 0.05). Without adjusting for baseline antibody concentration, serotype specific IgGGMCs were higher in the 
AHC group than the CP group 1 month post immunisation for 8/13 serotypes:  6A, 6B, 7F, 9V, 14, 18C, 19A and 23F (p<0.05). 
Higher antibody levels persisted to 6 months for 5/13 serotypes: 6A, 6B, 7F, 18C, 23F. After adjusting for baseline antibody 
concentrations GMCs were significantly higher in AHC than CP for serotypes 6A, 6B and 23F at both the 1 month (p<0.01) and 6 
month  (p<0.05) time points. (S= serotype, mcg=µg, CHC=child healthy control, AHC= adult healthy control, CP = Child patient, 0m = 
baseline, 1m/6m = 1 month/ 6 months post immuniaation.) Continued on next page. 
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Fig. 17 Continued 
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Children with perinatally acquired HIV have similar serotype specific IgG concentrations to healthy controls 
at baseline for some but not all PCV13 serotypes 
 
Proportions above each cut off were compared between groups using Chi2 or Fisher’s exact test as 
appropriate.   
 
When comparing AHC to CP, a higher proportion of AHC were above 0.35µg/ml serotype specific IgG at 
baseline for 6/13 serotypes: 6B (0.96 vs. 0.73 , p= 0.015), 7F (0.77 vs. 0.46, p= 0.01), 9V (0.85 vs. 0.58, 
p=0.021), 14 (0.85 vs. 0.6, p= 0.032), 18C (0.81 vs. 0.50, p= 0.01) and 23F (0.69 vs. 0.38, p = 0.009). When 
comparing CHC to CP, a higher proportion of CHC were above 0.35µg/ml serotype specific IgG at baseline 
for 3/13 serotypes: 6B (0.97 vs. 0.73, p=0.008), 18C (0.73 vs. 0.50, p= 0.042) and 23F (0.63 vs. 0.38, p= 
0.026). 
 
There was no significant difference between the proportions above 0.35µg/ml for AHC compared to CHC.  
 
 
When comparing AHC to CP, a higher proportion of AHC were above 1µg/ml serotype specific IgG at 
baseline for 4/13 serotypes: 7F (0.5 vs. 0.17, p =0.002), 9V (0.31 vs. 0.08, p= 0.012), 18C (0.5 vs. 0.25, 
p=0.030) and 23F (0.35 vs0.13, p= 0.024). When comparing CHC to CP, a higher proportion of CHC were 
above 1µg/ml serotype specific IgG at baseline for 4/13 serotypes: 3 (0.16 vs. 0.02, p=0.029), 6B (0.63 vs. 
0.4, p= 0.041), 9V (0.4 vs. 0.08, p=0.001) and 23F (0.37 vs. 0.13, p =0.012). 
 
There was no significant difference between the proportions above 1µg/ml for AHC compared to CHC. 
 
 
 
 
 
 
 
 Proportion>0.35µg/ml 
 S1 S3 S4 S5 S6A S6B S7F S9V S14 S18C S19A S19F S23F 
CHC 0.40 0.40 0.47 0.77 0.83 0.97 0.53 0.73 0.77 0.73 0.97 0.87 0.63 
AHC 0.62 0.38 0.58 0.85 0.96 0.96 0.77 0.85 0.85 0.81 0.96 0.89 0.69 
CP 0.48 0.27 0.42 0.77 0.79 0.73 0.46 0.58 0.60 0.50 0.92 0.77 0.38 
              
AHCvCP p 0.263 0.313 0.187 0.442 0.050 0.015 0.010 0.021 0.032 0.010 0.460 0.233 0.009 
CHCvCP p 0.494 0.234 0.665 0.966 0.650 0.008 0.519 0.179 0.139 0.042 0.380 0.296 0.026 
CHCvAHC p 0.108 0.906 0.410 0.455 0.122 1.000 0.066 0.305 0.455 0.511 0.918 0.839 0.642 
 
Table 14. Proportion with serum serotype specific IgG concentration > 0.35 µg/ml at baseline. (S = serotype, CHC= child healthy 
control, AHC= adult healthy control, CP= child patient) 
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Log transformed baseline serotype specific IgG concentrations were compared using ANOVA with 
Bonferroni correction for multiple comparison. Geometric mean concentrations (GMC) of IgG at baseline are 
reported in Table 16. 
 
GMCs were higher for AHC than CP for 6/13 serotypes: 7F (0.91 vs. 0.31 µg/ml, p= 0.001), 9V (0.67 vs. 0.34 
µg/ml, p= 0.024, 14 (2.3 vs. 0.73 µg/ml, p= 0.018), 18C (0.9 vs. 0.35 µg/ml, p= 0.007), 19F (1.43 vs. 0.66 
µg/ml, p= 0.028) and 23F (0.62 vs. 0.29 µg/ml, p= 0.049).  
 
GMCs were higher for CHC than CP for 3/13 serotypes: 6B (1.29 vs. 0.68 µg/ml, p= 0.009), 9V (0.81 vs. 
0.34 µg/ml, p= 0.001) and 23F (0.65 vs. 0.29 µg/ml, p= 0.024).  
 
GMC was higher for AHC than CHC for 1/13 serotypes: 7F (0.91 vs. 0.41 µg/ml, p= 0.043) 
 
 
 
 
 Proportion > 1µg/ml 
 S1 S3 S4 S5 S6A S6B S7F S9V S14 S18C S19A S19F S23F 
CHC 0.10 0.16 0.20 0.27 0.57 0.63 0.27 0.40 0.47 0.37 0.80 0.53 0.37 
AHC 0.27 0.03 0.15 0.35 0.54 0.50 0.50 0.31 0.65 0.50 0.85 0.58 0.35 
CP 0.15 0.02 0.15 0.31 0.48 0.40 0.17 0.08 0.44 0.25 0.81 0.40 0.13 
              
AHCvCP p 0.196 1.000 0.926 0.768 0.626 0.388 0.002 0.012 0.075 0.030 0.716 0.136 0.024 
CHCvCP p 0.556 0.029 0.532 0.666 0.452 0.041 0.287 0.001 0.801 0.272 0.892 0.235 0.012 
CHCvAHC p 0.099 0.200 0.653 0.519 0.832 0.315 0.072 0.472 0.160 0.315 0.653 0.743 0.873 
 
Table 15. Proportion with serum serotype specific IgG concentration > 1 µg/ml at baseline. (S = serotype, CHC= child healthy control, 
AHC= adult healthy control, CP= child patient) 
 
 GMC µg/ml 
 S1 S3 S4 S5 S6A S6B S7F S9V S14 S18C S19A S19F S23F 
CHC 0.29 0.30 0.33 0.56 1.03 1.29 0.41 0.81 1.06 0.67 2.22 1.10 0.65 
AHC 0.51 0.25 0.33 0.66 1.21 1.08 0.91 0.67 2.30 0.90 2.72 1.43 0.62 
CP 0.35 0.18 0.29 0.58 0.82 0.68 0.31 0.34 0.73 0.35 1.97 0.66 0.29 
              
Bonferroni p               
AHC v CP           0.108 0.001 0.024 0.018 0.007   0.028 0.049 
CHC v CP      0.009 0.941 0.001 1.000 0.082  0.204 0.024 
CHC v AHC           1.000 0.043 1.000 0.268 1.000   1.000 1.000 
 
Table 16. Geometric mean concentration of pneumococcal polysaccharide serotype specific IgG for each group at baseline. One-way 
ANOVA on log transformed data was used to compare groups. Bonferroni corrected p values for post hoc comparisons are reported when 
result of one-way ANOVA was found to be significant.  (GMC = geometric mean concentration, AHC = adult healthy control, CHC = child 
healthy control, CP = child patient) 
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5.4.3 Response to vaccination 
The proportions above each cut off at 1 month and 6 month post immunisation are shown in Tables 17 and 
18 and represented graphically in Figures 18 and 19. 
 
McNemar’s test was used to compare paired proportions above a cut off of 0.35 µg/ml and 1 µg/ml within 
groups at baseline vs. 1 month and baseline vs. 6 months post immunisation 
 
PCV13 leads to a significant increase from baseline in the proportion above 1 µg/ml for all vaccine serotypes 
which persists to 6 months in children with paHIV 
 
When comparing the proportion above a cut off of 0.35µg/ml at baseline with 1 month results there was a 
statistically significant increase for 11/13 serotypes for CP and 5/13 serotypes for AHC. In all cases where 
the increase in proportion was non-significant for the AHC group, the baseline proportion was already above 
0.8 and increased to 1 or just below. This was true for serotype 19A for the CP group. For serotype 5 in the 
CP group the non-significant increase was from 0.77 at baseline to 0.88 at 1 month (p= 0.125).  
 
When comparing baseline to 6 month proportions above 0.35 µg/ml a similar pattern was observed, however 
the difference from baseline became non significant for serotype 7F in the AHC group (0.77 vs. 0.96, p= 
0.063) and 6A in the CP group (0.79 vs. 0.92, p= 0.109). The post immunisation proportions were above 0.8 
for the majority of serotypes at both post immunisation time points for both groups. 
 
There was a statistically significant increase in the proportion above 1µg/ml for all serotypes in both groups 
at the 1 month time point. The same was true for the 6 month time point apart from for serotype 3 in the AHC 
group (0.03 vs. 0.19, p=0.125) and for serotype 19A for both groups however in the latter case baseline 
proportions were above 0.8 and 6 month proportions remained above 0.9. 
 
The proportion above a 1 µg/ml cut off are lower in children with paHIV compared to young healthy adults for 
almost half vaccine serotypes 1 month and 6 months following PCV13 
 
Chi2 was used to compare proportions above 0.35 µg/ml and 1 µg/ml cut offs between groups at 1 month 
and 6 months following immunisation.  
 
A high proportion AHC and CP achieved serotype specific concentration greater than 0.35 µg/ml at both 1 
month and 6 months post immunisation. The only serotype for which the proportion was higher in AHC than 
CP was 23F. This was true at 1 month and 6 months post immunisation: 1.00 vs. 0.81 (p = 0.023), 1.00 vs. 
0.75 (p =0.006) respectively. 
 
The proportions above a cut off of 1 µg/ml were significantly higher for AHC than CP at 1 month post 
immunisation for 6/13 serotypes: 6A (1.0 vs. 0.81, p= 0.023), 6B (1.0 vs. 0.83, p= 0.044), 9V (0.92 vs. 0.73, 
p=0.048), 14 (1.0 vs. 0.79, p= 0.012), 18C (0.96 vs. 0.75, p= 0.026), 23F (1.0 vs. 0.69, p=0.001). 
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 S1     S3     S4     S5     S6A     S6B     S7F     
 bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m 
                             
AHC 0.62 1.00 0.96 0.38 0.85 0.77 0.58 1.00 0.81 0.85 1.00 0.96 0.96 1.00 1.00 0.96 1.00 1.00 0.77 1.00 0.96 
CP 0.48 0.98 0.94 0.27 0.65 0.58 0.42 0.92 0.83 0.77 0.88 0.85 0.79 0.98 0.92 0.73 0.94 0.88 0.46 0.96 0.94 
                             
CPvsAHC                       
p  1.000 1.000  0.068 0.110  0.291 0.782  0.085 0.247  1.000 0.291  0.548 0.085  0.538 1.000 
                      
bl vs post                      
AHC p  0.002 0.004  0.001 0.002  0.001 0.031  0.125 0.250  1.000 1.000  1.000 1.000  0.031 0.063 
CP p  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  0.125 0.219  0.008 0.109  0.006 0.039  <0.001 <0.001 
 
 
 S9V     S14     S18C     S19A     S19F     S23F     
 bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m 
                         
AHC 0.85 0.96 0.96 0.85 1.00 1.00 0.81 0.96 0.92 0.96 1.00 1.00 0.89 1.00 1.00 0.69 1.00 1.00 
CP 0.58 0.88 0.85 0.60 0.90 0.90 0.50 0.85 0.81 0.92 0.98 0.98 0.77 0.96 0.94 0.38 0.81 0.75 
                   
CPvsAHC                   
p  0.410 0.247  0.155 0.155  0.247 0.309  1.000 1.000  0.538 0.548  0.023 0.006 
                   
                   
bl vs post                   
AHC p  0.250 0.250  0.125 0.125  0.125 0.250  0.317 0.317  0.250 0.250  0.008 0.008 
CP p  <0.001 <0.001  <0.001 0.001  <0.001 <0.001  0.250 0.250  0.004 0.008  <0.001 <0.001 
 
 
 
 
 
Table 17. Comparison between AHC and CP group for proportion above a cutoff of 0.35 µg/ml and within group comparison for baseline compared to 1 month and 6 months post immunisation.  
(S= serotype, bl= base line, 1m = 1 month post immunsation, 6m= 6 months post immunisation) 
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 S1     S3     S4     S5     S6A     S6B     S7F     
 bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m 
                             
AHC 0.27 0.92 0.65 0.03 0.46 0.19 0.15 0.88 0.58 0.35 0.81 0.73 0.54 1.00 0.96 0.50 1.00 0.96 0.50 0.96 0.85 
CP 0.15 0.81 0.67 0.02 0.29 0.21 0.15 0.75 0.52 0.31 0.73 0.56 0.48 0.81 0.71 0.40 0.83 0.75 0.17 0.92 0.65 
                      
CPvsAHC                       
p  0.309 0.911  0.144 0.870  0.169 0.644  0.452 0.154  0.023 0.010  0.044 0.026  0.651 0.068 
                      
bl vs post                      
AHC p  <0.001 0.002  0.001 0.125  <0.001 0.001  <0.001 0.002  <0.001 0.001  <0.001 <0.001  <0.001 0.004 
CP p  <0.001 <0.001  <0.001 0.004  <0.001 <0.001  <0.001 <0.001  <0.001 0.003  <0.001 <0.001  <0.001 <0.001 
 
 
 S9V     S14     S18C     S19A     S19F     S23F     
 bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m 
                         
AHC 0.31 0.92 0.77 0.65 1.00 1.00 0.50 0.96 0.85 0.85 1.00 0.92 0.58 0.96 0.88 0.35 1.00 0.92 
CP 0.08 0.73 0.60 0.44 0.79 0.81 0.25 0.75 0.60 0.81 0.94 0.92 0.40 0.88 0.75 0.13 0.69 0.56 
                   
CPvsAHC                   
p  0.048 0.152  0.012 0.023  0.026 0.032  0.548 1.000  0.410 0.169  0.001 0.001 
                   
bl vs post                   
AHC p  <0.001 <0.001  0.004 0.004  <0.001 0.004  0.046 0.157  0.002 0.008  <0.001 <0.001 
CP p  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  0.031 0.125  <0.001 <0.001  <0.001 <0.001 
 
 
 
 
Table 18 Comparison between AHC and CP group for proportion above a cut off of 1 µg/ml and within group comparison for baseline compared to 1 month and 6 months post immunisation.  
(S= serotype, bl= base line, 1m = 1 month post immunisation, 6m= 6 months post immunisation) 
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Figure 18 a-m) Bar charts showing the proportion of study subjects with serotype specific serum IgG concentration 
>0.35µg/ml before immunisation with PCV13 and 1 month and 6 months after immunisation. A higher proportion of AHC were 
above 0.35µg/ml serotype specific IgG at baseline for 6/13 serotypes: 6B, 7F, 9V, 14, 18C and 23F (p<0.05). When 
comparing baseline with 1 month results there was a statistically significant increase for 11/13 serotypes for CP and 5/13 
serotypes for AHC (p<0.05). When comparing baseline to 6 month, a similar pattern was observed. A high proportion AHC 
and CP achieved serotype specific concentration greater than 0.35 µg/ml at both 1 month and 6 months post immunisation. 
The only serotype for which the proportion was higher in AHC than CP was 23F. This was true at 1 month and 6 months post 
immunisation (p<0.05). (AHC = adult healthy control, CP = child patient, mcg = micrograms, pre = pre immunisation, 1m/6m = 
1 month/ 6months post immunisation) 
 
* significant difference in proportion above cut off compared with baseline within group (p<0.05) 
† significant difference comparing proportion above cut off,  AHC vs. CP (p<0.05) 
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Figure 13. continued 
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Figure 19 a-m) Bar charts showing the proportion of study subjects with serotype specific serum IgG concentration >1µg/ml 
before immunisation with PCV13 and 1 month and 6 months after immunisation. A higher proportion of AHC were above 
1µg/ml serotype specific IgG at baseline for 4/13 serotypes: 7F, 9V, 18C  and 23F. There was a statistically significant 
increase in the proportion above 1µg/ml for all serotypes in both groups at the 1 month time point (p<0.05). The same was 
true for the 6 month time point apart from for serotype 3 in the AHC group and for serotype 19A for both groups. The 
proportions above a cut off of 1 µg/ml were significantly higher for AHC than CP at 1 month post immunisation for 6/13 
serotypes: 6A, 6B, 9V, 14, 18C, 23F (p<0.05). The same was true at the 6 month time point apart from for serotype 9V 
(p<0.05). (AHC = adult healthy control, CP = child patient, mcg = micrograms, pre = pre immunisation, 1m/6m = 1 month/ 
6months post immunisation) 
 
* significant difference compared with baseline proportion within group (p<0.05) 
† significant difference comparing proportion of AHC with proportion of CP (p<0.05) 
 
 
	   	   	   	  108 
 
g) Serotype 7F
AH
C CP
0.0
0.2
0.4
0.6
0.8
1.0 * * * *
†
Pr
op
or
tio
n 
ab
ov
e 
1 
m
cg
/m
l
i) Serotype 14
AH
C CP
0.0
0.2
0.4
0.6
0.8
1.0 * * * *
† †
Pr
op
or
tio
n 
ab
ov
e 
1 
m
cg
/m
l
k) Serotype 19A
AH
C CP
0.0
0.2
0.4
0.6
0.8
1.0 * *
Pr
op
or
tio
n 
ab
ov
e 
1 
m
cg
/m
l
m) Serotype 23F
AH
C CP
0.0
0.2
0.4
0.6
0.8
1.0 * * * *
† ††
Pr
op
or
tio
n 
ab
ov
e 
1 
m
cg
/m
l
h) Serotype 9V
AH
C CP
0.0
0.2
0.4
0.6
0.8
1.0
pre
1m 
6m
* * * *
††
Pr
op
or
tio
n 
ab
ov
e 
1 
m
cg
/m
l
j) Serotype 18C
AH
C CP
0.0
0.2
0.4
0.6
0.8
1.0 * * * *
† ††
Pr
op
or
tio
n 
ab
ov
e 
1 
m
cg
/m
l
l) Serotype 19F
AH
C CP
0.0
0.2
0.4
0.6
0.8
1.0 * * * *
Pr
op
or
tio
n 
ab
ov
e 
1 
m
cg
/m
l
Figure 19. continued 
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The same was true at the 6 month time point apart from for serotype 9V: 6A (0.96 vs. 0.71, p=0.01), 6B 
(0.96 vs. 0.75, p= 0.026), 14 (1.0 vs. 0.81, p= 0.023), 18C (0.85 vs. 0.6, p=0.032), 23F (0.92 vs. 0.56, 
p=0.001). 
 
Geometric mean antibody responses to PCV13 are lower in children with paHIV than healthy young adults, 
an effect that is less pronounced after adjusting for baseline antibody concentration 
 
Repeated measures ANOVA and ANCOVA were used to analyse within group and between group 
differences at 1 month and 6 months post immunisation for log transformed serotype specific IgG 
concentrations. Analysis was performed with and without including baseline serum concentrations as a 
covariate. Where results of the main ANCOVA were significant, simple effects of time and group were then 
calculated.  
 
Results of this analysis are shown in Table 19. Geometric means are also summarised in Fig. 20. 
 
As can be seen from Table 20 and Fig. 20 antibody responses to all PCV13 serotypes increased significantly 
1 month post immunisation and continued to be significantly higher than baseline 6 months post 
immunisation in both CP and AHC group.  
 
Without adjusting for baseline antibody concentration, serotype specific IgG GMCs were higher in the AHC 
group than the CP group 1 month post immunisation for 8/13 serotypes:  6A (10.5 vs. 3.6 µg/ml, p<0.001), 
6B (11.3 vs. 3.3 µg/ml, p<0.001), 7F (7.7 vs. 3.0 µg/ml, p<0.001), 9V (4.6 vs. 2.2 µg/ml, p=0.017), 14 (18.5 
vs. 7.9 µg/ml, p=0.04), 18C (8.6 vs. 2.5 µg/ml, p<0.001), 19A  (10.5 vs. 7.1, p=0.020), 23F (17.1 vs. 2.1 
µg/ml, p<0.001). 
 
These higher antibody levels persisted to 6 months for 5/13 serotypes: 6A (5.2 vs. 2.1 µg/ml, p=0.006), 6B 
(5.1 vs. 2.0 µg/ml, p=0.004), 7F (3.4 vs. 1.7 µg/ml, p=0.090), 18C (3.9 vs. 1.3 µg/ml, p=0.001), 23F (7.2 vs. 
1.2, µg/ml, p<0.001). 
 
After adjusting for baseline antibody concentrations GMCs were significantly higher in AHC than CP for 
serotypes 6A, 6B and 23F at both the 1 month (p<0.01) and 6 month  (p<0.05) time points.  
 
The paired t-test was used to compare log transformed serotype specific IgG concentrations from baseline 
compared to 6 months later in the 8 unvaccinated children with paHIV. Although there was a slight 
downward trend in GMC for all serotypes this was only significant for serotype 4 (0.19 vs. 0.14 µg/ml, 
p=0.04).  
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 GMC:               
 S1   S3   S4   S5   S6A   
 bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m 
AHC 0.510 5.434 2.353 0.253 0.996 0.539 0.328 3.287 1.270 0.662 3.216 1.737 1.210 10.536 5.175 
CP 0.345 3.315 1.753 0.182 0.598 0.443 0.288 2.533 1.207 0.580 1.756 1.226 0.822 3.563 2.198 
                
p value                
bl vs 1m/6m                
AHC  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001 
CP  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001 
                
p value                
AHC vs CP (abl)              0.002 0.024 
AHC vs CP (xbl)              <0.001 0.006 
                
 S6B   S7F   S9V   S14   S18C   
 bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m bl 1m 6m 
AHC 1.082 11.316 5.117 0.910 7.684 3.448 0.671 4.584 1.933 2.298 18.531 11.359 0.900 8.576 3.930 
CP 0.676 3.309 2.043 0.314 3.005 1.656 0.340 2.219 1.176 0.729 7.881 5.435 0.355 2.508 1.314 
                
p value                
bl vs 1m/6m                
AHC  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001 
CP  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001 
                
p value                
AHC vs CP (abl)  0.001 0.036             
AHC vs CP (xbl)  <0.001 0.004  <0.001 0.009  0.017 0.099  0.044 0.083  <0.001 0.001 
                
 S19A   S19F   S23F         
 bl 1m 6m bl 1m 6m bl 1m 6m       
AHC 2.722 10.492 5.800 1.426 8.562 4.193 0.620 17.094 7.249       
CP 1.968 7.141 4.460 0.661 4.063 2.491 0.290 2.122 1.169       
                
p value                
bl vs 1m/6m                
AHC  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001       
CP  <0.001 <0.001  <0.001 <0.001  <0.001 <0.001       
                
p value                
AHC vs CP (abl)        <0.001 <0.001       
AHC vs CP (xbl)  0.022 0.107     <0.001 <0.001       
Table 19. Results of RMANOVA/RMANCOVA comparing baseline serotype specific antibody concentrations to those at 1 month and 6 months post immunisation with PCV13 in the AHC 
and CP group. Comparison between groups is also reported for both post immunisation timepoints. p values are reported for analysis with and without adjusting for baseline antibody 
concentration (highlighted in dark blue and light blue respectively). (GMC = geometric mean antibody concentration, S = serotype, bl = baseline, 1m/6m = 1 month and 6 months post 
immunisation, abl = adjusting for baseline, xbl = without adjusting for baseline) 
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Figure 20 a-m). Geometric mean serotype specific IgG concentrations with 95% confidence intervals for young healthy adults and 
children with paHIV at baseline, 1 month and 6 months post immunisation with PCV13. Antibody concentrations to all PCV13 
serotypes increased significantly 1 month post immunisation and continued to be significantly higher than baseline 6 months post 
immunisation in both CP and AHC group. Without adjusting for baseline antibody concentration, serotype specific IgGGMCs were 
higher in the AHC group than the CP group 1 month post immunisation for 8/13 serotypes (p<0.05):  6A, 6B, 7F, 9V, 14, 18C, 19A, 
23F. These higher antibody levels persisted to 6 months for 5/13 serotypes (p<0.05): 6A, 6B, 7F, 18C, 23F. After adjusting for 
baseline antibody concentrations GMCs were significantly higher in AHC than CP for serotypes 6A, 6B and 23F at both the 1 month 
(p<0.01) and 6 month  (p<0.05) time points. (GMC= geometric mean concentration, S = serotype, mcg = µg, bl = baseline, 1m/6m = 
1 month and 6 months post immunisation, CP= child patient, AHC = adult healthy control). Continued on next page. 
*  p<0.05 comparing baseline GMC between groups 
** p<0.05 comparing post immunisation GMC between groups 
†  p<0.05 comparing post immunisation GMC between groups after adjusting for baseline 
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Figure 20. Continued. 
	   	   	   	  113 
 
 
5.4.4 Relating antibody response to immunological status  
Linear regression analysis was used to assess for associations between log transformed antibody response 
1 month post immunisation and lymphocyte, B and T cell subsets.  
 
Resting memory B cell percentages are associated with higher antibody responses in children with paHIV for 
a proportion of serotypes 
 
Having adjusting for baseline antibody concentration, higher CD4 T cell percentage, higher resting memory 
B cell percentage and lower tissue like/ exhausted memory B cell percentage were most consistently 
associated with higher antibody response. This was true for 9/13, 9/13 and 8/13 serotypes respectively. After 
adjusting for detectable viraemia, higher resting memory B cell percentage remained significantly associated 
with higher antibody responses for 4/13 serotypes (9V (p=0.016), 19A (p=0.019), 19F (p<0.001), 23F 
(p=0.037)) whereas CD4 percentage and exhausted memory B cell were associated with higher antibody 
response in only 1 serotype each.   
 
No association was found between lymphocyte, B or T cell subsets and magnitude of antibody response in 
AHC group. 
 
5.4.5 Relating serological response to clinical parameters 
Linear regression was used to assess for associations between clinical parameters and log transformed 
baseline serology as well as log transformed antibody response one month post immunisation. 
 
The following factors were assessed for associations with baseline and one month serum IgG 
concentrations: detectable viraemia (yes/no), treated in the 1st year of life (yes/no), treated in the 1st 2 years 
of life (yes/no), received PCV7 (yes/no), received PPV (yes/no), proportion of life undetectable, nadir CD4 
percent. 
 
For children with paHIV, higher baseline antibody concentrations are associated with previous receipt of PPV 
for some PCV13 serotypes 
 
After adjusting for age, previous receipt of PPV was the factor most frequently associated with higher 
baseline serotype specific IgG (6/13 serotypes): 1 (antilog regression coefficient =  2.43 (95%CI: 1.19- 4.96), 
p= 0.016), 4 (antilog regression coefficient =  2.8 (95%CI: 1.66- 4.75), p<0.001) , 5 (antilog regression 
coefficient = 1.71 (95%CI: 1.02- 2.87), p= 0.043) , 7F (antilog regression coefficient =  2.44 (95%CI: 1.19- 
4.98), p= 0.016) , 9V (antilog regression coefficient =  2.08 (95%CI: 1.04- 4.15), p= 0.039), 14 (antilog 
regression coefficient = 5.97 (95%CI: 1.74- 20.4), p= 0.005). 
 
For children with paHIV, higher antibody concentrations at 1 month were associated with higher baseline 
antibody concentrations for all vaccine serotypes and undetectable viral load for the majority of vaccine 
serotypes 
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Results of analysis of factors predictive of 1 month antibody response are shown in Table 20 (overleaf). 
 
There was a highly significant association between higher baseline antibody levels and higher 1 month 
antibody levels for all 13 serotypes. Regression coefficients were all less than 1, thus predicting that this 
effect decreases in magnitude with higher baseline, suggestive of a ceiling to antibody levels. After adjusting 
for baseline, detectable viraemia was associated with lower 1 month antibody for 11/13 serotypes and older 
age was associated with lower 1 month antibody response for 6/13 serotypes. After adjusting for age, 
baseline and viraemia, higher percentage of life with undetectable viral load was associated with higher 1 
month antibody responses for 3/13 serotypes.  
 
5.4.6 Nasopharyngeal carriage 
No carriage was detected in either the adult or child healthy control groups. Results for CP group are 
reported in Table 21. 
 
 
 
 
 
 
 
 
 
9/56 (16%) of the children with paHIV were found to be positive for pneumococcal carriage at one or both 
time points. No child carried a PCV13 serotype, 4/9 children with detectable carriage were carrying 
serotypes present in PPV (11A and 15B), 11A was the most frequently carried serotype (3/9 children) and 
persistent carriage of 11A was detected in 2/9 children over the course of 6 months. 
 
Study no. CP02 CP03 CP05 CP15 CP17 CP27 CP31 CP44 CP51 
Age/y 6 1 10 16 6 13 3 11 2 
          
Pre ST NT  11A 11A 23B  15B  6C 
Post ST 38 11A 11A 11A  35B  34  
 Table 21. Nasopharyngeal carriage isolates from CP group pre and post immunisation. CP05 and CP17 were not 
vaccinated. Serotypes in red are a component of PPV. (Pre ST = prevacccination serotype, Post ST = serotype 6 
months later) 
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Table 20. Results of regression analysis to determine association between serotype specific IgG concentration at 1 month post immunisation with baseline concentration, detectable viraemia ( after 
adjusting for baseline ), age in years ( after adjusting for baseline ) and proportion of life with undetectable viral load (expressed as a percentage and after adjusting for baseline, detectable viraemia 
and age). As antibody concentrations were log transformed and for ease of interpretation antilog regression coefficients and 95% confidence intervals are presented for all independent variables 
except baseline antibody concentration (as this is also log transformed). Only results with a significance level p<0.05 are shown. (CI = confidence interval, coef = regression coefficient, exp = 
antilog). 
 
 
Serotype coeff    exp coef    exp coef    exp coef    
 baseline 95% CI  p viraemia 95% CI  p age/years 95% CI  p prop/% 95% CI  p 
1 0.47 0.15 - 0.79 0.005 4.31 2.09 - 8.88 0.000 0.92 0.85 - 1.00 0.043     
3 0.72 0.45 - 0.99 0.000 2.21 1.18 - 4.13 0.015 0.92 0.87 - 0.98 0.006     
4 0.43 0.07 - 0.79 0.022 4.58 2.12 - 9.88 0.000     1.02 1.00 - 1.04 0.017 
5 0.79 0.41 - 1.18 0.000 3.01 1.37 - 6.61 0.007         
6A 0.70 0.27 - 1.13 0.002             
6B 0.97 0.59 - 1.36 0.000 3.41 1.44 - 8.09 0.006 0.91 0.83 - 0.98 0.021     
7F 0.33 0.02 - 0.63 0.036 3.94 2.05 - 7.57 0.000 0.91 0.85 - 0.97 0.008     
9V 0.91 0.53 - 1.29 0.000 3.95 1.76 - 8.87 0.001         
14 0.72 0.45 - 0.99 0.000 5.31 1.79 - 15.78 0.003         
18C 0.74 0.42 - 1.06 0.000             
19A 0.61 0.34 - 0.88 0.000 2.74 1.44 - 5.19 0.003 0.93 0.87 - 1.00 0.044     
19F 0.71 0.37 - 1.06 0.000 3.62 1.49 - 8.78 0.005 0.88 0.81 - 0.81 0.003 1.02 1.00 - 1.04 0.013 
23F 0.53 0.16 - 0.90 0.007 3.99 1.43 - 11.16 0.010     1.04 1.02 - 1.06 0.001 
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5.5 Discussion 
 
To our knowledge this is the first report of the use of PCV13 in any HIV infected group. It is also the first to 
investigate any potential relationship between humoral response to this vaccine and detailed B cell 
phenotype. We have demonstrated that children with paHIV have pre-existing pneumococcal immunity to a 
number of PCV13 serotypes, indicating that response, at least in part, reflects a memory response. Baseline 
antibody concentrations were lower than in healthy controls for some vaccine serotypes and concentrations 
were correspondingly lower at 1 month and 6 months post immunisation. After adjusting for baseline these 
differences were less extreme, although impairment was still demonstrated for some serotypes. Viraemia 
and to a lesser extent, age at vaccination, appear to impact on magnitude of antibody response and there is 
also a suggestion that a lower percentage of resting memory B cells, a subset shown in the previous chapter 
to be only partially restored by HAART, may be associated with lower post immunisation antibody 
concentrations.  
 
Of 13 immunogenicity studies of pneumococcal conjugate vaccines in HIV infected children to date [198, 
199, 201, 324-327, 343, 410-414] 7 have examined responses in children older than 2 years of age [198, 
199, 201, 324-326, 414]. Of these studies, 1 investigated response to an experimental 5-valent vaccine, 5 
investigated PCV7 and 1 investigated an experimental 9-valent vaccine. All reported ELISA responses to at 
least 3 serotypes (6B, 14 and 23F), though ELISA methods varied, as did timing of blood sampling, dosing 
schedules, study setting, and immunological and HAART status, thus limiting direct comparison.  
 
We have shown that serotype specific IgG is detectable in a substantial proportion of both healthy control 
groups and in children with paHIV. A proportion of the children had previously received PCV7 or PPV, which 
may have partially contributed to this baseline humoral immunity, a suggestion that is supported by the 
finding of an association between previous receipt of PPV and higher baseline IgG for some serotypes. 
Nevertheless, the fact that young adult healthy controls, none of whom had ever receive pneumococcal 
vaccine, had existing serotype specific IgG concentrations of equivalent or higher levels indicates that 
natural immunity is acquired throughout childhood and early adult life, most likely as a result of natural 
exposure through nasopharyngeal carriage and non-invasive pneumococcal disease e.g. otitis media [415]. 
This natural acquisition of anti-pneumococcal IgG with age has been clearly demonstrated by a 
seroepidemiological study carried out in the UK prior to universal introduction of PCV [416] and numerous 
studies assessing prevaccination antibody levels outside of the infant period [417]. 
 
It is perhaps surprising that when comparing healthy children with children with paHIV using GMC or 
proportion above a cut off of 0.35 µg/ml or 1 µg/ml, HIV infected children had significantly lower baseline 
antibody levels for only 3-4/13 serotypes. Of all 13 vaccine serotypes only antibodies to serotype 6B and 23F 
were consistently lower at baseline in children with paHIV using all 3 methods of comparison. These findings 
are to some extent consistent with other reports comparing pre-vaccination pneumococcal serology in both 
HIV infected and healthy children. In a study from the pre-HAART era King et al found HIV infected children 
to have lower GMC serotype specific IgG to serotype 6B, 14 and 23F when compared to age matched 
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healthy controls. All children were less than 9 years of age and had not previously received PPV or PCV 
[414]. Spoulou et al found lower antibody to serotype 6B at baseline in a cohort of HIV infected children aged 
2-14 years compared to healthy age matched controls. The majority of HIV infected children were on HAART 
and had received PPV [201]. Abzug et al, although they did not compare results with healthy controls, report 
similar findings to ours in terms of geometric mean antibody concentrations at baseline and proportions 
above a cut-off of 1µg/ml in a large cohort of HIV infected children with a median age of 9.6 years. The 
majority of children were on HAART and had received PPV [198]. Madhi et al compared pre-vaccination 
antibody concentrations in HIV infected children with healthy controls and found lower GMCs for serotype 
9V, 18C, 19F and 23F [326]. The mean age was younger than our cohort (5.8 years) and the majority of 
children were not on HAART. A recent study of HIV infected children in Thailand compared HIV infected 
children (median age 97 months) with HIV exposed uninfected children and found no difference in baseline 
GMCs for any serotype tested. 90% were on HAART and they had not previously received PPV. It should be 
noted in this study however that the control group were significantly younger than the HIV infected group 
[325].  
 
Considering these previous findings alongside our own, it appears that children with paHIV acquire serotype 
specific pneumococcal IgG, most likely through natural exposure, and that steady state levels of antibody are 
equivalent to healthy control children for a proportion of vaccine serotypes. The persistent increased risk of 
IPD in children with HIV despite suppressive HAART [270-272] suggests that there may therefore be either 
some functional impairment measurable circulating antibody or perhaps continued susceptibility to specific 
serotypes.  
 
We have shown PCV13 to be immunogenic in children with paHIV, albeit less so than in young healthy 
adults. Vaccination results in a significant increase in the proportion above a cut-off of 1 µg/ml and increased 
GMC for all vaccine serotypes which persist to the 6-month time point. Without taking baseline antibody 
levels into consideration, proportions above 1 µg/ml and GMCs were higher at both time points in the young 
healthy adults than children with paHIV for between 5 and 8 vaccine serotypes. After adjusting for baseline, 
GMCs were lower in the HIV infected group for serotype 6A, 6B and 23F at 1 month and 6 months post 
immunisation. These findings are consistent with data from previously published studies of lower valency 
pneumococcal conjugate vaccines comparing response with healthy controls [201, 324-326, 414].  
 
Using GMC and fold change in antibody 6 weeks post immunisation as a read out of response to 
vaccination, King et al found a 5-valent vaccine to be less immunogenic in HIV infected children than healthy 
controls and in particular the proportion of children with ≥ 4 fold rises to serotype 6B and 23F were 
significantly lower in the HIV infected cohort [414]. Spoulou et al defined “response” to PCV7 vaccination as 
> 2-fold rise in antibody concentration to >2 of 4 assessed serotypes 1 month post- immunisation and found 
the proportion of responders to be lower in HIV infected children compared to healthy controls. They also 
found that 1 month GMC to be significantly lower for serotype 6B in the HIV infected cohort [201]. Madhi et al 
found significantly higher proportions >0.35 µg/ml and higher GMCs for all 7 vaccine serotypes in healthy 
controls 1 month post immunisation.  However, this study involved younger children than the present study 
and a very small proportion of HIV infected children were on HAART [326]. Costa Ide et al immunised HIV 
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infected children aged 2-9 years, 95% of whom were receiving ART, with PCV7. They did not include a 
healthy control group but did find 6B and 23F to be the least immunogenic serotypes when assessing 
antibody responses above a cut off of 1.3µg/ml and 4-fold change in antibody concentration [324]. Thanee et 
al found the ratio of GMCs pre to post immunisation were significantly lower in HIV infected children 
compared to HIVEU for serotype 9V and 14, and significantly lower proportion with 4 fold rise for serotype 
9V. The controls were significantly younger than the patients and for children over 24 months, HIV infected 
children received 2 doses of PCV7 whereas uninfected children received 1 [325].  
 
As stated earlier, differences in study setting, vaccine formulation, HAART status, immunological status and 
dosing schedules limit direct comparisons, however taken together with our findings it is clear that 
pneumococcal conjugate vaccines are immunogenic in HIV infected children but less so than in healthy 
controls and that HIV may impact upon the immune response to different serotypes to a varying extent. 
 
We found higher serotype specific antibody responses at 1 month to be associated with higher baseline 
antibody for all vaccine serotypes and with undetectable viraemia for the majority of vaccine serotype. After 
adjusting for these factors we found, out of all lymphocyte, B cell and T cell subsets assessed, higher resting 
memory B cell percentages were most frequently associated with higher antibody responses (4/13 
serotypes) and that a higher proportion of life spent with undetectable viral load was associated with higher 
antibody responses for 3/13 serotypes. Although numbers were small we found no evidence of 
hyporesponsiveness after having received PPV. The phenomenon of hyporesponsiveness following 
polysaccharide vaccination is well recognised, although clinical implications are unclear [418-420], it may 
well be the case that the timing of pneumococcal conjugate vaccine following polysaccharide vaccine may 
be an important factor in determining the degree of serological hyporesponsiveness observed. 
 
Abzug et al investigated predictors of higher antibody response to serotypes 6B, 14, 19F and 23F 8 weeks 
after a series of 2 doses of PCV7 8 weeks apart followed by a single dose of PPV 8 weeks later. They found 
higher 24 week antibody levels to be associated with higher entry antibody level and lower HIV viral load (for 
all serotypes tested), higher immune status based on nadir and current CD4% (for 3/4 serotypes tested) and 
age <7 years and longer duration of HAART (for 1/4 serotypes tested) [198]. Other groups found no 
association between immune status (based on CD4 count, CD4 percent or CDC classification) and response 
to vaccination [199, 326, 414] apart from Thanee at al who found that CDC category C disease was 
associated with lower response to serotype 23F [325].  
 
There are no published reports relating response to pneumococcal conjugate vaccine to B cell memory 
phenotype in HIV infected children. Iwajomo et al found that minimally symptomatic HIV infected not on 
HAART had lower numbers of circulating pneumococcal protein specific B cells [169]. It is tempting to 
speculate that this might also be the case for polysaccharide specific B cells. A recent report in HIV infected 
adults found a greater antibody response to PCV7 to be related to class switched memory B cell absolute 
numbers [164]. Direct comparison is substantially limited by the fact that study subjects received 2 double 
doses of PCV7 3 months apart, analysis included absolute cell counts rather than percentages, and a 
combined aggregate readout of immune response to all vaccine serotypes was used. Data from our own 
	   	   	   	  119 
group has shown impaired response to PPV and tetanus to be associated with decreased IgM and class 
switched memory B cell percentages respectively in HIV infected adults [162]. Our finding of an association 
of impaired antibody response to PCV13 with decreased resting memory B cell percentages suggests that 
the mechanisms and cell types involved in the immune response to PCV13 might be different from those in 
response to “pure” T dependent and T independent vaccines tested in this study. It also might suggest the 
pattern of impairment in vaccine response might differ in children with paHIV compared to adults with HIV. It 
is likely that a combination of these two possibilities contributes to the observed differences.  
 
Pneumococcal nasopharyngeal carriage is considered to be a necessary precursor for invasive disease. 
While pneumococcal conjugate vaccines have been shown to be protective against carriage of vaccine 
serotypes as well as IPD, replacement with non-vaccine serotypes has been shown to occur [246]. In 
addition nasopharyngeal carriage around the time of immunisation has been shown to be associated with 
impaired antibody responses to the carried serotype when infants are vaccinated with PCV7 [421, 422]. 
Licensure of new pneumococcal vaccine is currently based on non-inferiority to existing vaccines but it is of 
concern that use of these criteria alone might underestimate effectiveness at the community level especially 
in relation to herd immunity. For these and a number of other reasons, the inclusion of carriage as an 
endpoint in pneumococcal vaccine studies is under careful consideration [246].  
 
Pneumococcal carriage rates in healthy individuals are highest in the first 2 years of life then drop to much 
lower levels in adult life [423]. The finding of no carriage in either of the healthy control groups is possibly 
lower than expected [259], but may reflect the median age of the child group, the fact that none of the adult 
healthy controls lived with young children (a risk factor for carriage) as well as small group sizes. This 
contrasts with the relatively high carriage rates detected in children with paHIV. A recent 3 year 
epidemiological study of healthy children under 4 years of age in the UK found that since the introduction of 
PCV7, the proportion of carriage isolates that are vaccine serotypes have decreased and proportions of non-
vaccine serotypes (especially 6C, 11A, 19A and 22F) have increased. They found serotype 11A to be 
present in 6.9% of isolates in the 3rd year of the study whereas we have detected it in 3/6 (50%) of isolates at 
the 6 month time point. Our numbers are small thus limiting conclusions but higher rates of carriage in 
children with paHIV than in healthy children, over representation of serotype 11A and occurrence of 15B 
(both present in PPV) are worthy of note. The efficacy and therefore utility of PPV in children with HIV and 
other at risk groups is hotly debated [189, 418] and future studies of carriage and invasive disease due to 
serotypes present in PPV and not in PCV13 post universal introduction of PCV13 will be important in 
resolving this discussion.  
 
The relationship between replacement of carriage serotypes and pneumococcal disease is not completely 
clear [424] although evidence suggests that replacement pneumococcal disease (disease due to non-
vaccine serotypes after introduction of a conjugate vaccine) may have particular impact upon certain risk 
groups including adults with HIV and children with underlying medical conditions [425].  
 
The fact that baseline antibody levels are relatively low for certain serotypes and not others and response to 
vaccination is impaired for some serotypes and not others, raises the possibility that impact of HIV on 
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serotype specific immunity might vary, both after natural exposure and immunisation. Although possible 
reasons for this are not immediately obvious, it has been demonstrated in healthy adults that variation in 
antibody response occur to different polysaccharides following pneumococcal conjugate vaccination despite 
uniform T cell responses to the carrier protein, suggesting that this variation in response may be a result of 
variations in B cell repertoire [293]. The authors hypothesised that this may relate to variations in availability 
of rare antigen specific B cells prior to immunisation, which may vary according to serotype. Irrespective of 
the underlying mechanism, it is possible that the impact of HIV on various aspects of pneumococcal 
immunity may exaggerate any existing innate differences in the ability to respond to individual 
polysaccharides. 
 
When examining the serotype distribution of invasive pneumococcal disease in children and adults with HIV, 
certain serotypes are more commonly found than in the non-HIV infected population, in particular the 
“paediatric” serogroups (6, 9, 14, 19 and 23) [426-429]. We found responses to serotypes 6A, 6B and 23F to 
be particularly impaired in children with paHIV. This finding together with the observation that they are 
particularly implicated in invasive disease in the context of HIV is further evidence that HIV infection may 
impact upon both vaccine and naturally acquired immune response to some serotypes more than others. 
Serotype 6B and 23F have historically been considered to be less immunogenic than other serotypes [417]. 
In a recent study of comparing 2 different reduced dose schedules of PCV in infancy (dose at 2 and 3 
months vs. dose at 2 and 4 months of age), 6B and 23F were the serotypes associated with significantly 
lower antibody responses in the 2/3 month dosing schedule [430]. It is cause for concern that HIV infected 
children may respond least well to the vaccine serotypes to which they are most vulnerable. 
 
Are these differences in immunogenicity clinically relevant? There is no available clinical efficacy or 
effectiveness data for PCV13 for older HIV infected children on HAART. The introduction of PCV7 has had 
such dramatic effects on the incidence of invasive disease to vaccine serotypes that it would not be feasible 
or ethical to evaluate clinical efficacy of more recent vaccines such as PCV13 through clinical trials [308, 
431]. For this reason immunogenicity is used as a surrogate for clinical protection. Various markers of 
immunogenicity may be employed including proportion above a predetermined cut-off concentration, GMC, 
fold change in antibody concentration, avidity, boosting, OPA titre and the proportion of serotypes for which a 
predetermined level of “response” is achieved [255, 432, 433].  
 
For the purposes of this study, GMC and proportion above a cut-off of 0.35 µg/ml and 1 µg/ml were chosen 
as a read out of immunogenicity. An antibody concentration of 0.35 µg/ml 1 month post vaccination has been 
adopted as a cut-off for protection in the evaluation of current pneumococcal conjugate vaccines [255, 308, 
309, 431, 433]. This is based on data from 3 large clinical efficacy studies of PCV7. It is mainly of use in 
demonstrating non-inferiority of next generation conjugate vaccines to PCV7 [308]. It is however, not an 
indicator of individual protection and has not been validated for non-PCV7 serotypes or children with HIV.  A 
substantial proportion of those in our study, whether HIV infected or not had serotype specific antibody levels 
greater than 0.35 µg/ml at baseline, thus limiting the utility of this cut-off in examining immune response. 
Indeed, it has been suggested that a higher threshold may be more appropriate in HIV infected children 
[271]. 
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It has also been suggested that a more conservative cut-off of 1 µg/ml may be more relevant to long term 
protection, based on studies of Haemophilus influenzae conjugate vaccine [434]. This cut-off has also been 
used in other studies of vaccine immunogenicity in HIV infected children [198, 412, 413]. We found the 
proportion of study subjects above this cut-off at baseline to be relatively low, to increase significantly post 
immunisation and to indicate differences between immune response in the HIV group compared to healthy 
controls. It is therefore a more useful determinant of differences in immunogenicity in the context of paHIV 
than the 0.35 µg/ml cut-off. Whether this cut-off is clinically relevant is not known and therefore predictions 
about clinical efficacy should be made with caution.  
 
Many other definitions of individual protection against pneumococcal disease or successful response to 
immunisation (both PPV and PCV) have been proposed. These have been described in the context of 
studies of vaccine immunogenicity and primary immunodeficiency diagnostics. They include various 
combinations of fold-changes in antibody level, absolute antibody concentration and proportion of serotypes 
for which there is a “successful response” [417, 432]. With respect to fold-change in antibody concentration, 
it has been shown that there is likely to be a ceiling to post immunisation antibody concentration. Individuals 
with high starting concentrations antibody (as was the case particularly with our adult healthy control cohort) 
may therefore not achieve a given fold-change despite intact immunity [417]. For this reason we have not 
used this as a read out of immunity in this study.  
 
Using GMCs we have demonstrated significant differences in response to vaccination between HIV infected 
children and young healthy adults and between responses to individual vaccine serotypes. Again, the clinical 
relevance in terms of protection from IPD, either short term or long term is not known, but it seems likely that 
a higher antibody concentration at 1 month post immunisation would be associated with longer term 
protection. 
 
In summary,we have shown pneumococcal serotype specific serum IgG is detectable at baseline, indicating 
naturally acquired pneumococcal immunity in both HIV infected and healthy control groups. Lower antibody 
concentrations to some serotypes and not others in the HIV infected group suggests that HIV may 
differentially impact upon naturally acquired immunity to individual serotypes. Antibody concentrations one 
month and 6 month post immunisation were higher in healthy controls for a substantial proportion of vaccine 
serotypes. After adjusting for baseline antibody concentrations, the responses to serotypes 6A, 6B and 23F 
were still found to be relatively impaired. For some serotypes lower resting memory B cell percentages were 
associated with lower post immunisation serotype specific IgG. Detectable viraemia was associated with 
lower post vaccination antibody concentrations for the majority of serotypes tested and, as with T and B cell 
phenotype, results indicate a larger proportion of life spent with undetectable viral load to be associated with 
higher post vaccination antibody levels, at least for some serotypes. 
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5.6 Conclusion 
 
We have shown that PCV13 is immunogenic in children with paHIV, but that differences exist in the 
magnitude of the response to some vaccine serotypes. We have demonstrated that baseline antibody 
concentrations are lower for some serotypes and that higher antibody at baseline is associated with higher 
antibody levels at 1 month post immunisation. Detectable viraemia is an independent predictor of lower 
antibody responses for the majority of vaccine serotypes. In the absence of detectable viraemia, at least for 
some serotypes, lower resting memory B cell proportions are associated with impaired antibody response. 
The results of the previous chapter demonstrated detectable viraemia to be associated with marked 
abnormalities of the B cell compartment as well as a relationship between the proportion of life on 
suppressive HAART and the integrity of the B cell memory subsets. 
 
Taken together with the results of this chapter it is clear that both the phenotype and function of B cells are 
impaired in the context of detectable viraemia in paHIV. It is also apparent that even when on suppressive 
HAART, a larger proportion of life spent with undetectable virus can potentially minimise irreversible loss of 
resting memory B cells, which are also associated with improved response to pneumococcal conjugate 
vaccine. 
 
It is highly unlikely that the effects of paHIV on B cells alone are solely responsible for observed impairments 
in IgG response to PCV13. The next chapter will investigate cytokine responses to the CRM197 in vitro in 
order to help delineate to what extent disruption in the normal immune response to vaccine carrier protein 
might contribute to overall disruption of effective antibody response to PCV13.  
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Chapter 6: In vitro cytokine responses 
 
6.1 Introduction  
 
Protein polysaccharide conjugate vaccines are thought to enlist carrier protein specific T cell help to 
polysaccharide specific B cells and by doing so transform the antibody response from a T independent one 
to a T dependent one [155, 288, 435]. Through direct cell-cell contact polysaccharide specific B cells are 
subject to co-receptor signalling and local T cell cytokine production, which will determine their 
developmental fate including class-switching, affinity maturation and ultimately, memory cell vs. plasma cell 
lineage commitment [123, 136, 137, 436].  
 
Dysregulation of circulating cytokines and in vitro T cell cytokine production are a well-recognised 
phenomenon in untreated HIV disease. These abnormalities, observed in both HIV infected adults and 
children, are not fully corrected by HAART [43, 437-440]. The nature of persistent abnormalities of T cell 
function and cytokine production, and how this might impact upon the antibody response to conjugate 
vaccines, remains under-investigated in children with paHIV.  
 
This chapter describes a novel whole blood cytokine release assay used for assessing in vitro cytokine 
responses to CRM197 before and after vaccination with PCV13. By comparing the pattern of cytokine 
production in children with paHIV with healthy controls and relating it to serotype specific IgG production we 
aim to gain further insight in to the effects of HIV and HAART on the response to CRM197 and how this may 
(or may not) impact upon humoral responses to vaccine polysaccharide. By doing so we also hope to shed 
light on the mechanism of action of conjugate vaccines in this age group. 
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6.2 Chapter aims 
 
i) To compare CRM197 specific cytokine responses at baseline between children with paHIV and healthy 
children and young adults using a whole blood cytokine release assay and a high sensitivity multiplex 
cytokine detection platform. 
 
ii) To assess CRM197 specific cytokine release prior to and 1 month following immunisation compared to 
baseline in children with paHIV compared to healthy young adults. 
 
iii) To investigate any association between CRM197 specific cytokine response and serotype specific 
antibody response to immunisation. 
 
iv) To assess serum IL21 levels in children with paHIV compared to healthy children and healthy young 
adults. 
 
v) To investigate any association between change in serum IL21 1 month post immunisation with serotype 
specific antibody responses to PCV13. 
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6.3 Statistical methods 
 
For baseline comparisons, Chi2 and Fisher’s exact test were used to compare proportions. Mann-Whitney U 
test was used to compare baseline age and for contrasting baseline cell subset data between child and adult 
groups. Hodges-Lehman median differences with 95% confidence intervals were also calculated. For direct 
comparison of cell subsets from the two child groups, data was log transformed and compared using linear 
regression analysis to allow for adjustment for age and to assess age*group interactions. Mann-Whitney U 
test was used to compare time between vaccination and blood sampling between groups. 
 
A stimulation index (SI) was calculated by dividing cytokine concentration in CRM197 stimulated well by the 
concentration measured when incubated with medium alone (negative control). Concentrations less than the 
lower limit of quantification (LLQ) were assigned a value of half the LLQ for the assay. Linear regression was 
used to investigate correlation between log transformed SI of each cytokine at baseline. One-way ANOVA 
was used to compare log transformed SI between groups at baseline, while repeated measures ANOVA 
(RMANOVA) was used to assess differences in cytokine production between vaccinated groups after 
vaccination.  Chi2 and Fisher’s exact test were used to assess differences in proportions responding with 
different combinations of cytokines between groups at baseline and 1 month following immunisation, while 
McNemar’s test was used to assess for differences in proportions within groups pre and post immunisation. 
Linear regression was used to investigate association between cytokine response (pre and post 
immunisation), lymphocyte subsets, clinical parameters, serum serotype specific IgG concentrations.  
 
Linear regression and RMANOVA were similarly employed to compare serum IL21 concentrations within and 
between groups, before and after vaccination and to investigate associations between serum IL21 
concentration and serotype specific IgG concentration.  
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6.4 Results 
 
There was no loss to follow up. Cytokine release assay failed for one adult healthy control and one child 
healthy control (no cytokine detected in positive control well). These 2 subjects were therefore excluded from 
all analysis. 5 child healthy controls were recruited prior to the final modification to the whole blood assay 
protocol, these children were also therefore excluded from analysis. 
 
6.4.1 Baseline characteristics 
Baseline characteristics are shown in Table 22. 
In view of exclusion of 1 adult healthy control and 6 healthy children from the analysis, baseline 
characteristics were again compared using the same methods as in Chapter 4. The pattern of differences 
were as in Chapter 4 except for baseline CD3 absolute count being higher in the healthy children than 
healthy young adults (median difference= 279, 95%CI: 6-744, p= 0.04) and for CD8 percentage for which 
significant group and age effects were demonstrated rather than age*group interaction when comparing 
  CHC 
(n=24) 
 AHC 
(n=26) 
 CP 
(n=48) 
 
Sex  Female 13 (54.2) 15 (57.7) 21 
 
(43.8) 
 
 Male 11 (45.8) 11 (42.3) 27 
 
(56.3) 
 
Ethnicity White 4 (16.7) 18 (69.2) 2 (4.2) 
 Mixed 0 (0) 2 (7.7) 3 (6.3) 
 Asian 0 (0) 4 (15.4) 2 (4.17) 
 Black Caribbean 1 (4.2) 0 (0) 2 (4.17) 
 Black African 10 (41.7) 0 (0) 38 (79.2) 
 Other 9 (37.5) 2 (7.7) 1 (2.1) 
Age/months  119 (31-159) 319 (245-359) 154 (12-209) 
Lymphocyte lymph cells/µl 2187.5 (1688.5-3389.5) 1807.5 (1377 -2125) 2349.5 (1764-3308.5) 
subsets CD3 cells/µl 1628.5 (1210.5- 2468) 1389 (1094- 1706) 1854.5 (1390.5-2518) 
 CD3 % 71.1 (65.95- 76.95) 74.35 (70.1- 79.1) 75.45 (68.9-79.6) 
 CD4 cells/µl 849.5 (700.5-1344.5) 794 (694-1061) 855 (525.5-1118) 
 CD4 % 42.2 (35.2-46.45) 43.8 (39.8- 50.6) 34.55 (27.2-40.8) 
 CD8 cells/µl 560 (398.5- 878.5) 497 (383-  557) 913.5 (659-1074.5) 
 CD8 % 23.7 (21.3-27) 26.25 (22.2-28.9) 32.95 (28.9-44.5) 
 CD19 cells/µl 471 (310.5-622.5) 257 (153- 326) 403 (266-570.5) 
 CD19 % 18.5 (14.6-25.3) 12 (8.9-16.8) 17.3 (12.96-21.4) 
 CD56 cells/µl 134.5 (90- 247) 172.5 (96-263) 119 (72-184.5) 
 CD56 % 5.8 (2.8- 9.0) 9.4 (6.5-12.7) 4.35 (2.8-5.6) 
Prev PCV7  8 (33.3) 0 (0) 7 (14.6) 
Prev PPV  0 (0) 0 (0) 12 (25.0) 
Nadir CD4%  - - - - 13 (0-48) 
Proportion of life 
undetectable 
 - - - - 0.49 (0-0.98) 
VL <50 copies/ml  - - - - 34 (72.3) 
Treated 1st year  - - - - 7 (14.9) 
Treated 1st 2 years  - - - - 12 (25.3) 
 
Table 22. Baseline characteristics for all study participants assessed for cytokine responses. Sex, ethnicity, HIV viral load status, 
treated in the first year of life, treated in the 1st 2 years of life, previous PCV7 and previous PPV are presented as number and 
percentage. Age, nadir CD4% and proportion of life undetectable are presented as median and range. Lymphocyte subsets are 
presented as median and interquartile range. (CHC= Child healthy control, AHC= Adult healthy control, CP = Child patient, VL = HIV 
viral load, PCV7 = 1-valent pneumococcal conjugate vaccine, PPV= pneumococcal polysaccharide vaccine) 
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children with paHIV to healthy children. CD8 percentages were higher in older children than younger children 
and higher in the HIV infected group than the HIV uninfected group. 
 
Prior to this study, 2/24 (8%), 1/24 (4%) and 5/24 (21%) of healthy children had received 1,2 or 3 doses of 
PCV7 respectively as part of their routine immunisation schedule. Median time since last dose of PCV7 was 
29.5 months (range = 18-99 months). 1/48 (2%), 2/48 (4%) and 5/48 (11%) children with paHIV had received 
1,2 or 3 doses of PCV7 respectively. Median time since last dose of PCV7 was 16 months (range = 8-28 
months). No adult healthy control had received PCV7 at any time and no study subject had received PCV13.  
 
As in Chapter 5 there was no significant difference in time from immunisation with PCV13 to 1 month or 6 
month blood sampling between the 2 vaccinated groups. 
 
6.4.2 Baseline CRM197 specific cytokine responses  
In vitro IFNγ, IL1β, IL5, IL10 and IL13 were measured in whole blood culture supernatants after 6 days of 
incubation with medium alone (negative control), CRM197 or anti-CD3 (positive control). A stimulation index 
(SI) was calculated by dividing cytokine concentration in CRM197 stimulated well by the concentration when 
incubated with medium alone. Concentrations less than the LLQ were assigned a value of half the LLQ. 
There were negligible differences in concentrations of IL1β between CRM stimulated and medium only wells, 
this cytokine was therefore not included in the analysis. Results for IFNγ, IL5, IL10 and IL13 are reported in 
Table 23. 
 
 
 
 
 
 
 
 
 
 
 
Linear regression was used to assess correlation between log transformed SI for each cytokine. IL13 and 
IL15 SI were very highly correlated for all 3 groups (AHC (R2= 0.71, p<0.001), CHC (R2= 0.91, p<0.001), CP 
(R2= 0.94, p<0.001) as shown in Fig. 21. For this reason IL13 results were not analysed further and all 
subsequent analysis was therefore based on IFNγ, IL5 and IL10 production.  
 Geometric mean SI (95% CI) 
 IFNγ IL5 IL13 IL10 
CHC 19.4 (7.9-46.8) 21.8 (6.2- 77.0) 6.0 (2.5-14.0) 2.0 (1.4-2.9) 
AHC 11.0 (5.3-22.8) 6.4 (2.9-14.3) 3.4 (1.9-6.1) 1.5 (1.2-2.0) 
CP 4.1 (2.4-7.1) 4.7 (2.3-9.5) 2.7 (1.7-4.4) 1.1 (1-1.1) 
 
Table 23. Stimulation index (SI) for CRM197 stimulated cytokine production at baseline for 
children with paHIV, healthy children and healthy young adults. Results are reported as 
geometric mean SI (95% confidence interval). (CHC=child healthy controls, AHC= adult 
healthy controls, CP = child patients, CI = confidence interval) 
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R2= 0.71, p<0.001 
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Fig. 21. Correlation between log transformed stimulation index (SI) for each of the 3 studied groups at baseline 
(AHC= Adult healthy control, CHC = Child healthy control, CP = Child patient, LnSI = log stimulation index) 
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In vitro whole blood stimulation with CRM197 resulted in mixed cytokine production at baseline, which was 
lower in children with paHIV than healthy controls with a larger proportion of children being unresponsive for 
all 3 cytokines 
 
There was a general trend of higher cytokine responses in healthy children compared to healthy adults, 
which were in turn higher than those in children with paHIV. One way ANOVA with Bonferroni correction was 
used to compare log transformed baseline SI between the 3 groups. Geometric mean SI were significantly 
lower in CP than CHC for IFNγ (p=0.005), IL5 (p=0.044) and IL10 (p<0.001). IL10 SI were significantly lower 
in CP than AHC (p=0.035).  
 
The proportion of subjects classed as responding with a particular cytokine (SI > 2) at baseline is shown in 
Fig. 22A. Chi2 or Fisher’s exact test were used to assess difference in proportions of responders for each 
cytokine/cytokine combination. In both healthy groups a substantial proportion of individuals responded with 
IFNγ either alone or in combination with other cytokines. The proportion of children responding with all 3 
cytokines (IFNγ,IL5,IL10) was significantly less for children with paHIV compared to healthy young adults 
(p=0.013) and healthy children (p <0.001) while the proportion of children unresponsive for all 3 cytokines 
was significantly more in children with paHIV than healthy young adults (p=0.037) and healthy children 
(p=0.010). 
 
HAART treatment in the first two years of life is associated with higher baseline in vitro cytokine responses to 
CRM197 in children with paHIV  
 
Associations between lymphocyte subsets/clinical parameters and log transformed baseline SI for IFNγ, IL5 
and IL10 were assessed using linear regression. Univariate analysis showed younger age, treatment in the 
1st year of life, treatment in the 1st two years of life, previous receipt of PCV7 and higher CD4 absolute count 
to be associated with higher SI (p<0.05). Multivariate analysis showed that after adjusting for age and CD4 
count, treatment in the first 2 years of life remained a significant predictor of higher baseline SI for IFNγ and 
IL5 (p<0.05) with borderline significance for IL10 (p=0.05). 
 
 
6.4.3 Response following immunisation 
Results for both vaccinated groups at baseline and 1 month following immunisation are shown in Table 24 
and Fig. 23.  
 
Repeated measures ANOVA was used to assess differences in log transformed SI at baseline compared to 
1 month post immunisation in the 2 vaccinated groups. Analysis was performed with and without including 
log transformed CD4 absolute count and log transformed baseline SI’s as covariates. Main effects were 
significant for both group and time for all 3 cytokines. Therefore post hoc contrasts for simple effects were 
performed in all cases. 
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Figure 22. Proportion responding to CRM197 with in vitro cytokine SI >2 in children with paHIV and young healthy children and adults at 
baseline (A) and in children with paHIV and young healthy adults pre and post immunisation (B). At baseline, the proportion of children 
responding with all 3 cytokines was significantly less for children with paHIV compared to healthy young adults (p=0.013) and healthy 
children (p<0.001) while the proportion of children unresponsive for all 3 cytokines was significantly more in children with paHIV than 
healthy young adults (p=0.037) andhealthy children (p=0.010). The proportion responding with all 3 cytokines increased in both young 
healthy adults and children with paHIV (p< 0.01). The proportion with no response for any cytokine did not change significantly for either 
group. The proportion responding with all 3 cytokines 1 month post immunisation was significantly higher in young healthy adults than 
children with paHIV (p<0.001) and the proportion with no response for any cytokine were significantly lower (p=0.003).(CHC = child 
healthy control, AHC = adult healthy control, CP = child patient, SI = stimulation index, pre = pre immunisation, post = 1 month post 
immunisation) 
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Figure 23. Stimulation index (SI) for a) IFNγ, b) 
IL5 and c) IL10 following in vitro stimulation of 
whole blood before and 1 month following 
immunisation with PCV13. Error bars indicate 
geometric mean SI and 95% confidence 
interval. Geometric mean SI significantly 
increased 1-month post immunisation 
compared to baseline for all 3 cytokines in 
young healthy adults (p<0.001) but only for 
IL10 in children with paHIV (p<0.001). 
Geometric mean SI were higher in young 
adults than children with paHIV for all 3 
cytokines at 1 month post immunisation: IFNγ 
(p<0.001), IL5 (p=0.002), IL10 (p<0.001). 
These differences remained significant after 
adjusting for CD4 absolute count and baseline 
SI. (AHC = adult healthy control, CHC = child 
healthy control, pre = pre immunisation, post = 
1 month post immunisation) 
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Cytokine responses increased post immunisation for all 3 measured cytokines in healthy young adults but 
only for IL10 in children with paHIV 
 
Geometric mean SI significantly increased 1 month post immunisation compared to baseline for all 3 
cytokines in young healthy adults (p<0.001) but only for IL10 in children with paHIV (p<0.001). Geometric 
mean SI were higher in young adults than children with paHIV for all 3 cytokines at 1 month post 
immunisation: IFNγ (p<0.001), IL5 (p=0.002), IL10 (p<0.001). These differences remained significant after 
adjusting for CD4 absolute count and baseline SI. 
 
PCV13 immunisation results in enhanced in vitro cytokine responses 1-month post immunisation in healthy 
young adults, much more so than is observed in children with paHIV 
 
The proportion of subjects classed as responding with a particular cytokine (SI > 2) at baseline and 1 month 
post immunisation are shown for both vaccinated groups in Fig. 22B. Chi2 or Fisher’s exact test were used to 
assess difference in proportions of responders for each cytokine/cytokine combination between groups at 1 
month post immunisation and McNemar’s test was used to compare proportions at baseline with those at 1 
month within group.  
 
The proportion responding with all 3 cytokines increased in both young healthy adults and children with 
paHIV (p< 0.01). The proportion with no response for any cytokine did not change significantly for either 
group although it should be noted that it started low and remained low in the young healthy adult group. The 
proportion responding with all 3 cytokines 1 month post immunisation was significantly higher in young 
healthy adults than children with paHIV (p<0.001) and the proportion with no response for any cytokine were 
significantly lower (p=0.003). It can be seen from comparing Fig 22A and Fig 22B that the cytokine response 
of children with paHIV 1 month post immunisation resemble those of healthy children pre immunisation.  
 
Higher baseline in vitro cytokine responses to CRM197 are predictive of higher in vitro cytokine responses 1 
month post immunisation in children with paHIV 
 
Associations between lymphocyte subsets/clinical parameters and log transformed SI one month post 
immunisation for IFNγ, IL5 and IL10 were assessed using linear regression for children with paHIV. The only 
 IFNγ  IL5  IL10  
 pre 1 month pre 1 month pre 1 month 
AHC 11.0 (5.3-22.8) 60.7 (27.8-132.6) 6.4 (2.9-14.3) 54.1 (24.0-121.8) 1.5 (1.2-2.0) 4.8 (3.3-7.0) 
CP 4.1 (2.4-7.1) 6.5 (3.1-13.4) 4.7 (2.3-9.5) 7.9 (3.4-18.0) 1.1 (1-1.1) 1.9 (1.4-2.6) 
 
Table 24. Stimulation index (SI) for CRM197 stimulated cytokine production at baseline and 1 month following 
immunisation for children with paHIV and healthy young adults. Results are reported as geometric mean SI (95% 
confidence interval). (CHC=child healthy controls, AHC= adult healthy controls, CP = child patients, pre = pre 
vaccination) 
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parameter to remain significantly associated with higher post immunisation SI for all 3 cytokines was higher 
baseline SI (p<0.02). 
 
There is no significant association between magnitude of in vitro cytokine response and serotype specific 
IgG production for any vaccine serotype in healthy controls or children with paHIV 
 
Linear regression was used to assess association between in vitro cytokine responses 1 month post 
immunisation with serotype specific IgG responses. SI and antibody concentrations were log transformed.  
 
No significant association was found between SI and IgG concentration for any vaccine serotype. This 
remained true after adjusting for baseline serotype specific IgG, age and CD4 count. 
 
6.4.4 Serum IL21 
A small proportion of study subjects had insufficient serum for testing. Only those with serum IL21 and 
pneumococcal ELISA results for baseline and 1 month post immunisation were included in the analysis. 
(CHC n=28, AHC n=26, CP n=43) 
 
Linear regression was used to assess for correlation between log transformed T helper cell subsets and log 
transformed serum IL21 for each group and also to compare baseline GMC IL21 concentration, after 
adjusting for CD4 count. Repeated measures ANOVA was used to assess for change in serum IL21 
concentration from baseline to one month post immunisation within group and to compare 1 month results 
between groups. Results are shown in Fig. 24. 
 
Serum IL21 correlates with CD4 count in children with paHIV, however concentrations do not differ between 
the HIV infected children and young healthy adults and children and do not change 1 month post 
immunisation with PCV13 
 
Serum IL21 concentrations significantly correlated with CD4 count for the CP group (R2 = 0.10, p=0.023) but 
not for AHC and CHC. There was no difference in GMC IL21 between the 3 groups, which remained true 
after adjusting for CD4 count (CHC vs. AHC (p=0.317), CHC vs. CP (p=0.378), CP vs. AHC (p=0.818)). 
There was no significant change in IL21 concentration 1 month following immunisation in either CP or AHC 
group and no difference between groups at this time point. 
 
Linear regression was used to assess for association between serum IL21 concentrations and serotype 
specific IgG responses to PCV13 
 
Serum IL21 levels do not correlate with serological response to PCV13 
 
There was no significant association between serum IL21 concentrations (pre or post immunisation) with 
serotype specific IgG concentrations for any vaccine serotype. This remained true after adjusting for baseline 
IgG concentrations and CD4 count. 
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Figure 24. A. Correlation between log transformed CD4 count and serum IL21 concentration in children with 
paHIV at baseline.  B. Serum IL21 concentrations at baseline and 1 month following immunisation (CHC = child 
healthy controls, AHC = adult healthy controls, CP = child patients, bl = basleine, 1m = 1 month post 
immunisation) 
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6.5 Discussion 
 
This is the first report of in vitro whole blood cytokine responses to CRM197 before and after vaccination with 
a CRM197 containing conjugate vaccine. It is also the first to investigate cytokine responses to CRM197 
resulting from PCV13 vaccination in healthy adults or children with paHIV.  
 
We have shown that in vitro CRM197 stimulation results in mixed production of the cytokines IFNγ, IL10, IL5 
and IL13 at baseline in children with paHIV and healthy controls. The magnitude of response and the 
proportion responding with all 4 cytokines was lower in HIV infected children. HAART treatment commenced 
in the first 2 years of life was associated with higher baseline cytokine responses.  
 
Vaccination with PCV13 resulted in increased CRM197 specific production of all 4 cytokines in healthy 
controls but only IL10 in HIV infected children. Levels of cytokine production did not correlate with serotype 
specific antibody responses in either group. Despite this relatively disordered/impaired cytokine response to 
CRM197, PCV13 had comparable immunogenicity for the majority of serotypes when comparing HIV 
infected children with healthy adults (after adjusting for baseline antibody levels).  
 
These results together suggest that children on HAART have relatively impaired T cell responses to 
CRM197, but that pre-existing immunity to CRM197 and the nature of CRM197 specific T cell responses 
elicited by PCV13 have relatively little impact on the magnitude of IgG responses to the majority of vaccine 
serotypes. However, variations in T cell response may well have implications for antibody function, class 
switching in general (class and subclass) and the establishment and longevity of immune memory, which 
may in turn impact upon clinical efficacy and the response to booster doses of the vaccine. 
 
A number of studies have assessed CRM197 specific T cell responses to CRM197 containing vaccines in 
animal models [441], healthy human adults [293, 294, 442], young children [443] and infants [319, 444, 445] 
and in HIV infected adults [48]. 5 of the human studies involved administration of PCV7 [48, 293, 319, 444, 
445] and 1 involved and experimental 9-valent vaccine [443]. All human studies examined in vitro CRM197 
specific responses of PBMC using a variety of methods including detection of secreted cytokine in culture 
supernatants, lymphocyte proliferation, T cell ELISPOT, real time polymerase chain reaction (PCR) and 
microarray. Studies varied in terms of dosing schedule, timing of blood sampling and duration of in vitro cell 
culture. 
 
Our finding of mixed whole blood IFNγ, IL5, IL13 and IL10 responses in healthy control adults and children at 
baseline are consistent with findings in the human studies which report mixed CRM197 specific cytokine 
responses in PBMC from healthy individuals without prior exposure to CRM197 [293, 294, 319, 443-445]. 
These responses were even present in 3 month old infants [319, 444, 445] and are most likely as a result of 
near universal exposure to multiple doses of diphtheria toxoid containing vaccines in infancy, childhood and 
adolescence. No study has directly compared CRM197 cytokine responses in healthy adults to those of 
healthy children. Our finding of a trend toward lower CRM197 specific cytokine responses in healthy adults 
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compared to healthy children may result from increased time since last exposure to diphtheria toxoid 
vaccination. A proportion of the healthy children were known to have prior exposure to CRM197 in the form 
of PCV7, which is likely to have contributed to their observed heightened responsiveness. The healthy 
children may also have been exposed to CRM197 in the context of other routine conjugate vaccines 
(although it was not possible to investigate this formally), which could also contribute to baseline responses.  
 
To our knowledge only one study has examined CRM197 specific cytokine responses in the context of HIV 
infection [48]. As part of a randomised trial comparing prime boost PCV followed by PPV to PPV alone (not 
including healthy controls), 30 HIV infected adults with mean age of 45 were shown to have CRM197 
specific lymphoproliferative responses, and IFNγ and IL2 production at baseline. Levels of IL5 and IL10 were 
also measured but not reported.   
 
Despite differences in experimental design and methodology, these reports alongside ours clearly 
demonstrate that memory responses to CRM197 exist at baseline even in individuals unexposed to CRM197 
and that a mixed pattern of cytokine production is characteristic. Our results show in addition that children 
with paHIV, although responding with a similarly mixed pattern of cytokines, do so less vigorously than 
healthy control children and respond in a way similar to adult healthy controls. One possible reason for this 
may be lower prior exposure to diphtheria toxoid or CRM197 containing vaccines. Vaccination records were 
incomplete for many of the HIV infected children so it was not possible to accurately assess this possibility 
although a previous audit including some of our cohort [446] found rates of vaccination with primary series of 
diphtheria vaccines to be relatively high with lower rates for preschool booster dose compared to regional 
reports for the population as a whole [447]. However, our finding that HAART commenced in the first 2 years 
of life was associated with higher baseline CRM197 specific cytokine responses suggests that HIV 
associated immune suppression is contributory, and that earlier HAART may preserve antigen specific T cell 
responses. Studies comparing lymphoproliferative responses to tetanus toxoid in older children with paHIV 
on HAART with those of healthy adults and children have demonstrated significantly impaired baseline 
responses to this classic recall antigen [195, 196, 448]. This gives support to the idea that CRM197 acts as a 
recall antigen reflecting prior exposure to diphtheria toxoid and for this reason, findings of impaired 
responses in HIV infected children on HAART mirror those observed when assessing in vitro cellular 
response to tetanus.  
 
Reports of in vitro responses to CRM197 1 month following vaccination with CRM197 containing conjugate 
vaccines in both healthy adults and infants have demonstrated enhanced production of IFNγ, IL5 and IL13. 
Adult studies have also demonstrated enhanced IL10 production whereas infant studies found no increase in 
IL10 response [293, 294, 319, 445]. Consistent with these reports we have demonstrated significantly 
enhanced production of IL5, IL13, IL10 and IFNγ in young healthy adults 1 month following PCV13. The only 
published study of CRM197 specific cytokine responses in HIV infected individuals demonstrated that 
vaccination with PCV7 resulted in enhanced production of IFNγ but not IL5 or IL10 in HIV infected adults 
vaccinated with PCV7 [48]. Our finding of significantly increased production of only IL10 in children with 
paHIV contrasts with findings in HIV infected adults. Although it is possible that these differences may be a 
result of differences in immune phenotype in children with paHIV, it should be noted that the adult 
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experiments were performed on PBMC, and culture supernatants were harvested after 2 days rather than 6, 
which limits direct comparison.  
 
The majority of healthy young adult in our study responded to CRM197 in vitro with all 3 cytokines assessed 
following vaccination. While the proportion responding with all 3 cytokines increased in the paHIV group, it 
was not to the extent of the healthy controls. This finding is reminiscent of findings of lower polyfunctional T 
cell cytokine responses to tuberculosis antigens in the context of HIV infection [449, 450], although it is 
important to note that we have not shown definitively demonstrated the source of cytokine production in our 
assay. 
 
In their study of healthy neonatal/infant responses to PCV7, Van den Biggelaar et al found that while a 
significant proportion respond with mixed production of IL5/IL13 and IFNγ, a roughly equal proportion 
respond with only IL5/IL13 [319, 445]. This is in contrast with our healthy control and HIV infected groups, 
very few of whom respond with IL5/IL13 in isolation, the majority responding with a combination of 
IFNγ/IL5/IL13 together or IFNγ alone. This observation may well reflect the general skew of cytokine 
responses known to occur in infants, favouring production of Th2 cytokines such as IL5, IL13 and IL4, over 
Th1 cytokines such as IFNγ and IL12 [451-454].  
 
We found no significant correlation between the magnitude of in vitro cytokine response to CRM197 either at 
baseline or 1 month post immunisation and serotype specific IgG responses to PCV13. Despite profound 
differences in in vitro responses to CRM197, for the majority of serotypes, PCV13 is similarly immunogenic 
in children with paHIV and young healthy adults, as assessed by serotype specific IgG after adjusting for 
baseline concentrations (reported in Chapter 5). This is at first somewhat surprising in view of the fact that 
CRM197 specific T cell help is considered to be fundamental to successful polysaccharide specific antibody 
response to CRM197 containing conjugate vaccines [155, 288, 295, 435]. 
 
A substantial proportion of CRM197 specific cytokine production 1 month post immunisation is likely to 
reflect, at least in part, up-regulation of cytokine production by and/or proliferation of antigen specific T helper 
cells. The magnitude of this response will be impacted upon by previous antigenic exposure and persistence 
of resultant immune memory. The effects of carrier priming on response to conjugate vaccines are complex. 
Previous exposure may enhance, suppress or have minimal effect on subsequent immune response to the 
polysaccharide depending on various factors including the nature of carrier protein and polysaccharide and 
antigen dose [455]. Furthermore, observations that the antibody responses to different pneumococcal 
polysaccharides vary despite uniformly vigorous T cell responses to CRM197 [293, 456] provide additional 
evidence that the relationship between the CRM197 specific immunity and polysaccharide specific immunity 
following conjugate vaccination is not a straightforward one.  
 
Patterns of in vitro whole blood cytokine response might not directly reflect patterns of response in lymphoid 
tissue. Cytokine responses at 1 month post immunisation may not reflect T cell responses around the time of 
vaccination, which may be more likely to impact upon the development of the antibody secreting cells 
responsible for peak antibody concentrations one month post immunisation. They give little information on 
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direct cell/cell contact and co-receptor signalling. The pattern of T cell cytokine response may not impact 
upon the magnitude of cytokine response, but may still affect class switch recombination (IgG1, IgG2, IgG3, 
IgG4, IgA, IgE), B cell maturation (memory vs. plasma cell) and antibody function [138, 139, 457-459].  
 
Taking the above in to consideration alongside recent reports that carbohydrate epitopes may be processed 
and presented alongside carrier protein in the context of MHCII and that carbohydrate specific T cells may 
also be playing a role, it is perhaps less surprising that we have not observed a direct relationship between 
CRM197 specific cytokine responses in whole blood and serotype specific IgG responses. 
 
Van Den Biggelaar et al found there to be a correlation between CRM197 specific IFNγ production in PBMC 
and pneumococcal antibody responses in immunised infants [445]. This, alongside our finding of no 
correlation in young healthy adults and HIV infected children, raises the possibility that the response to 
conjugate vaccine in older children and adults may not be as dependent on CRM197 specific T cell help as it 
is in infants. This possibility is supported by findings in healthy and HIV infected adults suggesting that 
pneumococcal conjugate vaccines may not prime as well for memory responses in adults and offer little 
advantage, at least in terms of serotype specific IgG concentrations, over PPV [271, 460]. 
 
What then may we hypothesise from the results of the whole blood assay about the mechanism of action of 
CRM197 conjugated vaccines, how HIV impacts on this process and potential clinical implications of our 
findings?  
 
Firstly it is worth considering the possible differences in the read out from our whole blood cytokine release 
assay as compared to that of published PBMC based assays. One advantage of the use of PBMC assays is 
the ability to standardise concentrations of PBMC in culture, thus facilitating direct comparison within and 
between study subjects. It can be argued that it only partially achieves this aim and that use of PBMC is a 
less accurate reflection of in vivo antigen response than whole blood. PBMC isolation, storage and 
processing can alter the ratio of monocytes to lymphocytes and affect cell function. Although allowing 
standardisation of mononuclear cell concentrations, variations in lymphocyte/monocyte proportions are often 
not taken into account. The preparation process removes many other cells and soluble factors, both 
stimulatory and inhibitory that may be influential in the immune response to a given antigen. For these 
reasons, whole blood stimulation, although it does not allow standardisation for mononuclear cell frequency, 
may be a more accurate reflection of in vivo immune responses [341, 461]. Indeed whole blood cytokine 
release assays may be highly standardised and have great clinical value as demonstrated by the 
QuantiFERON-TB® Gold In-Tube test used for diagnosis of latent TB infection [462]. A recent publication in 
the field of visceral leishmaniasis research has reported striking differences in the readout from whole blood 
assays compared to PBMC, which has shed interesting new light on disease immunopathogenesis [463]. 
 
It is clear that in vitro response to CRM197 in healthy controls, whether using PBMC or whole blood, involves 
mixed cytokine production including IFNγ, IL5, IL13 and IL10. Kamboj et al demonstrated that CRM197 
specific proliferative and cytokine responses in PBMC are abrogated by depletion of CD4+ T cells, 
suggesting that the PBMC assay results reflect predominately CRM197 specific CD4+ T cell responses [293, 
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294]. It is therefore likely that our own findings in whole blood similarly reflect CD4+ T cell responses in the 
main although we have not shown this to be the case experimentally and other potential sources of these 
cytokines should be taken in to consideration.  
 
IFNγ is a pleiotropic cytokine, mainly produced by T lymphocytes and NK cells, but also known to be 
produced by APCs and B cells [171, 172, 464]. It is known for its role as a classical Th1 cytokine, promoting 
immune responses to certain viral and intracellular pathogens. It also impacts upon humoral immunity, 
affecting B cell development, antibody production and class switch recombination (both class and subclass) 
[250, 464-470]. 
 
Of the two cytokines IL5 and IL13, IL13 has a more established role in humoral immunity in humans, Il5 
being more associated with eosinophil immunity. IL13 is mainly produced by T lymphocytes and NK cells, 
though it is also produced by basophils, eosinophils, dendritic cells and B cells [172, 471]. Its influence on B 
cell development, class switch and antibody production hold much in common with IL4 and it is classically 
considered an important Th2 cytokine involved in parasite immunity and allergic disease [471]. Our finding of 
highly correlated production of IL5 and IL13 in both healthy controls and children with paHIV, pre and post 
immunisation, is unsurprising. IL4/IL5/IL13 co-expression is a well-documented phenomenon, the genes for 
these cytokines are found clustered on chromosome 5 and regulation of their transcription has been shown 
to share many common elements (e.g. GATA3) [471-474].  
 
IL10 is considered to be a cytokine with a generally more regulatory role. It is produced by activated T cells, 
B cells and monocytes [475] and, as with the other cytokines mentioned above, contributes to B cell 
development, class switch and antibody production [476-478]. It is being increasingly studied in the context 
of B cell immunity in relation to regulatory B cell function in health and disease [171, 172]. 
 
The balance of production of these cytokines resulting from exposure to CRM197 is therefore likely to 
contribute to the overall pattern of humoral response following conjugate vaccination. We have shown that 
despite dramatically different in vitro cytokine responses to CRM197, children with paHIV produce significant 
amounts of serotype specific IgG. In view of the altered cytokine milieu at the time of vaccination it is 
probable that there are differences in IgG subclass, IgA and IgM responses, antibody avidity/function and in 
the development of memory cells and long lived plasma cells, all of which warrant further investigation. 
Lower baseline immunity was associated with lower antibody concentrations at 1-month post immunisation. 
This, together with the factors discussed above may explain the lower efficacy of PCV observed in HIV 
infected children and will have implications with regards to the need for booster doses [271, 312, 327, 343].  
 
IL21 is a relatively recently characterised member of the family of cytokines signalling via the common γ 
chain, which include IL2, IL4, IL7, IL9 and IL15. It is produced by T cells, in particular CD4+ TFH and Th17 
cells, as well as NKT cells [320, 479]. The IL21 receptor (IL21R) is expressed on a number of immune cell 
types including T cells, B cells, NK cells and dendritic cells resulting in pleiotropic effects. Of particular 
relevance to this study are its critical role in TFH development, TFH signalling to B cells, B cell maturation, 
class switch recombination and affinity maturation [458, 459, 479-489]. Furthermore, over the past 4 years 
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evidence has accumulated implicating IL21 in many aspects of HIV immunology. In vitro work in HIV infected 
adults has found IL21 to enhance and/or modulate cytotoxic CD8+ and NK cell function and its potential 
immunotherapeutic properties are currently under investigation in animal models [479]. To our knowledge, 
there are no reports regarding IL21 in children with paHIV to date.  
 
Studies in HIV infected adults have shown serum IL21 to be reduced, that levels correlate with CD4+ T cell 
count and that HAART only partially restores levels to those observed in healthy controls [321, 322]. Ruffin et 
al demonstrated IL21R upregulation on B cells from HIV infected patients and showed an association with 
measures of immune activation, increased B cell apoptosis and reduced proportions of resting memory B 
cells [377]. A recent investigation of response to H1N1/09 vaccination in HIV infected adults and healthy 
controls, found successful antibody response to the vaccine to be associated with an increase in serum IL21 
1 month post immunisation, expansion of circulating IL21 producing TFH-like cells as well as HIV specific 
plasmablasts and memory B cells [47, 323]. This led us to investigate serum levels IL21 in children with 
paHIV pre and post immunisation with PCV13 and any association with antibody response to immunisation.  
 
Consistent with adult studies described above, we found a moderate positive correlation between CD4+ T 
cell count and serum IL21 concentration in the HIV infected cohort. In contrast with these studies, we found 
no difference in serum IL21 concentrations between children with paHIV and healthy young adults and 
children. This suggests either that HIV has less of an impact on circulating IL21 in children than in adults, or 
considering the fact that the majority of our cohort were on suppressive HAART, antiretroviral therapy may 
be more effective in restoring IL21 levels to normal in children with paHIV than in adults. A formal study 
comparing IL21 levels in untreated children to those on HAART and a longitudinal study of children 
commencing HAART therapy would serve to clarify this further. 
 
We also found there to be no significant increase in serum IL21 1 month post immunisation with PCV13 
either in healthy controls or children with paHIV and no correlation between IL21 concentrations and 
serotype specific IgG concentrations. This indicates that the mechanism of action of PCV13 in older children 
and adults may differ from that of H1N1/09 influenza vaccine. PCV13 consists of bacterial polysaccharide 
bound to CRM197 carrier protein with aluminium phosphate as an adjuvant [332], whereas the H1N1/09 
influenza vaccine is a sub-unit (purified surface antigen) vaccine with a squalene based MF59 adjuvant 
[490].  Differences in the mechanism of action are therefore likely. Robust IgG responses to PCV13 in our 
vaccinated cohorts, in the absence of significant increase in serum Il21, lead us tentatively to suggest once 
more that the IgG response to PCV13 in adults and older children may not be entirely T dependent.  
 
6.6 Conclusion 
 
The resounding success of protein polysaccharide conjugate vaccines in protecting against invasive 
bacterial disease has transformed the epidemiology of severe infection in vaccinated infants and young 
children. In the case of pneumococcal conjugate vaccines, additional protection against nasopharyngeal 
carriage has, through the process of herd immunity, provided the additional benefit of reducing vaccine 
serotype invasive disease in older unvaccinated populations. Yet it is still debated whether vaccination with 
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PCV offers additional protection over and above that provided by PPV in at risk individuals outside of early 
childhood. PCV has proven immunogenicity and clinical efficacy in HIV adults and infants and young children 
[312, 327, 330], yet efficacy data in older HIV infected children on HAART is lacking. As universal access to 
HAART is achieved and the global paediatric population enters adolescence, it will be increasingly important 
to study vaccine immunogenicity in this unique cohort in order to ensure protection against vaccine 
preventable disease that lasts into adulthood.    
 
We have demonstrated PCV13 to be immunogenic in a cohort of HIV infected children and adolescents 
despite altered in vitro T cell cytokine responses. As well as providing much needed vaccine immunogenicity 
data, we have shown persistent alterations in T cell function in older children on HAART, which has shed 
light on the possible mechanism of action of CRM197 conjugated vaccines in both HIV infected and 
uninfected older age groups. 
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Figure 25. Illustration of the presumed mechanism of action of CRM-polysaccharide conjugate vaccine and the way in which 
HIV infection might influence antibody response with respect to T cell involvement. a) Vaccine polysaccharide is recognised by 
polysaccharide specific B cell receptor.b) Vaccine is processed by the B cell and c) the CRM protein epitopes are presented in 
the context of MHC II to CRM specific T cells. d) We have shown that HIV infection impacts upon the magnitude and balance of 
the mixed CRM specific T cell cytokine production. Depending on the nature of T cell help, polysaccharide specific B cells can 
either develop e) into short lived plasma cells, producing low affinity, unswitched antibody, or via the germinal centre reaction, 
resulting in f) long lived plasma cells, producing class switched, higher affinity antibody, or g) memory B cells. In chapter 4 we 
have demonstrated differences in memory B cell phenotype between children with HIV and healthy controls. In chapter 5 we 
have shown that quantitative antibody responses are relatively in tact for the majority of vaccine serotypes in children with 
paHIV on HAART. This leads us to hypothesise that impairments in T cell cytokine production described in this chapter, may 
have more of an impact on antibody function and subsequent B cell development, than on concentration of antibody in serum 
directly after immunisation. 
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Chapter 7: Overall discussion and final conclusion 
 
7.1 Summary of study  
 
This work set out to characterise circulating T and B cell phenotype in a cohort of children with paHIV in 
comparison to healthy controls and to relate any observed abnormalities in phenotype to clinical parameters 
such as HAART treatment history and detectable viraemia. Baseline pneumococcal serology was quantified 
alongside short and long term antibody responses to the newly licensed 13-valent pneumococcal conjugate 
vaccine and associations between the magnitude of serological response and lymphocyte phenotype were 
investigated. A novel whole blood assay was used to measure in vitro cytokine responses to vaccine carrier 
protein, before and after vaccination, so as to determine the possible contribution of altered antigen specific 
cytokine production to any observed impairment in serological response and to provide further information on 
the mechanism of action of conjugate vaccines outside of the infant period. Serum levels of IL21, a key 
cytokine involved in T cell help to B cells, were measured before and after immunisation, to evaluate any 
association between cytokine concentration and antibody response to immunisation.  Finally, pneumococcal 
nasopharyngeal colonisation was assessed before and after vaccination to provide data on carriage 
serotypes in HIV infected children 4 years after introduction of universal infant immunisation in the UK as 
well as the potential interaction between carriage and vaccine responses.  
 
7.2 Summary of findings 
 
We have found significant abnormalities of B cell and T cell phenotype in children with paHIV when 
compared to healthy controls, specifically reduced proportions of memory B cell subsets and TFH-like cells. 
These differences were present despite fully suppressive HAART in the majority of patients. Viraemia was 
associated with higher proportions of CD21- B cell populations including transitional cells, activated mature 
and tissue like/exhausted memory B cells. In relation to treatment history, results suggest that a greater 
proportion of life spent with undetectable viral load is associated with a more preserved lymphocyte 
phenotype. 
 
Pneumococcal serotype specific serum IgG was detected at baseline, indicating naturally acquired 
pneumococcal immunity in both HIV infected and healthy control groups. Lower antibody concentrations to 
some serotypes and not others in the HIV infected group suggests that HIV may differentially impact upon 
naturally acquired immunity to individual serotypes. Antibody concentrations one month and 6 month post 
immunisation were higher in healthy controls for a substantial proportion of vaccine serotypes. After 
adjusting for baseline antibody concentrations, the responses to serotypes 6A, 6B and 23F were still found to 
be relatively impaired. For some serotypes lower resting memory B cell percentages were associated with 
lower post immunisation serotype specific IgG. Detectable viraemia was associated with lower post 
vaccination antibody concentrations for the majority of serotypes tested and, as with T and B cell phenotype, 
results indicate a larger proportion of life spent with undetectable viral load to be associated with higher post 
vaccination antibody levels, at least for some serotypes.  
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Nasopharyngeal colonisation was only detectable in the HIV infected group. Carried serotypes were not 
those included in PCV13, but a proportion of them are covered by the currently available PPV formulation. 
Although numbers were small, serotype 11A was isolated most frequently, at a higher rate than observed in 
recently reported UK carriage studies [215]. Lower than expected frequency of carriage prevented 
meaningful analysis of the interaction between carriage and serological response to vaccination. 
 
CRM197 specific cytokine production was present at baseline in both children with paHIV and healthy 
controls, most likely as a result of previous exposure to diphtheria toxoid vaccination. A higher proportion 
responding with all 4 measured cytokines and a greater magnitude of cytokine response was observed at 
baseline in healthy control groups. Immunisation resulted in enhanced in vitro cytokine responses in healthy 
controls, the majority responding with a combination of all 4 measured cytokines. Although an increase in the 
proportion responding with all 4 cytokines was also observed in the paHIV group, this proportion was 
significantly lower than that of the healthy control group. A substantial proportion remained unresponsive for 
all measured cytokines, and the increase in magnitude of cytokine response was significant for IL10 alone. In 
vitro cytokine production was not found to correlate with antibody response in either vaccinated group. These 
dramatic differences in in vitro cytokine production were in contrast to the relatively well-preserved serotype 
specific IgG responses described above. 
 
As in recent studies in HIV infected adults [321, 322], serum IL21 was found to correlate with CD4 count in 
children with paHIV. However, in contrast to adult studies, there was no significant difference between IL21 
concentrations in the HIV infected group and healthy controls, there was no detectable increase in serum 
IL21 1 month post immunisation and there was no correlation between serum IL21 and post vaccination 
antibody concentrations.  Taken together with the in vitro cytokine data described above, it seems possible 
that the response to conjugate vaccines outside of the infant period may not be as dependent on T cell help 
as in the infant period when the response to both polysaccharide and carrier protein is predominately a 
primary rather than memory response.  
 
7.3 Model of conjugate vaccine response outside of infant period and impact of paHIV 
 
Considering our findings alongside existing published data and current opinion on T and B cell responses to 
T dependent, T independent and protein-polysaccharide conjugate antigens and current theories of HIV 
pathogenesis [40, 120, 123, 136, 137, 347, 491], I propose a summary model of the response to conjugate 
vaccines in antigen experienced children and adults (Figs. 26 and 27). The ways in which paHIV infection 
may impact on the various aspects of this immune response are highlighted.  
 
Fig. 26 illustrates elements of the immune system likely to be involved in antibody responses to 
pneumococcal conjugate vaccine outside of the infant period.  
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Prior to immunisation, baseline immunity to both carrier and polysaccharide will have been affected by paHIV 
infection. Our findings indicate that baseline polysaccharide antibody concentrations are lower for some 
serotypes and circulating memory B cell and TFH-like cell proportions are reduced. The pattern of carrier 
protein specific T cell cytokine production is also altered. Published data indicates that FDC and lymphoid 
tissue architecture are also disrupted by HIV infection and that lymphoid tissue may actually be a sanctuary 
site for latent HIV or even ongoing viral replication [390, 397, 398, 406]. Therefore the stage is already set for 
suboptimal antibody responses. A proportion of these abnormalities may be prevented/corrected by HAART, 
with younger age at HAART commencement and sustained viral suppression possibly associated with a 
more intact immune armoury. 
 
Fig. 27 summarises the immune mechanisms likely to be of importance in response to pneumococcal 
conjugate vaccine outside of the infant period and highlights points at which HIV may have a detrimental 
effect.  
 
Following immunisation, lower circulating antibody levels may impact upon the efficiency of immune complex 
formation and consequently the efficiency by which professional APC bind vaccine antigen as well as 
antigen presentation to B cells by subcapsular sinus macrophages. Differences in the proportion and 
numbers of naive and memory carrier specific T cells would influence the rate and magnitude of T cell 
activation via APC. Similarly, a reduction in memory B cell proportions might affect the rate and likelihood of 
extrafollicular short-lived plasma cell development and the nature and efficiency of extrafollicular T/B cell 
interaction. An alteration in the balance of cytokine expression by extrafollicular T cells would impact upon 
short lived plasma cell development and also developmental programming of B cells destined for the 
germinal centre reaction. Once the germinal centre is established, dysregulated TFH function is likely to affect 
the process of B cell affinity maturation and class switch recombination.  
 
We (and others [120, 165, 169]) have found numbers of CD21lo/- B cells to be increased in untreated HIV. 
Interestingly, in studies of germinal centre dynamics in mice, it has been demonstrated that B cells play a 
key role in shuttling of antigen to FDC in GC via non-cognate binding of immune complexes. This binding is 
most likely mediated via CD21 (also known as CR2) [491-494]. These findings in mice, although not yet 
demonstrated in humans lead us to speculate that reduced CD21 expression on circulating B cells, and 
reduced antigen shuttling capacity, might be an important mechanism by which GC reaction and antibody 
responses are particularly impaired in HIV infected individuals.  
 
Reduced antigen delivery, altered lymphoid architecture and altered FDC function are all likely to contribute 
to disruption of GC dynamics and the efficient production of class switched, affinity matured antibody. 
Developmental programming of B cells (into memory B cells or long lived plasma cells) and T cells (into 
memory T cell subsets) will also be influenced by altered B cell, T cell and FDC function and phenotype. 
Long term survival and effective functioning of memory B and T cells are also impaired while viral replication 
is ongoing, possibly even after viral suppression by HAART. 
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7.4 Clinical implications 
 
What are the clinical implications of our findings in the context of published data on responses to conjugate 
vaccines and the immunology of paHIV?  
 
When considering the implications for planning pneumococcal conjugate vaccination for children outside the 
infant period, our results suggest that the magnitude of IgG responses is related to pre-immunisation 
antibody concentrations, that the immunogenicity of each serotype varies and that viraemia has a negative 
effect. The latter finding would lead us to recommend that in order to optimise antibody response to PCV13, 
vaccination should be delayed until after viral load is undetectable on HAART. If HAART is not indicated then 
PCV13 may be given but the prospect of waning immunity and the potential benefit of booster doses once 
HAART is indicated and initiated should be considered. The fact that certain serotypes appear less 
immunogenic in HIV infected children, lead us to suggest that vaccine formulations with altered dosing of 
these particular serotypes be considered especially when planning and developing lower cost alternatives to 
existing conjugate vaccines specifically for resource poor countries, where the incidence of paHIV might be 
relatively high. This, however, is unlikely to be a feasible option and consideration should also be given to 
the possibility of providing booster doses in HIV infected children to increase response to less immunogenic 
serotypes, or even doubling the dose of PCV, as has been shown to increase immunogenicity in older adults 
[495]. 
 
Our finding that earlier HAART initiation and sustained viral suppression is associated with a more preserved 
immune phenotype and potentially enhanced immune response to vaccination lends support to current 
guidelines to commence HAART in all HIV infected infants irrespective of immune status [181, 186]. The 
possibility of raising the CD4 threshold for HAART initiation in older children is also supported. Alongside 
findings in adults with HIV infection [165, 182], our results do not support the suggestion of prolonged 
treatment interruption in later childhood or adolescence, at least in terms of preservation of the B cell 
compartment and humoral immunity.  
 
Detectable pneumococcal carriage of non-PCV13 serotypes in a proportion of children with paHIV might be 
an early indicator of serotype replacement in the UK and highlights the importance of carriage studies in risk 
groups now and following introduction of future pneumococcal vaccines into national schedules [246]. 
 
7.5 Limitations 
 
When considering the limitations of this study, it is worth considering those specific to individual aspects of 
the research and then some more general limitations. 
 
As discussed in Section 4.3 the T and B cell flow panels were designed after consideration of existing 
published literature and current quality assurance measures. This resulted in reliable and accurate 
determination of cell surface phenotype and quantification of some relatively rare cell populations. The 
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inclusion of further markers of exhaustion, apoptosis and proliferation to both the T and B cell panel would 
have enabled further characterisation of identified subsets, although addition of further colours to each panel 
would bring its own limitations in terms of cost, fluorescence spillover effects and complexity of data analysis. 
The addition of further antibody isotypes to the B cell panel would have allowed more detailed phenotyping 
of B cell subsets in line with the most recent published data on memory B cells subsets in humans [146]. We 
assessed immune phenotype at baseline and 6 months post immunisation, allowing us to confirm that 
measured subsets were relatively stable over time and not significantly influenced in the long term by 
immunisation. Assessing phenotype at 1 month post immunisation may have revealed more short-term 
impacts of vaccination on T and B cell subsets as observed, for example, in HIV infected adults following 
immunisation with flu vaccine [47, 323]. As discussed in Section 4.5 measurement of circulating cell 
phenotype might not reflect cell populations in secondary lymphoid tissue. The ability to examine parallel 
samples from tissues such as lymph nodes, tonsils, spleen, MALT and bone marrow would provide valuable 
extra information to that effect. However, access to these sites is extremely limited, especially in children, 
therefore it is unlikely that studies of these compartments will be included in paediatric HIV research in the 
near future. Nevertheless, research in HIV infected adults and animal models of HIV are providing tissue 
data [46, 347, 387], which are of relevance to studies of peripheral blood in paediatric disease. 
 
We employed current WHO reference lab methodology to assess serotype specific IgG for all 13 vaccine 
serotypes using relatively low sample volumes. This method is extremely well validated and guaranteed 
highly accurate ELISA results which can be directly compared with published data produced using the same 
protocols. As discussed in Sections 1.3.3 and 5.5, the IgG cut off for protection are not definitively 
established in HIV infected and uninfected older children and adults, which limits interpretation of our data. 
Bearing in mind the many other aspects of pneumococcal immunity that may be affected by HIV, it is unlikely 
that an absolute cut off antibody concentration will be established in immunologically heterogeneous HIV 
infected groups. In vitro assays such as the OPA are somewhat more likely to provide an accurate prediction 
in the context HIV, however it is still not a perfect model of in vivo pneumococcal immunity. In the future, in 
depth analysis using systems biology methods to integrate gene expression data, flow cytometry derived 
phenotypic information and read outs of quantitative and functional antigen specific cellular and humoral 
vaccine response, or “vaccinomics” will hopefully allow us to more accurately predict clinical protection in 
healthy and diseased groups [496]. We measured only serotype specific IgG in serum, measurement of 
additional immunoglobulin isotypes and subclass in serum and at mucosal sites might reveal additional 
differences in serological response to vaccine. We have not measured antibody avidity or response to a 
booster dose of the conjugate and/or polysaccharide vaccine, which would provide further knowledge of the 
impact of HIV on functional immunity following vaccination. 
 
The relative merits of whole blood cytokine release assays compared to those using PBMC have been 
discussed in Section 6.5. It stands that information on cytokine release from PBMC may have yielded 
additional information, however one of the aims of this research was to perform multiple assays on minimal 
blood volume and we maintain our view that results of whole blood assays can yield useful, informative and 
replicable results which may reflect in vivo cellular responses more accurately. Concentrations of 5 cytokines 
were measured in culture supernatants on day 6 of incubation at baseline and one month following 
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immunisation. Early optimisation experiments indicated that cytokine concentrations were highest by day 6. 
Nevertheless, increasing the number of relevant measured cytokines (in particular IL21) and analysis of 
samples from earlier time points during incubation, while increasing the complexity of data analysis, may well 
have revealed further differences in the dynamics and balance of in vitro cytokine production. We measured 
antigen specific cytokine production in culture supernatants. The addition of further methods for assessment 
of antigen specific cellular cytokine responses including ELISPOT, flow cytometry and lymphocyte 
proliferation assays would also have provided further insights into the cellular sources of measured cytokine.  
 
We have used standard WHO and HPA methodology to detect single pneumococcal carriage isolates. 
Coincident carriage of more than 1 serotype is a well-recognised phenomenon and the complex interplay 
between pneumococcus and other pathogenic viruses and bacteria in the nasopharynx is being increasingly 
investigated. Larger study numbers and the use of multiplexed carriage techniques and even determination 
of the nasopharyngeal microbiome as a whole in healthy and HIV infected individuals, before and after 
immunisation would be a useful addition to our carriage data. 
 
One obvious general limitation is the use of young adult healthy controls rather than age matched healthy 
controls to compare vaccine responses. While an age matched group would have been desirable, we did not 
deem it either ethically or logistically feasible to recruit a large enough group of children of an appropriate 
age to receive a vaccine outside of the national schedule and licensed indication and willing to have blood 
sampling on 3 separate occasions. Bearing in mind that the most dramatic changes in immune phenotype 
and development occur in the first 2 years of life, the comparison between young adults and adolescents 
with paHIV is a valid one, yet we acknowledge that observed differences due to age can not be completely 
excluded. 
 
The large amount of data acquired through the techniques employed in this study, while providing a wealth 
of information, has inevitably also resulted in multiple statistical comparisons. This can lead to an increase in 
the likelihood of Type 1 error (false positive). To minimise the impact of this, we have adhered strictly to a 
pre-formulated analysis plan. Where possible we have used statistical techniques that integrate corrections 
for multiple comparisons. We have maintained reporting of results at the p<0.05 significance level, while fully 
acknowledging that a more conservative cut-off might be considered more appropriate. We have reported 
confidence intervals as much as possible in order to allow assessment of the nature of observed differences 
and have been cautious in drawing strong conclusions when p values are closer to 0.05. Whenever possible 
we have used parametric tests and only used non-parametric tests when data violate parametric test 
assumptions.  
 
We have assessed responses to pneumococcal conjugate vaccine in a cohort of older children with paHIV in 
the UK. The prevalence of paHIV in the UK is thankfully decreasing. Secondary to the phenomenal success 
of universal infant vaccination in reducing vaccine serotype pneumococcal disease at the population level 
through herd immunity, vaccine serotype disease is also disappearing in the UK. It may then be argued that 
knowledge of response to this vaccine is no longer relevant in this setting. However our findings are of 
relevance when considering the response to other conjugate vaccines, future higher valency pneumococcal 
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conjugate vaccines and other routine vaccines. Although disease due to vaccine serotypes is dwindling in 
the UK, our patient cohort frequently travel to countries that unfortunately do not have well established infant 
pneumococcal conjugate vaccination programmes and still have high levels of invasive disease due to 
vaccine serotypes. PCV13 in this respect might almost be therefore considered a “travel vaccine” in this 
context. We are fortunate to have had access to HAART and pneumococcal vaccines for children for a 
number of years in the UK. This is by no means the case in resource poor countries with much higher 
prevalence of paHIV and IPD. Our findings are still therefore very relevant for vaccination and treatment 
practice in these settings. 
 
Due to logistic considerations we were unable to include a follow up time longer than 6 months post 
immunisation. Blood sampling extending to 1 year following immunisation may have revealed differences in 
the persistence of antibody response that were not apparent at the 6 month time-point. Finally, it is worth 
considering the ongoing debate surrounding the use of PPV vs. PCV in HIV infected older children and 
adults [271]. Our data suggests that the response to PCV in older children may be more polysaccharide 
dependent rather than carrier dependent. It would have been very interesting to include a cohort of children 
and adults immunised with PPV in the study to interrogate this possibility further and provide further 
evidence to guide practice. 
 
7.6 Future directions 
 
There are many avenues for further research based on findings from this and other published studies to 
date. With the recommendation of HAART for all HIV infected infants it would be of great interest to perform 
longitudinal studies combining B and T cell phenotypic analysis and information on B cell repertoire with 
readouts of vaccine induced immunity in HIV infected children on HAART compared to HIV exposed 
uninfected children (as controls). In doing so, the persistent effects of HIV on the developing immune system 
in the absence of detectable viraemia in peripheral blood could be clearly delineated. Furthermore it now 
seems clear that studies of B cell phenotype and function should be included in longitudinal studies on 
treatment interruption in older children with paHIV as well as in randomised trials investigating the possible 
benefits of lower thresholds for HAART initiation. 
 
Higher valency pneumococcal conjugate vaccines are in the pipeline as are candidate protein vaccines. 
Early involvement of HIV infected individuals (and other risk groups) in immunogenicity studies such as ours 
would hopefully serve to expedite guideline and policy decision making for these groups allowing more rapid 
access to potentially life saving vaccines. Multiplex technology, such as the MSD technique used for cytokine 
detection in this study, can also be applied to antibody detection techniques and their validation for this 
purpose is currently under investigation [497]. The low sample volumes required for these assays make 
them very useful in paediatric studies and it is hoped that they will facilitate rapid, thorough and accurate 
analysis of serological response to vaccines in future immunogenicity studies in the paediatric age range. 
Moreover they allow analysis of cytokines and antibody in low volume specimens such as those obtained 
from mucosal sites including the nasopharynx. The importance of immune responses at mucosal sites to 
protection against pneumococcal carriage and invasive and non-invasive pneumococcal disease is clear and 
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analysis of the immune response at these sites may be an important aspect of future pneumococcal vaccine 
efficacy studies. 
 
The dynamics of the immune response to vaccine antigens in the days, weeks and months following 
immunisation in HIV infected children compared to healthy controls could be assessed through blood 
sampling at earlier and later time points and by the inclusion of methods for detection of antigen specific T 
and B cells, including T and B cell ELISPOT and flow cytometry based methods employing fluorescently 
labelled MHC tetramers and antigen. It would be of interest to compare HIV infected groups with others that 
have increased susceptibility to pneumococcal disease including children with sickle cell disease, those with 
bone marrow transplant and chemotherapy induced immunosuppression, CVID patients and children with 
monogenic mutations associated with invasive pneumococcal disease (MyD88/IRAK4 deficiency). Indeed, 
the susceptibility of MyD88/IRAK4 deficient children to invasive pneumococcal disease and abnormalities in 
B cell phenotype of a similar nature to those observed in HIV [498], suggests that these innate pathways 
might also be of relevance in paHIV, it will therefore be important to include analysis of these and other 
innate signalling pathways in future work. Studies of pneumococcal immunity (including gene expression 
data) in otherwise healthy children with no known immune deficiency who nevertheless develop invasive 
pneumococcal disease, warrants further investigation in the hope that insights into the failings of an 
apparently intact immune system would allow more focussed investigation of the more generalised 
immunological disorder characteristic of HIV infection.  
 
The lack of an appropriate murine model for HIV infection has significantly hampered research efforts to 
date. Humanised murine models have recently allowed murine HIV infection that mirrors many aspects of 
human HIV infection [499]. It is hoped that these will provide new insights into the HIV disease process that 
will mirror the wealth of information on T and B cell immunity and vaccine immunogenicity that studies in 
mice have provided to date.  
 
Immunological research often involves the study of the T cell or B cell immunity in isolation. This project set 
out to try and integrate analysis of both T cell and B cell immunity in children with paHIV. Although the 
importance of B cells in HIV immunology has been somewhat sidelined by research into T cell immunology, 
it is now increasingly recognised that a knowledge of both T and B cell immunity is of importance when 
investigating the response to not only vaccine antigens, but also other potential infectious pathogens and 
HIV itself. In addition and in light of observations consistent with ongoing immune activation with wide 
ranging consequences in HIV infected patients despite suppressive HAART, the potential immune regulatory 
role of B cells seems likely to be a key area for future research [407]. 
 
7.7 Final conclusion 
 
It is now 100 years since the first trial of a candidate pneumococcal vaccine [280]. Since that time, 
progressive improvements in vaccine technology and a greater understanding of vaccine induced protection 
have allowed the almost complete elimination of vaccine serotypes invasive disease in populations with high 
levels of vaccination coverage. Conjugate vaccines have been a resounding success in protecting vulnerable 
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infants against invasive bacterial disease and much is now known about immune mechanisms of conjugate 
vaccine response in this age group. Despite these advances, invasive pneumococcal disease continues to 
be a problem for other risk groups such as the elderly and HIV infected older children and adults. The 
potential role for conjugate vaccines, and the characteristics of the immune response in these groups is 
subject to ongoing research, but it is likely that they may provide additional benefits over and above that 
provided by existing polysaccharide vaccines. The establishment of in vitro correlates of vaccine-induced 
protection is an urgent priority and will hopefully expedite development and licensing of novel and improved 
vaccine candidates. Studies of immunogenicity in individual risk groups may also contribute to directed 
vaccine discovery and development aimed at protecting those with differing reasons for increased disease 
susceptibility.  
 
It is 30 years since the HIV pandemic started to take hold. The development of HAART, the success of 
PMTCT strategies and the success of basic methods in preventing horizontal onward transmission have 
made dramatic differences in the epidemiology of the infection and it is now possible to almost guarantee 
that the infant of an HIV infected mother will not be infected (at least in the resource rich setting). 
Nevertheless, it is still the case that approximately 1000 HIV infected children are born per day, 
predominately in sub-Saharan Africa, an area where rates of invasive pneumococcal disease are also at 
their highest. With access to HAART these children have the potential to survive in to adulthood. We hope 
that this research will provide a piece of the jigsaw that will inform HAART and vaccination practices in this 
particularly vulnerable group and that optimal treatment in childhood might prevent the immune system being 
potentially scarred for life. Knowledge of the impact of HIV on the developing immunity will be key to 
ensuring that children with paHIV can live a long and healthy life, protected from vaccine preventable 
disease. 
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Appendix 1  
 
WHO clinical staging of HIV/AIDS for children with confirmed HIV infection 
 
World Health Organization. WHO Case Definitions of HIV for Surveillance, and Revised Clinical Staging and 
Immunological Classification of HIV Related Disease in Adults and Children. Geneva, World Health 
Organization, 2006 
 
Clinical Stage 1 
• Asymptomatic 
• Persistent generalized lymphadenopathy 
 
Clinical Stage 2 
• Unexplained persistent hepatosplenomegaly 
• Papular pruritic eruptions  
• Extensive wart virus infection  
• Extensive molluscum contagiosum 
• Fungal nail infections  
• Recurrent oral ulcerations  
• Unexplained persistent parotid enlargement 
• Lineal gingival erythema  
• Herpes zoster Recurrent or chronic upper respiratory tract infections (otitis media, otorrhoea, sinusitis, tonsillitis) 
 
Clinical Stage 3 
• Unexplained* moderate malnutrition not adequately responding to standard therapy 
• Unexplained persistent diarrhoea (14 days or more)  
• Unexplained persistent fever (above 37.51C intermittent or constant, for longer than one month) 
• Persistent oral candidiasis (after first 6–8 weeks of life)  
• Oral hairy leukoplakia  
• Acute necrotizing ulcerative gingivitis/periodontitis  
• Lymph node TB 
• Pulmonary TB  
• Severe recurrent bacterial pneumonia  
• Symptomatic lymphoid interstitial pneumonitis  
• Chronic HIV-associated lung disease including bronchiectasis  
• Unexplained anaemia (<8 g/dL), neutropenia (<0.5 x 109/l) or chronic thrombocytopenia (<50 x 109/l) 
 
Clinical Stage 4  
• Unexplained severe wasting, stunting or severe malnutrition not responding to standard therapy  
• Pneumocystis pneumonia  
• Recurrent severe bacterial infections (e.g. empyema, pyomyositis, bone or joint infection, meningitis, but excluding 
pneumonia)  
• Chronic herpes simplex infection; (orolabial or cutaneous of more than one month’s duration or visceral at any site)  
• Extrapulmonary/disseminated tuberculosis  
• Kaposi’s sarcoma  
• Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)  
• Central nervous system toxoplasmosis (after one month of life)  
• HIV encephalopathy  
• Cytomegalovirus infection retinitis or CMV infection affecting another organ, with onset at age over 1 month  
• Extrapulmonary cryptococcosis (including meningitis)  
• Disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidiomycosis)  
• Chronic cryptosporidiosis  
• Chronic isosporiasis  
• Disseminated non-tuberculous mycobacteria infection  
• HIV associated tumours including cerebral or B cell non-Hodgkin lymphoma  
• Progressive multifocal leukoencephalopathy  
• Symptomatic HIV-associated nephropathy or HIV-associated cardiomyopathy 
 
*Unexplained refers to where the condition is not explained by other conditions 
**Some additional specific conditions can also be included in regional classifications (e.g. reactivation of American trypanosomiasis)
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Appendix 2 
 
CDC 1994 revised classification system for HIV infection in children less than 13 years of age Centers 
for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years 
of age. Morbid Mortal Wkly Rep 1994; 43 (RR-12): 1–10. 
 
Clinical categories for children with HIV infection  
 
Category N: Not symptomatic  
 
Children who have no signs or symptoms considered to be the result of HIV infection or who have only one of the conditions listed in 
Category A 
 
Category A: Mildly symptomatic  
 
Children with two or more of the conditions listed below but none of the conditions listed in Categories B and C: 
 
• Lymphadenopathy ( ≥0.5 cm at more than two sites; bilateral = one site) 
• Hepatomegaly 
• Splenomegaly 
• Dermatitis 
• Parotitis 
• Recurrent or persistent upper respiratory infection, sinusitis, or otitis media 
 
Category B: Moderately symptomatic 
 
Children who have symptomatic conditions other than those listed for Category A or C that are attributed to HIV infection. Examples of 
conditions in clinical Category B include but are not limited to: 
 
• Anaemia (<8 g/dL), neutropenia (<1.0 x109/L), or thrombocytopenia (<100 x109/L) persisting ≥30 days 
• Bacterial meningitis, pneumonia, or sepsis (single episode) 
• Candidiasis, oropharyngeal (thrush), persisting (>2 months) in children >6 months of age 
• Cardiomyopathy 
• Cytomegalovirus infection, with onset before 1 month of age 
• Diarrhoea, recurrent or chronic 
• Hepatitis 
• Herpes simplex virus (HSV) stomatitis, recurrent (more than two episodes within 1 year)  
• HSV bronchitis, pneumonitis, oroesophagitis with onset before1 month of age 
• Herpes zoster (shingles) involving at least two distinct episodes or more than one dermatome 
• Leimyosarcoma 
• Lymphoid interstitial pneumonia (LIP) or pulmonary lymphoid hyperplasia complex 
• Nephropathy 
• Nocardiosis 
• Persistent fever (lasting >1 month) 
• Toxoplasmosis, onset before 1 month of age 
• Varicella, disseminated (complicated chickenpox) 
 
Category C: Severely symptomatic 
 
• Serious bacterial infections, multiple or recurrent (i.e. any combination of at least two culture-confirmed infections within a 2-year 
period), of the following types: septicaemia, pneumonia, meningitis, bone or joint infection, or abscess of an internal organ or 
body cavity (excluding otitis media, superficial skin or mucosal abscesses, and indwelling catheter-related infections)  
• Candidiasis, oesophageal or pulmonary (bronchi, trachea, lungs) 
• Coccidioidomycosis, disseminated (at site other than or in addition to lungs or cervical or hilar lymph nodes) 
• Cryptococcosis, extrapulmonary 
• Cryptosporidiosis or isosporiasis with diarrhoea persisting > 1 month 
• Cytomegalovirus disease with onset of symptoms at age > 1 month (at a site other than liver, spleen, or lymph nodes) 
• Encephalopathy (at least one of the following progressive findings present for at least 2 months in the absence of a concurrent 
illness other than HIV infection that could explain the findings):  
o failure to attain or loss of developmental milestones or loss of intellectual ability, verified by standard developmental 
scale or neuropsychological tests;  
o impaired brain growth or acquired microcephaly demonstrated by head circumference measurements or brain 
atrophy demonstrated by computerised tomography or magnetic resonance imaging (serial imaging is required for 
children >2 years of age); 
o acquired symmetric motor deficit manifested by two or more of the following: paresis, pathological reflexes, ataxia, 
or gait disturbance 
• Herpes simplex virus infection causing a mucocutaneous ulcer that persists for >1 month; or bronchitis, pneumonitis, or 
oesophagitis for any duration affecting a child >1 month of age 
• Histoplasmosis, disseminated (at a site other than or in addition to lungs or cervical or hilar lymph nodes) 
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• Kaposi’s sarcoma 
• Lymphoma, primary, in brain 
• Lymphoma, small, noncleaved cell (Burkitt’s), or immunoblastic or large cell lymphoma of B-cell or unknown immunological 
phenotype 
• Mycobacterium tuberculosis, disseminated or extrapulmonary 
• Mycobacterium, other species or unidentified species, disseminated (at a site other than or in addition to lungs, skin, or cervical 
or hilar lymph nodes) 
• Mycobacterium avium complex or Mycobacterium kansasii, disseminated (at site other than or in addition to lungs, skin, or 
cervical or hilar lymph nodes) 
• Pneumocystis jiroveci pneumonia (formerly carinii) 
• Progressive multifocal leukoencephalopathy 
• Salmonella (nontyphoid) septicaemia, recurrent 
• Toxoplasmosis of the brain with onset at >1 month of age  
• Wasting syndrome in the absence of a concurrent illness other than HIV infection that could explain the following findings:  
o persistent weight loss 410% of baseline OR  
o downward crossing of at least two of the following percentile lines on the weight-for-age chart (e.g., 95th, 75th, 50th, 
25th, 5th) in a child ≥1 year of age OR 
o <5th percentile on weight-for-height chart on two consecutive measurements, ≥30 days apart PLUS a) chronic 
diarrhoea (i.e., at least two loose stools per day for ≥30 days) OR b) documented fever (for ≥30 days, intermittent 
or constant) 
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Appendix 3 
 
CHIVA treatment grid for children with HIV 
First and second line antiretroviral choices – 2009 
 
This table summarises the basic principles of first and second line treatment choices. For complete notes 
and guidance see reference 181 (Welch et al)  
 
First line antiretroviral therapy  
<3 years >3 years <40kg >40kg 
Nevirapine + lamividune + abacavir 
+ (zidovudine) 
 
or 
 
lopinavir/ritonavir + lamivudine + 
abacavir + (zidovudine 
Efavirenz + lamivudine + abacavir 
 
or 
 
lopinavir/ritonavir + lamivudine + 
abacavir 
Efavirenz + (emtricitabine + 
tenofovir)* or (lamivudine + 
abacavir)** 
 
or 
 
lopinavir/ritonavir + (emtricitabine + 
tenofovir) or (lamivudine + abacavir) 
 
Most likely second-line ART when first line NNRTI based 
<30kg >30kg >40kg 
Lopinavir/ritonavir + zidovudine + 
didanosine 
Lopinavir/ritonavir + zidovudine + 
tenofovir 
Previous (emtricitabine + tenofovir): 
 
Lopinavir/ritonavir + didanosine + 
abacavir) 
 
Previous (lamivudine + abacavir): 
 
Lopinavir/ritonavir + zidovudine + 
tenofovir 
Most likely second-line ART when first line PI based 
<3 years >3 years <30kg >30kg >40kg 
Nevirapine + zidovudine + 
didanosine 
Efavirenz + zidovudine + 
didanosine 
Efavirenz + zidovudine + 
tenofovir 
Previous (emtricitabine + 
tenofovir): 
 
efavirenz + didanosine + 
abacavir 
 
Previous (lamivudine + 
abacavir): 
 
Efavirenz + zidovudine + 
tenofovir 
 *”Truvada”, **”Kivexa” 
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Appendix 4: Ethical approval 
 
 
 
 
 
West London REC 3 
Room 4W/12, 4th Floor West 
Charing Cross Hospital 
Fulham Palace Road 
London W6 8RF 
Tel: 020 3311 7282  
Fax: 020 3311 7280 
 
Dr Alasdair R J Bamford 
Imperial College London 
Academic Department of Paediatrics 
2nd Floor Wright-Fleming Building 
Norfolk Place, Paddington, London 
W2 1PG 
 
28 May 2010 
 
Dear Dr Bamford 
 
Study title: The impact of impaired T cell function on B cell memory 
responses in HIV infected children 
REC reference: 09/H0706/23 
Protocol number: CRO1262 
Amendment number: 1 
Amendment date: 30 April 2010 
 
The above amendment was reviewed by the Sub-Committee in correspondence.  
 
Ethical opinion 
 
Favourable Opinion  
 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
 
I would also like to inform you that you will need to amend all documentation to correctly 
state that West London REC 3 has reviewed the application. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
 Document  Version  Date  
Letter to GP: Healthy Control  3  28 April 2010  
Participant Consent Form: Healthy Control: Consent Form  4  28 April 2010  
Participant Consent Form: Healthy Control - Patient Consent Form: 
Child Control  
4  28 April 2010  
Participant Consent Form: Healthy Control - Assent Form: Child 
Control  
3  28 April 2010  
Participant Consent Form: Healthy Adults  3  28 April 2010  
Participant Information Sheet: Information Sheet: Child Healthy 
Control  
4  28 April 2010  
Participant Information Sheet: Teenage Information Sheet: (na)  3  28 April 2010  
Participant Information Sheet: Teen Information Sheet: Child Control 4  28 April 2010  
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Participant Information Sheet: Information Sheet: Healthy Adult  4  28 April 2010  
Participant Information Sheet: Child Information Sheet: Child Control 4  28 April 2010  
Protocol  6  28 April 2010  
Notice of Substantial Amendment (non-CTIMPs)  1  30 April 2010  
Covering Letter    30 April 2010  
Letter to GP  2  28 April 2010  
Participant Consent Form: Assent Form: (a)  3  28 April 2010  
Participant Consent Form: Assent Form: (na)  3  28 April 2010  
Participant Consent Form: Patient Consent Form: Family Clinic  3  28 April 2010  
Participant Information Sheet: Child Information Sheet: (a)  3  28 April 2010  
Participant Information Sheet: Child Information Sheet: (na)  3  28 April 2010  
Participant Information Sheet: Information Sheet: Family Clinic  3  28 April 2010  
Participant Information Sheet: Teenage Information Sheet: (a)  3  28 April 2010  
Participant Consent Form: Consent Form: Family Clinic  3  28 April 2010  
  
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached 
sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
09/H0706/23:     Please quote this number on all correspondence 
 
Yours sincerely 
 
 
 
 
Louise Moran 
Committee Co-ordinator 
E-mail: louise.moran2@imperial.nhs.uk 
 
Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to: Mr Gary Roper, Research Service 
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West London REC 3 
 
Attendance at Sub-Committee of the REC meeting on 28 May 2010 
 
Name   Profession   Capacity    
Dr Matthew Hyde  Research Scientist  Lay  
Dr Sabita Uthaya  Consultant Neonatologist  Expert  
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Appendix 5: Substantial amendment approval letter 
 
 
National Research Ethics Service
Riverside Research Ethics Committee
Room 4W12,4th Floor West
"illi:."!Hff;'J:x
London W6 8RF'F:?"i'lffiiffi33X3;:3;
DrAlasdair R J Bamford
lmperial College London
Academic Department of Paediatrics
2nd Floor Wright-Fleming Building
Norfolk Place, Paddington, London
W2 1PG
3'1 March 2009
Dear Dr Bamford
Full title of study: The impact of impaired T cell function on B cell memory
resDonses in HIV infected children
REC reference number: 09/H0706/23
Thank you for your letter of 19 l\4arch 2009, responding to the Commiftee's request fof
further information on the above research and submittinq revised documentation.
The further information has been considered on behalf of the Committee by the Chair.
Confirmation of ethical opinion
On behalf ofthe Committee, I am pleased to confirm a favourable thical opinion for the
above research on the basis described in the application form, pfotocol and supporting
documentation as revised, subject o the conditions pecified below.
Ethical review of research sites
The favourable opinion applies to the research sites listed on the attached form.
Conditions of the favourable ooinion
The favourable opinion is subject o the following conditions being met prior to the start of
the study.
Manaqement permission or approval must be obtained from each host orqanisation prior to
the start ofthe studv at the site concerned.
l\ranagement permission at NHS siies ("R&D approval") should be obtained from the
relevant care organisation(s) in accordance with NHS research governance arfangements.
Guidance on applying for NHS permission is available in the Integrated Research
Application System or at hitp://www.rdforum.nhs.uk.
This Research Ethics Committee is an advisory commitree to London Strategic Hea th Althority
The NationalReseaKh Ethics Seryice (NRES) rcpresentsthe NRES Dire(tarute within
the NationalPatient Safety Agen.y and Research Ethks Committees in England
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Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Stalement of compliance
The Committee is constituted in accordance with the Governance Arrangemenis for
Research Ethics Committees (July 2001) and complies fully with the Standard Opefating
Procedures for Research Ethics Committees in the UK
Thi5 Research Ethics Committee is an advkory committee to London Strategic Health Authority
The NationalResearch Ethks Seryice (NRES) rcpresenbthe NRES Dircctorate within
the National Patient Safery Agen.y and Research Ethi.s Comnitlees in England
o!ffienffip- @ion l 6t*x :
lnformation Sent to l\,4HRA
E-mail to MHRA 10 November 2008
Sample Size Calculation 23 Novernber 2007
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After ethical review
Now that you have completed the application process please visit the National Research
Ethics Website > After Review
You are invited to give your view of the service that you have received from the National
Research Ethics Service and the application pfocedure. lf you wish to make your views
known please use the feedback form available on the website.
The attached ocumeni "After ethical review -guidance for researchers" gives detailed
guidance on reporting requirements fof studies with a favourable opinion, including:
. Notifyingsubstantialamendments
. Progress and safety reports
. Notifying the end of the study
The NRES website also provides gujdance on these topics, which is updated in the l ight of
changes in reporting requirements or pfocedufes.
We would also like to inform you that we consult regularly with stakeholders to improve our
service. lf you would like to join our Reference Group please email
referenceqroup@nres.nosa. nhs uk.
09/H0706/23 Please quote this number on all correspondence
With the Committee's best wishes for the success of this project.
Yours sincerely
PP
Dr Sabita Uthaya
Chair
Email: atul.patel@imperial.nhs.uk
Enclosures:
Copy to:
"After ethical review - guidance for researchers"
Mr Gary Ropet, Research SeNice
This Research Ethics Committee is an advjsory cohmitteeto London Strategic Heatth AuthoriB
The NationalReseard Ethi6:ENice (NRES) rcprcsents the NRES Djrectarate withjn
the Natianal Patient Salety Agency and Research Ethics Conmittees in Engtand
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Training manual for Enzyme linked immunosorbent 
assay for the quantitation of Streptococcus pneumoniae 
serotype specific IgG (Pn PS ELISA). 
 
(007sp Version) 
 
 
 
 
A guide to procedures for qualification of materials and analysis of assay 
performance. 
 
This manual describes procedures utilizing 007sp as a standard.  Click here 
for the manual utilizing 89SF as a standard. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prepared by the World Health Organization Pneumococcal Serology 
Reference Laboratories at the Institute of Child Health, University College 
London, London, England and the Department of Pathology at the 
University of Alabama at Birmingham, Birmingham Alabama, USA. 
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Introduction 
 
To develop and evaluate the efficacy of pneumococcal vaccines it is important to have an accurate method for 
measuring the concentration of human antibodies directed against pneumococcal capsular polysaccharides (Pn 
PS).  In 2000, representatives from academia, government, and industry met at the WHO in Geneva, 
Switzerland, and selected an enzyme-linked immunosorbent assay protocol for quantitation of human IgG 
antibodies specific for Streptococcus pneumoniae capsular polysaccharides (Pn PS ELISA).  The protocol was 
selected to guide assay development within individual laboratories. 
 
The selected protocol is as follows.  Human serum samples are mixed before analysis with an absorbent 
containing C-polysaccharide (C-PS) and 22F capsular PS to neutralize antibody binding to C-PS and other 
common contaminants present in the Pn PS coating antigens.  22F PS is used because it is a rare serotype, not 
present in any conjugate vaccine, and is thought to contain contaminating non-Pn PS epitopes.  ELISA plates 
are coated with Pn PS by adsorbing individual Pn PS serotype antigens to micro-titer plates.  Dilutions of 
absorbed human sera are then added to the ELISA plates.  The serotype specific antibody bound to the ELISA 
plate is detected with anti-human IgG antibody conjugated with alkaline phosphatase, followed by addition of 
the substrate, p-nitrophenyl phosphate.  The optical density of each well is measured at 405 nm and 690 nm 
(reference) using an ELISA plate reader.  By comparing the optical density of the sample wells to that of the 
standard (human anti-pneumococcal reference serum, 007sp) the level of antibody in the human serum can be 
calculated. 
 
To facilitate the development of Pn PS ELISA with uniform assay performance throughout the world, we have 
prepared this training document describing the selected assay in detail and have explained how the assay can 
be set up in a laboratory.  General good laboratory practices are described as SOP 1.  In addition, this training 
document provides a set of standard operating procedures (SOP’s) that describe the procedures for the basic 
Pn PS ELISA assay (SOP 2), selecting the lot of ELISA plates (SOP 3), determining the optimal antigen 
coating concentration (SOP 4), selecting the enzyme conjugated polyclonal anti-human antisera with proper 
specificity, sensitivity and high enzyme activity (SOP 5) and determining the titer of the enzyme conjugated 
polyclonal anti-human antisera (SOP 6).   This document and additional information can be found in a website 
(http://www.vaccine.uab.edu) and a review article (CM Wernette et al, Clinical and Diagnostic Laboratory 
Immunology 10(4): pages 514-519). 
 
This manual was prepared with the financial support of the Vaccines, Immunization and Biologicals 
Department of WHO in Geneva Switzerland; by Dr. David Goldblatt and Ms. Lindsay Ashton of University 
College, London, England; and Drs. Moon H. Nahm and William H. Benjamin at the University of Alabama 
at Birmingham, Birmingham, Alabama, USA with technical assistance from Wyeth Lederle Vaccines, 
Rochester, NY, USA.  We are indebted to Mr. Keith Friedman, Dr. Dan Sikkema and Dr. Dace Madore of 
Wyeth Lederle Vaccines, Rochester, NY and Dr. Luis Jodar and Dr. Elwyn Griffiths at WHO, Geneva.   
 
Comments and queries should be addressed to: 
 
Dr. Moon H. Nahm 
WHO Pneumococcal Serology  
Reference Laboratory 
Department Of Pathology 
University Of Alabama  
BBRB 614,  
845, 19th St. South  
Birmingham, AL 35294 
 
Telephone: 205-934-0163  
Fax:  205-975-2149 
Email: nahm@uab.edu 
 
Dr. David Goldblatt 
WHO Pneumococcal Serology  
Reference Laboratory 
Immunobiology Unit 
Institute of Child Health 
30 Guilford St London 
WCIN 1EH 
United Kingdom 
 
Telephone: +44(0)207 813 8491 
Fax:  +44(0)207 813 8494 
Email: d.goldblatt@ich.ucl.ac.uk 
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SOP 1: Good Laboratory Practice Guidelines 
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt 
History of Revision:     July 31, 2002; November 26, 2002; June 9, 2004 
Referenced SOP:          SOP 1 
 
  
Safety first: All serum samples are potentially infectious and all chemicals are potentially toxic.  Wear gloves, 
protective clothing, and/or eye protection when handling human sera or chemicals.  Prepare only the minimum 
amounts necessary and discard any remaining solutions or samples properly.  Any potentially contaminated 
materials should be disinfected and discarded properly. Disinfect laboratory benches after work. 
 
Water:  Use a water purification system such as a Synergy 185 from Millipore (Bedford, MA).  This water is 
defined as reagent grade water type 1.  Avoid prolonged storage since microorganisms can grow and contaminate 
the water.  In some critical cases (e.g., preparation of antigen coating solution), use commercially available, 
bottled, pyrogen-free water (for example, sterile water for irrigation distributed by Abbott Laboratories, North 
Chicago, IL).  
 
Equipment:  Equipment must be in good working order (e.g., pH meter, single and multi-channel micropipettors). 
 
Supplies:  Store supplies properly.  ELISA plates should not be stored in areas exposed to heat, direct sunlight or 
excessive humidity.  Also, minimize dust, particulates or fingerprints on plates.  Solution storage containers must 
be free of contaminants as residual amounts of detergent on glassware can inhibit the binding of antibody to 
antigen or could strip adsorbed polysaccharides from the microtiter plates.  All glassware/plastic ware used for 
preparing buffers/solutions must be depyrogenated by heating in an oven at 180?C for a minimum of 2 hours to 
remove endotoxin.  The decontaminated glassware/plastic ware must be stored aseptically.  For critical 
applications, use brand new magnetic stir bars, glassware or plastic ware. 
 
Labels: All containers for solutions prepared in-house should be labeled with reagent name, date prepared, name 
of technician, and expiration date.  Discard all solutions after the expiration date.  When necessary, the preparation 
date can be used as the lot number. 
 
Contamination: Before use, check buffers/solutions for signs of contamination, which may include flocculence 
or cloudiness.  Discard the solution if there are signs of contamination. Also, all reagents and antigen-coated plates 
should be equilibrated to room temperature prior to use to reduce variability in daily assay performance. 
 
Temperature and humidity: Conditions in the laboratory can affect day-to-day performance of ELISA methods.  
Very low humidity (often found in winter) can cause evaporation of components during incubation steps, which 
can result in an increase in blank values or overestimation of the titer for unknown or control sera.  Care should be 
taken to minimize evaporation of assay components during incubation steps. 
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SOP 2: Quantitation of human IgG antibodies specific for Streptococcus pneumoniae 
capsular polysaccharides by enzyme linked immunosorbent assay (Pn PS ELISA)   
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt  
History of revision dates:        June 30, 2002; November 26, 2002; June 9, 2004; 
March 31, 2011 
Referenced SOP:                    SOP 1 
 
Purpose 
 
To quantitate human IgG antibody to S. pneumoniae capsular polysaccharide in human serum using a 
standardized ELISA assay. 
 
Principle of the assay 
 
The ELISA measures type specific IgG anti-S. pneumoniae capsular polysaccharide (PS) antibodies present in 
human serum.  When dilutions of human sera are added to type-specific capsular PS-coated microtiter plates, 
antibodies specific for that capsular PS bind to the microtiter plates.  The antibodies bound to the plates are 
detected using a goat anti-human IgG alkaline phosphatase-labeled antibody followed by a p-nitrophenyl 
phosphate substrate.  The optical density of the colored end product is proportional to the amount of anti-
capsular PS antibody present in the serum.  
 
Materials  
 
? Microtiter plates for ELISA: 96 well, flat bottom, polystyrene, medium binding plate (Greiner 
655001/Costar 9017, or equivalent)  
? Plate lids (Greiner 656161/Costar 3931, or equivalent) 
? Serum dilution plates: Deep well, large capacity microtiter plates, 96 well conical bottom (BD Falcon 
353966, or equivalent) or cluster tube strips (Costar 4408, or equivalent) 
? Disposable polypropylene containers: 50 ml, 110 ml (Falcon 354014, or equivalent) 
? Tissue culture media bottles with screw cap and pouring ring: 250 ml, 500 ml, 1000 ml (Pyrex or Duran, 
brands that can be heated to 200?C, or equivalent) 
? Plastic beakers: 1000 ml, 2000 ml  
? Weighing boats 
? Pipette tips for pipettors 
? Sterile 0.2 ?m filter units (Millipore, SCGPT05RE, or equivalent) 
? Sterile disposable serological pipettes: 10 ml, 20 ml, 50 ml   
? Freezer pen (Sanford Sharpie, extra fine point permanent markers or equivalent) 
? Graduated cylinders: 100 ml, 250 ml, 1000 ml, 2000 ml 
? Micropipettors : Gilson P20, P200, P1000 or equivalent 
? Multichannel pipettors (12 channel): 50 ?l-200 ?l, 50 ?l-300 ?l 
? Microtiter 12 well washing device (Nunc ImmunoWash 12 or Automated ELISA microtiter plate washer 
or equivalent). (Note 1) 
? Mixer (Tube Rotator, Scientific Equipment Products, Cat. No: 60448 or equivalent) 
? Magnetic stirrer (Corning, PC- 353, or equivalent) 
? Bench top vortex mixer (Scientific products, S-8220, or equivalent) 
? pH meter (Tris-compatible)  (Orion Research, model- 601A/analyzer, or equivalent)  
? Analytical balances (Ohaus, Galaxy-400 and Galaxy-110 or equivalent) 
? ELISA microtiter plate reader with 405 nm and 690 nm filters 
? Cryovials, 1.5 ml (Sarstedt, 72.694.005; Corning, 430489, or equivalent) 
? 37?C incubator 
? 2?C to 8?C refrigerator for storage of sera and reagents 
? -70?C freezer for storage of sera and reagents 
? 180 ?C oven 
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Reagents and Chemicals 
 
?  Pneumococcal capsular polysaccharide (Pn PS) – American Type Culture Collection (ATCC)  
 
Detailed instructions on re-suspending lyophilized materials 
Remove the vial of lyophilized material from the freezer and allow it to come to room temperature 
(approximately one hour).  Remove the septum and take care not to let any lyophilized material escape.  
Reconstitute the lyophilized antigen to 1 mg/ml by adding the necessary volume of sterile reagent grade 
water (type 1) to the vial and replace the septum.  Gently shake the vial to moisten any lyophilized 
material along the top of the vial and place the vial in a mixer (rotator) at 4o C overnight.  The mixer turns 
the vials slowly and helps the polysaccharide dissolve.  Aliquot the polysaccharide into 1.5 ml cryovials, 
label with reagent name, date, lot number, initials and store at –70?C.   
 
 
     Ordering information for capsular Pn PS from ATCC 
 
Danish Pn PS Serotype Catalogue # American 
Serotype # 
Order size  
1 164-X Type 1 200 mg  
2 168-X Type 2 200 mg  
3 172-X Type 3 200 mg  
4 176-X Type 4 200 mg  
5 180-X Type 5 200 mg  
6B 228-X Type 26 200 mg  
7F 240-X Type 51 200 mg  
8 188-X Type 8 200 mg  
9V 256-X Type 68 200 mg  
9N 192-X Type 9 200 mg  
10A 232-X Type 34 200 mg  
11A 236-X Type 43 200 mg  
12F 196-X Type 12 200 mg  
14 200-X Type 14 200 mg 
15B 244-X Type 54 200 mg  
17F 204-X Type 17 200 mg  
18C 248-X Type 56 200 mg 
19A 252-X Type 57 200 mg  
19F 208-X Type 19 200 mg 
20 212-X Type 20 200 mg  
22F 216-X Type 22 200 mg  
23F 220-X Type-23 200 mg 
33F 260-X Type 70 200 mg  
 
Note:  A typical 9 valent conjugate vaccine may have capsular PS of serotypes 1, 4, 5, 6B, 9V, 14, 
18C, 19F, and 23F.   
 
? Pneumococcal cell wall polysaccharide (C-PS, Statens Serum Institut, 3459;  Distributed in the US by 
MiraVista Diagnostics, Indianapolis, IN). Reconstitute lyophilized antigen to 1 mg/ml with sterile reagent 
grade water (type 1) and store in aliquots at -70?C as described above for capsular polysaccharide. 
? Sterile reagent grade water (type 1) (See Note 1) 
? Alkaline phosphatase-conjugated goat anti-human IgG (binding all 4 IgG subclasses, Southern Biotech, 
Birmingham, AL, catalog number 2040-04, or equivalent), store at 4?C. 
? US Reference Pneumococcal antiserum (007sp).  To obtain this, contact Dr. Mustafa Akkoyunlu at US FDA 
(Mustafa.Akkoyunlu@fda.hhs.gov). 
? Quality control (QC) sera:   (QC sera, which are often referred to as “in house control sera”, are human sera 
with known ranges of acceptable results.  Store in aliquots at – 70?C. (Note 2) 
? Diethanolamine (Fisher D45-500) 
? p-nitrophenyl phosphate powder (Sigma 104-0) 
? Brij-35 solution (30% w/v, Polyoxyethylene 23 lauryl ether, Sigma, 430AG-6) 
? Disodium hydrogen phosphate, hydrate, (Na2HPO4·7H2O; Sigma S-9390 or Fisher S373) 
? Sodium azide (NaN3; Sigma, S-2002) 
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? Sodium chloride (NaCl; BDH,10241AP or Sigma, S-9625) 
? Potassium phosphate, monobasic, (KH2PO4; BDH  102034B or Sigma  P-0662) 
? Potassium chloride (KCl; BDH 101984L or Fisher  P-217) 
? Tween-20 (Polyoxyethylenesorbitan monolaurate; Sigma P-5927)   
? Magnesium chloride, hydrate, (MgCl2.6H2O; Sigma M-9272 or Fisher BP-214-500) 
? Concentrated hydrochloric acid (HCl , Fisher A-144-500) 
? Sodium hydroxide (NaOH; BDH  102524X or Sigma S-0899) 
? Trizma HCl  (Sigma T-3253) 
? Trizma Base (Sigma T-1503) 
       
Solutions 
 
Instructions herein are for commonly used volumes as indicated in square brackets.  The solution volume can 
be adjusted depending on specific needs.  Use only reagent grade water (type 1) or equivalent. DO NOT USE 
OTHER TYPES OF WATER (Note 1). Use disposable plastic ware for all containers or dedicate glassware to 
use with these solutions. Never use glassware that has been washed with detergent. See Note 9 for more 
information on containers. Use sterile technique whenever possible to prolong the shelf life of the solutions.  
 
Substrate stop solution: 3M NaOH [1 liter]  
 
Preparation of this solution generates extreme heat and can be dangerous. Detailed steps are provided here. 
 
Place 800 ml of water and a magnetic stir bar in a new 2000 ml plastic beaker.  Place the beaker on top of a 
magnetic stirrer.  Weigh 120 gm of NaOH pellets and slowly add NaOH pellets.  If the water becomes too hot, 
stop adding the NaOH pellets and wait for it to cool.  After adding all the NaOH pellets, mix the solution 
thoroughly, let it cool and bring the solution to 1 liter with water using a 1000 ml graduated cylinder.  Mix 
well and store in a bottle at room temperature for up to 12 months. 
 
6M HCl [200 ml] 
 
Place 100 ml of water in a beaker in a fume hood.  Add 100 ml of concentrated HCl slowly with stirring.  
Extreme care should be taken when handling concentrated HCl. 
 
Coating Buffer: 10 X PBS /0.2% NaN3 [1L] (Note 3) 
  
Dry chemical Weight (grams) 
NaCl 80.00  
KH2PO4  3.14  
Na2HPO4·7H2O  20.61  
KCl  1.60  
NaN3 2.00  
 
Add 800 ml of Abbott Laboratories water to a 2-liter beaker placed on a magnetic stirrer.  Weigh out the dry 
chemicals listed above and add them to the water.  Dissolve the chemicals and bring the volume to 1000 ml 
with Abbott Laboratories water.  Do not adjust pH (see instructions for preparing 1X coating buffer below).  
Sterilize the solution by filtering it with a 0.22 ?m filter and store it in a sterile container at room temperature. 
 
Coating Buffer: 1X PBS / 0.02% NaN3  [1L] 
 
Add 900 ml of sterile Abbott Laboratories water to 100 ml 10X PBS/0.2% NaN3 prepared above.  Check the 
pH of a small aliquot (do not insert the pH probe into the entire solution to avoid possible contamination).  
The pH should be 7.2 ± 0.2.  If the pH is not within this range, discard the solution, and prepare new 10X 
buffer. 
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Antibody Buffer: 10 X PBS /0.2% NaN3/0.5% Tween-20 [1L] (Note 3) 
  
Dry chemical Weight (grams) 
NaCl 80.00  
KH2PO4  3.14  
Na2HPO4·7H2O  20.61  
KCl  1.60  
NaN3 2.00  
 
Add 800 ml of reagent grade water type 1 to a 2-liter beaker placed on a magnetic stirrer.  Weigh out the dry 
chemicals listed above and add them to the water.  Dissolve the chemicals and bring the volume to 1000 ml 
with reagent grade water type 1.  Add 5 ml Tween-20.  Do not adjust pH (see instructions for preparing 1X 
antibody buffer below).   
 
Antibody Buffer: 1X PBS /0.02% NaN3/0.05% Tween-20 [1L] 
 
Add 900 ml of reagent grade water type 1 to a 1000 ml graduated cylinder and add 100 ml 10X PBS/0.2% 
NaN3/0.5% Tween-20.  Check the pH of a small aliquot (do not insert the pH probe into the entire solution to 
avoid possible contamination).  The pH should be 7.2 ± 0.2.  If the pH is not within this range, discard the 
solution, and prepare new 10X buffer.    
 
10X TBS/1% Brij solution [1 liter] 
 
Dry chemical Weight (grams) 
NaCl  80  
KCl  1.60  
Trizma Base 0.94  
Trizma HCl  14.56  
  
Weigh out dry chemicals and dissolve in approximately 800 ml of reagent grade water (type 1) in the 
appropriate size container.  Mix the solution thoroughly using a magnetic stir plate and a stir bar.  Add 33 ml 
of Brij-35 (30% w/v) and mix thoroughly.  Bring the solution to 1 liter with reagent grade water (type 1).  
Store at room temperature for up to 12 months. 
 
Wash buffer: 1X TBS /0.1% Brij solution 
 
Mix one part of 10X TBS/1.0% Brij-35 with 9 parts of Reagent grade water type 1 in an appropriate size 
container.  The pH should be 7.2 ± 0.2. 
 
Substrate Buffer: 1M diethanolamine, 0.5 mM MgCl2 [1 liter] 
 
Calibrate the pH meter before making this solution. Details for preparing the solution are given below 
because the pH of the substrate buffer is very important.   
 
1. Place a 2000 ml plastic beaker with a magnetic stir bar on a magnetic stirrer in a fume hood.  (Use a 
beaker with 1liter calibration marker.) 
2. Add about 800 ml of water. 
3. Add 97 ml of diethanolamine to the water using a 100 ml graduated cylinder and mix the solution well 
with the magnetic stirrer.   
4. Add 0.1 gm of MgCl2.6H2O to the solution. 
5. While thoroughly mixing with a magnetic stirrer, adjust the pH to 9.8 ? 0.05 by slowly adding 6M HCl. 
(~60 ml.) 
6. Allow the solution to cool to room temperature. 
7. Check the pH again and adjust to pH 9.8 ? 0.05 with 6M HCl if necessary. 
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8. Bring the solution to 1 liter with water and a 1000 ml graduated cylinder. 
9. Since pH is critical, recheck the pH.  If the pH is not 9.8 ? 0.05, discard the diethanolamine buffer.   
10. This buffer may be stored sealed in a light protected container at room temperature for up to 6 months. 
 
 
SOP 2A: Adsorption of type-specific capsular polysaccharide antigen to microtiter plates 
(“Coating” the plates with the antigen) 
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt 
History of revision dates:       June 30, 2002; November 26, 2002; March 31, 
2011 
Referenced SOP:                    SOP 2 
 
1. Retrieve the appropriate frozen aliquot of capsular PS that was stored at –70oC at 1 mg/ml.  Thaw the aliquot 
at room temperature.  
2. Dilute the capsular PS to a predetermined concentration (generally 1-10 µg/ml) with sterile antigen-coating 
buffer (1X PBS/0.02%NaN3). (See SOP 4 for additional information).  
3. Pipette 100 ?l of capsular PS antigen into each well of the microtiter plate(s) and cover with a lid.   
4. Incubate the plates at 37?C for 5 hours in an appropriate tissue culture grade incubator.  Plates should not be 
stacked more than 2 layers high, and no more than 18 plates per shelf (using a standard tissue-culture grade 
incubator of 5.7 cu ft).  This precaution is taken in order to maintain the air circulation in the incubator, to 
allow the heat penetration to microtiter plates, and to warm the plates evenly.  Stacking plates higher or 
overloading an incubator can lead to ‘edging’ or poor quality coating of pneumococcal polysaccharide 
antigens.  
5. Store the plates in a humidified chamber kept at 4?C.  If sodium azide is used, coated plates may be stored for 
several months at 4?C, provided that storage conditions are suitable to prevent evaporation and contamination 
of the coating solution.  
 
 
SOP 2B: Procedure for testing human sera with unknown anti-Pn PS antibody 
concentrations 
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt  
History of revision dates:       June 30, 2002; November 26, 2002; June 9, 2004; 
August 2010; March 31, 2011 
Referenced SOP:                   SOP 2 
 
This protocol assumes that each serum sample is analyzed for 9 Pn PS serotypes.  If this is not the case, adapt 
this protocol for the particular situation. 
 
1.   Plan the sample layout: 
 
The example of a plate layout (shown below) has 4 samples with unknowns (Unknowns 1-4), one QC, and 
one standard (007sp).  All samples are analyzed in duplicate (e.g. columns 1 and 2 for Unknown 1, etc).  Place 
the least diluted samples in row A and the most diluted in row H.  The reference serum, 007sp, is used as the 
standard and is placed in rows A through G of columns 7 and 8.  Wells H7 and H8 (marked Blank) are used as 
“blank wells”.  Serial dilutions of a QC are placed in columns 11 and 12.  See Note 2 for additional 
description of QC.   
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Typical microtiter plate layout for Pn PS ELISA 
 
 Unknown 1 Unknown 2 Unknown 3 Standard 
007sp 
Unknown 4 QC 
Serum 
dilutions 
1 2 3 4 5 6 7 8 9 10 11 12 
A   1:50             
B   1:125             
C   etc.             
D             
E             
F             
G             
H       Blank Blank     
 
2. Retrieve all serum samples, controls and reference sera stored frozen and place them at room temperature to 
thaw (~30 minutes).  Samples should not be freeze/thawed more than 3 times and markings on the lid can be 
used to track the number of freeze/thaw cycles. After using the samples, mark the remainder on the lid with a 
freezer pen and immediately return them to the freezer.   
3. Retrieve all the required antigen-coated plates from the refrigerator.  Place them on the bench at room 
temperature.  Prepare wash and antibody buffers. 
4. Prepare the absorption solution by adding C-????????????????????????????????????????????? ????????????????-
?????????????????????????????????????????????????? ??????????????????????????????????????????????-microtiter 
plate assay.  (Note 11)  
5. Mix the thawed samples, QC, and the standard (007sp) thoroughly.  It is convenient to dilute the samples in 
the “serum dilution plates” (i.e., deep-well 96-well plates or 1.1 ml tubes arranged in a 96-well plate format).  
Remove appropriate amounts of the samples (or QC) and mix them with the appropriate amounts of the 
absorption solution in Row A.  For instance, to prepare a 50-fold diluted serum sample for 9 serotypes, one 
???????????????????????????????????????????????????????????????????????????convenient to dilute the samples in 
the “serum dilution plates”.   
6. Perform serial dilutions (usually 2- to 3-fold; see Note 10) as necessary with absorption solution.  A 2.5-fold 
????????????????????????????????????????????????????????????????????????????? solution to all columns of rows B 
through H in the “serum dilution plates”.  Then, mix the wells in row A and ????????????????to Row B.  Next, 
mix the well in Row B and ?????????????????????w C. Repeat these steps through Row H.  When transferring 
the 400 ul from Row G to Row H, make sure that no serum is transferred for columns 7 and 8—these 
are the “blank wells”.   
7. Incubate the diluted samples at room temperature for 30 minutes.  
8. Wash the antigen-coated microtiter plates 5 times with wash buffer.  During the first wash, allow the wash 
buffer to soak on the plate 30 seconds to 1 minute after filling the wells.  (Note 4) (Note 5) (Note 6)   
9. Using a multichannel pipettor, transfer 50 ?l of each serum dilution from the dilution plates to the washed 
antigen coated plates.  Add only antibody buffer to two wells (H7 and H8) in each plate to serve as blanks. 
10. Cover plates with lids and incubate at room temperature for 2 to 18 hours (see Note 12).  For the longer 
incubations or in low humidity situations, use a humidified sealed box (with an anti-microbial agent), to 
prevent excessive evaporation. 
11. Prepare the appropriate dilution of goat anti-human IgG conjugate in antibody buffer 15 minutes before its use 
(SOP 6). 
12. Wash the plates 5 times with wash buffer.  During the first wash, allow the wash buffer to soak on the plate 30 
seconds to 1 minute after filling the wells. 
13. Add 100 ?l of diluted enzyme conjugate to all microtiter plate wells.  Cover plates with lids and incubate for 2 
hours at room temperature. 
14. Prepare a 1 mg/ml solution of p-nitrophenyl phosphate in the diethanolamine substrate buffer 15 minutes 
before it is required.  Mix the substrate solution on the shaker while wrapped in a paper towel to protect it 
from light. 
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15. Wash the plates 5 times with wash buffer.  During the first wash, allow the wash buffer to soak on the plate 30 
seconds to 1 minute after filling the wells. 
16. Add 100 ?l of substrate solution to all microtiter plate wells.  Put lids on plates and incubate for 2 hours at 
room temperature. 
17. Add 50 ?l of 3M NaOH to all wells to stop the enzyme reaction.  
18. Wait at least 5 minutes before reading the optical density of the plates on a microtiter plate reader at 405 nm 
and 690 nm (Note 7). 
 
 
Data analysis 
 
1. Optical density data is converted to antibody concentrations with a computer program like Genesis, Softmax 
PRO, Revelations, or “ELISA”.  Acceptable results are obtained with computer programs using a standardized 
curve-fitting four parameter logistic method, a weighted log-logit method, or a logistic/log linear regression 
analysis.  See Note 8 for obtaining the programs mentioned here.  
2. The program calls for a “calculation template”, which tells the calculation-program the location of samples, 
standards, QC, the initial dilutions and serial dilutions.  Wells H7 and H8 should be labeled as “blank wells” 
in the template.  The program should subtract the average OD of the two “blank wells” from the OD of other 
wells.     
3. The anti-Pneumococcal capsular PS antibody concentration for each sample is found by calculating the mean 
of the serial dilutions of the sample.  The following data inspection rules should be followed to ensure that the 
assay results are valid. 
 
Data inspection rules 
 
1. Blanks -The optical density of blank wells should be less than 0.1 OD units for all assay plates.  In general, 
the optical density will be less than 0.05. 
 
2. Duplicates - If the absorbance values of  replicates at one dilution vary widely and have a coefficient of 
variation (CV) >15%, the concentrations obtained with the absorbance data at that dilution should be excluded 
from the calculation of the antibody concentration of the sample. 
 
3. Standards - The slope of the linear portion of the reference standard curve (e.g., OD 0.1 to 2.0) should be very 
near 1.0 (0.9-1.1) when the log of the OD signal is graphed against the log of the standard concentration. 
 
4. Sensitivity - Calculate the lower detection limit for the assay and confirm that the detection limit is within the 
established range.  
 
5. Quality control sera - Control sample values must be within the established range (which is 3 SD), or the plate 
is rejected and samples are reanalyzed. 
 
6. Rules for the samples with unknown concentrations:  
a. If a sample has OD readings greater than 2.0 at the highest dilution used in the assay, the sample should 
be reassayed after additional dilution.  
b. If the antibody concentration of the sample was calculated by averaging the data from multiple 
dilutions and the CV of the concentration exceeds 30%, then the data should be examined for 
inappropriate results (e.g., poor duplications, and/or non-linearity) and should be reassayed if no apparent 
causes are found.  
c. If upon reassay, the %CV value is greater than 30% due to the fact that the titration slope is not parallel 
to the assay reference standard sera, the median predicted value should be reported. For additional 
information on data analysis see CM Wernette et al, Clinical and Diagnostic Laboratory Immunology 
10(4): pages 514-519.  
d. If the lower limit of detection is equal to or less than the established value and a sample has 
undetectable antibody concentration, report one half of the established assay lower limit as the 
concentration for the sample. If the lower limit of detection is more than the established value and a 
sample has undetectable antibody concentration, do not report the result for the sample and reanalyze the 
sample.   
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Assay notes 
 
Note 1:  Water is extremely important.  We use fresh water from Synergy 185 water purification system from 
Millipore (Bedford, MA).  If the water is stored for a prolonged period, microorganisms grow and contaminate the 
water.  To prepare solutions used in coating the plates with Pn PS, we use pyrogen-free water from Abbott (North 
Chicago, IL, catalog# NDC 0074-7139-36).   
 
Note 2:  QC (Quality control) refers to in-house controls used to monitor inter-assay variation.   Human serum 
pools are commonly used as QC after their antibody levels have been very well characterized.  Some control sera 
should have high values and some should have low values.  All QC samples should have known ranges of 
acceptable results.  There should be one QC per plate and at least one QC with high values for every 3 assay runs.  
A set of serum samples with known concentrations (referred to as “calibration sera”) is available from Dr. David 
Goldblatt (consult http://www.vaccine.uab.edu/refer/qc3.pdf for additional information on the sera).  The 
calibration sera are to validate a procedure and each laboratory will need to obtain their own standard sera for 
routine QC checks.  These can be made from Red Cross plasma or from sera collected from subjects immunized 
with a vaccine.  Usually screening 30 plasmas from expired units high and low titer sera can be found.  If plasma 
is used, it needs to be converted to serum. 
 
Note 3:  To simplify making PBS buffers, there are PBS tablets, which contain pre-measured amounts of all the 
required chemicals.  However, these PBS tablets often include stabilizers or other components, which can affect 
ELISA results.  Instead of tablets, use of ACS grade chemicals in preparation of buffers improves assay 
performance. 
 
Note 4: ELISA plates can be washed manually by repeatedly filling the wells with the buffer and removing the 
buffer.  Alternatively, one can wash the plates with a 12-well washing device or a machine that washes 96 wells 
simultaneously.  A popular model of 96-well washing machine is ELx 405 Microplate washer from Bio-Tek 
(Princeton, NJ). 
 
Note 5:  Follow the manufacturer’s recommendations to remove proteins from plate washers. Alternate use of HCl 
and NaOH, following with several rinses with deionized water.  Use of alcohol for the cleaning or 
decontamination of the plate washers should only be considered once proteins have been removed from the system 
as alcohol can further cement the proteins to the hardware. 
 
Note 6: Do not allow microtiter plates to dry between wash steps and reagent addition; they should not be left 
empty for more than 10 minutes.   
 
Note 7:  Signal for each well = OD405 – OD690.  The wavelength for the reference may vary from 600 to 690 nm.   
 
Note 8: “ELISA” is a computer program developed by Mr. Brian Plikaytis at The Centers for Disease Control and 
Prevention in Atlanta, Georgia.  To obtain this free program, obtain the necessary contact information from: 
http://www.cdc.gov/ncidod/dbmd/bimb/elisa.htm.  Softmax PRO can be purchased from Molecular Devices Corp. 
(Sunnyvale CA). 
 
Note 9: Glassware that is detoxified by heating at 180ºC can be used. Glassware should never be contaminated 
with detergent, as this will affect binding of some of the Ps antigens more than others (type 14 is particularly 
sensitive). 
 
Note 10: Some high titer sera will not be sufficiently diluted in 7 wells to use 2-fold dilutions, but by turning the 
plate the other way, 11 dilutions may allow sufficient dilution. Some low titer sera may not give enough usable 
points with 3-fold dilutions. Thus, 2.5-fold dilutions have been found to be the best except under special 
circumstances. 
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Note 11:  Some use 10 µg/ml instead of 5 µg/ml for absorption. 
 
Note 12:  If measuring antibodies to serotype 3, this incubation should be done for only 2 hours.  For the other 
serotypes tested (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), incubation times of 2 to 18 hours are 
acceptable. 
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SOP 3:  ELISA plate lot selection    
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt  
History of Revision dates: July 31, 2002; November 26, 2002; June 9, 2004; June                       
12, 2006; March 31, 2011 
Referenced SOP:                         SOP 1, SOP 2 
 
To qualify a new lot of plates, establish that: 
 
1) The optimal antigen coating concentration is within the acceptable limit by determining the 
optimal concentration for Pn PS serotypes (eg, 9 serotypes)  using an antigen titration experiment.   
2) The “plate CV” is within the acceptable limit by testing 3 or more plates from different locations in 
one box with Pn PS ELISA  
3) The plates produce comparable results by performing a side-by-side comparison with a minimum 
of 10 control sera and at least 4 QC sera for all serotypes  with old and new plates and show that the 
new plates yield similar values and lower limits of detection.   
 
Tests designed to establish these aspects are described below as SOP3A, SOP 3B, and SOP 3C. 
 
 
SOP 3A:  Determine the optimal Pn PS antigen coating concentration for a lot of ELISA 
plates  
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt 
History of Revision: July 31, 2002; November 26, 2002; June 12, 2006; March 31, 2011 
Referenced SOP:           SOP1, SOP 2 
 
Purpose  
 
To determine whether the optimal antigen-coating concentrations of the Pn PS for the new lot of ELISA plates 
are similar to those for the old lot.  
  
Principles of the test 
 
Antigen is adsorbed on to the surface of a microtiter plate in increasing concentrations.  Reference serum is 
added at one dilution across the plate and the ELISA is completed using the type specific Pn PS ELISA (SOP 
2).  The optimal coating concentration of an antigen lot is determined by inspecting optical density values vs. 
antigen concentration. Try to achieve the maximum signal without increasing the OD of the blank wells. The 
antigen concentration should not be greater than 10 ?g/ml. 
 
Materials and reagents  
 
Materials and reagents are outlined in type specific Pn PS  ELISA (SOP 2). 
 
Methods 
 
1. ?????????????????????????????????????????????????????????????????????????????????????????????????????????????
column (8 wells).  
 
 
 
 
 
 
 
 
	   	   	   	  191  
www.vaccine.uab.edu                                Page 15 of 29                            Filename:  WHO15                               
 
 
ANTIGEN CONCENTRATION (?g/ml) 
   
 20 10 5 2.5 1.25 0.625 0.312 0.156 0.078 0.039 0.020 Buffer 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
 
Rows A, B, C and D: optimum dilution of the reference serum (007sp). 
Rows E, F, G, and H: buffer  (“background wells”) 
Column 12 contains “blank wells” 
 
2. Fill the wells in columns 2-????????????????????????????????????????????????-fold serial dilutions from 
column 1 to column 11 ?????????????? ????????????????????????????????????????????????????????????????
After the 11???????????????????????????????????11th column (so that the wells in column 11 have only 100 
???????????????????????????????????????????????????????????? 
3. Incubate the plate at 37?C for 5 hours and then keep the plates at 4oC for storage (See SOP 2A). 
4. Dilute the human anti-pneumococcal PS standard reference serum, 007sp, in the absorption solution 
(antibody buffer with C-PS and 22F PS, each at 5 micrograms/ml) so it is expected to give an OD of 1.0 
under conditions explained in the Pn PS ELISA (SOP 2).   
5. Wash the plates 5 times with wash buffer.  During the first wash, allow the wash buffer to soak on the 
plate 30 seconds to 1 minute after filling the wells. 
6. Add the diluted reference serum to all wells in rows A, B, C and D and the antibody buffer to all wells in 
rows E, F, G, and H.  Incubate as specified in the Pn PS ELISA (SOP 2). 
7. Wash the plates 5 times with wash buffer.  During the first wash, allow the wash buffer to soak on the 
plate 30 seconds to 1 minute after filling the wells. 
8. Add goat anti-human alkaline phosphatase-labeled secondary antibody at the optimal dilution to each well 
and incubate, as specified in the Pn PS ELISA (SOP 2). 
9. Wash the plates 5 times with wash buffer.  Allow the wash buffer to soak on the plate 30 seconds to 1 
minute after the first filling. 
10. Add substrate, incubate, and read the optical density of the plate as specified in the  
      type specific Pn PS ELISA (SOP 2). 
 
Data analysis 
 
1.   ???????????????? ????????????????????????????????????????????????????????????????????????????????????????
must be repeated (Note 1). All background wells should have optical densities less than 0.1.  
2.   Obtain average OD of rows A, B, C and D, and E, F, G, and H for each column. 
3.   For each antigen concentration, obtain the “signal” by subtracting the average OD value of the 
background wells (antigen and 2? antibody) from the average OD value of the corresponding wells that 
contain the reference serum (007sp). 
4.   Plot the signal on the Y-axis and the logarithm of antigen concentration on the X-axis. 
5.   Possible outcomes: 
a) a sigmoid curve with a plateau occurring at high antigen concentrations, 
b) a sigmoid curve where the plateau falls to base-line (X-axis, sometimes the signal decreases when the 
antigen coating concentration is too high).   
c) an increasing semi-linear plot with no observable plateau or peak in the range of antigen 
concentrations. 
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6.   For outcomes a) and b), pick the antigen concentration yielding the maximum signal because any higher 
concentrations of antigen will not yield a higher signal.  
7.   For outcome c), pick a coating concentration yielding the maximum possible signal with a low 
background. 
8.   The optimal coating concentration chosen in this manner provides maximum sensitivity, consistent 
ELISA performance, and acceptably low signals from blank wells (Note 2).    
 
Assay notes 
 
Note 1: If optical density values are repeatedly higher in the blank wells in the new lot of plates but not in the 
old lot of plates, there may be a problem with the new lot of microtiter plates.    
 
Note 2: Antigen titration should yield similar optimal coating concentrations. If marked differences in optimal 
coating concentrations are found, a different lot of plates should be requested, and the testing procedure 
should be repeated.  
 
SOP 3B:  Determine the variability of results between different lots of ELISA plates  
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt  
History of Revision: July 31, 2002; November 26, 2002; June 9, 2004; June 
12, 2006; March 31, 2011 
Referenced SOP: SOP 1, SOP 2 
 
Purpose 
 
To select a new lot of microtiter plates producing results with minimal well-to-well variation. 
 
Principle of the assay 
 
A single dilution of serum is added to 92 out of 96 wells of an antigen-coated plate with 4 wells acting as 
blank controls with buffer only.  Mean absorbance values and their variation from the 92 wells are calculated 
between wells on a single plate and between each of the plates.  Standard deviation and % CV are assessed 
where the inter-?????????????????????????????????????????????-????????????????????????????????????????????
Although this procedure can be performed using only one Pn serotype, it is desirable to test all  serotypes that 
will be used in the ELISA. If select Pn serotypes are used, choose ones that give consistent results with 
controls (e.g., serotype 1).  
 
 
Materials and reagents  
 
? 3 microtiter plates (for each serotype) from a new lot number from different positions in the box. (See 
Note 1) 
? 3 microtiter plates (for each serotype) from a previously qualified lot number  
? Materials and reagents listed in SOP 2 
 
Methods 
 
1. Obtain 3 plates of the qualified lot and 3 plates of a new lot. 
2. Using the optimal antigen coating concentration determined in SOPA 3A, a???????????????????????????????
to each of the 6 microtiter plates (see SOP 2A).   
3. Prepare a dilution of reference serum 007sp in absorption solution (antibody buffer with C-PS and 22F 
PS, each at 5 micrograms/ml) that will give an OD of approximately 1.0 within 2 hours of addition of 
substrate. 
4. Wash the plates 5 times with wash buffer.  During the first wash, allow the wash buffer to soak on the 
plate 30 seconds to 1 minute after filling the wells. 
5.   Add the serum dilution to all wells of the plates, excluding 4 blank wells where diluent alone is added.   
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      The blank wells are typically B2, B9, F4 and F11 (see template below). 
 
 
                       1         2         3         4        5        6         7         8         9        10      11       12 
A             
B  Buffer       Buffer    
C             
D             
E             
F    Buffer       Buffer  
G             
H             
 
6.   Incubate according to the type-specific Pn PS ELISA procedure (SOP 2). 
7.   Wash the plates 5 times with wash buffer.  During the first wash, allow the wash  
       buffer to soak on the plate 30 seconds to 1 minute after filling the wells. 
8.   Add goat anti-human IgG alkaline phosphatase labeled secondary antibody at the  
      optimal dilution (SOP 6) to each well and incubate as specified in the Pn PS ELISA  
      procedure (SOP 2). 
9.  Wash the plates 5 times with wash buffer.  During the first wash, allow the wash  
      buffer   to soak on the plate 30 seconds to 1 minute after filling the wells. 
10. Add substrate to each well and incubate until OD is approximately 1.0 (check OD frequently).  After OD 
      has reached approximately 1.0, stop the reaction, and read optical density in the ELISA plate reader as in 
      SOP 2. 
 
Data analysis 
 
1. Calculate the mean optical density of the 4 blank wells (i.e. buffer only wells) and subtract this from the 
optical density of all 92 other wells.  Average optical densities for the test wells must be between 0.8 and 
1.5 units. 
2. Calculate the intra-plate mean, standard deviation, and %CV of the absorbance for the 92 wells of all 6 
plates to determine well-to-well variation.   If the CV of each of the previously qualified plates is not 
within the specification for acceptance, the assay must be repeated. 
3. Calculate the inter-plate mean, standard deviation, and %CV of the absorbance for the three plates in each 
group.  If the CV of the previously qualified plates is not within the specification for acceptance, the assay 
must be repeated. 
4. Evaluation criteria for intra-plate variation:   
a. ????????????????????????? ?????????????????????????????????????????????????????? 
b. Intra-plate well-to-???????? ?????????????? 
c. Trends should not be observed in a single plate (e.g., spotting, edge effects).  Note any trends 
in locations of the wells with standard deviations greater than 20% from the intra-plate mean 
OD.  
5. Evaluation criteria for inter-plate variation:  
a. ????????????????????????? ???????????????????????????????????????????????????????? 
b. Inter-plate CV for the 3 new plates must be less than 20%. 
c. No significant inter-plate trends should be observed from the intra-plate mean OD.  
 
 
Assay notes 
 
Note 1:  Medium binding ELISA-grade microtiter plates should be used for the Pn PS ELISA (NUNC, 
Greiner, Costar, Dynatech etc.).   
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SOP 3C:  Side by side comparison of antibody concentrations and lower limits of antibody 
detection between old and new lots of ELISA plates 
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt 
History of Revision: July 31, 2002, November 26, 2002; March 31, 2011 
Referenced SOP:           SOP1, SOP 2 
 
Purpose 
 
To demonstrate that the new lot of ELISA plates produces comparable results and comparable lower limits of 
detection as the old lot of ELISA plates using real serum samples.   
 
Principles of the assay 
 
Perform the assay for anti-Pn PS antibody with a set of serum samples and compare the results. 
 
Materials and reagents 
 
? ELISA plates:  new and old lots. 
? Test serum samples: Use a minimum of 12 unknown samples (testing 24-32 samples is better) and at least 
4 QC sera or any well-established samples.  They should have antibody levels in all ranges (high and 
low). 
? QC serum samples:  Use different sera with high and low antibody levels for each of the 9 serotypes. 
? All other materials and reagents as described in SOP 2. 
 
Methods 
 
1. Perform the Pn PS ELISA for all 9 serotypes with the 10 (or more) serum samples and also for QC serum 
samples on both the new and old ELISA plates as described in SOP 2.  
 
2.   Plot the concentrations obtained with the new plates (Y-axis) against those obtained with the old plates 
(X-axis).  The axes should be in log scale.  Obtain the best-fit line using the least squares method and log- 
      transformed results.  The slopes of the best-fit lines should be 1 + 0.1 and the intercept must be  
      <0.1 and the r2 should be >0.95.    
 
3.  Calculate the lower limits of detection for new and old ELISA plates. It should be <0.01 for both lots of  
     plates. 
 
Data analysis 
 
1. Perform a separate linear regression analysis on the optical density values from the 7 dilutions of 
reference serum (007sp) for both new and old ELISA plates. 
 
2. Calculate the ‘absolute detection limit’ as determined by the antibody concentration present in the dilution 
of reference serum yielding two times the assay background. 
 
3. Calculate the ‘lower limit of detection’ by multiplying the ‘absolute detection limit’ by the lowest dilution 
of serum tested in the assay (i.e., 1:50 for human serum). 
 
4.  The ‘lower limit of detection’ should be comparable (+20%) between old and new lots of ELISA plates.   
 To be practical, more than 99% of the samples should be above the ‘lower limit of detection’.  This is  
 about 0.01 ?g/ml in the case of the Pn PS ELISA. 
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SOP 4: Procedures for selecting a new lot of Pn PS antigen 
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt 
History of Revision: July 31, 2002, November 26, 2002; March 31, 2011 
Referenced SOP:           SOP 1, SOP 2, SOP 3 
 
 
When new lots of antigen are purchased from the ATCC, they must be tested as discussed earlier for new lots 
of ELISA plates.  The tests are:  
1. To determine the antigen titration curve with all 9  serotypes.  
2. To determine uniformity of antigen coating by calculating %CV.  
3. To determine lower limit of detection (LLQ), and to perform a side-by-side comparisons for 
acceptability of results using at least 10 serum samples representing the test population.   
Methods for testing these aspects are described in SOP 4A, SOP4B, and SOP4C.  
   
SOP 4A: Determine the optimal antigen coating concentration for a new lot of Pn PS antigen 
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt 
History of Revision: July 31, 2002, November 26, 2002; March 31, 2011 
Referenced SOP:           SOP 1, SOP 2, SOP 3, SOP 4 
 
Purpose  
 
To determine the optimal antigen-coating concentration for a new Pn PS antigen lot. 
  
Principle of the assay 
 
Antigen is adsorbed on to the surface of a microtiter plate in increasing concentrations.  Reference serum is 
added at one dilution across the plate and the ELISA is completed using the Pn PS ELISA (SOP 2).  The 
optimal coating concentration of an antigen lot is determined by inspecting optical density values vs. antigen 
concentrations.  
 
Materials and reagents 
 
? Materials and reagents are outlined in type specific Pn PS ELISA (SOP 2). 
 
Methods 
 
1. ??????????????????????????????????????????????????????????????????????????????????? ???????????????????????
first column.  If the old, established lot of antigen is available, wells A1, B1, C1, and D1 are filled with 
the old qualified antigen, and wells E1, F1, G1 and H1 are coated with the new antigen (see the plate 
layout figure below).  If the old, qualified antigen is not available, all 8 wells are filled with the new 
antigen. 
2. Fill the wells in columns 2-????????????????????????????????????????????????-fold serial dilutions from 
column 1 to column 10 by repeatedly mixing and transferri????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????? 
3. Incubate the plate at 37?C for 5 hours and then keep the plates at 4 o C for storage (see SOP 2A).   
4. Dilute the human anti-pneumococcal standard reference serum, 007sp in the absorption solution (antibody 
buffer with C-PS and 22F PS, each at 5 micrograms/ml) to give an OD of 1.0 under conditions explained 
in the Pn PS ELISA (SOP 2).   
5. Wash the plates 5 times with wash buffer.  During the first wash, allow the wash buffer to soak on the 
plate 30 seconds to 1 minute after filling the wells. 
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ANTIGEN CONCENTRATION (?g/ml) 
   
 20 10 5 2.5 1.25 0.625 0.312 0.156 0.078 0.039 Buffer  
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
 
Rows A, B, C, D:  Old qualified capsular Ps antigen (if old antigen is not available, these 
rows are coated with new antigen) 
Rows E, F, G, H:  New capsular Ps antigen 
Columns 11 and 12 are “blank wells”. 
 
Rows A and B: optimum dilution of the reference serum (007sp). 
Rows C and D: Buffer  (“background wells”) 
Rows E and F:  optimum dilution of the reference serum (007sp). 
Rows G and H: Buffer  (“background wells”) 
 
6. Add the diluted reference serum to all wells in rows A, B, E and F and the diluent buffer to all wells in 
rows C, D, G and H.  Incubate as specified in the Pn PS ELISA (SOP 2). 
7. Wash the plates 5 times with wash buffer.  During the first wash, allow the wash buffer to soak on the 
plate 30 seconds to 1 minute after filling the wells. 
8. Add goat anti-human IgG alkaline phosphatase-labeled secondary antibody at the optimal dilution to each 
well and incubate, as specified in the Pn PS ELISA (SOP 2). 
9. Wash the plates 5 times with wash buffer.  Allow the wash buffer to soak on the plate 30 seconds to 1 
minute after the first filling. 
10. Add substrate, incubate, and read the absorbance of the plate as specified in the Pn PS ELISA (SOP 2). 
 
Data analysis 
 
1. ???????????????? ????????? ????????????????????????????????????????????????????????????? ????????????????
(Note 1). (If new antigen-coated background wells have high OD, then the new antigen lot is not 
acceptable.  Old antigen was tested and should give low OD.) 
2. Obtain average OD of rows A and B, C and D, E and F, and G and H for each column. 
3. For each antigen concentration, obtain the “signal” by subtracting the average OD value of the 
background wells (antigen and 2? antibody) from the average OD value of the corresponding wells that 
contain the reference serum. 
4. Plot the signal on the Y-axis and the logarithm of antigen concentration on the X-axis. 
5. Possible outcomes: 
a. a sigmoid curve with a plateau occurring at high antigen concentrations, 
b. a sigmoid curve where the plateau falls to base-line (X-axis,  sometimes the signal decreases when the 
antigen coating concentration is too high), 
c. an increasing semi-linear plot with no observable plateau or peak in the range of antigens.   
6. For outcomes a) and b), pick the antigen concentration yielding the maximum signal because higher 
concentrations of antigen do not yield a higher signal.  
7. For outcome c), pick a coating concentration yielding the maximum possible signal with low background. 
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8.  The optimal coating concentration chosen in this manner provides maximum sensitivity, consistent ELISA 
performance, and acceptably low signals of blank wells (Note 2). 
 
 
 
Assay notes  
 
Note 1:  If OD values are repeatedly higher in the blank wells, there may be a problem with the microtiter 
plate.  However, this should not occur since the plates that were tested in the past are being used in this test.   
 
Note 2:  Antigen titration should yield similar (to the previous) optimal coating concentrations.  If marked 
differences in optimal coating concentrations are found, the new lot of the antigen should be evaluated for 
differences in purity and for differences in composition with other analytical techniques (e.g., NMR, chemical 
analysis) or with serological analysis (e.g., competition ELISA using homologous and heterologous antigens). 
 
SOP 4B: Determine the variability of antigen coating between old and new lots of Pn PS 
antigen  
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt 
History of Revision: July 31, 2002, November 26, 2002; March 31, 2011 
Referenced SOPs: SOP 1, SOP 2 
 
Purpose 
 
To determine whether the new lot of Pn PS antigen coats the ELISA plates uniformly. 
 
Principle of the assay 
 
A single dilution of serum is added to 92 out of 96 wells of an antigen-coated plate with 4 wells acting as 
blank controls with buffer only.  Mean absorbance values and their variation from the 92 wells are calculated 
between wells on a single plate and between each plate.  Standard deviation and % CV are assessed where an 
average CV should be equal to or less than 10% for acceptability. 
 
Materials and reagents  
 
? Pn PS of old and new lot numbers 
? Materials and reagents listed in SOP 2 
 
Methods 
 
1. Using the optimal antigen coating concentration determined in SOP 4A, coat three ELISA plates with the 
new antigen, and three ELISA plates with the old antigen (at the previously determined antigen coating 
concentration).  See SOP2A.  
2. Prepare a dilution of reference serum 007sp in absorption solution (antibody buffer with C-PS and 22F 
PS, each at 5 micrograms/ml) that will give an OD of approximately 1.0 with the particular Pn PS 
serotype. 
3. Wash the plates 5 times with wash buffer.  During the first wash, allow the wash buffer to soak on the 
plate 30 seconds to 1 minute after filling the wells. 
4. Add the serum dilution to all wells of the plates, excluding 4 blank wells where diluent alone is added.  
The 4 blank wells are typically B2, B9, F4 and F11 (see template below). 
5. Incubate according to the Pn PS ELISA procedure (SOP 2). 
6. Wash the plates 5 times with wash buffer.  During the first wash, allow the wash buffer to soak on the 
plate 30 seconds to 1 minute after filling the wells. 
7. Add goat anti-human IgG alkaline phosphatase labeled secondary antibody at the optimal dilution (SOP 6) 
to each well and incubate as specified in the ELISA procedure (SOP 2). 
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8. Wash the plates 5 times with wash buffer.  During the first wash, allow the wash buffer to soak on the 
plate 30 seconds to 1 minute after filling the wells.  
9.  Add substrate to each well and incubate, stop the reaction, and read absorbance in the ELISA plate reader 
as in SOP 2.     
                             
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B  Buffer      
 
Buffer    
C             
D             
E             
F    Buffer      
 
Buffer 
 
G             
H             
 
 
Data analysis 
 
1. Find the mean optical density of the 4 blank wells (i.e., buffer only wells) and subtract this from the 
optical density values of all 92 other wells.  The average optical density for the test wells must be between 
0.8 and 1.5 units. 
 
2. Calculate the intra-plate mean, standard deviation, and %CV for the 92 wells to determine well-to-well 
variation.  If the CV of the previously qualified Pn PS lot is not within the specification for acceptance, 
the assay must be repeated. 
 
3. Evaluation criteria for intra-plate variation:   
????????????????????????? ?????????????????????????????????????????????????? 
      Intra-plate well-to-???????? ???????????????????????????????????????????????????????????????????????????????
edge effect).  Note any trends in locations of the wells with deviations greater than 20% from the intra-
plate mean optical density.  
 
 
 
SOP 4C: Side by side comparison of the antibody concentrations and the lower limits of 
antibody detection (LLQ) between old and new lots of Pn PS antigen 
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt 
History of Revision: July 31, 2002, November 26, 2002; March 31, 2011 
Referenced SOPs: SOP 1, SOP 2 
 
Purpose 
 
To demonstrate that the new lot of Pn PS produces comparable results and comparable lower limits of 
detection as the old lot of Pn PS using real serum samples.   
 
Principle of the assay 
 
Perform the assay for anti-Pn PS antibody with a set of serum samples using new and old lots of Pn PS 
antigens and compare the results. 
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Materials and reagents 
 
? Pn PS:  new and old lots. 
? Test serum samples:  Use at least 10 QC samples or any well established samples (testing 24-32 
samples is better).  They should have antibody levels in all ranges (high and low).  
? All other materials and reagents are described in SOP 2. 
 
Methods 
 
1. Analyze at least 10 samples with new and old Pn PS for anti-Pn PS IgG antibody as described in SOP 2.  
 
2. Plot the results with new and old Pn PS.  Plot the concentrations with the new lot (Y-axis) against those 
with old lot (X-axis).  The axes should be in log scale.  Obtain the best-fit line using the least squares 
method.  The slope of the best-fit line should be 1 + 0.1.  The scatter among the data points should be within 
3-fold. 
 
3. Calculate the lower limits of detection for new and old lots of Pn PS. 
 
 
 
Data analysis 
 
1. Perform a separate linear regression analysis on the OD values from the 7 dilutions of reference serum 
(007sp) for both new and old Pn PS lots. 
2. Calculate the ‘absolute detection limit’ as determined by the units of antibodies present in the dilution of 
reference serum yielding two times the assay background. 
3. Calculate the ‘lower limit of detection’ by multiplying the ‘absolute detection limit’ by the lowest dilution 
of serum tested in the assay (i.e., 1:50 for human serum).  The ‘lower limit of detection’ should be 
comparable (+20%) between old and new lots of PnPS.  To be practical, more than 99% of the samples 
should be above the ‘lower limit of detection’.  This is about 0.01 ?g/ml in the case of the anti-Pn PS 
assay. 
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SOP 5:  Selection of a new lot of enzyme-labeled secondary antibody specific for all human 
IgG subclasses.   
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt  
Effective date:               June 30, 2002, November 26, 2002; March 31, 2011 
Applicable to:               The Pn PS assay, SOP2 
 
Purpose 
 
Polyclonal secondary antibodies (e.g., goat anti-human IgG) are more sensitive than monoclonal antibodies in 
the Pn PS ELISA.  However, properties of polyclonal antisera vary from lot to lot, and each lot of polyclonal 
antisera must be tested for its binding specificity.  The polyclonal antisera for human IgG should bind to all 
human IgG subclasses (IgG1, IgG2, IgG3, and IgG4) equivalently with minimal cross-reactivity to IgA or 
IgM (less than 5%).  This SOP describes how to evaluate the isotype specificity of the secondary antibody 
specific for human IgG.  
 
Materials and reagents 
 
? Purified human IgG1 (Sigma I-5154, or equivalent)  
? Purified human IgG2 (Sigma I-4264, or equivalent)  
? Purified human IgG3 (Sigma I-4389, or equivalent)  
? Purified human IgG4 (Sigma I-4639, or equivalent)  
? Bovine serum albumin (RIA grade, Sigma A2934, or equivalent) 
? Enzyme labeled secondary antibody to be tested (“new secondary antibody”)  
? Enzyme labeled secondary antibody currently in use (“old secondary antibody”) 
? Sodium carbonate (Na2CO3 , BDH #10240, or equivalent) 
? Sodium bicarbonate (NaHCO3, BDH #102474V, or equivalent) 
 
All other reagents and materials are itemized in the Pn PS ELISA (SOP 2). 
 
Solutions  
 
? Sterile carbonate/bicarbonate buffer pH 9.6: 
 
0.76g Na2CO3 
1.50g NaHCO3 
0.10g NaN3 
 
Dissolve the dry chemicals in 400 ml reagent grade water (type 1) and bring up to 500 ml with reagent grade 
water (type 1).  Adjust the pH to 9.55-9.65 with 6M HCl/6 M NaOH and sterile filter the solution using a 0.2 
?m filter.  Remove aliquots from this stock solution using sterile technique.  Store at 4?C for a maximum of 1 
week. 
 
? 2% BSA in carbonate/bicarbonate buffer 
 
Dissolve 2.0 g of RIA grade bovine serum albumin (BSA) in 100 ml of sterile carbonate/bicarbonate.  Must be 
made fresh on day of use.  All other solutions are described in SOP 2. 
 
Procedure 
 
Conditions used for all steps below should conform to those used in the Pn PS ELISA as defined in SOP 2.  
This procedure is used for testing one lot of polyclonal antiserum. 
 
1. Dilute each of the human proteins (IgG, IgA, IgM, IgG1, IgG2, IgG3, and IgG4) to 1 ?g/ml in 
carbonate/bicarbonate buffer.  Add 100 ?l of diluted human proteins to appropriate wells of the microtiter 
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plates as shown in Diagram 1 (to show specificity for IgG) and Diagram 2 (to analyze Ig isotypes).  Cover 
the plate with a lid and incubate for 90 minutes at 37?C. (NOTE THE SHORT INCUBATION TIME.) 
 
Diagram 1 
 Old qualified 2º antibody New candidate 2º antibody 
 1 2 3 4 5 6 7 8 9 10 11 12 
A  1:250 IgG IgG IgA IgA IgM IgM IgG IgG IgA IgA IgM IgM 
B  1:500             
C    etc.             
D             
E             
F             
G             
H             
             
Diagram 2 
 1 2 3 4 5 6 7 8   
A 1:250 IgG1 IgG1 IgG2 IgG2 IgG3 IgG3 IgG4 IgG4 Old 
qualified 2º 
antibody 
B 1:500             
C 1:1000         
D 1:2000         
E 1:250         New 
candidate 
2º antibody 
F 1:500         
G 1:1000         
H 1:2000         
 
2. Without removing the above antigens, add 100 ?l of 2% BSA in carbonate/bicarbonate buffer to all wells.  
Cover the plates with lids and incubate for 60 minutes at room temperature. 
 
3. Prepare serial 2-fold dilutions for the new and old secondary antibodies in antibody buffer (SOP2), in 50 
ml polystyrene tubes, starting at 1:250 and ending at 1:16000 as shown in Diagram 2.  Typically prepare 
about 20 ml for each dilution. 
 
4. Wash the plates 5 times with wash buffer.  During the first wash, allow the wash buffer to soak on the 
plate 30 seconds to 1 minute after filling the wells. 
 
5. Add 100 ?l of the dilutions of the secondary antibody to the appropriate wells (rows A through G) of the 
plate, and antibody buffer as a blank (see Diagram 2). Incubate at room temperature for 1 hour. 
 
6. Wash the plates 5 times with wash buffer.  During the first wash, allow the wash buffer to soak on the 
plate 30 seconds to 1 minute after filling the wells. 
 
7. Add 100 ?l of p-nitrophenyl phosphate solution to all wells of the plate.  Incubate for 15 minutes at room 
temperature and then add 50 ?l 3M NaOH to stop the reaction (SOP 2). 
 
8. After 5 minutes, read optical density values at 405 nm and 690 nm (SOP 2). 
 
 
Data analysis 
 
1. Average the duplicate optical density values. 
2. Subtract the average background (OD of blank wells) from each of the wells for each of the 
immunoglobulin antigens.  Background should be less than 0.1.  If not, reject the secondary antibody. 
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3. To test for IgG specificity, select the dilution that produces an optical density of roughly 1 in the wells 
coated with IgG.  Obtain the optical density of IgG, IgA and IgM isotype coated wells at the dilution of 
the secondary antibody.  Calculate the % cross reactivity as shown below.  A specific reagent should have 
cross reactivity less than 3%. 
 
[% cross reactivity=(Average OD of IgA wells (X100) / (average OD of IgG wells)] 
 
4. To test for equivalent binding of all IgG subclasses, select the dilution of secondary antibody that 
produces OD of approximately 1 for IgG2.  Obtain the optical density for IgG1, IgG2, IgG3 and IgG4 
wells at the dilution.  Calculate the binding ratio for all IgG subclasses as shown below by using OD of 
different IgG subclass in the numerator.  A balanced reagent should have a binding ratio close to 1 for all 
IgG subclass combinations.  
 
[binding ratio of IgG1= (Average OD of IgG1 wells)/(Average OD of IgG2 wells)] 
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SOP 6:  Determine the optimum working dilution for the enzyme labeled secondary antibody  
 
Prepared by the laboratories of: Dr. Moon Nahm and Dr. David Goldblatt 
Effective date:      June 30, 2002, November 26, 2002; March 31, 2011 
Applicable to:      Pn Ps ELISA (SOP 2) 
 
Purpose 
 
The purpose is to determine the optimal working dilution of the enzyme-labeled secondary antibody, which is 
used for the Pn PS ELISA. 
 
Materials and reagents  
 
? Reagents and materials specified in the Pn PS ELISA for which the enzyme-labeled secondary antibody will 
be used.   
? Enzyme-labeled secondary antibody to be tested (“new secondary antibody”) 
? Enzyme-labeled secondary antibody currently used (“old secondary antibody”) 
 
All other reagents and materials are specified in SOP 2.   
 
Procedure 
 
Conditions for all steps below should conform to those used in the antigen specific Pn PS ELISA as defined in 
SOP 2.  Also it is assumed that one new secondary antibody is being tested with one old secondary antibody.  
Depending on the situation, the reagent volumes can be changed. 
 
1. Coat 4 microtiter plates with Pn PS (one plate each of serotypes 4, 6B, 14 and 18C) at the optimal antigen 
concentration (SOP 4A) for each lot of enzyme-labeled secondary antibody to be tested.  
 
2. Prepare 4 ml of “absorption solution” (i.e. antibody buffer containing C-PS and 22F PS, each at 5 
micrograms/ml).  Dilute the standard serum (007sp) with 4 ml of the “absorption buffer” such that the optical 
density value at the end of the assay would be about 2.0.  Although the exact dilutions are serotype specific, 
this dilution is usually about 1:1500 for 007sp ??????????????????????????????????????????????????????????????????
each well in row A of the “dilution plate”.  
 
?????????????????????????????????????????????????????????????????????????????????????????????????????????-fold 
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????
those in row B etc.  These dilutions should yield a linear range of optical density values between 0.1 and 2.0.  
Incubate for 30 minutes. 
 
4. Wash the antigen-coated assay plates 5 times with wash buffer.  During the first wash, allow the wash 
buffer to soak on the plate 30 seconds to 1 minute after filling the wells. 
 
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????
G then move up the next row etc.  Add only the antibody buffer to the wells in row H.  Incubate the plate for 2 
hours (SOP 2).  
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Diagram 1 
 
Dilution 
of 007sp  
      ? 
 New candidate 2º antibody Old qualified 
2º antibody 
at in use 
dilution 
 D1 
1:500 
D2 
1:1000 
D3 
1:2000 
D4 
1:4000 
D5 
1:8000 
 1 2 3 4 5 6 7 8 9 10 11 12 
1:500 A             
1:1000 B             
1:2000 C             
1:4000 D             
1:8000 E             
1:16000 F             
1:32000 G             
Antibody 
buffer 
H             
 
 
6.  In 15-ml polystyrene tubes, prepare five 2-fold serial dilutions (dilutions D1, D2, D3,  
    D4, D5 and D6) of the new secondary antibody.  Generally, 2 ml of the new antibody  
    dilutions are prepared at 1:500, 1:1000, 1:2000, 1:4000, 1:8000 and 1:16000 dilutions,  
    but the exact dilutions may vary with the new secondary antibody type, source, and lot.   
    If the old secondary antibody is available, prepare the working dilution of the old  
    secondary antibody and use it instead of D6.  
 
7.  Wash the plates 5 times with wash buffer.  During the first wash, allow the wash  
      buffer to soak on the plate 30 seconds to 1 minute after filling the wells. 
 
8.  Add serial dilutions of enzyme-labeled secondary antibodies in duplicates (100  
     ?l/well) to appropriate columns as shown in Diagram 1.  For instance, D1 dilution of  
     the new antibody will be added to wells in columns 1 and 2 (including rows G and H),  
     D2 to columns 3 and 4, etc.  The old antibody (or D6) will be added to wells in  
     columns 11 and 12.  Incubate the plates according to antigen specific Pn PS ELISA  
     (SOP 2).   
 
9.  Wash the plates 5 times with wash buffer.  During the first wash, allow the wash  
     buffer to soak on the plate 30 seconds to 1 minute after filling the wells. 
 
10.  Add substrate to the plates, incubate the plates, and obtain the OD of the plates using  
       an ELISA reader as described in SOP 2. 
 
Data analysis 
 
Choose the dilution of new secondary antibody that satisfies all 5 requirements described below. 
 
1. Signal strength: Examine OD values of the wells in row A and determine the dilution of the new 
secondary antibody with OD values close to 2.  Usually, 1:1000 or higher dilutions would provide the 
high OD values.   Occasionally, a working dilution as low as 1:250 may be required for a very poor 
secondary antibody to achieve the required high OD. At these low dilutions, the secondary antibody may 
have high background binding.   
 
2. Background binding: Examine OD values of the wells in rows G and H (antigen + enzyme labeled 
secondary antibody) and determine the dilutions of the new secondary antibody with OD values less than 
0.1.  If a new secondary antibody has a working dilution 1:1000 or higher, it usually has low background 
binding.  Occasionally, the secondary antibody with high working dilution may bind the antigen and may 
have high background binding. The overall performance of the secondary antibody is determined by the 
signal to noise ratio.  Therefore, select the optimal working dilution, which maximizes the signal and 
minimizes the noise. 
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3.  Lower limit of detection: Perform a separate linear regression analysis on the absorbance from the 6 
dilutions of reference serum for each dilution of enzyme labeled secondary antibody.  Calculate the ‘lower 
limit of detection’ as determined by the units of antibodies present in the dilution of reference serum 
yielding two times the assay background.  Calculate the units/ml detectable at the lowest dilution of serum 
tested in the assay (i.e., 1:50 for human serum).  The optimal dilution chosen must yield values on more 
than 99% of cases.  In the case of the Pn PS ELISA assay, the sensitivity limit is about 0.01 ?g/ml. 
 
4. Comparability: Select the dilution of new secondary antibody that yields equivalent OD (i.e., ± 10% of the 
current lot) while meeting the lower limit of assay sensitivity.  A side-by-side analysis of a panel of sera 
should confirm that results obtained using the ‘new’ lot of the secondary antibody is equivalent to those 
attained with the old, previously qualified antibody. 
 
5.  Enzyme development time: If robotic applications of the ELISA are planned, the substrate development 
time for the alkaline phosphatase enzyme is often made similar to typical ELISA antibody incubation 
times (e.g. 1-2 hours).  Incubation periods less than one hour may severely limit the number of plates the 
robot can process. 
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Appendix 7 
 
CDC Skim-milk tryptone glucose glycerol (STGG) transport and storage medium recipe 
 
STGG transport medium 
 
Skim milk powder 2 g 
Tryptone Soy Broth 3 g  
Glucose 0.5 g 
Glycerol 10 ml 
Distilled water 100 ml 
 
- Mix to dissolve all ingredients. 
- Dispense in 1.0 ml amounts in screw-capped 1.5-ml vials. 
- Loosen the screw-cap tops and autoclave for 10 minutes (at 15 pounds). 
- Tighten caps after autoclaving. 
- Store STGG frozen at -20°C or refrigerate until use. 
 
STGG storage medium 
 
Skim milk powder 10g 
Glycerol 10ml 
Distilled water 90ml 
 
-10g of Skim milk in 90 mL of distilled water in flask A 
-10 mL of glycerol (autoclave in separate flask B) 
-Autoclave at 115 C for 10 min, and exhaust the pressure carefully.  
-Mix flasks A and B after autoclaving while still hot  
-Use 1.0 mL of skim milk solution for each isolate in a cryotube 
-Freeze at -70C 
  
 
